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Preface
Interleukin-6 (IL-6) is a pleotropic cytokine produced by a wide range of mammalian 
cell types, with actions on a variety of cellular mechanisms. It is predominantly 
involved in mediating adaptive immune responses to inflammation, both in the acute 
and chronic setting, regulating B-cell and T-cell function, stimulating the acute phase 
reaction, influencing haemopoiesis and cellular bone formation.
The systemic arthritis (SA) form of juvenile idiopathic arthritis (JIA) is characterised 
by an inflammatoiy arthritis, a daily spiking fever and an evanescent rash, with 
serositis, lymphadenopathy, hepatosplenomegaly, thrombocytosis, anaemia, 
hypergammaglobulinaemia, osteoporosis and growth retardation also occurring. This is 
the most severe form of JIA, associated with the highest morbidity and mortality.
Several observations implicate IL-6 as having a pivotal role in the pathogenesis of SA. 
IL-6 levels together with the soluble IL-6  agonist receptor sIL-6R are significantly 
elevated in the serum and synovial fluid of children with SA, more so than in other 
forms of JIA or in inflammatoiy arthritides occurring in the adult population. Serum 
peaks of IL-6 precede the daily fever spike and are associated with the appearance of 
rash, and unlike other inflammatory conditions such as infection or rheumatoid 
arthritis, the peak in IL-6 is not preceded by a rise in levels of other inflammatory 
cytokines such as IL-1 and TNFa. In addition, many of the manifestations of SA 
involve mechanisms in which IL-6 is involved in the pathogenesis. IL-6 was therefore 
considered a candidate gene for susceptibility and severity of SA.
Several polymorphisms have been identified in the 5’-flanking region of the IL-6 gene, 
a G to C at position -174, a G to C at -572, a G to A at -597 and a variable length AT- 
tract from -373 to -392. As IL-6 is predominantly regulated by transcription, these 
polymorphisms were considered to potentially influence the production of IL-6 . This 
thesis set out to investigate the association of these IL-6  polymorphisms with SA using 
case-control genotype studies. This led to an investigation of the functional 
significance and possible mechanisms of the polymorphisms found to be associated 
with SA using transfection studies and electrophoretic mobility shift assays.
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Abstract
This thesis investigates the hypothesis that the high levels of EL-6 in SA is pathogenic 
and is influenced by polymorphisms in the 5’-flanking region of IL-6 , resulting in 
altered IL-6 transcriptional regulation, susceptibility to and severity of SA.
Genotype studies of SA cases and controls found the -174G/C polymorphism to be 
associated with SA. The -174CC genotype was under-represented in SA and this was 
due to under-representation of this genotype in the early disease onset group (<5 years 
of age), indicating association with susceptibility and severity of SA. The -572G/C 
and -597G/A polymorphisms were not associated with disease despite strong allelic 
association between -174C & -597A and weak allelic association between -174G & 
-572C. The most common naturally occurring haplotypes were -597G-572G-174G 
and -597A-572G-174C.
In HeLa cell transfections with luciferase reporter constructs stimulated with IL-ip or 
TNFa, the -174G allele was associated with higher levels of expression than the 
-174C allele. The -597 polymorphism lacked independent function, whereas the 
-572G allele was associated with higher levels of expression than -572C. The AT-tract 
polymorphism showed functional influence, with AgT 12 associated with higher levels 
of expression than A9T11. These effects were cell-specific, with no difference in levels 
of transcription between haplotypes in Huh7 cells. Deletion mutant constructs 
indicated that the -174G/C allelic effect was modulated by a region between -310 and 
-550, which includes the AT-tract. Dexamethasone inhibition of IL-1-induced IL-6 
transcription was associated with significantly more inhibition of expression for the 
-174G allele than-174C.
Electrophoretic mobility shift assays with HeLa cell nuclear extracts found a 
transcription factor(s) bound to the IL-6  gene between -134 and -184 more strongly 
with the -174C allele than -174G. This appeared to involve C/EBPp, and NF1 may 
have been involved. An additional novel finding was the binding of an IL-1 p inducible 
factor between-161 and-235.
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DMEM Dulbecco’s modified Eagles medium
DMSO Dimethyl sulphoxide
DNA Deoxyribonucleic acid
dsDNA Double-stranded DNA
ssDNA Single-stranded DNA
dNTP Deoxynucleotide triphosphate
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dATP Deoxyadenosine triphosphate
dCTP Deoxycytosine triphosphate
ddNTP Dideoxynucleotide triphosphate
DTT Dithiothreitol
E. coli Escherichia coli
ECL Enhanced chemiluminescence
ECV304 Human cell line, possibly endothelial cell
EDTA Ethylene glycol-bis (b-aminoethylether) N, N, N \  N ’-tetraacetic acid
EH Estimation o f haplotype
ELISA Enzyme-linked immunosorbent assay
EMSA Electrophoretic mobility shift assay
ER Oestrogen receptor
ERK Extracellular regulated kinase
EULAR European League Against Rheumatism
FACS Fluorescence-activated cell sorter
FCS Foetal calf serum
FITC Fluorescein isothiocynate
FLSs Fibroblast-like synoviocytes
Fras Fos-related antigens
G418 Neomycin analogue
P-gal p-galactosidase
X-gal 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside
Gab Grb2-associated binder protein
GC Glucocorticosteroid
G-CSF Granulocyte colony stimulating factor
GM-CSF Granulocyte macrophage colony stimulating factor
GOOD Goodinge controls
gpl30 Glycoprotein 130
sgpl30 Soluble glycoprotein 130
Grb2 Growth factor receptor bound protein
GR Glucocorticoid receptor
GRE Glucocorticoid response element
dH20 Distilled water
HBS Hanks buffered saline
HC1 Hydrochloric acid
HeLa Human epithelial cell line
HEPES N-2-hydroxyethylpiperazine-N’-2-ethanesulphonic acid
HepG2 Human hepatoma cell line
HGMP Human genome mapping project
HLA Human leukocyte antigen
HPV18 Human papilloma virus type 18
HRP Horseradish peroxidase
Hsp Heat shock protein
HSV-TK Herpes simplex virus-thymidine kinase
HTLV1 Human T-cell leukaemia virus 1
Huh7 Human hepatoma cell line
HUVEC Human umbilical vein endothelial cell
H-W Hardy-Weinberg
ICAM Intercellular adhesion molecule
ICER Inducible cAMP early repressor
IFNy Interferon gamma
Ig Immunoglobulin
IGF1 Insulin-like growth factor 1
IKK Inhibitor o f kappa B kinase
IL-1 Interleukin-1
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IL-1 stim IL-1 (3 stimulated
IL-1R Interleukin-1 receptor
IL-1RI Type I interleukin-1 receptor
IL-4 Interleukin-4
IL-6 Interleukin-6
IL-6R Ineterleukin-6 receptor
hIL-6 Human interleukin-6
rIL-6 Recombinant human IL-6
sIL-6R Soluble Interleukin-6 receptor
vIL-6 Viral interleukin-6
IL-8 Interleukin-8
IL-10 Interleukin-10
IL-11 Interleukin-11
ILAR International League Against Rheumatism
Inr Transcription initiation region
IPTG Isopropyl p-D thiogalactopyranoside
IRAKI Interleukin-1 receptor associated kinase 1
IRF Interferon regulatory factor
IkB Inhibitor o f kappa B
JAK Janus kinase
JCA Juvenile chronic arthritis
JIA Juvenile idiopathic arthritis
JRA Juvenile rheumatoid arthritis
K4Fe(CN)6 Potassium ferrous cyanate
KAc Potassium acetate
KC1 Potassium chloride
kDa kiloDaltons
KH2PO4 Potassium hydrogen phosphate
LAP Liver-enriched transcription activating protein (C/EBPp)
LB Luria-Bertani medium
LIF Leukaemia inhibitory factor
LIFR Leukaemia inhibitory factor receptor
LIP Liver transcription inhibitory protein (truncated form of C/EBPp)
Ln(L) Log likelihood o f allelic association
LPS Lipopolysaccharide
mAb Monoclonal antibody
MADGE Micro-titre array diagonal gel electrophoresis
MAPK Mitogen activated protein kinase
MAPKAP kinase2 MAPK-activated protein kinase 2
MCP1 Macrophage chemotactic protein 1
M-CSF Macrophage colony stimulating factor
M-CSFR Macrophage colony stimulating factor receptor
MgCl2 Magnesium chloride
mgpl30 Membrane bound gp l30
MgS04 Magnesium sulphate
MHC Human major histocompatibility complex
MIF Migratory inhibitory factor
MIP Macrophage inflammatoiy protein
MnCl2 Manganese chloride
MRA Myeloma regression antibody, mAb to IL-6R
MRC Medical research council
NaAc Sodium acetate
Na2H P04 Sodium hydrogen phosphate
NaCl Sodium chloride
NaOH Sodium hydroxide
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N-CoR Nuclear receptor co-receptor
NF1 Nuclear factor 1
NF-IL6 Nuclear factor of IL- 6  (also known as C/EBPp)
NF-kB Nuclear factor for kappa B
NH4AC Ammonium acetate
NIH3T2 Mouse adipocyte cell line
NIK NF-kB inducing kinase
NLS Nuclear localisation sequence
NP-40 Nonidet P-40
NPH Northwick Park Hospital controls
NRD Negative regulatory domain
Nun Nuneaton controls
OCT1&2 Octamer binding transcription factors
OD Optical density
OR Odds ratio
OSM Oncostatin M
OSMR Oncostatin M receptor
PAGE Polyacrylamide gel electrophoresis
PBMC Peripheral blood mononuclear cell
PBS Phosphate buffered saline
PC Personal computer
PCR Polymerase chain reaction
PE Phycoerythrin
Pfu Pyrococcus furiosns
PHA Phytohaemagglutinin
PIAS Protein inhibitors o f activated STATs
PDK Phosphatidylinositol 3-kinase
PMA Phorbo-13-myristate-12-acetate
PMSF Phenylmethylsulfonyl fluoride
PolydI.dC Poly(dI-dC).poly(dI-dC), synthetic double stranded polymer of inosine 
and cytosine
Pr Probe
PTH Parathyroid hormone
PVDF Polyvinyl idene difluoride
QR Quantum red
RA Rheumatoid arthritis
RANK Receptor activator of nuclear factor
RANKL RANK ligand
RBP Recombination binding protein
RBP-Jk Recombination signal sequence binding protein-jK
RCE Retinoblastoma control element
RD Regulatory domain
RFLP Restriction fragment length polymorphism
RHD Rel homology domain
RIP Receptor interacting protein
RNA Ribonucleic acid
mRNA Messenger RNA
rpm Revolutions per minute
RSV Respiratory syncitial virus
RT-PCR Reverse transcription polymerase chain reaction
SA Systemic arthritis
SAA Serum amyloid A
SDS Sodium dodecyl sulphate
SDW Sterile distilled water
SIC Src homology domain
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SHP2 Two-SH2 domain-containing tyrosine-phosphatase
SLE Systemic lupus erythematosus
SNP Single nucleotide polymorphism
SOCS Suppressor of cytokine signalling
Spl Specificity protein 1
SRC-1 Steroid receptor coactivator-1
SRE Serum response element
SSC Salt sodium citrate
SSc Systemic sclerosis
SSCP Single-strand conformational polymorphism
SSOP Sequence specific oligonucleotide probing
STAT Signal transducers and activators of transcription
str-FCS Stripped foetal calf serum
SV40 Simian virus type 40
TAE Tris acetic acid EDTA
Tag Thermits aquations
TBE Tris boric acid EDTA
TBP TATA binding protein, also known at TFilD
TDT Transmission disequilibrium test
TE Tris EDTA buffer
TEMED Tetraethylmethylene diamine
TFI1B Transcription factor IIB
TH T-helper cell
THP1 Human monocyte cell line
TIMP Tissue inhibitor o f metalloproteinases
Tm Melting temperature
TNF Tumour necrosis factor
TNFR Tumour necrosis factor receptor
TPA T etradecanoy 1 phorbo-13 -acetate
TPO Thrombopoietin
TRADD TNF-receptor associated death domain protein
TRAF TNF-receptor associated factor
Tween Polyoxyethelenesorbitan monolaurate
Tyk Tyrosine kinase
Tyr Tyrosine
Ub Ubiquitination
UHG Universal heteroduplex generator
UK United Kingdom
Unstim Unstimulated
US United States
UTR Untranslated region
UV Ultraviolet
VC AM Vascular cell adhesion molecule
VNTR Variable number of tandem repeats
WEDC West-end donor controls
YY1 Ying yang 1
ZIA Zymosan induced arthritis
P probability-value (statistical measure)
A Delta co-efficient (linkage disequilibrium)
x2 Chi-square
Xs Sibling relative risk o f disease
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CHAPTER 1 
INTRODUCTION
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1.1. Interleukin 6
1.1.1. The history of interleukin 6
The cytokine interleukin 6 (IL-6) is a mammalian glycoprotein involved in adaptive 
immune responses to inflammatory stimuli, with regulatory roles on B-cell and T-cell 
function, haematopoiesis and acute phase reactions. In humans, IL-6 is a single 
polypeptide chain 184 amino acids in length (212 amino-acid precursor), with a 
molecular weight of between 21 and 28 kDaltons depending on the glycosylation state. 
It was initially identified as a protein produced by fibroblasts stimulated with 
poly(I)poly(C) in the presence of cyclohexamide and named interferon-p2 
(Weissenbach et al., 1980). Independently, it was identified and described by another 
group as a mitogen-inducible lymphokine acting on B-cells to promote their terminal 
maturation into immunoglobulin-producing cells, and was named B-cell differentiation 
factor (Yoshizaki et al., 1984). Subsequently it was changed to B-cell stimulatory 
factor-2 after purification and characterization (Hirano et al., 1985). The name 
interleukin 6 (first proposed by Poupart et al., 1987) was universally adopted, as 
molecular cloning and nucleotide sequencing revealed that these previously described 
and differently named molecules were identical (Sehgal et al., 1989). Additional 
previous names for IL-6 reflect the pleiotropic actions of this cytokine; hepatocyte 
stimulatory factor, hybridoma/plasmacytoma growth factor, monocyte granulocyte 
inducer type 2 and cytotoxic T-cell differentiation factor (Gauldie et al., 1987, Van 
Damme et al., 1987, Takai et al., 1988). IL-6 additionally has roles in induction of T- 
cell growth, thrombopoiesis, bone metabolism and neuronal differentiation. The 
diversity of cell types that can produce IL-6 also reflects its pleiotropic biological 
activity. This includes lymphoid cells (B-cells and T-cells), macrophages, bone 
marrow stromal cells, fibroblasts, chondrocytes, adipocytes, keratinocytes, mesangial 
cells, astrocytes, endothelial cells, epithelial cells, hepatocytes and osteoblasts.
1.1.2. The IL-6 family of cytokines and their receptors
Cytokines can be classified according to the structure of their receptors. IL-6 is the 
prototype for the IL-6 family of cytokines that in combination with their specific 
receptors, signal through a common signal transducer gpl30. Other members of this 
family are interleukin 11 (IL-11), leukaemia inhibitory factor (LIF), oncostatin M 
(OSM), ciliary neurotrophic factor (CNTF), cardiotrophin 1 (CT-1) and cardiotrophin- 
like cytokine (CLC). These other members have many similarities in biological
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activities to IL-6 including enhancement of immunoglobulin secretion, stimulation of 
erythropoiesis and thrombopoiesis, involvement in maturation and activation of 
macrophages, activation of osteoclasts, stimulation of acute phase protein synthesis 
and regulation of neuronal differentiation. There is homology between amino acids 
153-165 of IL-6 and equivalent regions in OSM, CNF, LIF and EL-11, indicating a 
common region involved in signalling via gpl30 (de Hon et al., 1995, Heinrich et al., 
2003).
The receptors for the IL-6 family of cytokines form a sub-type of class I cytokine 
receptors characterised by an extracellular cytokine binding module (CBM), a 
haematopoietin-binding homologous domain with 4 positionally conserved cysteine 
residues and a conserved 5 amino-acid C-terminal domain motif (WSXWS) (Bazan, 
1990). The receptors also contain a common immunoglobulin homologous domain, a 
transmembrane domain and a short, non-signalling intra-cellular domain. Despite these 
structural similarities, each of the a-chain receptors is cytokine specific and occurs in 
cell membrane anchored and soluble extra-cellular form. Cellular response to cytokine 
is regulated by the distribution (spacial and temporal) of a-chain receptors (Taga and 
Kishimoto, 1997). The a-chain receptor is a low affinity receptor. For IL-6, IL-11 and 
CNTF, cytokine binding to the a-chain receptor initiates ordered assembly of 
cytokine/a-chain receptor with membrane bound gpl30, which increase the receptor 
affinity. This forms the receptor-signalling complex. IL-6 and IL-11 signal via a gpl30 
homodimer, whereas the other IL-6 family cytokines signal via a heterodimer of gpl30 
and LIF receptor (LIFR) for LIF, CNTF, CT-1 and CLC, or gpl30 and OSM receptor 
(OSMR) for OSM (Heinrich et al., 2003).
1.1.3. The IL-6 protein structure and its binding to receptor
The crystal structure of human recombinant IL-6 has confirmed predictions that it is a 
long-chain helical cytokine. It consists of four helices, two running in one direction 
(designated A and B) and two running anti-parallel (C and D), with two long linking 
loops (between A-B, and C-D) and one short loop (between B-C), (figure 1.1, Somers 
et al., 1997). A network of hydrophobic interactions at the core of the molecule 
stabilises the helical structure and a series of hydrogen bonds formed by water 
molecules in surface clefts link the helices and loops of the crystallised structure. This
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tertiary structure is common to the other IL-6 -type cytokines, such as LIF and CNTF 
(Robinson et al., 1994, McDonald et al., 1995a). Comparison of known and predicted 
structures for other related long-chain a-helix-bundle cytokine/haemopoietic factors, 
such as granulocyte colony-stimulating factor (G-CSF), also show close structural 
similarity despite low amino acid homology (Somers et al., 1997).
Figure 1.1. Ribbon diagram of the structure of the human IL-6 protein.
As determined by 1.9A x-ray crystallography (Brookhaven databank accession number IL6). A & B = 
parallel helices, C & D =anti-parallel helices, C-D =long linking loop between C & D domain, C-ter = 
C-terminal end o f protein. Site I interacts with IL-6R, sites II and III with gpl30 (Somers et al., 1997).
Distinct sites on the IL- 6  protein are important for binding the a-chain specific 
receptor for IL- 6  (IL-6 R) and for signal transduction via gpl30. Brakenhoff and co­
workers (1994) found that neutralising monoclonal antibodies (mAbs) to a region of 
the A-B loop of human IL- 6  inhibited IL-6 R-binding, while neutralising mAbs to a 
distinct second region permitted IL-6 R binding but interfered with signal transduction 
in bioassays. Further analysis of the A-B loop region (amino acids 41-95) using
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chimeric human/murine IL-6 proteins, where murine IL-6 does not permit binding to 
the human IL-6R, identified a region of 7-10 amino acids in the C-terminai portion of 
the loop that was necessary to confer human IL-6R binding capacity to IL-6 (Ehlers et 
al., 1994). In addition, the region of amino acids 175-181 appears to be important in 
binding to soluble IL-6R as single base mutations within this region resulted in 
reduced IL-6 biological activity, correlating with reduced affinity for soluble IL-6R 
(Savino et al, 1993). The region corresponds to a cleft in the 3D structure of the C- 
terminal region of helix D that may accept amino acid bases from the IL-6R as is seen 
with the similarly structured molecule human growth hormone when it engages with 
its specific receptor (Somers et al., 1997). The crystal structure of IL-6 shows the C- 
terminal A-B loop and the C-terminal portion of helix D to lie in close proximity, to 
form one binding interface for IL-6R. Mutational studies of two regions of the A & C 
helices, and a region of the terminal part of the C-D loop, resulted in reduced or 
abolished signal transduction without altering the binding affinity for IL-6R (Paonessa 
et al., 1995). This was due to prevention of gpl30 binding and dimerization. IL-6 has 
an essential role in the formation of the IL-6 signalling complex binding directly to IL- 
6R and gpl30 via specific domains and facilitating activation of gpl30 (see 1.1.4&5).
Immunoprecipitation, size-exclusion chromatography and analytical centrifugation 
analysis of the assembled soluble receptor-signalling complex have shown it to consist 
of two IL-6, two IL-6R and two gpl30 molecules (Ward et al., 1994, Paonessa at al.,
1995). Therefore, a hexameric model for complex assembly has been proposed. 
Although study has shown that dimeric-IL-6 bound with higher affinity to sIL-6R by 
cross-linking two sIL-6R molecules (Ward et al., 1996), this 4-unit complex resulted in 
reduced biological potency due to decreased ability to couple with gpl30. The 
hexameric complex was therefore proposed to arise from the formation of two trimeric 
complexes of IL-6/IL-6R/gpl30 (in a 1:1:1 ratio) coupling via dimerization of the 
complexed gpl30 molecules (see figure 1.2).
1.1.4. The IL-6 receptor
IL-6R is expressed on a range of cell types facilitating pleiotropic actions of IL-6. This 
includes activated but not resting B-lymphocytes, plasma cells, T-lymphocytes, 
monocytes, macrophages, epithelial cells, fibroblasts, hepatocytes, neural cells and 
osteoclasts. The crystal structure of IL-6-type receptors has yet to be resolved, but
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predictions have been made from the amino-acid sequence and the structure of IL- 6  
and gpl30. Residues in the cytokine-binding motif (CBM) of IL-6 R, near the hinge 
region between the upper and lower domains, are involved in IL- 6  binding (figure 1.2), 
(Kalai et al., 1997, Grotzinger et a l, 1997). Large aromatic and hydrophobic residues, 
surrounded by hydrophilic amino acids, are necessary for the IL-6 /IL-6 R interaction. 
The immunoglobulin (Ig)-like domain is not required for signal transduction by IL- 6  
through gpl30 and therefore not necessary for IL- 6  binding (Yawata et al., 1993). The 
cytoplasmic domain of IL-6 R though not required for receptor complex formation or 
signal transduction, has a role in targeting the receptor complex to the basolateral 
membrane of polarised cells (Martens et al., 2000). This targeting of the receptor may 
influence specific signalling functions of the receptor complex.
gp!30 molecules
IL-6 IL-6
Cell membrane
IL-6R 1 
(a-chain)
IL-6R
(a-chain)
Jak/Stat Activation
Figure 1.2. The IL-6 receptor-signalling complex - a hexameric model for IL-6 /IL- 
6R/gpl30 signal-transduction complex assembly (adapted from Heinrich et al., 1998).
The IL-6/IL-6R complex binds membrane bound gpl30 and induces gpl30 homodimerization. This 
results in specific tyrosine phosphorylation in the intracellular cytoplasmic tail o f gpl30 and Jak/Stat 
pathway activation (see section 1.1.6).
=Immunoglobulin homologous domain
=Cytokine binding module (CBM)
(red band = 4 conserved cysteine residues, green band =  conserved WSXW S motif)
|  = Transmembrane domain
■ =60 amino acid intracellular domain essential for signal transduction 
(Murakami et al., 1991)
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1.1.5. The gpl30 molecule
The gpl30 molecule is ubiquitously expressed, with cellular response limited by the 
expression and binding of specific a-receptors such as IL-6R. The Ig-like domain as 
well as the CBM domain of gp-130 (figure 1.2) and particularly a valine residue at 
position 252, are necessaiy for gp l30 interaction with IL-6/IL-6R complex (Horsten et 
al., 1997, Moritz et al., 1999). The crystal structure has been determined for the 
uncomplexed CBM domain of gp l30 and recently for ligand-bound extracellular part 
of gp l30 (with viral IL-6 (vIL-6) capable of signalling through gp l30 without the 
requirement of a-chain receptor), (Bravo et al., 1998, Chow et al., 2001). As predicted 
from the amino acid sequence, the extracellular fragment of gp l30 comprises three 
domains; a seven-stranded p-sandwich module with an Ig fold (Ig-like domain), a 
proline-rich linker, and two P-sandwich fibronectin type HI domains (CBM). The 
gpl30 molecule appears to be a rigid structure with little or no structural adaptation to 
cytokine/ligand binding. The exposed hydrophobic residues on the surface of the CBM 
in combination with an amphipathic-binding surface (capable of polar and non-polar 
interactions) possibly explain the diversity of cytokine/receptor ligands that can bind 
and activate gpl30. Anti-gpl30 mAbs have been created that specifically block 
signalling by a single member of the IL-6 family, but not by other members (Wijdenes 
et al., 1995, Chevalier et al., 1996). This indicates that distinct regions of the gpl30 
molecule facilitate signalling by different IL-6-family cytokines and goes some way to 
explaining how a common signal transducer may elicit different cellular responses 
with different cytokine ligands. This is supported by more recent work where g p l30 
mutants, lacking the Ig-like domain, were unresponsive to IL-6 and IL-11 but still 
capable of signal transduction in response to LIF or OSM that dimerize gpl30 to LIFR 
or OSMR (Timmermann et al., 2000). Point mutations in the CBM of gp l30 also 
severely impaired signal transduction by IL-6 and IL-11, but differentially affected LIF 
and OSM responses. Similar to the IL-6R, the cytoplasmic domain of gpl 30 contains a 
motif that targets gpl 30 to the basolateral membrane of polarised cells (Heinrich et al., 
2003). In certain cell types localisation of gpl 30 to specific sites such as lipid rafts and 
caveolae may facilitate special signalling functions.
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1.1.6. IL-6 signal transduction through gpl 30
IL-6 bound IL-6R induces disulphide-linked homodimerization of gp l30 and only 
once dimerized is gpl30 associated with tyrosine kinase activity (Murakami et al., 
1993). Two serine residues (amino acids 656 and 658) in the cytoplasmic tail of gpl 30 
were found to be essential for this tyrosine kinase activity. Dimerization of gp l30 
alone however, may not be sufficient for receptor activation as a single mAb, though 
inducing dimerization, did not result in efficient activation (Muller-Newen et al., 
2000).
Dimerization of gp l30 by IL-6 bound IL-6R leads to activation of three of the four 
known mammalian Janus kinases (Jakl, Jak2 and Tyk2), with different cell types 
having different patterns of Jak-Tyk phosphorylation (Narazaki et al., 1994, Stahl et 
al., 1994). The gpl30-mediated activation of other tyrosine kinases, Hck, Fes, Btk and 
Tec, has also been reported in certain cell types (Heinrich et al., 1998). The N-terminal 
region of Jaks is involved in their association with the cytoplasmic part of receptors 
(Yan et al., 1998). Heinrich et al. (1998) observed that close contact between Jaks, 
appears to be sufficient to trigger cross-activation, as over-expression of Jaks without 
stimulation is associated with tyrosine phosphorylation. Jakl deficient cells could not 
respond to IL-6-family cytokines, but Jak-2 deficient cells could, suggesting that in at 
least some cell types Jak-1 plays an essential role in IL-6 signalling (Rodig et al., 1998, 
Parganas et al., 1998). Jaks associate with gp l30 via two sequences in the membrane- 
proximal cytoplasmic tail (conserved between Jak-activating cytokine receptors). 
Mutations in box 1 of gp l30 (an 8 amino acid proline-rich motif, figure 1.3) reduced 
gpl30 association with Jaks and abolished both Jakl and Jak2 activation, while 
deletion of box 2 (a cluster of hydrophobic residues, figure 1.3) reduced only Jak2 
binding and activation (Tanner et al., 1995, Narazaki et al., 1994, Murakami et al., 
1993). The inter-box region of gp l30 is also important in Jak association. Distinct 
amino acids appear to regulate Jak binding and Jak activation in association with 
gp l30. Mutation of the tryptophan residue at position 666 of gp l30 (in the inter-box 
region) reduced Jak binding (Haan et al., 2000), where as mutation of the tryptophan 
residue at position 652 (within the box 1 region) reduced Jakl activation, though 
binding was not altered (Haan et al., 2002).
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Box Box 
1 2
1 1 1 ■ I N  1 1 1 1
Ig 1<NIII FNIII FNIII FNIII FNIII TM[ Y ^ { LL Y YY
Figure 1.3. The structural organisation of the gpl30 molecule
(adapted from Heinrich et al., 2003).
Ig=Immunoglobulin-like domain, FNIII=fibronectin type III domain, CBM=cytokine binding module 
(consisting o f 2 FNIII domains with 4 conserved cysteine residues [shown in red] & a conserved 
WSXWS motif [shown in green]), TM=transmembrane region, Y=specific tyrosine residues that 
undergo phosphorylation, LL=di-leucine motif, Box 1&2 are important for Jak interaction.
The context of the Jak binding site is clearly important. Transfer of the box 1/2 region 
to the C-terminal region instead of the proximal part of the intra-cellular gpl30 
sequence did not permit Jak binding (Greiser et al., 2002). The N-terminal domain of 
Jaks, the FERM domain (so called as it is also contained in four-point-one, ezrin, 
radixin and moesin) is crucial for Jak association with gpl30 (Heinrich et al., 2003, 
figure 1.4).
FERM (SH2) Kinase-like tyrosine kinase
Y Y
Figure 1.4. The structural organisation of Jak  molecules.
FERM=4.1/ezrin/radixin/moesin domain, (SH2)=potential Src homology 2 domain, Y=tyrosine residue.
Multiple Jaks become activated by gpl30 dimerization, resulting in the induction of 
distinct intracellular signalling pathways. The pathways are dependent not on the Jak 
that is activated, but on phospho-tyrosines in the cytoplasmic tail of gpl 30 (figure 1.3). 
These specific tyrosine motifs, once phosphoiylated by tyrosine kinase activity, act as 
docking sites for specific signal transducers and activators of transcription (STATs), 
(Stahl et al., 1995, Hemman et al., 1996). IL- 6  activated gpl30 has two tyrosine motifs 
within the cytoplasmic tail that specifically mediate STAT3 activation and two other 
motifs that specifically recruit STAT1 and STAT3 (Gerhartz et al., 1996). The highly 
conserved STAT src homology domain (SH2, figure 1.5) determines the binding 
specificity to tyrosine motifs (Hemman et al., 1996). STAT3 seems to be preferentially 
activated compared to STAT1 by cytokine-induced gpl 30 activation regardless of 
which Jak/Tyk kinases are activated (Boulton et al., 1995). Once recruited to the gpl30 
molecule STATs become tyrosine phosphorylated on a specific tyrosine residue
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(Kaptein et al., 1996). This phosphorylation was found to be essential for STAT 
dimerization via the SH2 domain and the dimerization is essential for STAT 
dissociation from the receptor and for its nuclear translocation, DNA binding and gene 
activation (Shuai et al., 1993, Shuai et al., 1994).
N- m SH2 Transact
f t
Y S
Figure 1.5. The structural organisation of STAT molecules.
N=N-terminal, DNA=DNA binding domain, SH2=Src homology 2 domain, Transact=transactivation 
domain, Y=tyrosine residue & S=serine residue that undergo phosphorylation.
STAT1 and STAT3 can form homo- or hetero-dimers that are probably translocated to 
the nucleus via associated shuttle proteins with nuclear localisation sequences (NLSs). 
STATs themselves do not seem to contain any conventional NLSs (Heinrich et al., 
1998). More recently in transfection studies, Zhang and Darnell (2001) have 
demonstrated that tetrameric complexes of STAT3, forming via N-terminal domain 
interactions, were required for maximal IL- 6  induction of the acute phase protein 
promoter a2-macroglobulin. Serine/threonine protein kinases in the cytoplasm result in 
phosphorylation of STAT1 and STAT3 and this augments their transactivating 
potential (Wegenka et al., 1993, Boulton et al., 1995, Wen and Darnell, 1997). Serine 
phosphorylation of STAT may regulate the DNA binding of some STAT dimer 
combinations (STAT3 homo-dimers), but not of others (STAT1 homo-dimers or 
STAT1/STAT3 hetero-dimers), (Zhang et al., 1995). The DNA-binding domain is 
located centrally in the STAT dimer (figure 1.5) and may be stabilised by the SH2 
phosphotyrosine domains (Chen et al., 1998a). The DNA element recognised is 
principally determined by the STATs involved (Seidel et al., 1995, Lamb et al., 1995). 
STAT1 and STAT3 preferentially bind a six base sequence (TTCN3GAA) with the 
central spacing of the two halves of the recognition site being critical. STAT1 and 
STAT3 induce a range of target genes including acute phase protein genes, 
transcription factors, apoptosis regulators and gpl30.
The signal transduction of IL- 6  via gpl30 and the negative regulatory mechanisms 
involved are summarised in figure 1 .6 .
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Figure 1.6. The signal transduction pathway of IL-6 via gpl30 and negative regulatory 
mechanisms (adapted from Heinrich et al., 1998).
Dimerisation o f gp l30 by binding o f IL-6/IL-6R results in recruitment & activation of cytoplasmic Janus 
kinases (Jaks). Phosphorylation o f specific tyrosines in the cytoplasmic tail o f gp l30 allows signal 
transducers and activators of transcriptions (STAT1 & STAT3) to dock and become tyrosine 
phosphorylated. STAT phosphorylation is essential for dimerisation o f STAT molecules and for nuclear 
translocation via a shuttle protein containing a nuclear localisation signal (NLS). Further phosphorylation 
via serine/threonine protein kinases may influence STAT DNA binding. Dephosphorylation o f STAT 
occurs in the nucleus via tyrosine phosphatases. The two SH2 domain-containing tyrosine-phosphatase 
(SHP2) is also recruited, phosphorylated and activated by gp l30 signal transduction, dependent on 
phosphoryplation o f gpl 30 tyrosine-759 and the presence o f Jakl. Activated SHP2 can bind growth factor 
receptor bound protein (grb2) and activate the mitogen-activated protein kinase (MAPK) pathway in 
some cells. The MAPK pathway can inhibit tyrosine phosphorylation of STATI, gp l30 and SHP2. SHP2 
has inhibitory effects on the Jaks, STATs & gpl30. STAT specific protein inhibitors of activated STATs 
(PIAS) bind & inhibit activated STATs. Suppressors o f cytokine signalling (SOCS), induced by the 
Jak/STAT pathway inhibit tyrosine phosphorylation of STATs & gp!30.
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1.1.7. Negative regulation of IL-6 signal transduction
STAT activation is transient. Phosphorylated STATs enter the nucleus and then return 
to the cytoplasm in a dephosphorylated (de-activated) state (Haspel et al., 1996). 
Tyrosine phosphatases in the nucleus are required for dephosphorylation of STAT1 
(Haspel and Darnell, 1999). Dephosphorylation by these phosphatases requires the N- 
terminal region of STAT1, as N-terminal mutants of STAT1 did not undergo nuclear 
dephosphorylation, resulting in prolonged phosphorylation. Three families of proteins 
are involved in the down-regulation of IL-6 signalling; SH2 domain-containing 
protein-tyrosine phosphatases, protein inhibitors of activated STATs (PIAS) and 
suppressors of cytokine signalling (SOCS).
Signal transduction through gpl 30, in addition to activation of Jaks and STATs, results 
in recruitment and activation of the two-SH2 domain-containing tyrosine-phosphatase 
SHP2 (Schaper et al., 1998). This SHP2 activation is dependent on the presence of 
phosphotyrosine-759 (Tyr 759) in the cytoplasmic domain of gpl 30 and requires Jakl. 
The main effect of SHP2 seems to be as an inhibitor of IL-6 induced Jak/STAT 
activation. Mutation of the gpl 30 recruitment site for SHP2, preventing its recruitment 
and activation, resulted in elevated and prolonged activation of STAT1 and STAT3, 
Jaks and gpl30 (Kim et al., 1998, Schaper et al., 1998). Only one SHP2-recruiting 
Tyr-759 was required on the cytoplasmic tail of dimerized gp l30 to allow SHP2 
association with g p l30 and attenuate IL-6 signal transduction (Anhuf et al., 2000). The 
Tyr-759 did not have to be on the same gpl30 molecule in the dimer as the STAT 
recruitment sites. There is evidence that modulation of Jaks and STATs occurs via 
direct interaction with SHP2, as in vitro at least, binding to SHP2 has been 
demonstrated (Yin et al., 1997). In addition, phosphorylated SHP2 can bind the growth 
factor receptor bound protein (grb2), and links to activation of the mitogen-activated 
protein kinase (MAPK) pathway, which is activated in some IL-6-stimulated cells. 
MAPK stimulated by phorbo-13-myristate-12-acetate (PMA) inhibited IL-6 induced 
STAT3 activation and inhibited tyrosine phosphorylation of STAT1, gpl30 and SHP2 
(Terstegen et al., 2000). The inhibitory effect of MAPK was dependent on the Tyr-759 
residue of gp l30 indicating a requirement for SHP2 recruitment. The grb2-associated 
binder 1 (gabl) protein, involved in activation of the MAPK cascade, becomes 
tyrosine phosphorylated by IL-6 activation of gp l30 and can then bind to SHP2 and 
phosphatidylinositol 3-kinase (Takahashi-Tezuka et al., 1998). Although no direct
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interaction is required between gp l30 and gabl, the Tyr-759 residue of gp l30 is 
required, indicating that activated SHP2 is required for the interaction. Gabl binding to 
SHP2 leads to activation of ERK2 MAPK. The functional significance of Tyr-759 has 
been demonstrated in a mouse strain generated to contain a gpl30 knock-in point 
mutation of Tyr-759. These mice died sooner and at a higher rate than controls when 
exposed to Listeria infection (Kamimura et al., 2002).
Protein inhibitors of activated STATs (PLAS) are important regulators of the Jak/STAT 
pathway. PLAS bind to a specific STAT molecules only after ligand stimulation and 
once bound are able to block STAT-DNA binding and gene activation (Chung et al., 
1997, Liu et al., 1998). PIAS1 is specific for STAT1, requiring the STAT1 
phosphotyrosine-701 (figure 1.5) for interaction, the same phosphotyrosine that is 
critical for STAT dissociation from gp l30 and formation of STAT dimers. PIAS3 is 
specific for STAT3. Another member of the PLAS family, PLASy, inhibits STAT1 
gene activation though not DNA-binding (Liu et al., 2001). Methylation of STAT1 by 
methyltransferases reduces STAT1 interaction with PLAS, permitting increased DNA 
binding (Mowen et al., 2001). The methylation is independent of tyrosine or serine 
phosphorylation. Though complex interactions are clearly involved in STAT inhibition 
by PIAS, little is known at present about the mechanism o f the inhibitory actions.
A further negative regulatory mechanism for IL-6 signalling is induced by Jak/STAT 
pathway activation. This induces suppressors of cytokine signalling (SOCS), leading to 
feedback inhibition of STATs, Jaks and gpl30 by inhibition of their tyrosine 
phosphorylation by Jaks (Naka et al., 1997). SOCS family members share a common 
C-terminal domain (the SOCS box) but have different lengths of N-terminal domain 
(figure 1.7). The N-terminal domain is required for activity, though for SOCS1 and 
SOCS3 this region is functionally interchangeable (Nicholson et al., 1999). The 
conserved SOCS box can mediate SOCS binding to elongins B & C, and may target 
SOCS with coupled proteins such as Jak2 to proteasomal degradation (Zhang et al., 
1999, Ungureanu et al., 2002). SOCS family members also contain an SH2 domain 
preceding the SOCS box that is involved in their inhibitory function via interaction 
with respective targets. In the case of SOCS1, an inhibitor of STAT1 and STAT3, the 
SH2 domain interacts directly with the kinase domain of Jak2 (Endo et al., 1997). In 
the case of SOCS3, the SH2 domain recognises the phosphotyrosine-759 of gpl 30, the
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binding site for SHP2 and can reduce SHP2 phosphorylation (Schmitz et al., 2000). 
Expression of SOCS family members SOCS1, 2, 3 and cytokine inducible SH2 protein 
(CIS) can be induced by IL-6 . However, SOCS1, 2, 3 & 5 inhibit IL- 6  signalling (Starr 
et al., 1997, Nicholson et al., 1999). SOCS proteins may have an additional role in 
mediating cross-communication between cytokine signalling pathways. They inhibit 
the signalling of other cytokines that influence expression levels of IL- 6  and IL- 6  
signal transduction mediators, for example, TNFa can inhibit IL-6 -induced STAT3 
activation via up-regulation of SOCS3 in macrophages (Bode et al., 1999).
N- SH2 SOCS
Figure 1.7. The structural organisation of SOCS molecules.
N=N-terminal domain, SH2=Src homology 2 domain, SOCS=conserved SOCS box.
Mechanisms of inhibition of IL- 6  signalling that are independent of Jak/STAT 
pathways have also been demonstrated (Thiel et al., 1998). Rapid removal of 
radiolabelled IL- 6  from the circulation was observed in rat hepatocytes, T-cells and 
macrophages, with internalisation and degradation of cell surface bound IL- 6  (Sonne et 
al., 1990, Munck et al., 1990). This effect is IL-6 R dependent and results from 
endocytosis of the IL-6/IL-6R/gpl30 complex (Zohlnhofer et al., 1992). 
Replenishment of IL- 6  binding sites on the cell surface required de novo protein 
synthesis. Truncated forms of the cytoplasmic domain of gpl30, but not IL-6 R, 
prevented IL6 -receptor complex endocytosis, with the di-leucine internalisation motif 
of gpl30 sufficient to mediate and target endocytosis to lysosomes (Dittrich et al.,
1996). Though internalisation of gpl 30 can occur independent of ligand binding, it is 
modulated by phosphorylation of the serine residue at position 782, adjacent to the di­
leucine motif (figure 1.3, Gibson et al., 2000). Mechanisms of inhibition of IL- 6  
signalling are still not fully understood, however they are clearly of major importance 
in regulating the effects of IL-6 .
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1.1.8. Soluble IL-6R and soluble gpl30
Soluble forms of IL-6R (sIL-6R) and gp l30 (sgpl30) are found in human plasma. 
Although the soluble form of IL-6R can be generated by proteolytic cleavage of the 
membrane bound receptor, in vivo, both sIL-6R and sgpl30 are also generated by 
translation of alternatively spliced mRNA transcripts (Mtiller-Newen et al., 1996, 
Diamant et al., 1997). In the presence of IL-6, sIL-6R can combine with membrane- 
bound gpl30 (mgpl30) to initiate signal transduction and in this way function as an 
agonist. This contrasts to many other cytokine soluble-receptors which act as 
antagonists of cytokine activity by blocking cytokine binding to cell-surface receptors. 
sIL-6R can therefore widen the effects of IL-6 in some cells that only have mgpl30 but 
not membrane bound IL-6R. However, sgpl30 antagonises IL-6/sIL-6R signal 
transduction by competing for binding to mgpl30 and sIL-6R enhances the 
neutralising effect of sgpl30 (Mtiller-Newen et al., 1998). It is therefore not clear 
whether sIL-6R plays a predominantly agonist or antagonist role in vivo. The relative 
concentrations of sIL-6R, sgpl30 and mgpl30 may be a deciding factor. In conditions 
where high plasma levels of sIL-6R occur, it is more likely to act as an agonist, 
enhancing IL-6 signalling via mgpl30. Hence, sIL-6R has the potential to regulate 
both local and systemic IL-6 effects.
1.2. Biological and pathological effects of IL-6
In common with other cytokines, IL-6 acts as an intercellular communicator in multi- 
cellular organisms, regulating target cell functions, at nanomolar to picomolar 
concentrations. In response to a myriad of immunological stimuli, it is rapidly 
synthesised by cells in secretory form and released without storage. In keeping with 
the diversity of cells expressing IL-6 and IL-6R, the actions of IL-6 are diverse.
1.2.1. IL-6 as a B-cell differentiation and growth factor
IL-6 plays a crucial role in the maturation of B-cells to immunoglobulin-secreting 
plasma cells (Takatsu, 1997). The principal factor from rheumatoid synovium found to 
induce B-cells to secrete immunoglobulins, was IL-6 produced by synovial monocytes 
(Nawata et al., 1989). C57BL/6 mice transgenic for the human IL-6 gene had massive 
polyclonal plasmacytosis with associated hypergammaglobulinaemia (Hirano et al., 
1992). Although IL-6 deficient mice had normal levels of anitgen-specific 
immunoglobulin (IgM), levels of IgG isotypes were reduced (Kopf et al., 1998). Re­
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exposure of cultured cells from the germinal centres of these IL-6 deficient mice to IL- 
6 resulted in increased levels of antibody production. In humans, IL-6 is implicated in 
the hypergammaglobulinaemia associated with atrial myxoma (a benign intra-arterial 
neoplasm) and multicentric Castleman’s disease (a lymphoproliferative disorder of 
mononuclear cells) with both conditions producing high levels of IL-6 (Parissis et al., 
1996, Nishimoto et al., 2000). Surgical removal of the tumour in the case of atrial 
myxoma, or treatment with anti-IL-6R blocking antibodies in the case of Castleman’s 
disease resulted in remission of clinical disease and normalisation of gammaglobulin 
levels. In peripheral blood mononuclear cells (PBMCs) from patients with systemic 
lupus erythematosus (SLE), IL-6 neutralising antibody produced a 30% reduction in 
spontaneous polyclonal IgG production and a 44% reduction of IgG mAb production 
(Linker-Israeli et al., 1991).
IL-6 has been shown to induce IgM, IgG and IgA synthesis without affecting B-cell 
proliferation and it can enhance IL-4-dependent T-cell driven IgE production by 
immature B-cells in vitro (Muraguchi et al., 1988, van Kooten et al., 1990 and Bjorck 
et al., 1998). Two mechanisms seem to be involved, transcriptional up-regulation of 
the immunoglobulin gene (Tanner and Tosato, 1992) and altered transcriptional 
termination to select secretory rather than membrane-specific polyadenylation sites 
(Raynal et al., 1989). The transcription factors Oct-2 and C/EBPp can be induced by 
IL-6 in B-cells, both having specific binding sites in the 5’-flanking region of the 
immunoglobulin gene with enhancer actions (Natkunam et al., 1994, Cooper et al.,
1992). In a chicken B-cell line, over-expression of the polyadenylation/cleavage 
stimulation factor CstF-64 was sufficient to switch IgM heavy chain expression from 
membrane-bound to the secreted form (Takagaki et al., 1996). In a human B-cell line 
however, IL-6 induced switching to secretory Ig mRNA by shifts in poly(A) site 
preference and occurred without an increase in CstF-64 (Martincic et al., 1998).
In addition to induction of immunoglobulin secretion, EL-6 can act as a B-cell growth 
factor, stimulating the growth of B-cell and plasma cell tumour lines from multiple 
myelomas, non-malignant plasmablasts, B-cell lymphomas, and chronic lymphocytic 
leukaemias (Wang et al., 2001, Jego et al., 2001, Eray et al., 2003).
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Furthermore, IL-6 is implicated in autoantibody production in SLE and systemic 
sclerosis (SSc). In a mouse model of SLE induced by pristane, high levels of IgG 
autoantibodies were produced to ssDNA, dsDNA and chromatin in IL-6 competent 
mice, but not IL-6 knockout mice (Richards et al., 1998). The generation of other 
autoantibodies (anti-nRNP/Sm and anti-Su) were not affected by the absence of IL-6, 
suggesting that there may be IL-6-dependent and IL-6-independent mechanisms of 
autoantibody generation. In vitro studies of the ability of Topoisomerase I specific T- 
cell clones from patients with SSc to induce HLA-DR matched SSc B-cells to produce 
anti-topoisomerase I antibodies showed close correlation to the IL-2 and IL-6 
producing ability of the T-cells (Kuwana et al., 2000). In kinetic studies, IL-6 was 
found to be important in the late phase of the T-cell dependent B-cell activation. In 
summary, IL-6 has important roles in B-cell differentiation, proliferation and antibody 
production.
1.2.2. IL-6 as a macrophage differentiation factor
Monocytes from the circulation, attracted to an area of inflammation or injury that 
facilitates crossing of the endothelium, will differentiate under local tissue influences 
into either dendritic cells or macrophages. It has been reported that IL-6 released by 
fibroblasts during monocyte-fibroblast contact resulted in preferential differentiation of 
monocytes into CD14+CDla- macrophage phenotype cells displaying characteristic 
macrophage morphology with numerous vacuoles (Chomarat et al., 2000). This was 
despite culture in the presence of granulocyte macrophage-colony stimulating factor 
(GM-CSF) and IL-4 that favours dendritic cell formation (CD14-CDla+, high HLA- 
DR expressing cells). Anti-IL-6 and anti-IL-6R blocking monoclonal antibodies 
(mAbs) prevented fibroblast induced macrophage differentiation, favouring dendritic 
cell differentiation. The mechanism of IL-6 induced macrophage differentiation was 
via up-regulation of functional macrophage-colony stimulating factor (M-CSF) 
receptors on monocytes. Neutralisation of M-CSF activity with anti-M-CSF or anti-M- 
CSFR blocking antibodies prevented IL-6-mediated macrophage differentiation.
Although IL-6 does not induce maturation of dendritic cells, it may have a role in the 
generation of auto-immunity by allowing dendritic cells to present previously cryptic 
and weakly presented epitopes to T-cells, resulting in an antigenic response 
(Drakesmith et al., 1998). Dendritic cells treated ex-vivo with IL-6 and exposed to the
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antigen hen-egg lysozyme (HEL), once injected into mice were able to prime T-cells in 
vivo against cryptic epitopes. Mice immunised with HEL and incomplete Freund’s 
adjuvant together with IL-6 exposure, also produced T-cell responses to cryptic 
determinants. The IL-6 treated dendritic cells contained endosomes that were more 
acidic than control dendritic cells and this may have resulted in altered processing and 
presentation of antigen.
1.2.3. IL-6 as a T-helper cell proliferation and differentiation factor 
As well as potential influences on antigen presentation to T-cells, IL-6 acts as a potent 
enhancer of the proliferation of naive CD4+ T-helper (TH) cells (Joseph et al., 1998). 
TH cells are classified into TH1 and TH2 subsets based on the cytokines they produce. 
TH1 cells produce IL-2, interferon-y (IFNy) and tumour necrosis factor- 
p. (TNFP), cytokines involved in regulation of cell-mediated immune responses. TH2 
cells produce IL-4, IL-5, IL-6, IL-10 and IL-13, cytokines that mediate T-cell 
dependent B-cell activation and antibody production. The local cytokine environment 
plays a critical role in determining TH1 and TH2 differentiation. IL-12, IL-18 and 
IFN-y direct differentiation to the TH1 phenotype and IL-4 produces TH2 phenotypic 
differentiation (Murphy, 1998). IL-6-deficient mice fail to efficiently control infections 
with facultative intracellular pathogens due to impaired T-cell dependent antibody 
mediated responses (Kopf et al., 1994, Anguita et al., 1997). Studies of TH2 specific 
response to injected Schistosoma eggs in EL-6 deficient mice, have shown that though 
IL-6 is not essential for TH2 cell differentiation it is important for TH-proliferation, 
possibly through induction of the IL-2 receptor (La Flamme et al., 1999). Rincon et al. 
(1997) showed that IL-6 could modulate the TH phenotype. IL-4 production was 
significantly less in naive TH cells differentiated in the presence of antigen presenting 
cells (APCs) from IL-6 deficient mice compared to in the presence of wild-type (IL-6 
producing) APCs. Anti-IL-4 mAbs blocked IL-6 induced TH2 differentiation in the 
presence of IL-6 or IL-4, and mRNA transcripts of EL-4 were 100-fold higher in TH 
cells differentiated with IL-6 or IL-4. There was no evidence of differential distribution 
of IL-6R between TH sub-types to account for differential response to EL-6. These 
results support a role for EL-6 as a TH2 differentiation factor, mediated via up 
regulation of IL-4 expression.
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In addition to stimulation of TH2 differentiation, IL-6 has been reported to inhibit TH1 
differentiation. IL-6 inhibited IFNy production and stimulated IL-4 synthesis by TH1 
cells differentiated with IL-12 (Rincon et al., 1997). The inhibition of IFNy production 
by IL-6 was independent of IL-4. It was not blocked by anti-IL-4 mAbs, though IL-4 
synthesis was blocked (Diehl et al., 2000). IFNyR-/- CD4+ T-cells, from IFNyR 
deficient mice, prevented IL-6 from inhibiting TH1 differentiation, although IL-6 
treatment itself did not affect levels of IFNyR expression on wild-type CD4+ T-cells 
during activation (Diehl et al., 2000). STAT1, the main signal transducer for IFNyR, 
showed decreased levels of tyrosine phosphorylation (indicative of reduced activation), 
in the presence o f IL-6 when wild-type CD4+ T-cells were stimulated with IFNy. This 
IL-6 inhibition of IFNy-induced STAT1 phosphorylation was prevented by SOCS1 
deficient CD4+ T-cells. STAT3, a known mediator of IL-6-induced SOCS1 expression 
was unregulated in activated CD4+ T-cells in the presence of IL-6. IL-6 inhibition of 
TH1 differentiation therefore seems to be mediated by increased expression of SOCS1 
because of IL-6-induced STAT3 expression. SOCS1 expression then reduces 
signalling via IFNyR and results in reduced autocrine production of IFNy.
A different group, found that IL-6 only augmented IL-4 synthesis and inhibited IFNy 
production in primed CD4+ T-cells from wild-type and IL-6 deficient mice, but 
inhibited IL-4-induced TH2 differentiation in naive T-cells (Tanaka et al., 2001). The 
nature of the antigenic stimulus may be important in determining TH cell response to 
IL-6. IL-6 deficient mice infected with Candida albicans showed preferential 
augmentation of the TH2 response (Romani et al., 1996), whereas IL-6 deficient mice 
infected with Streptococcus pneumoniae or injected with lipopolysaccharide (LPS) 
showed augmented IFNy synthesis, associated with a TH1 response (Poll et al., 1997, 
Xing et al., 1998). IL-6 appears to have a complex role in T-cell differentiation and 
proliferation.
1.2.4. IL-6 and bone metabolism
Bone metabolism is regulated by a balance between osteoclast-induced bone resorption 
and osteoblast derived bone formation. Ishimi et al. (1990) showed that IL-6 was 
produced by a murine osteoblast cell line, inducible by agents such as IL-1, TNF, LPS 
and parathyroid hormone (PTH), (Greenfield et al., 1993). PTH is a key regulator of
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bone metabolism in response to serum calcium levels. IL-6 appears to act as a 
downstream effector of PTH as neutralising IL-6 antibodies block PTH-induced bone 
resorption (Greenfield et al., 1995). IL-6 stimulates osteoclast formation and 
activation. Murine bone cultures with IL-6 exposure had three-times more osteoclasts 
than control cultures grown without the addition of IL-6, and osteoclast calcium efflux 
was stimulated in a dose dependent manner by IL-6 (Ishimi et al., 1990). The IL-6R is 
necessary for IL-6 induced osteoclast formation from bone marrow (Tamura et al.,
1993). Interestingly, IL-6R expression was required on osteoblasts rather than 
osteoclasts, indicating that the IL-6 effect on osteoclastogenesis is mediated via 
osteoblasts, at least ex vivo (Udagawa et al., 1995). The mechanisms by which IL-6 
may mediate bone cell effects is unknown. However, an inter-play between cytokines 
and their signalling systems is likely to be involved. Neutralising antibodies to IL-1 
inhibited recombinant IL-6-induced osteoclast differentiation from normal human bone 
marrow cultures (Kurihara et al., 1990). In turn, it has also been shown that 
antagonism of IL-6R signalling can inhibit the effects of IL-1 and TNF-induced 
osteoclastogenesis (Devlin et al., 1998).
Serum from patients with Paget’s or Gorham-Stout disease, conditions characterised 
by increased bone remodelling and osteolysis, were found to stimulate osteoclast-like 
multinucleated cell formation from normal bone marrow cultures (Roodman et al., 
1992, Devlin et al., 1996). The sera from these patients contained high levels of IL-6 
when compared to normal controls, and neutralising antibody to IL-6 was able to block 
induced osteoclast formation by disease serum. Osteoblast levels of mRNA for IL-6, 
IL-6R and C/EBPp (an EL-6 transcription factor, see section 1.3.2.2) were significantly 
higher from Pagetic bone than from non-Pagetic bone (Hoyland et al., 1994). In 
addition, osteoclasts from Pagetic bone expressed IL-6 mRNA where as osteoclasts 
from control bone did not. Ex vivo studies on mouse parietal bone confirmed 
osteoblasts and stromal cells, rather than osteoclasts, as the main source of IL-6 in 
normal bone (Holt et al., 1996). There is indirect evidence that IL-6 plays a role in 
pathological bone resorption in rheumatoid arthritis (RA). This inflammatory 
arthropathy is associated with periarticular osteopenia and bony erosions of affected 
joints. IL-6 mRNA expression was found to be significantly elevated in the absence of 
elevation of other pro-inflammatory cytokines, IL-1 p and TNFa, in periarticular 
cancellous bone from RA patients with radiological bone loss (Sugiyama, 2001).
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Osteoblast-lineage cells derived from RA affected bone produced higher IL-6 
expression than osteoblast-lineage cells derived from non-RA bone.
In a murine model of post-menopausal osteoporosis, oestrogen loss as a result of 
oophorectomy resulted in increased osteoclast development, increased bone turnover 
and a significant loss in bone mass (Poli et al., 1994). IL-6 was essential for this 
process as IL-6 deficiency in IL-6 knockout mice undergoing the same procedure, 
completely prevented the bone changes. Interestingly, the IL-6 knockout mice had 
normal amounts of trabecular bone, but had higher rates of bone turnover (formation 
and resorption) when compared to control mice. This may be due to increased numbers 
of osteoblasts and osteoclasts. Mice transgenic for human IL-6 had reduced numbers of 
osteoblasts, osteoblast precursors and osteoclasts, with suppressed bone turnover 
(formation and resorption), (Kitamura et al., 1995). This indicates a complex role for 
IL-6 in the metabolism of bone in vivo. Although the predominant effects of IL-6 
appear to be on osteoclasts, this may require osteoblasts to mediate the IL-6 effects, as 
was seen in vitro. Oestrogen has an inhibitory effect on IL-6 expression (see section 
1.3.2.6), so its removal by oophorectomy in the murine model of postmenopausal 
osteoporosis (Poli et al., 1994) would permit IL-6 levels to rise and increase bone 
resorption. In support of this in humans, oestrogen-deficient women when compared to 
oestrogen competent women, were found to have significantly higher levels of IL-6 
expression from bone marrow aspirates (as well as other bone-resorbing cytokines), 
(Bismar et al., 1995). In a longitudinal study of 137 post-menopausal women, serum 
levels of IL-6 were highly predictive of femoral bone loss during the first decade past 
menopause in nonusers of hormone replacement therapy, and was independent of 
potential confounders or plasma sex hormone levels (Scheidt-Nave et al., 2001). Bone 
explants from patients with osteoporotic vertebral fractures show enhanced IL-6 
mRNA expression (Ralston, 1994). Recently, IL-6 genotypes associated with lower IL- 
6 expression have been associated in postmenopausal women with lower bone 
resorption and reduced loss of bone mass, and in healthy pubertal men with higher 
peak bone mass (Ferrari et al., 2001, Lorentzon et al., 2000, discussed in section 6.9).
The effects of IL-6 on physiological and pathological bone resorption can at least in 
part be explained by the induction of receptor activator for nuclear factor (RANK) 
ligand on the cell surface of osteoblasts and stromal cells (Horowitz et al., 2001).
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RANK ligand (RANKL) interacts with RANK expressed on osteoclast-precursors and 
induces terminal differentiation into mature osteoclasts with bone-resorbing function.
1.2.5. IL-6 and growth retardation
IL-6 transgenic mice (of the rat neurospecific enolase promoter-hIL-6 construct), 
expressing high levels of circulating human IL-6 from shortly after birth, v/ere found 
to be 50-70% smaller than non-transgenic littermates (De Benedetti et al., 1997a). This 
growth retardation could be partially prevented by blocking the actions of IL-6 with 
administration of anti-murine IL-6 receptor antibodies. The mechanism is probably via 
the inhibition of insulin-like growth factor-1 (IGF-1) before completion of skeletal 
growth. Serum levels of IGF-1 were significantly reduced in the IL-6 transgenic mice, 
while circulating and pituitary cell growth hormone levels were normal. IL-6 
administered to non-transgenic mice produced a reduction in IGF-1 levels. In children 
with systemic arthritis-associated growth retardation, reduced circulating IGF-1 levels 
have been reported and found to negatively correlate with the degree of active 
inflammation, which in turn correlates with the levels of IL-6 (Davies et al., 1997).
1.2.6. IL-6 and the acute phase response
Both acute and chronic inflammation trigger a series of systemic reactions 
characterised by altered hepatic production of a family of proteins called the acute 
phase proteins (APPs), the process known as the acute phase response (APR). APPs 
mediate various inflammatory functions: inhibition of phagocyte-derived proteases and 
cathepsins (ai-antitrypsin, ai-antichymotrypsin, haptoglobulin), control of 
inflammatory mediator pathways (antithrombin III, complement C l, factor I and factor 
H), activation of clotting (factor VIII, prothrombin and fibrinogen), activation and 
opsonisation of complement (plasminogen and C-reactive protein), chemotaxis and 
mast cell degranulation (complement components), free-radical scavenging 
(caeruloplasmin), removal of cellular debris (haptoglobulin, C-reactive protein) and 
promotion of fibroblast growth (ai-acid glycoprotein), (Banks et al., 1998). These 
APPs can be classified into two types depending on the main inducing cytokine 
stimulus (Baumann and Gauldie, 1994). Type-1 APPs, including C-reactive protein, 
complement component C3, serum amyloid A protein and ai-acid glycoprotein, are 
mainly induced by IL-1 and TNF, but can also be induced by IL-6. IL-6 synergistically
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enhances IL-1- and TNF-mediated production of type-1 APPs. In contrast, type-2 
APPs, including fibrinogen, ai-antitrypsin, ai-antichymotrypsin, haptoglobulin and 
caeruloplasmin, are specifically induced by IL-6, with IL-1 or TNF having little effect. 
IL-6 therefore plays a key role in mediating activation of the acute phase response and 
the resultant effects.
1.2.7. IL-6 as a thrombopoietic factor
In mice, monkeys and humans IL-6 is a potent thrombopoietic factor stimulating 
megakaryocytopoiesis and thrombocytosis. Recombinant human IL-6 (rIL-6) increased 
the size and proportion of megakaryocytes (platelet producing stem cells) in the bone 
marrow of mice after 48-72 hours of treatment (Hill et al., 1991). Mice implanted with 
an IL-6 secreting murine fibroblast, developed elevated peripheral blood platelet 
counts and increased numbers of megakaryocyte-colony forming units in the bone 
marrow and spleen (Cao et al., 1998). In primates, rIL-6 alone produced a 2 to 3 fold 
increase in platelet count, with no additional synergy from concomitant administration 
of IL-3, GM-CSF or LIF (Zeidler et al., 1993). Monkeys that had undergone bone 
marrow irradiation and received rIL-6 therapy underwent a shortened time of 
thrombocytopenia (3 days instead of 5) compared to irradiated animals with the same 
degree o f thrombocytopenia that did not receive rIL-6. Megakaryocyte numbers were 
not altered by IL-6 treatment in healthy or irradiated animals but the ploidy of the 
megakaryocytes was increased, indicating a stimulation of megakaryocytes to rapidly 
produce platelets. Though IL-6 is not the main inducer of megakaryocytopoiesis and 
thrombocyte production, these roles are fulfilled by megakaryocyte-colony stimulating 
factor and thrombopoietin (TPO). IL-6 clearly has modulatory effects on platelet 
production and may account for the secondary thrombocytosis seen in association with 
many inflammatory conditions. Levels of IL-6 and associated biological activity 
closely correlate with circulating platelet counts in inflammatory conditions in humans 
(Gastl et al., 1993, Heits et al., 1999). Subcutaneous rIL-6 in a phase 1 trial for the 
treatment of refractory cancer produced a dose-related induced thrombocytosis 
(Olencki et al., 2000). A polymorphism in the 5’-flanking region of IL-6, associated 
with lower levels of IL-6 transcription, correlated with lower circulating platelet counts 
in healthy subjects (Fernandez-Real et al., 2001). The effects of IL-6 on 
thrombopoiesis appear to be mediated by TPO. IL-6-induced thrombopoiesis could be 
abrogated in mice by neutralising antibodies to TPO (Kaser et al., 2001), and plasma
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TPO levels were elevated in cancer patients who had received rIL-6. Hepatic TPO 
mRNA was induced by IL-6 in human hepatoma cell lines (Wolber and Jelkmann, 
2000). It remains unclear however whether IL-6 has a role in the normal 
thrombopoiesis in man.
1.2.8. Anti-inflammatory effects of IL-6
IL-6 is critically involved in the generation of the immune response via effects on T- 
cells, B-cells, macrophages, induction of the acute phase response, fever and 
corticosteroid release. Use of neutralising antibodies to IL-6 in chronic inflammatory 
conditions such as rheumatoid arthritis has shown reduction in joint damage and 
clinical indices of inflammation (discussed in section 1.2.9). IL-6 may in addition have 
anti-inflammatory or inflammation modulatory functions, particularly in acute 
inflammation. IL-6 knockout mice (-/-) with local endotoxin-induced acute lung 
inflammation or systemically induced endotoxaemia had significantly worse markers 
of acute inflammation and lower survival rates than IL-6 competent mice (Xing et al.,
1998). Levels of pro-inflammatory cytokines were significantly higher in IL-6 -/- mice 
after induced inflammation (TNFa and macrophage inflammatory protein (MIP)-2 in 
lung injury, TNFa, MIP-2, GM-CSF and IFNy in endotoxaemia) with an associated 
higher neutrophilic response. Similar results were reported for mice induced to develop 
pneumococcal meningitis. Increased levels of TNFa, IL-ip and MIP-2 mRNA and 
increased cerebrospinal fluid leukocytosis was detected in the brain of IL-6 -/- mice 
compared with IL-6 competent wild-type animals (Paul et al., 2003). Administration of 
rIL-6 to IL-6 -/- mice abolished these differences. In hyperoxic acute lung injury, 
transgenic IL-6 mice over-expressing IL-6 in the lung, showed enhanced survival 
compared to wild-type mice (Ward et al., 2000). Improved survival correlated with 
significant reduction in endothelial and epithelial damage, reduced cell-death and 
diminished DNA fragmentation. Levels of the cell-death inhibitor Bcl-2 and regulator 
tissue inhibitor of metalloproteinase-1 (TIMP-1) were enhanced in the IL-6 transgenic 
mice. In vitro, EL-6 can prevent apoptosis in lymphoid cell-lines via activation of Bcl-2 
(Rollwagen et al., 1998). In vivo, in mice with haemorrhagic shock induced intestinal 
apoptosis, mice fed oral IL-6 showed reduced apoptosis and increased Bcl-2 gene 
expression relative to non-IL-6 treated animals. In wild-type mice given intra-tracheal 
injections of endotoxin to induce local inflammation, co-injection with IL-6 was found
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to inhibit the acute neutrophilic infiltrate and resulted in reduced levels of TNFa in 
bronchoalveolar lavage (Ulich et al., 1994). Interestingly, endogenous IL-6 was up 
regulated by IL-6 co-injection suggesting a possible auto-regulatory mechanism. 
Cancer patients who had received rIL-6 in phase 1 and phase 2 trials were found after 
IL-6 infusion to have elevated levels of IL-1 receptor antagonist (IL-IRa) and soluble 
TNF receptor p55 (sTNFRp55), antagonists to the pro-inflammatory cytokines IL-1 
and TNF respectively (Tilg et al., 1994). A neutralising antibody to IL-6 used in mice 
with orally induced Yersinia enterocolitis, showed inhibition of IL-IRa expression 
locally and systemically (Jordan et al., 1995). This anti-IL-6 antibody directly inhibited 
the expression of IL-IRa from macrophages and polymorphonuclear leukocytes in 
culture. Increased bone resorption was seen in dental-pulp induced infection in IL-6 -/- 
mice compared to wild type mice and was associated with an increase in the bone- 
resorptive cytokines, IL-1-a and -p and reduced expression of the anti-inflammatory 
cytokine IL-10 (Balto et al., 2001).
These experiments indicate two main mechanisms by which IL-6 may exert anti­
inflammatory effects in acute inflammation: via induction of apoptosis regulatory 
genes Bcl-2 and TIMP-1 and via induction of pro-inflammatory cytokine antagonists 
IL-IRa and sTNFRp55 with down-regulation of TNF. In chronic inflammation, the 
balance of cytokines may differ and the effect of IL-6 may favour inflammation. 
Different inflammatory stimuli may induce a differing profile of cytokine induction 
with influences on IL-6 effects. IL-6 knockout mice have shown impaired 
inflammatory responses to turpentine and Candida albicans, but preserved or 
exaggerated responses to endotoxin (Fattori et al., 1994, Romani et al., 1996, Xing et 
al., 1998). A paper by Marin and co-workers (2001) suggests that IL-6-sIL-6R may act 
as an intermediate between acute and chronic inflammation in activated endothelium, 
though the context of activation may be relevant. Human umbilical vein endothelial 
cells (HUVECs) activated in vitro with thrombin, induced IL-8 secretion, neutrophil 
infiltration, IL-6 and macrophage chemotactic protein (MCP)-l production. IL-8 
induced IL-6R shedding from neutrophil membranes to produce a rise in sIL-6R levels. 
sIL-6R increased the amounts of MCP-1 produced by activated HUVECs, which could 
be blocked by anti-IL-6 or anti-IL-6R antibody indicating that IL-6 is required as a 
complex with sIL-6R. Increased levels of MCP-1 lead to infiltration by monocytes and 
the establishment of a chronic inflammatory picture. An in vivo model of
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inflammation, antigen-induced arthritis in mice, also supports a role for IL-6 in the 
progression of initial joint inflammation into chronic inflammation (de Hooge et al., 
2000 and discussed below).
1.2.9. IL-6 and arthritis
Mouse models of inflammatory arthritis demonstrate an important role for IL-6 in the 
generation and propagation of inflammatory joint disease. When mice from the 
DBA/1J strain, susceptible to arthritis induced by immunisation with collagen II 
antigens, were crossed with IL-6 knockout mice to prevent IL-6 production, collagen 
induced arthritis was completely abolished (Alonzi et al., 1998). This could not simply 
be explained by a reduction in antibody production involved in the pathogenesis in this 
model. Anti-collagen IgG levels were reduced in IL-6 -/- mice, however IgGl, IgG2a 
and IgG2b isotypes were equally present in IL-6 -/- and IL-6 competent mice 
compatible with disease inducibility. Histological joint examination revealed an 
absence of inflammatory cells and tissue damage in IL-6 -/- mice after collagen 
induction. In another mouse model with a C57BL/6 genetic background, also 
susceptible to antigen-induced arthritis (AIA) with methylated bovine serum albumin 
(mBSA), cross-breeding with IL-6 -/- mice resulted in only mild arthritis and preserved 
articular cartilage, compared to severe arthritis and cartilage destruction in IL-6 
producing littermates (Ohshima et al., 1998). Levels of the pro-inflammatory cytokines 
IL-lp and TNFa were not different between IL-6 -/- and IL-6 competent mice 
suggesting that IL-6 plays a crucial role in induction of arthritis as well as in cartilage 
destruction. Antigen-specific lymph node cell proliferative-responses in vitro and 
antibody production in vivo were present though reduced in IL-6 -/- mice. 
Interestingly, IL-6 -/- lymph node cells produced more TH2 cytokines (IL-4 and IL-10) 
than IL-6 competent lymph node cells, in response to antigen-specific and non-specific 
stimuli in vitro. IL-4 and IL-10 are thought to play a preventative role in arthritis 
generation (Jorgensen et al., 1998). de Hooge and co-workers (2000), found onset of 
inflammation in mBSA injected joints of IL-6 -/- C57BL/6-AIA mice at day 1, which 
then disappeared within 1-week, but which developed into a chronic, severe 
destructive arthritis in IL-6 competent C57BL/6-AIA animals. Even low levels of 
antigen-induction in IL-6 competent mice produced chronic arthritis though only low 
levels of antibody were produced, indicating that lower antibody levels in IL-6 -/- mice 
were not primarily responsible for a milder inflammatory reaction. In IL-6 -/- animals,
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a similar non-sustained inflammatory response was seen in zymosan-induced arthritis 
(ZIA), a non-immunological, irritant-induced arthritis. Inflammation was equal in the 
joints of IL-6 -/- and IL-6 competent ZIA mice at day-7, but cleared from IL-6 -/- 
joints by day-21 while chronic inflammation became established in IL-6 competent 
joints. TNFa, IL-ip, MCP-1, MIP-2, intercellular adhesion molecule (ICAM)-l, 
vascular cell adhesion molecule (VCAM)-l, e- and p-selectin expression were not 
reduced in IL-6 -/- synovium. The type of inflammatory stimulus may be important in 
determining the cytokine profile induced, as with bronchial or intravenous endotoxin 
and cerebral pneumococcus TNF and IL-1 were reduced in IL-6 -/- mice (see section 
1.2.8). Polymorphonuclear cells and macrophages from the IL-6 -/- ZIA mice did not 
display any differences in chemotaxis in vitro compared to IL-6 competent cells. Even 
after transfer of antigen-specific lymph node cells from IL-6 competent ALA mice to 
IL-6 -/- mice, though producing increased acute joint inflammation and cartilage 
damage at day-2, it did not lead to sustained chronic inflammation at day-7 or -14. 
Transfer of antigen-specific lymph node cells from IL-6 -/- AIA mice to other IL-6 -/- 
mice or to IL-6 competent mice, had no influence on joint inflammation. Transfer of 
bone marrow cells from antigen immunised AIA mice was able to establish an arthritis 
in recipient irradiated non-immunised wild type mice, when the donor bone marrow 
cells were from IL-6 competent mice but not from IL-6 -/- mice (Kobayashi et al., 
2002). IL-6 appears to have an important role in maintaining inflammatory infiltrate 
and propagating chronic arthritis. The effects of IL-6 in the acute inflammatory setting 
may be different to the chronic inflammatory environment. Research from de Hooge 
and co-workers (2002) implicates a balance between activation levels of STAT1 and 
STAT3 in influencing the chronicity of arthritis. In the ZIA mouse model, activated 
STAT3 was found in the synovium during the acute and chronic phase of arthritis in 
IL-6 competent mice. Activated STAT1 was only detected in the synovium during the 
chronic inflammatory phase. In IL-6 -/- mice where no chronic arthritis is established, 
no STAT1 activation was detected and only transient STAT3 activation. STAT1 -/- 
ZIA mice developed an increased granulomatous joint inflammation, suggesting that 
STAT1 may have a regulatory role on the inflammatory response in the chronic phase. 
This model suggests that the balance between STAT3 activation, up regulating 
inflammation, and STAT1 activation, down regulating inflammation, both STATs 
induced by IL-6 in the synovium, could influence the switch between acute and 
chronic inflammation. Interestingly, another inflammatory arthritis mouse model, a
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DBA/1 mouse strain expressing the human TNF-a transgene and spontaneously 
developing arthritis, still developed arthritis when crossed with the IL-6 -/- mouse 
(Alonzi et. al, 1998). This suggests that the TNF-a over-expression model may 
represent a different disease process, involving a pathogenic mechanism independent 
of IL-6.
Transgenic mice with a C-terminal gpl30 mutation such that STAT binding and 
signalling were prevented on activation of the gp-130 receptor, developed severe 
destructive joint disease (Ernst et al., 2001). Although at first this may seem 
contradictory to expectation, the mutation resulted in impaired SOCS protein inhibition 
of gp-130 signalling via the SHP-2/ras/Erk MAPK pathway. This indicates the dual 
role for SHP2 in inhibition of the STAT pathway but activation of the MAPK 
pathway. SHP-2 and STAT seem to have mutually inhibitory mechanisms. If both 
SHP2 and STAT binding to gpl30 are inhibited then the net result is reduced signal 
transduction. However, if  only one pathway is blocked as in this model, then the net 
result is loss of inhibition of the other pathway and hence increased signal 
transduction. Increased gpl30 signal transduction resulted in reduced circulating IgA 
and IgG levels, synovial hyperplasia, establishment of chronic joint inflammation and 
cartilage destruction, gastrointestinal ulceration and failure of uterine implantation. An 
enhanced mitotic response was seen in synovial fibroblasts when IL-6 was applied.
Anti-IL-6R antibodies that block IL-6-gpl30 signal transduction have been used in 
animal trials and early clinical trials in humans as potential treatment for arthritis. In 
Cynomolgus monkeys with collagen-induced arthritis, such an antibody infused from 
the day of collagen immunisation resulted in inhibition of the acute phase response and 
suppression of joint inflammation and destruction (Mihara et al., 2001). In two 
randomised controlled trials, adults with active rheumatoid arthritis showed significant 
reduction in joint inflammation and improvement in inflammatory markers after 
treatment with IL-6 neutralising monoclonal antibody therapy (Choy et al., 2002, 
Nishimoto et al., 2002, and discussed in section 6.32). Initial studies of this 
monoclonal antibody therapy in children with systemic arthritis have also shown 
significant reduction in systemic and joint inflammatory symptoms and normalisation 
of inflammatory markers (Yokota et al., 2002, discussed in section 6.32).
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1.2.10. IL-6 and the systemic arthritis form of juvenile idiopathic arthritis
Systemic arthritis (SA) is the most severe and disabling form of a group of arthritides 
that affect children, called juvenile idiopathic arthritis (Laxer and Schneider, 1998). 
Hie annual incidence of juvenile idiopathic arthritis (JIA) in the UK is approximately 1 
in 10,000 with 11% suffering from SA (Symmons et al., 1996), making it one of the 
most common causes of chronic childhood disability. These diseases are characterised 
primarily by arthritis of unknown aetiology persisting for a minimum of 6-weeks, once 
other causes have been excluded. This encompasses a heterogeneous group of 
arthritides that are sub-classified according to the number of joints involved, the 
pattern of extra-articular involvement and the associated features (Petty et al., 1998, 
table 1.1). Many different terms have been used over the years for this group of 
diseases, however international collaboration has now resulted in a unified 
classification as JIA (Petty et al., 1998, Hofer et al., 2001), enabling standardisation 
and comparison of genetic, immunological, epidemiological and therapeutic trial data 
from around the World. Previous terminology included juvenile rheumatoid arthritis 
(American College of Rheumatology, ACR, Cassidy et al., 1986, used in Europe only 
to refer to a specific sub-group of children with rheumatoid factor positive disease), 
juvenile chronic arthritis (European League Against Rheumatism, Wood, 1978) and 
Still’s disease for what is now called SA. The terminology is not interchangeable 
however, underlying the need for a unifying classification such as JIA, as the ACR 
classification juvenile rheumatoid arthritis excludes the sub-type juvenile ankylosing 
spondylitis (JAS), where as, juvenile chronic arthritis includes JAS, but required 3- 
months of arthritis before establishing a diagnosis.
Despite immunosuppressive treatments, many children with JIA (particularly the 
polyarticular and SA forms that tend to be more aggressive) have prolonged active 
disease throughout childhood and into adulthood. This is associated with joint 
destruction, poor function, need for surgical joint replacement and fatality secondary to 
disease and treatment (Wallace and Levinson, 1991, Zak and Pedersen, 2000). Current 
treatment strategies with corticosteroids and immunosuppressive drugs (such as 
methotrexate, sulphasalazine, cyclosporin, cyclophosphamide, azathioprine and more 
recently anti-TNF therapy) are toxic and may be ineffective, particularly in SA. 
However, a more detailed knowledge of factors affecting disease phenotype and 
responsiveness may allow more specific and targeted treatments.
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Systemic Arthritis Arthritis -  any pattern
Daily fever for at least 2 weeks
(documented to be quotidian for at least 3 days)
PLUS one or more of:
• evanescent erythematous rash
• generalised lymph node enlargement
• hepatomegaly and/or splenomegaly
•  serositis
Exclusion by investigation of infectious or malignant disorders
Oligoarthritis Arthritis affecting 1 -  4 joints during the first 6 months of disease 
Can be:
Persistent: never more than 4 ioints involved throughout disease 
Extended: cumulative involvement o f 5 or more ioints after first 6 
months
HLA-B27 negative if  male and > 8 years of age
No family history o f psoriasis or HLA-B27 associated disease
No systemic features
Polyarthritis Arthritis affecting 5 or more joints during first 6 months 
Rheumatoid factor negative
Tests negative for rheumatoid factor, no systemic features 
Rheumatoid factor positive
Positive rheumatoid factor test on 2 occasions at least 3 months apart
Psoriatic Arthritis Arthritis and psoriasis OR 
Arthritis and 2 or more of:
• dactylitis
• nail pitting/onycholysis
• family history of psoriasis 
Rheumatoid factor negative, no systemic features
Enthesitis Related 
Arthritis
Arthritis and enthesitis OR
Arthritis or enthesitis PLUS 2 or more of:
• sacroiliac j  oint tenderness/inflammatory spine pain
• HLA-B27 positive
• family history o f HLA-B27 assoc, disease
• anterior uveitis
• male > 8 years
No psoriasis, no systemic features
Other Arthritis Arthritis o f unknown cause for 6 weeks or more
• not fulfilling criteria for other categories
•  fulfilling criteria for more than one other category
Table 1.1. Classification of Juvenile Idiopathic Arthritis.
International League of Associations for Rheumatology, Durban 1997 (adapted from Petty et al, 1998).
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SA has an equal prevalence between the sexes, with the youngest median age of onset 
of any form of JIA at 4-years of age (Symmons et al., 1996). It is associated with 
extra-articular features and characterised by a cyclical spiking fever, a salmon pink 
rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis, together 
with an acute phase response, anaemia, hypergammaglobulinaemia, thrombocytosis, 
linear growth retardation and osteoporosis (Laxer and Schneider, 1998). IL-6 is 
implicated in the pathogenesis of this disease.
Serum and synovial fluid levels of IL-6 are elevated in patients with SA and are higher 
than levels in other forms of JIA (oligoarticular or polyarticular) or than in adult 
arthritides such as rheumatoid arthritis (De Benedetti et al., 1991, 1992, 1997b, 
Rooney et al., 1995). IL-6 levels correlate with disease activity as determined by the 
number of joints involved and the acute phase response. The levels of other 
inflammatory cytokines such as IL-lp, IL-lra, TNFa, IL-2, IFN-y and -0  did not 
correlate with disease activity in SA (Lepore et al., 1994, De Benedetti et al., 1995). In 
SA, the already elevated serum levels of IL-6 have been shown to rise just preceding, 
and to fall in parallel with, the cyclical fever (Rooney et al., 1995, Prieur et al., 1996). 
IL-lra was found to rise after the fever spike, probably driven by IL-6. The rise in IL-6 
levels in SA were not preceded by a rise in other pro-inflammatory cytokines, IL-1 and 
TNF, known to induce IL-6 production and thought to be the mechanism of elevated 
IL-6 in rheumatoid arthritis (Feldmann et al., 1998). In addition to elevation of IL-6 in 
SA, levels of sIL-6R and IL-6/slL-6R complex are elevated in SA and correlate with 
disease activity (De Benedetti et al., 1994). In two patients with SA in whom IL-6 
levels were shown to correspond to the fever curve, sIL-6R levels also tended to follow 
the fever (Keul et al., 1998). Levels of sgpl30 were no different in SA patients than 
matched controls. The unique IL-6-fever association of SA and the multiple features of 
SA that can be induced by IL-6, implicates IL-6 in the pathogenesis of SA and hence 
the IL-6 gene as a candidate for susceptibility and/or severity of disease.
An estimation of the genetic component of susceptibility to a disease can be derived 
from the ratio of disease prevalence in affected siblings to disease prevalence in the 
general population, Xs. If there were no genetic component, A,s would be expected to 
be 1.0. The higher the value of Xs the stronger the genetic component is likely to be.
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From the JIA affected sib-pairs registry in the US, compared to the prevalence of JIA 
in the general US population, the A,s for JIA as a whole has been calculated as 15, 
suggesting a significant genetic component in these diseases (Glass and Giannini,
1999).
1.3. The human IL-6 gene
The human IL-6 gene is approximately 5 kb in length, consisting of 5 exons and 4 
introns (Yasukawa et al., 1987, figure 1.8). The gene is located on the short arm of 
chromosome 7 at 7p21 (Bowcock et al., 1988). Sequence homology in the coding 
region of the gene is moderately conserved between species (human versus mouse 
65%, human versus rat 68%). However, it is highly conserved in the 5’ flanking 
region, particularly within the first 300bp with greater than 80% homology between 
human and mouse (Tanabe et al., 1988) and highly conserved across other species such 
as rat and bovine (figure 1.9). Humans and mice are thought to have diverged from a 
common mammalian ancestor tens of millions of years ago (Gojobori et al., 1984). It 
has been estimated that random mutational events during this time would have resulted 
in approximately two out of every three nucleotides having been changed. The fact that 
the first 300bp of the 5’-flanking region of IL-6 have been so highly conserved over 
evolution indicates that this region is likely to be important in regulation of the gene.
(5’ flanking region) (3’ flanking region)
3 to +82 +1474 to +1588 +2294 to +2441 +4178 to +4343
-1000 +1 +237 to +427 +1000 +2000 +3000 +4000
 ■ ■ — — ■ — - a — 1------------>-1=1—
Exons 3oobp I II HI IV V
conserved
V /A  transcribed but untranslated flanking regions
Figure 1.8. The human IL-6 gene.
Schematic representation based on sequencing information from Yasukawa et al., 1987. The positions of 
exons are marked in relation to the primary start site o f transcription.
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TGCTTGACAA CAGACAGAAG 
GGAGTGCTTG ATGACAGAAG 
GTGACGGATC TGGCCCAAGT 
GCAGCCAACC TCCTCTAAGT
ATATTTCTGT ACTTCACCCA 
ATATTTCTGT TCTTCACTCC 
GAGCAGGCGC AGGTGAGGAG 
GGGCTGAAGC AGGTGAAGAA
CT. . TTACCC ACCTGGCAAC 
ATAGTAGCCC ACCTGGCAAC 
GAAGCTGGCA GATGCCTCGT 
ATGGCAG.. .  AAGACGCGGT 
ATGGCAG. . .  ACAA. GC. GC
TCCTGGAAAC AACTGCACAA 
TCCTGGAAAC AACTGCACAA 
GGCGGCATTT ATGTGTGAAC 
GGTGGCAAAA AGGAGT. . . C 
GGTGG
AATTTGGAGG TGAACAAACC 
AATTTGGAGG TGAACAAACC 
CCCCACTGCA CCTGGAGACT 
ACACACTCCA CCTGGAGACG
625 -5 9 7  -5 7 2
ATTAGAAACA ACTGGTCCTG ACAAGACACA GGAAAAACAA GCAATAT...... GCAACA TTACTGTCTG T . . . TGTCCA GGTTGGGTGC TGGGG............
ATTAGAAGCA GCTGGTCCTG ATAACATGCA GGAAGAACAA GCAATATGCA GCAGGCATCA CTACTGTCTG TGTGACTCCA GGTCAGGTGC TGGGGGTGGA
CCTAG. AGAA CGTCCACAAG A T G T G ....G  GGGGAGTCAG GAGGTTCTGC AACAGCTGGC .CACAGTGAG AGCCAGGAAA TAACAGTACT GCTG..AGGG
CCTTGAAGTA ACTGCACGAA ATTTG A GGGTGGCCAG GCAGTTCTAC AACAGCCGCC TCACAGGGAG AGCCAGAACA CAGCAAGAAC TCAG..ATGA
G GCAG. TCTAC AACAGCCG.C CAG. AAGAAC
A C
531
GTGGGAGAGG GAGTGTGTGT 
GTGGGAGTGG GAGTGTGTGT 
CTCACAGTAT CCTTTTTGAG 
CTGGTAGTAT TACCTTCTTC
CTTTGTATGA TCTGAAAAAA 
CTTTGTATGA TCTGAAGAAA 
GGAGTGGAGG GATGGAGAGG 
ATAATCCCAG GCTTGGGGGG 
ATAAT. CCAG
CTCAGGTCAG AACATCTGTA 
CTTAGGTCAG AACATCTTTA 
CTCATAGTAT ATTATTTGTA 
CTGCGATGGA GTCAGAGGAA
GATCCTTACA GACATACAAA 
GATTCTCACA GACATGAAAA 
ATCCCAGGCC AGCAGGCTGT 
ACTCAGTTCA GAACATCTTT
AGAATCCTAG CCTCTTATTC
A .................AT TAGAAGAGTA
GGAGTGGTCT GAGGAAACTG 
ggtttttaca  ATACAAATTA 
GGTTTTTACAAATACAAA
431
ATGTGTGTGT GTGTGTGTGT 
AATCCTGGCC TCTTATTAAT 
AGGTCAGAAC ATCTTAGGTT 
A ................................................ C
GTGTGTGTGT GTGTGTGTGT 
TCATGAGTGT TTGTGTGT.. 
TTTTACAAAT ACAAATAAAC 
TGGAACGCTA AATTCTAGCC
- 3 9 2
GTGTGTGTAT GTGTGTGTCG
TGGAATACTA AAGCCTAACC 
TGTTAATCTG GTCACTGA..
TCTGTCATGC GCGCGTGCCT
.................................GCGCACAT
AGTGGTAATT AAAGTATTTT 
AAAAAAAAAT TTTTTTTTTT  
A A A A A A A A .. TTTTTTTTTT
GCGTTTAAAT AACATCAGCT 
GTGTTTAAAT AACATCAGCT 
TAAAATCAGT CAGCCTTAGC 
TCAAAAAACA TAGCTTTAGC
353
TTACGTTCTC TTTCT..CCT TATAAAACAT TGTGAAT.. .  TTCAGTTTTC TTTCCCATCA AGACATGCTC AAGTGCTGAG TCACTTTTAA AGAAAAAAA.
TTAGCTTCAC TTTCT..CCT TATAAAACAT TGTGCAT.. .  TTCAGTTTTT CCCCCTATCA AG...TGCTC AAGTGCTGAG TCACTTTTAA AGAAAGAAA.
TTCTCCCCAC CCGCTACCCC TCTAAAACTC TGTGCATGAT TTCAGCTTTA CTTTTTCTCA AGACATGCTA ATGTGCTGAG TCACTAA...............AAAAAAAA
TTATTTTTTT TTTCT..CTT TGTAAAACTT CGTGCATGAC TTCAGCTTTA C.TCTTGTCA AGACATGCCA A.GTGCTGAG TCACTAATAA AGAAAAAAGA
TTA..TTTTT C.TCTTTGTCAAGACATGCCA AAGTGCTGAG TCACTAATAAAAGAAAAAAAAGA
Figure 1.9
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-2 5 6  -1 7 4
m ouse  GAA GAGTGCTCAT GCTTCTTAGG GCTAGCCTCA AGGATGACTT AAGC  ACACTTTTCC CTTCCTAGTT GTGATTCTTT CGATGCTAAA
r a t   AA GAGTGATCAG GCTTCTTAAG GATAGCCTCA AGGATGACTT AAAC  ACACTTTCCC CCTCCTAGCT GTGATTCTTT GGATGCTAAA
b ov AGTAAAGAAA GAGTGATCCA GCTTCTGAGG ACTAGCTTTA GTAATGATCT AAGCTTCTAC GCGGCACTTT TTGCCCTGGT TTGATTCCTG TGATGCTAAA
hu AGTAAAGGAA GAGTGGTTCT GCTTCTTAGC GCTAGCCTCA ATGACGACCT AAGCTGC..........................ACTT TTCCCCCTAG TTGTGTCTTG CGATGCTAAA
hu2 AGTAAA G
C
-1 6 5
m ouse CGACGTCACA TTGTGCAATC TTAATAAGGT TTCCAATCAG CCCCACCCAC TCTGGCCCCA CCCCCACCCT CCAACAAAGA TTTTTATCAA ATGTGGGATT
r a t  TGACGTCACA TTGTGCAATC TTAATAAGGT TTCCAATCAG CCCCACCCAC TCTGGCCCCA CCCCCACCCT CCAACAAAGA TTTTTATCAA ATGTGGGATT
b ov  GGACGTCACA TTGAGCAATC TTAATAAGGT TTCCAATCAG CCCCACCCGC TCTGGCCCCA CCCCCACCCT CCAACAAAGA . . TTTATCAA ATGTGGGATT
hu GGACGT. . CA TTGCACAATC TTAATAAGGT TTCCAATCAG CCCCACCCGC TCTGGCCCCA CCCTCACCCT CCAACAAAGA . . TTTATCAA ATGTGGGATT
hu2 GGACGTCACA
-6 5
m ouse TTCCCATGAG TCTCAAAATT AGAGAGTTGA CTCCTAATAA ATATGAGACT GGGGATG. . T CTGTAGCTCA TTCTGCTCTG GAGCCCACCA AGAACGATAG
r a t  TTCCCATGAG TCTCAAAAGT AGAGAGTCGA CTCCCAATAA ATATGAGACT GGGGATG..T CTGTAGCTCA TTCTG.TCTC GAGCCCACCA GGAACGAAAG
b ov  TTCCCATGAG TCTCAATATT AGAGTCTCAA CCCCCAATAA ATATGAGACC GGGGATG..T CTGAGACTCA GTCTGCCCTC GGGCCCACCA GGAACGAAAG
hu TTCCCATGAG TCTCAATATT AGAGTCTCAA CCCCCAATAA ATATAGGACT GGAGATGTCT CTGAGGCTCA TTCTGCCCTC GAG-----------------------------------
hu2 GGAGATGT. .  CTGAGGCTCA TTCTGCCCTC GAGCC.ACCG GGAACGAAAG
+ 33
m ouse TCAA.TTC—  
r a t  TCAA.CTC—
hu ----------------
hu2 AGAAGCTC~~
Figure 1.9. DNA sequence of the 5’ flanking region of the human IL-6 gene (+40 to -719) compared to rat, mouse and bovine sequences.
The sequences show many conserved regions between species, particularly from the transcriptional start site to -344. Only the human sequence has a TATA-site and an AT- 
tract.
hu =human (Ray et. al, 1988), hu2 =human (Yasukawa et al., 1987), rat (Northemann et al., 1989), mouse (Tanabe et al., 1988), bov =bovine (Droogmans et al., 1992).
Red lettering = differences compared to human sequence; pink lettering = differences between Yasukawa et al. and Ray et al. human sequence; green lettering =TATA site; bold 
lettering = polymorphisms in human sequence.
Numbering is from the transcriptional start site based on the human sequence (Yasukawa et al., 1987 GenBank Accession number Y00081; Ray et al. GenBank Accession 
number M22111).
1.3.1. Transcriptional control of IL-6
As with other eukaryotic genes, IL-6 expression is mainly controlled at the level of 
transcription (Latchman, 1998), though post-transcriptional mechanisms play a 
modifying role. Three potential sites of transcriptional initiation in the human IL-6 
gene have been identified by SI nuclease mapping and primer extension analysis. Each 
site is associated with TATA-like sequences (Yasukawa et al., 1987, figure 1.10). 
Different cell types may preferentially use different initiation sites to produce IL-6 
mRNA transcripts. Yasukawa et al. (1987) detected three lengths of transcript in a 
glioblastoma cell line SK-MG-4 stimulated with IL-1 p, compatible with transcriptional 
initiation from each of the three potential sites, C l, C2 and C3. Phytohaemagglutinin 
(PHA) stimulation produced two transcript lengths in an epithelial cell line (bladder 
carcinoma T24), in a tonsillar lymphocyte-derived line and in a human T-cell 
leukaemia virus (HTLV)-l transformed T-lymphocyte line. These were compatible 
with transcription initiation at sites Cl and C3. In a fibroblast cell line stimulated with 
poly(I).poly(C), the main transcript product arose from initiation of transcription at site 
C l, with a second weaker initiation site compatible with C2 (Zilberstein et al., 1986, 
Haegeman et al., 1986). The Cl site seems to be the main transcription initiation site in 
most cell lines expressing IL-6 and producing the 212 amino acid protein product. It 
has been proposed that the upstream initiation sites C2 and C3 would code for a 
protein with a hydrophobic N-terminus tail, which could act as a membrane bound 
form of IL-6 (Hirano et al., 1986), though the existence of such a variant has not been 
established.
C3 (-113) C2 (-23 to -25) Cl (-1 to +1)
1 i 1
-200
|
TTAATAA AATATTA TAAATATA +1
l
(-144 to -138) (-52 to -46) (-29 to -22)
Figure 1.10. The human IL-6 gene promoter, potential transcription initiation 
sites and TATA boxes.
Based on SI nuclease mapping with primer extension analysis and sequence information from 
Yasukawa et al., 1987. Three potential transcription initiation sites were identified C l, C2 and C3. Cl is 
the main initiation site in most cell lines and base numbering for the gene is determined with respect to 
C1 initiation site.
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1.3.2. Regulation of IL-6  transcription
Specific transcription factors can act as enhancers or repressors of transcription 
(Ptashne, 1986, 1988). Each transcription factor binds to a sequence specific element, 
which in eukaryotes can be position-, orientation- or strand-independent to the 
transcriptional initiation site, and may be located within introns, 3’- or more commonly 
5’-flanking regions of the gene, with some acting over several kilobases. More than 
one member of a transcription factor family may bind to a specific regulatory element, 
multiple regulatory elements may be present within one gene and each transcription 
factor may bind more than one regulatory sequence. This allows a large diversity of 
transcriptional control for eukaryotic genes and enables cell-specific diversity 
depending on which transcription factors are expressed in a cell-type.
Hybrid-protein genetic engineering techniques allowing expression of individual 
transcription factors, deletion mutations and domain interchanges, have enabled 
detailed analysis of the structure, binding and function of transcription factors. In 
common, they tend to have bi-modular domains, one making specific DNA contact 
and the other interacting with transcription initiation factors, either directly or 
indirectly (Pabo and Sauer, 1992). The DNA between regulatory elements and the 
promoter can loop out (Schleif, 1992) facilitating transcription regulatory and initiation 
factors to interact. Transcription factors can act as enhancers by increasing the binding 
affinity or speed of assembly of the transcription initiation complex, facilitating 
opening of double helical DNA, recruiting other transcription factors that increase the 
rate of transcription, or preventing repressor factors from acting, either by blocking 
their binding to DNA or by blocking their protein action domain (Mitchell and Tjian, 
1989). Transcription factors can act as repressors by competing with transcription 
initiation or enhancer factors for DNA binding sites, masking protein activation 
domains on other transcription factors, binding and mopping up transcription factor 
availability, or blocking protein-protein interactions required for transcription complex 
assembly (Jackson, 1991). As complexes, transcription factors can act synergistically 
to increase binding affinity, where one factor alone may have too weak an affinity to 
bind. Factors binding the DNA may not contain the effector site themselves, but may 
enable other co-factors with effector-domains to bind via protein-protein interactions 
(Lemon and Tjian, 2000). The same transcription factor or co-factor may have 
different effects in different complexes, depending on which portions are bound and
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exposed. It is clear that these multiple steps in gene regulation facilitate an enormous 
diversity of transcriptional control.
Transcription regulatory sites in the IL-6 gene have been demonstrated in the 5’- 
flanking region. There is no evidence that sites elsewhere in the IL-6 gene play an 
active role in controlling the rate of gene expression. Figure 1.11 shows schematically 
the location of many of these transcription regulatory sites, discussed below.
Cl
-466 to -461 -163 to -158 -83 to -75 -25to-22
-557 to -552 -392 to -373 -283 to -277 -225 to -164 -158 to -146 -73 to -63 -lto + 1
GRE2 GREi AnTn tract
(TGAGTCA)
NRD |C/EBPP C/E 
T
(ACATTGCACAATCT)
BPP NFkB TATA Inr 
T
(GGGATTTTCC)
CRE (TTATCAAAT)
▼
(ACGTCA)
Figure 1.11. Transcriptional regulatory sites in the human IL-6 gene.
Schematic representation of transcription factor sites in the 5’-flanking region o f IL-6 (see discussion 
below for references to each site). Base numbering is in relation to the transcription initiation site C l. 
Confirmed transcription factor sites are shown as solid boxes with the DNA sequence indicated below, 
putative transcription regulatory sites are shown as hatched boxes.
1.3.2.1. N F-kB
Deletion mutants of the 5’-flanking region of hIL-6 revealed an essential IL-1 response 
element, and strong TNFa and LPS response element, in the region -63 to -73 that 
bound the nuclear factor binding protein NF-kB, (Libermann and Baltimore, 1990, 
Shimizu et al., 1990, Zhang et al., 1990). Site-directed mutagenesis of this NF-kB site 
confirmed the importance of NF-kB in activation of IL-6 transcription by LPS 
(Matsusaka et al., 1993, Dendorfer et al., 1994). Electrophoretic mobility shift assay 
(EMSA) showed that NF-kB p50 and p65 homodimers (see below), and p50/p65 
heterodimers, bind avidly to this site (Matsusaka et al., 1993).
N F-kB is a eukaryotic transcription factor, first discovered in B-cells as a nuclear 
factor that bound as an enhancer of the immunoglobulin k light-chain gene (Sen and
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Baltimore, 1986). It is strongly evolutionarily conserved in terms of sequence 
homology and signal transduction pathways from Drosophila to human (Gonzalez- 
Crespo and Levine, 1994, Medzhitov et al., 1997). Numerous mammalian genes are 
regulated by NF-kB including many cytokines, acute phase response proteins and cell 
adhesion molecules, and hence it plays a key role in co-ordinating and enhancing the 
adaptive immune response to situations of infection, stress or injuiy. NF-kB exists as a 
dimer of specific proteins, members of the Rel homology domain (RFID) family, 
containing a 300 amino acid N-terminal conserved domain (figure 1.12). The RHD 
determines the DNA-binding, dimerization and protein interaction characteristics of 
the molecule. In humans, NF-kB forms as homodimers or heterodimers of p50, p52, 
p65 or c-rel, each with unique DNA binding capacity and transactivation potential 
(Kunsch et al., 1992). The majority of dimeric combinations, such as p50/p65, p50/c- 
rel, p65/p65 or p65/c-rel, activate gene transcription. However, the homodimers p50 
and p52 appear to repress transcription, probably due to their lack of a variable C- 
terminal activation domain and by competing with transactivation complexes for 
binding sites (Plaskin et al., 1993, Brown et al., 1994). X-ray crystallography of p50 
homodimers and p50/p65 heterodimers bound to a kB site, showed each molecule to 
comprise two domains linked by a flexible region (Ghosh et al., 1995, Chen et al., 
1998b). Dimerization occurred exclusively via the interaction of hydrophobic amino- 
acid side chains in the C-terminal domain of RHD. Differential contributions of key 
residues may dictate selectivity of dimer formation between NF-kB members 
(Sengchanthalangsy et al., 1999). Both N- and C-terminal regions of RHD are involved 
in binding to DNA, with multiple contacts between loop regions (joining P-sheet 
domains of the protein) and the nucleotide bases and sugar phosphate backbone of 
specific DNA sequences. Mutational analyses have revealed the importance of DNA 
sequence specificity at the binding site and the bases involved in the interactions 
(Toledano et al., 1993, Liu et al., 1994). For example, the p65 homodimer, though 
sharing the same basic structure as p50, binds asymmetrically to DNA target sites with 
one subunit binding to a specific four-base half-site, but the second sub-unit requiring 
only partial specificity in the other half-site (Chen et al., 1998c). This contributes to the 
diversity of DNA sequences recognised by NF-kB. In addition, NF-KB-induced 
transcription may be influenced by the context of the binding site(s) within a promoter, 
producing different degrees of DNA bend within different promoter sequences
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(Berkowitz et al., 2002). This may influence the transactivation function of NF-kB or 
other promoter bound factors.
Messenger RNA for p50 & p52 encodes for larger precursor proteins, p i05 & p i00 
that are then cleaved post translation, to produce the p50 & p52 molecules, 
respectively (figure 1.12), (Ghosh et al., 1990, Schmid et al., 1991). Within the C- 
terminal region of the larger proteins, an ankyrin-repeat motif masks the nuclear 
localisation signals of p50 & p52, and enables the unprocessed proteins to function as 
iKB-like (see below) domains (Henkel et al., 1992, Blank et al., 1991, Rice et al.,
1992). Degradation of this C-terminal region to release p50 or p52 appears to be 
regulated by a signal-dependent mechanism in cells stimulated with NF-kB activating 
agents, and by a signal-independent mechanism in unstimulated cells. Cellular 
stimulation results in an increased rate of degradation of the C-terminus (Mellits et al.,
1993). A glycine-rich region in the N-terminus portion of pl05 & plOO is necessary 
and sufficient for cleavage of the C-terminal region (Lin and Ghosh, 1996, Betts and 
Nabel, 1996). In the signal-dependent mechanism, this requires phosphorylation of the 
C-terminus resulting from cell stimulation.
c-Rel, RelB, p65
N- RHD
pl05/p50, pl00/p52 
N- RHD
licBa, |3, 8, y, Bcl-3 
ARR
Figure 1.12. The structural organisation of NF-kB and IkB molecules.
N=N-terminus, RHD=Rel homology domain, P=phosphorylation site, Gly=glycine-rich motif, 
ARR=ankyrin repeat regions.
Chapter 1. Introduction. 66 R Jeffery
N F-kB is pre-formed in the cytoplasm of most cells and maintained in an inactive form 
bound to its cytoplasmic inhibitor, IkB. IkB acts as the main regulator of N F-kB  
activation by masking the NF-kB nuclear localisation signals and retaining it in the 
cytoplasm (Verma et al., 1995). At least five IkB family members have been identified 
to date (IkBoc, IkBP, IkB c, hcBy, Bcl-3), each containing multiple ankyrin-repeat 
regions that specifically interact with the RHD of N F-kB (figure 1.12). The number of 
ankyrin-repeats influences the specificity for RHD. This inhibitory mechanism is 
further tuned by members of the IkB family having different kinetics of degradation 
and re-synthesis in response to simulators of N F-kB. Both IkBoc and IkBP regulate 
p50/p65 and p50/c-rel heterodimers (Thompson et al., 1995). IkBcx and IkBP both 
rapidly degrade after stimulation of N F-kB inducing pathways, however only hcBa is 
rapidly re-transcribed, maintaining only a transient effect of inducing agents. Levels of 
IkBP remain low until the N F-kB activating signal is attenuated. This is explained by 
the fact that the IkBcx gene, but not the IkBP gene, contain an NF-kB enhancer site 
(Brown et al., 1993, Chiao et al., 1994). hcBe exclusively binds p65/p65 and p65/c-rel 
(Whiteside et al., 1997). It is slowly degraded on activation of the NF-kB pathway. 
hcBy (only detected in lymphoid cells) is generated from the same gene as p i05 
(Heron et al., 1995). It seems only to bind and inhibit p50 and p52 homodimers (Bell et 
al., 1996). Bcl-3 is unique in that it localises to the nucleus rather than the cytoplasm 
and can act as a transactivator by specifically binding and removing the inhibitory p50 
& p52 homodimers (Nolan et al., 1993).
Multiple activators of NF-kB stimulate cells to signal tissue injury, inflammation and 
infection. These activators include cytokines IL-1 & TNFa, products from infection 
such as lipopolysaccharide (bacterial), double-stranded RNA & tax nuclear proteins 
(viral), CD30 & CD40 ligands, lymphotoxin-a & p, and stress mediators such as 
reactive oxygen intermediates & UV light (May and Ghosh, 1998, McDonald et al., 
1995b, Nakano et al., 1996). In the context of IL-6 gene induction, the IL-1 P and 
TNFa mediated signalling pathways resulting in activation of NF-kB, and hence 
induction of IL-6  transcription, are shown in figure 1.13.
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Figure 1.13. Signal transduction pathways for IL-1 (3 and TNFa mediated 
activation of NF-kB via their specific receptors.
IL-1 P binding to the IL-1R1 and IL-1R accessory protein receptor complex induces association of 
MyD88 (a cytosolic adapter molecule) with the intracellular domain of IL1R complex (Wesche et al., 
1997). This triggers the recruitment and phosphorylation of Interleukin-1 Receptor Associated Kinase-1 
(IRAK-1). Activated IRAK-1 can then associate with TNF-receptor associated factor 6 (TRAF6). TNFa 
binding to the TNFR1 (p55) receptor complex allows TNF-receptor-associated death domain protein 
(TRADD) to bind and recruit receptor interacting protein (RIP) and TRAF2 (Hsu et al., 1996). RIP and 
TRAF2 activate NF-kB inducing kinase (NIK), (Malinin et al., 1997). Both activated NIK and TRAF6 
activate the IKK complex (the common component o f both pathways), though mechanisms are not fully 
understood, and result in phosphorylation o f IKKa and IKK0. This in turn leads to phosphorylation of  
IxBa, leading to ubiquitination and degradation of the protein to release the dimeric NF-kB molecule 
that can then translocate to the nucleus and activate target genes.
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Via their own specific cell surface receptor, IL-lp and TNFa activate members of the 
TRAF family of proteins that in turn activate an IkB kinase (IKK) complex of at least 
three proteins (IKKa, IKKp, DCKy). The activated IKK’s specifically phosphorylate 
two critical serine residues on hcBa (Ser-32 and Ser-36) and IkBP (Ser-19 and Ser- 
23), (DiDonato et al., 1996). This specific phosphorylation leads to ubiquitin- 
proteasome degradation of IkB, with release and nuclear translocation of NF-kB 
(Brown et al., 1995).
1.3.2.2 C/EBP
In addition to the NF-kB activation site in the hEL-6  gene, another IL-1 response 
element was identified as a 14bp site around position -150 that bound a nuclear factor 
designated nuclear factor IL-6 , NF-IL6 (Isshiki et al., 1990). This NF-IL6 site was also 
shown by site-directed mutagenesis to be necessary for LPS-induced IL-6 expression 
(Zhang et al., 1994). Zhang and co-workers (1994) identified a second NF-IL6 site 
from position -75 to -83 that conferred LPS and lipoarabinomannan (a constituent of 
Mycobacterium cell walls) inducibility to IL-6 in a human monocyte cell line. It was 
subsequently shown by site-directed mutagenesis that this downstream NF-IL6 site 
was essential in combination with the NF-kB site for IL-6 induction by IL-1 P in an 
osteoblast cell line (Stein and Yang, 1995). The up-stream NF-1L6 site (-146 to -158) 
however, did not seem important for IL-lp-induced expression of IL-6 in these 
osteoblasts, as deletion of this region in transfected constructs did not significantly 
affect levels of induction. NF-IL6 is a member of the CCAAT/enhancer binding 
protein (C/EBP) family and has been re-designated C/EBPp (Akira et al., 1990, Poli et 
al., 1990). Matsusaka and co-workers (1993) showed that C/EBPp and NF-kB act 
synergistically in the activation of IL-6 gene transcription. More recently, a third 
C/EBP site has been identified within the region -45 to -74 of the IL-6 gene (Vales 
and Friedl, 2002, and see section 1.3.2.9). This site was shown to be functionally 
significant in co-activation of IL-6  expression in HepG2 and COS cells.
C/EBP is a family of eukaryotic transcription factors comprising six known members, 
C/EBPa, p, 8 , e, y and encoded by different genes with a tissue-specific pattern of 
expression (Lekstrom-Himes and Xanthopoulos, 1998). They are highly conserved in 
evolution and are important in normal tissue development, cellular function, cellular
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proliferation and differentiation, as determined from studies with C/EBP knockout 
mice. Each member has a different pattern of cell-specific expression. They contain 
three functional domains, an activation, a dimerization and a DNA-binding domain. 
The C-terminal dimerization domain is highly conserved between members and has a 
basic-leucine zipper (bZIP) structure (figure 1.14), allowing homo- and hetero-dimers 
to form. Electrostatic interactions between amino-acids along the dimerization 
interface determine the specificity of dimer formation with other C/EBP family 
members and with other transcription factors such as NF-kB and Fos/Jun family 
members (Vinson et al., 1993). Dimerization is necessary for DNA binding 
(Landschultz et al., 1989). The DNA binding specificity of C/EBP is determined by a 
20 amino-acid region in the C-terminal domain of the molecule that contains three key 
residues for protein-DNA interaction (Johnson, 1993). The bZIP domain assumes an 
a-helical configuration and from DNA modelling based on x-ray crystallographic 
studies, is thought to form an inverted Y-shaped structure with the bZIP region of the 
other dimerized C/EBP molecule to enable binding to a palindromic DNA recognition 
site (Ramji and Foka, 2002). The optimal C/EBP binding site has a symmetrical repeat 
sequence, however, most sites contain a conserved half-site paired with a more 
divergent sequence, indicating that considerable variation in binding sequence is 
tolerated (Osada et al., 1997a).
LAP
N- AD AD RD RD basic ZIP
L L L L L
LIP
N- RD basic ZIP
1 “ 1 m u 1
L L lL 1LIL
Figure 1.14. The structural organisation of C/EBPp (LAP & LIF isoforms), adapted 
from Ramji and Foka, 2002.
LAP=liver-enriched transcriptional activating protein (full-length C/EBPP), a 35kDa polypeptide, 
LIP=liver transcription inhibitory protein (truncated isoform o f C/EBPP), a 20kDa polypeptide (see text 
below).
N=N-terminus, AD=activation domain, RD=negative regulatory domain (influencing DNA binding), 
basic=region containing basic amino acid residues, ZIP=leucine zipper region (together with the basic 
region this forms the bZIP region that facilitates dimerization and DNA-binding), L=leucine residue.
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The activation domains at the N-terminal end of the protein are least conserved 
between family members, most interact with the basal transcription machinery to 
enhance transcription, however, in several C/EBP molecules the N-terminal region 
also contains negative regulatory regions that can act as dominant-negative repressors 
(Williams et al., 1995). C/EBPy lacks an activation domain and acts only as a repressor 
of gene transcription (Cooper et al., 1995).
C/EBPp, though initially identified and cloned as a transcriptional activator of IL-6 , 
also binds many other genes involved in inflammation, haemopoiesis and acute phase 
response such as TNFa, IL-8 , G-CSF and class I APR genes (Akira et al., 1990, Poli et 
al., 1990, Betts et al., 1993). It is constitutively expressed in liver, intestine, lung, 
adipose cells and myeloid cells, though it can also be strongly induced by cell 
stimulation with LPS, IL-6 , IL-1, dexamethasone and glucagon. Cytokine stimulation 
promotes nuclear localisation of C/EBPp and enhances its binding to DNA (Yin et al., 
1996). This may involve post-translational modification of C/EBPp, via protein kinase 
specific phosphorylation, which has been shown to increase the transcriptional 
enhancing activity of C/EBPp (Nakajima et al., 1993). In the serum amyloid A gene, 
increased transactivation by C/EBPp or 8  was seen in the presence of inhibition of 
cellular phosphatases and associated with increased DNA binding activity (Ray and 
Ray, 1994). Auto-regulation of the C/EBPp gene also occurs in response to 
inflammatory stimuli (cytokines, turpentine oil, LPS) via C/EBPp binding sites 
contained within the C/EBPp promoter (Akira and Kishimoto, 1997, Niehof et al., 
2001a). The C/EBPp promoter contains two cAMP-response element (CRE)-like sites 
(see section 1.3.2.3) that can bind the transcription factor CRE-binding protein 
(CREB) to up-regulate C/EBPp transcription (Niehof et al., 1997). The CRE-like sites 
are required for IL-6-mediated induction of C/EBPp (Niehof et al., 2001b), producing 
an auto-regulatory feed-back-loop as C/EBPp induces IL-6 , which in turn can induce 
C/EBPp. In addition, inflammatory stimuli in hepatocytes and macrophages, have been 
shown to alter the balance of C/EBP members by reducing the levels of C/EBPa 
transcription while inducing C/EBPp and 8 transcription to varying degrees (Alam et 
al., 1992, Tengku-Muhammad et al., 2000). In this way, the kinetics and magnitude of 
response for different C/EBP members can be influenced to favour enhanced
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transcription of genes containing binding sites for the up-regulated factors (such as IL- 
6 in the case of C/EBPp).
A further complexity in the tissue-specific regulation of C/EBPp is added by 
translational control of the formation of isoforms. Two isoforms of the protein can 
occur, generated through initiation of translation from two separate AUG sequences 
within the same reading frame of a single mRNA transcript (Descombes and Schibler,
1991). The larger generated polypeptide is 35kDa (liver-enriched transcriptional 
activating protein LAP, figure 1.14) and contains the conserved C/EBP activation 
domain, two negative regulatory domains (RD) that influence DNA binding (Williams 
et al., 1995) and the bZIP domain. The truncated form is 20kDa (liver transcription 
inhibitory protein LIP, figure 1.14) and contains only one RD and the bZIP 
dimerization domain, but no activation domain. Heterodimers of LAP and LIP can 
form, with LIP acting as a dominant negative repressor, inhibiting the transactivational 
function of C/EBPp (Descombes and Schibler, 1991).
The C/EBP family members can form dimers via protein-protein interactions with 
other bZIP and non-bZIP containing transcription factors. C/EBPp has been shown to 
interact with the p50 & p65 subunits of NF-kB, CREB/activating transcription factor 
(ATF), Fos & Jun, glucocorticoid receptor and retinoblastoma protein (Hsu et al., 
1994, Xia et al., 1997, Ramji and Foka, 2002). These heterodimers may have different 
transactivation potential and binding specificity compared to homodimers for each 
factor. For example, Fos and Jun hetero-dimerization to C/EBPp, reduced the C/EBPp 
binding affinity for the C/EBPp consensus sequence, and repressed transcription of a 
reporter gene containing C/EBPp sites in the promoter (Hsu et al., 1994). In contrast, 
NF-kB interaction with C/EBPp is co-operative and results in enhancement of 
transcriptional activation (Matsusaka et al., 1993, Xia et al., 1997). This interaction 
and co-operation requires both the Rel homology domain (RHD) of NF-kB (figure 
1.12) and the leucine-zipper domain of C/EBPp (figure 1.14). Each factor binding to 
DNA can increase the DNA binding affinity of the other (Ruocco et al., 1996). Up- 
regulation of C/EBPp after an inflammatory stimulus is slow compared to the early 
availability of pre-transcribed NF-kB (Poli, 1998). In genes such as IL-6 that have dual 
responsiveness to NF-kB and C/EBPp, C/EBPp may provide a slower, more sustained
Chapter I. Introduction. 72 R Jeffery
induction of transcription, while NF-kB provides a faster, more immediate response, 
enhanced by the availability of small amounts of constitutive C/EBPp, probably 
activated by phosphorylation as discussed above. The influence of synergy between 
C/EBPp and NF-kB in possible prolongation of transcriptional transactivation is not 
known.
Though C/EBPp can clearly up-regulate IL-6 transcription, it may not be essential for 
IL-6 induction in some cell types. Peritoneal macrophages from C/EBPp deficient 
mice still resulted in induction of IL-6 following bacterial infection and in fact, basal 
levels of IL-6 mRNA were elevated (Tanaka et al., 1995). Screpanti and co-workers 
(1996) found elevated serum IL-6 levels with associated pathological features similar 
to Castleman’s disease (see section 1.2.1) in C/EBPp -/- mice. Targeted elimination of 
C/EBPp mRNA to prevent C/EBPp expression in human fibroblasts did not inhibit IL- 
6 expression though the expression of other pro-inflammatory cytokines with C/EBPp 
sensitive promoters (TNFa, G-CSF) was inhibited (Tanaka et al., 1995). This suggests 
that redundancy may occur between transcription factors and transduction pathways in 
the transcription of IL-6 . Indeed, LPS-induced IL-6 expression was restored in a 
murine lymphocytic cell line deficient for C/EBPa, P and 6  (shown to poorly express 
IL-6 in response to LPS), by transfection with any one of the three C/EBP members 
(Hu et al., 1998). This contrasts however, with the findings of Gorgoni and co-workers 
(2002) who found LPS- and IFNy/LPS-induced IL-6 levels to be impaired in splenic 
macrophages from C/EBPp deficient mice compared to wild-type mice. In some cell 
types, C/EBPa or 8 may be able to substitute for C/EBPp in transactivation of IL-6 
transcription induced by certain stimuli. C/EBP5 may be a more likely candidate as it 
is up regulated by LPS and other inflammatory stimuli, where C/EBPa is down 
regulated. C/EBP5 and a  have been shown in vitro to induce reporter gene expression 
through a region of the human IL-6 promoter and bind to the same DNA-sequences as 
C/EBPp (Kinoshita et al., 1992, Vales and Friedl, 2002). In fact, C/EBP8 and a  were 
associated with stronger induction than C/EBPp, displaying synergy with NF-kB p65, 
and C/EBP8 forming heterodimers with C/EBPp. The significance of these regulatory 
mechanisms in vivo remains to be established.
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1.3.2.3 cAMP response element and negative regulatory domain 
Ray et al. (1989) reported 70% sequence homology between the IL-6  5’-flanking 
region -124 to -170 and the serum response element (SRE) of the c-Fos gene 
promoter. On electrophoretic mobility shift assay, HeLa nuclear factors bound to the -  
151 to -173 region of IL-6  could be competed out by the SRE sequence of c-Fos, 
suggesting that similar factors could bind each regulatory region. The -151 to -173 
sequence of IL-6 was found to confer responsiveness to serum, tetradecanoyl phorbo- 
13-acetate (TPA), IL-1 and TNFa when inserted up stream of a herpes simplex virus- 
thymidine kinase (HSV-TK) promoter driving CAT reporter gene expression. Within 
this sequence, the motif CGTCA at -158 to -163 (a cAMP response element, CRE, 
consensus sequence) was found to be essential for TPA inducible transcription, but not 
for serum, IL-1 or TNFa induction. Site-directed mutagenesis confirmed that the 
CGTCA motif was functional in conferring cAMP responsiveness (Ray et al., 1989), 
although IL-6 inducibility by cAMP and prostaglandin El was not completely 
abolished by mutation of this site (Dendorfer et al., 1994). Mutation of three additional 
sites of the IL-6 5’-flanking region, the API, C/EBPp and NF-kB sites, also 
contributed to reduction of IL-6  responsiveness to cAMP. This suggests that cAMP 
can act through multiple, partially redundant regulatory elements, including the CRE.
Intracellular levels of cyclic 3’,5’-monophosphate (cAMP) rise in response to 
activation of the membrane-associated enzyme adenylyl cyclase by engagement of cell 
specific receptors by stimulating factors such as adrenaline, glucagons, vasopressin or 
thyroid stimulating hormone (Montminy, 1997). A family of CRE binding factors has 
been identified, known as the CRE binding protein/activating transcription factor 
(CREB/ATF) family, and share a common basic DNA-binding domain and leucine 
zipper structure (figure 1.15). CREB, a 43kDa protein, binds to the CRE as a dimer. In 
unstimulated cells, this is in an inactive form producing no activation of transcription. 
As cellular levels of cAMP are stimulated to rise, this results in activation of the 
enzyme protein kinase A, which produces phosphorylation of the serine residue at 
position 133 (ser-133) of CREB (McKnight et al., 1988). Phosphorylation of ser-133 
produces a conformational change in CREB that permits activation of transcription.
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CREB/ATF
N- AD P AD basic ZIP
L L L L L
Activating CREM  
N- AD P AD basic ZIP( l )  basic ZIP (2)mu
L L L L L L L L L L
Inhibiting CREM
N- P basic Z IP (l) N- P basic ZIP (2)
L L L L L L L L L L
ICERs
basic Z IP (l)
L L L L L
basic ZIP (2)
L L L L L
Figure 1.15. The structural organisation of CREB, CREM and ICERs.
The inhibiting forms of CREM are alternative splice products o f a single RNA transcript o f CREM. 
They compete with CREB and activating CREM for CRE binding, but lack the activation domain. 
ICERs are formed from a distinct promoter within the CREM gene that is activated in response to 
cAMP to produce transcripts encoding these short proteins. They also exert an inhibitory effect by 
competing with CREB and activating CREM (Sassone-Corsi, 1998).
CREB=CRE-binding protein, ATF=activating transcription factor, CREM=CRE modulator, 
lCERs=inducible cAMP early repressors. N=N-terminus, AD=activation domain, P=phosphorylated 
region, in response to cAMP, basic=basic domain, ZIP=leucine-zipper domain.
Screening of cDNA expression libraries, revealed a 265kDa protein CREB-binding 
protein (CBP) that binds to phosphorylated CREB, but not to unphosphorylated CREB 
(Chrivia et al., 1993). Screening of cDNA expression libraries, revealed a 265kDa 
protein CREB-binding protein (CBP) that binds to phosphorylated CREB, but not to 
unphosphorylated CREB (Chrivia et al., 1993). The activation domain of CREB 
undergoes a structural change from a coiled to a two a-helices structure when it 
interacts with CBP (Radhakrishnan et al., 1997). CBP acts as a co-activator and 
appears to be essential for gene activation by cAMP as antibodies to CBP injected into 
cells before stimulation prevented activation of transcription by cAMP. CBP may 
mediate activation of transcription by bridging between CREB and the basal 
transcriptional complex. It has been identified as part of the RNA polymerase II/ basal 
transcription factor holoenzyme complex and has been shown to produce protein-to- 
protein interactions with components such as transcription factor IIB, TFIIB (Nakajima
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et al., 1997). Another possible mechanism is via alteration of the DNA chromatin 
structure. CBP has been shown to have histone-acetyltransferase activity (Ogryzko et 
al., 1996), and this may produce a more open chromatin structure facilitating 
transcription (Wade et al., 1997). CBP is not exclusive to CREB but can also act as a 
co-activator to other transcription factors such as API, nuclear receptors and NF-kB 
(Shikama et al., 1997). A limited amount of CBP within a cell will result in 
competition and mutual antagonism between transcription factors for this co-activator.
The CRE modulator (CREM) is another member of the CREB/ATF family that can 
bind to the CRE and activate transcription in response to cAMP via a similar 
mechanism to CREB requiring the co-activator CBP (Sassone-Corsi, 1998). 
Alternative splicing products of CREM, that lack the activation domain (figure 1.15) 
but can still form dimers and bind to DNA, inhibit transcriptional activation by 
competing with CREB or CREM for the CRE site. This is a cell specific regulatory 
mechanism with different proportions of activating and inhibitory CREM influencing 
the level of transcriptional activation following cAMP stimulation. In addition, there 
are two distinct exons in the CREM gene coding for distinct DNA-binding domains 
(bZIP (1) & (2), figure 1.15) and hence alternative splicing can result in a molecule 
with a different DNA-binding specificity in different cells. The rate of production of 
these CREM splice-variants is not affected by levels of cAMP. However, the CREM 
gene promoter contains a CRE that induces the production of short protein transcripts. 
These short proteins (inducible cAMP early repressors, ICERs), like the splice-variants 
of CREM, lack the activation domain (figure 1.15). ICERs act as repressors of cAMP 
activation by inhibiting CREB and the activating form of CREM from binding to the 
CRE. This limits the cAMP response via CRE to a transient effect on gene expression. 
This contrasts with the constitutive expression of CREB and the activating form of 
CREM, expression of which is not induced by cAMP, but which are activated by 
cAMP solely at the post-translational level by phosphorylation through protein kinase 
A followed by recruitment of CBP.
During investigation of the cAMP response element of IL-6 , Ray and co-workers 
(1989) found that the region -111 to -164 of IL-6 , inserted up stream of the HSV-TK- 
CAT reporter construct, was associated with higher levels of expression than similar 
constructs with the region -111 to -225. This suggested that the region -165 to -225
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contained a negative regulatory domain (NRD). The only known transcription factor 
site with inhibitory action localised within the NRD is a glucocorticoid receptor site at 
-201 to -210 (see section 1.3.2.5).
1.3.2.4 API
An API consensus sequence between -277 and -283 of the IL-6 gene was initially 
thought unimportant in the regulation of gene expression. Deletion constructs of this 
region had not altered levels of IL-6 transcription when induced by IL-1, TNFa, virus 
components or LPS (Ray et al., 1988, Shimizu et al., 1990). However, site-directed 
mutagenesis of the API site by Dendorfer and co-workers (1994) showed that this site 
was important in mediating cAMP responsiveness.
Several cellular proteins have been identified as capable of binding API sites including 
Jun, Jun B, Fos and Fos-related antigens (Fras), (Karin et al., 1997). Jun homodimers 
can bind an API site, though Fos-Jun heterodimers have an approximately 30-fold 
higher binding affinity for the site. Fos cannot bind API without the presence of Jun 
(Rauscher et al., 1988). Fos and Jun were originally identified as oncogenes from 
retroviruses, however, cellular counterparts have since been identified and function as 
transcription factors that can be induced by serum, phorbol esters such as TP A, or by 
treatment with growth factors (Lamph et al., 1988). Fos and Jun induction is usually 
only transient, and plays a critical role in genes involved in cell growth. Uncontrolled 
growth with persistently elevated levels of Fos and Jun is seen as part of malignant 
transformation (Land et al., 1983). The Fos/Jun complex requires the co-activator CBP 
to activate transcription. This can result in competition for limited quantities of CBP 
between the Fos-Jun-APl system and other CBP dependent systems such as the 
nuclear receptors (Kamei et al., 1996) or CREB (see 1.3.2.3), with mutual repression 
of the systems dependent on the relative concentration of factors. This illustrates cross 
talk between different induced pathways, via shared co-activators (Janknecht and 
Hunter, 1996).
1.3.2.5 Glucocorticoid response element
Glucocorticosteroids (GCs) are strong repressors of the transcription of IL-6  (Ray et 
al., 1990). They complex in the cytoplasm with the specific glucocorticoid receptor 
(GR), this activates the receptor and leads to translocation of the complex to the
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nucleus, where the GR can bind DNA as a homodimer, or heterodimer with other 
members of the nuclear receptor family such as mineralocorticoid, progesterone or 
androgen receptors (Wang et al., 1995). In vitro foot-printing studies of short 
constructs of the 5’-flanking region of IL-6 revealed that GR could bind at several sites 
on the IL-6 gene, at the TATA box and transcription initiation site (Inr), at the region 
between -145 and -173 (overlapping the CRE) and at the region between -201 and -  
210. The consensus sequence for GR binding (the glucocorticoid response element, 
GRE) is a palindrome AGAACAnnnTGTTCT, but can vary significantly between 
genes. Two GRE consensus sequences occur in the IL-6  gene between positions —461 
to -466 and -552 to -557, though GR binding has not been confirmed.
The glucocorticoid receptor is a member of an evolutionarily related gene family 
known as the nuclear receptor family that code for steroid hormone, thyroid hormone 
and retinoic acid receptors that share a common structure with distinct DNA-binding, 
hormone-binding and transcriptional effector domains (figure 1.16), (Mangelsdorf et 
al., 1995). The most conserved region between nuclear receptors is the multi-cysteine, 
zinc-finger motif that forms the DNA-binding domain, resulting in the similarity of 
binding-sites between receptors. This DNA-binding is dependent on the presence of 
zinc. Nuclear receptors in the intact cell are only found bound to DNA in the presence 
of the hormone, though nuclear receptors uncoupled to hormone have been shown to 
bind to DNA in vitro in electrophoretic mobility shift assays and footprint studies. In 
the absence of hormone, the GR is found in the cytoplasm bound to a 90kDa heat- 
inducible chaperone protein, hsp90 (Pratt, 1997). Exposure to steroid results in 
dissociation of this complex and release of the GR that is then able to dimerize and 
move to the nucleus. In addition to inducing dissociation of hsp90 from the nuclear 
receptor, hormone binding induces a conformational change in the C-terminal effector 
domain that unmasks transcriptional activity. Other steroid hormone receptors are 
similarly bound to hsp90 in the cytoplasm and released by specific hormone binding, 
however the related nuclear receptors for thyroid hormone and retinoic acid are not 
associated with hsp90 and are already bound to DNA prior to exposure to ligand 
(Mangelsdorf and Evans, 1995). With all nuclear receptors, ligand binding brings the 
effector domain into close association with the hormone-binding domain and allows 
co-activator proteins to bind the receptor, including CBP (Glass et al., 1997, Torchia et 
al., 1998).
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GR
Effector DNA Hormone
ZnZn
ER
Effector DNA I Hormone / Eff
Figure 1.16. The structural organisation of nuclear receptors.
GR=glucocorticoid receptor, ER=oestrogen receptor. Effector=transcriptionaI effector domain, 
DNA=DNA-binding domain containing conserved multi-cysteine zinc-finger motif (ZnZn), 
Hormone=hormone/ligand-binding domain, ^interaction domain of ER, necessary for binding to NF- 
kB & C/EBPP, Eff=C-terminus transcriptional effector region o f ER.
Three mechanisms have been shown by which GR can produce repression of gene 
expression once DNA bound; direct inhibition of transcription via the effector domain, 
neutralisation of an enhancing factor, or competition with a co-activator. These 
mechanisms all require activation of the receptor by ligand binding as described above. 
Negative effects of GR on transcription seem to be mediated by binding to distinct 
GRE sites. Although related in sequence to the GRE associated with positive effects on 
transcription, the receptor may bind these negative-GREs in a different configuration 
to the positive-GREs. For example, in the pro-opiomelanocortin gene, GR has been 
shown to bind as a trimer to the negative-GRE rather than as a dimer (Drouin et al.,
1993). The bound GR can then act by exerting a direct inhibitory influence on 
transcription, or by preventing binding of a positive acting factor. GR binding in the 
human glycoprotein hormone a-subunit gene only results in repression of gene 
expression when the CRE is intact (Akerblom et al., 1988). The GRE overlaps the 
CRE in this gene. Interestingly, mutation of the GRE or GR DNA-binding domain did 
not abolish repression (Stauber et al., 1992). It was also found that inhibition by GR 
was only effective when transcription was activated by CREB. In vitro, no high 
affinity protein-to-protein interactions were identified between GR and CREB 
implicating a third protein in the interaction. The nuclear factors, like CREB (see 
1.3.2.3), can bind CBP resulting in mutual repression (Kamei et al., 1996) and this may 
be the mechanism involved for this gene. A similar mechanism could be postulated for 
the IL-6 gene where the -145 to -173 GRE site overlaps the CRE. Co-repressor 
molecules play a role in gene inhibition by nuclear receptors as identified for the
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thyroid hormone and retinoic acid receptors. Nuclear receptor co-receptor (N-CoR), 
together with two other proteins mSIN3 and mRPD3, bind to the nuclear receptors as a 
co-repressor complex (Heinzel et al., 1997, Horlein et al., 1995). In addition to 
transcriptional inhibition by binding to GRE, the GR can inhibit transcription in genes 
that do not contain a GRE, such as the collagenase promoter (Yang-Yen et al., 1990). 
This is via direct protein-to-protein interactions with the transcriptional activators Fos 
and Jun resulting in repression of AP-1 activity. NF-kB induced expression of IL-6 can 
be inhibited by GR association with the p65 subunit of NF-kB (Ray and Prefontaine,
1994). Mutual repression has been shown between N F-kB p65 and GR, and was 
dependent upon the co-activators CBP and steroid receptor coactivator-1 (SRC-1), 
(Sheppard et al., 1998). Increased levels of CBP were able to relieve glucocorticoid 
repression of NF-kB, while CBP and SRC-1 were able to relieve NF-kB repression of 
GR activity. This is another example of cross-talk between transcriptional pathways. 
GR inhibition of NF-kB activity can also occur via an indirect inhibitory mechanism. 
In some genes, GR can have enhancing roles on transcription. This is seen with the 
IkB<x gene where glucocorticoid exposure induces expression, resulting in increased 
levels of IkB o, protein and increased inhibition of N F-kB activity (Scheinman et al., 
1995, also see section 1.3.2.1).
The predominant influence of glucocorticoids on the transcription of IL-6  is inhibitory. 
This is via direct effects of activated GR binding to GREs, with potential inhibition of 
CREB binding, competition of co-activators such as CBP, inhibition of Fos and Jun 
activation through the API site, and possibly also by direct inhibitory mechanisms on 
the basal transcription machinery. Other mechanisms include non-DNA-bound GR- 
protein interactions such as described with NF-kB.
1.3.2.6. Oestrogens and androgens
Oestrogen has been shown to down-regulate IL-6 expression in osteoblasts and bone 
marrow stromal cells (Girasole et al., 1992). This inhibition occurs at the level of 
transcription and is oestrogen receptor (ER) dependent. However, it does not involve 
ER binding to the IL-6 5’-flanking region where there are no known binding sites for 
oestrogen or androgen receptors (Pottratz et al., 1994, Ray et al., 1994). ER repression 
is via direct protein-protein interaction with the transcriptional activators NF-kB (p65
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and p50 subunits) and C/EBPp, inhibiting their ability to bind DNA (Stein and Yang, 
1995, Ray et al., 1997). Mutation studies revealed that a region adjacent to the DNA- 
binding domain of the ER was necessary for these protein interactions (see figure 
1.16). ER interaction was via the Rel homology domain of NF-kB and the leucine- 
zipper domain of C/EBP. Although the DNA-binding domain was not necessary for 
ER interaction with NF-kB or C/EBPp, it was necessary, together with the hormone- 
binding domain and C-terminus effector region (figure 1.16), for repression of the IL-6 
promoter (Stein and Yang, 1995). In Cos-7 monkey cells, oestrogen was found to 
inhibit NF-kB but not C/EBPp induced IL-6  transcription, a process that may involve 
oestrogen induced conformational changes of the ER hormone-binding domain 
(Kurebayashi et al., 1997). Like GR, ER has been shown to bind API Jun, but not Fos, 
transcription factors, via direct protein-protein interaction requiring a similar 
interaction domain as for N F-kB and C/EBPp (Doucas et al., 1991, Teyssier et al., 
2001). It is not known however whether such interactions have a modulatory effect on 
IL-6 transcription. Androgens, in contrast to oestrogens, have been shown to inhibit the 
expression of IL-6 through maintenance of IkBcx levels and hence inhibition of N F-kB 
activation, and not via direct interaction with NF-kB (Keller et al., 1996). Oestrogens 
were shown not to significantly modulate hcBa levels (Stein and Yang, 1995).
1.3.2.7. Interferon regulatory factor
Interferon regulatory factor-1 (IRF-1) is an interferon-y inducible transcription factor 
that in HeLa cells was shown to bind the 5’-flanking region of the IL-6 gene from -  
254 and -267, and in the co-presence of NF-kB (p65) to up-regulate IL-6 expression 
(Faggioli et al., 1997). This co-operative induction required the concomitant removal 
of the negative effect of a retinoblastoma control element (RCE) and involved the 
presence of the transcription factor Spl (Sanceau et al., 1995).
1.3.2.8. Sp I
Deletion mutation studies of the human IL-6 gene indicated a negative regulatory 
region between -73 and -181 (Shimizu et al., 1990, Sanceau et al., 1995). This region 
contains a consensus sequence for retinoblastoma control element (RCE) and Spl. 
EMSA studies using interferon-y and TNFa induced nuclear extracts from THP1 cells 
(a human monocyte cell line), showed the presence of Spl in the protein-complex
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binding to this negative regulatory region (Sanceau et al., 1995). It is not known 
whether this is a cell specific phenomenon, as studies in other cell-types have not been 
reported. However, in murine IL-6  studies, Spl binding to three CCACC motifs 
between the NF-kB and C/EBPp binding sites was important in both basal and 
inducible expression (Kang et al., 1996). Deletion mutant constructs revealed that 
these Spl sites were necessary for murine IL-6 transcription via NF-kB and C/EBPp. 
It remains to be established whether this is an important mechanism in human IL-6 
transcription.
1.3.2.9. Recombination binding protein
The transcriptional repressor recombination binding protein (RBP, also known as 
CBF1 or RBP-Jk) has been shown in transient-expression assays to repress IL-6 
transcription (Kannabiran et al., 1997). EMSA studies with nuclear extracts from an 
embryonal carcinoma cell line F9, showed binding from -62 to -69 (AAAGGGT) of 
the IL-6 gene, a site overlapping the NF-kB site. Studies with nuclear extracts from a 
mouse fibrosarcoma cell line L929, reported RBP to be constitutively bound to this site 
at a 10-fold lower affinity than NF-kB and suggested that RBP may have a role in the 
constitutive repression of the IL-6  gene under normal physiological conditions 
(Plaisance et al., 1997). Kannabiran and co-workers (1997) showed that RBP repressed 
co-operative activation of IL-6 expression by NF-kB and C/EBPp. This required all 
three sites, the RBP, NF-kB and C/EBPp to be bound by their transcription factors for 
repression to occur. The mechanism is therefore not simply due to prevention of NF- 
kB or C/EBPp binding, but involves inhibition of interaction between NF-kB and 
C/EBPp. In HeLa cells, RBP has also been shown to bind at this site on the hIL-6 gene 
and inhibits transcription (Palmieri et al., 1999). This inhibition may be effected 
through conformational change in the IL-6 promoter region as the topology of the 
RBP-DNA bound complex was influenced by surrounding sequences, and in IL-6 
induced a bend in the DNA. In the course of investigating the mechanism of RBP 
inhibition of NF-kB and C/EBPp transactivation of IL-6 , a third C/EBP site was 
identified that overlaps the RBP site in hIL-6  (Vales and Friedl, 2002). Deletion 
mutant constructs of IL-6  lacking the two up-stream C/EBP sites (-146 to -154 & -75 
to -83) were found to still bind C/EBPp, 8 and a  via direct DNA-binding. 
Interestingly, these constructs could bind NF-kB p65 or C/EBP family members alone,
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but combined C/EBP & p65 binding was not seen in the absence of the up-stream 
C/EBP site. This suggests that co-operative binding between NF-kB and C/EBP at this 
down-stream site requires co-operation from the up-stream C/EBP site. Site-directed 
mutagenesis of the RBP site produced a mutant construct with reduced RBP binding 
that could still bind NF-kB p65, but had reduced binding of C/EBP family members. 
This construct produced significantly lower levels (similar to those of wild-type 
construct inhibited with RBP) of IL-6 transcription in response to NF-kB and C/EBPp 
exposure in HepG2 and COS cell transient transfections and could not be repressed by 
exposure to RBP (Vales and Friedl, 2002). A second mutant prevented RBP binding 
but still facilitated similar levels of NF-kB and C/EBP binding as the wild-type 
sequence. This construct displayed levels of IL-6 expression similar to the wild-type 
construct, but was not repressed by RBP. This confirms that RBP repression requires 
DNA-binding of RBP and that the third, down-stream C/EBP site, over-lapping the 
RBP site, is functionally significant for optimal induction of IL-6  expression. In 
addition, it suggests that RBP binding may produce its repressor effect by disruption of 
C/EBP binding to the third C/EBP site. RBP has also been shown to have two other 
mechanisms of transcriptional repression. It can interact with co-repressors such as N- 
CoR (see 1.3.2.5) and histone deacetylase (see 1.3.2.3), and can interact with the basic 
transcriptional machinery to reduce transcriptional activation (Kao et al., 1998, Olave 
et al., 1998). These mechanisms may also be relevant to inhibition of IL-6 
transcription.
1.3.2.10. Regulation of IL-6 expression in rheumatoid fibroblast-like synoviocytes 
Cell-type specific differences in the regulation of the human IL-6 gene are evident. In a 
murine monocyte/macrophage cell line, PU5-1.8, the API site, CRE and adjacent 
C/EBPp and NF-kB sites were all important for IL-6  expression (Dendorfer et al.,
1994). In a human monocytic cell line, THP1, two C/EBPp binding sites (-75 to -83 & 
-148 to -155) were important together with NF-kB (Zhang et al., 1994). In contrast, 
cells infected with the human T-cell leukaemia virus type-I required only NF-kB for 
full expression of IL-6 (Mori et al., 1994).
In the inflammatory arthritis, rheumatoid arthritis, the main producer of IL-6 with in an 
inflamed joint is believed to be fibroblast-like synoviocytes (Firestein et al., 1990,
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Gueme et al., 1989). Site-specific mutagenesis studies of IL-6 promoter constructs in 
rheumatoid fibroblast-like synoviocytes (FLSs) identified regulation by C/EBPp, NF- 
kB and RBP as important for IL-6 expression (Miyazawa et al., 1998a). NF-kB 
(p65/p65 and p50/p65 dimers) were the main enhancers of IL-1 induced expression of 
IL-6 in these cells, but were not significantly involved in basal IL-6 regulation. 
C/EBPp in contrast was a significant enhancer of both basal and IL-1 induced 
expression of IL-6 . RBP binding was thought by this group to be a positive regulator 
of IL-1-induced expression of IL-6 . However, in light of the findings by Vales and 
Friedl (2002, discussed in section 1.3.2.9), who identified a third C/EBP site 
overlapping the RBP site, it is likely that the mutation preventing RBP binding was 
also preventing C/EBP binding to this down-stream site. The reduced expression seen 
with this construct was probably due to loss of C/EBP activity rather than RBP.
In addition, the p38 mitogen activated protein kinase (MAPK) pathway was activated 
in response to IL-lp stimulation of human FLSs (Miyazawa et al., 1998b). Using a 
pyridinylimidazole inhibitor specific for p38 MAPK, SB203580, Miyazawa and co­
workers (1998b) showed that levels of IL-6  protein and mRNA were inhibited in a 
dose and time dependent manner. This appeared to be a mechanism independent of 
transcription, as the inhibition was not prevented by the blocking of transcription with 
actinomycin D, nor did SB203580 alter the levels of transcription of transfected IL-6 
reporter constructs. Activation of the p38 MAPK pathway appeared to stabilise IL-6 
mRNA, with SB203580 significantly reducing the half-life in FLSs. This may be a cell 
specific, species specific and/or inducer specific effect, as in the mouse fibrosarcoma 
cell line L929, SB203580 repressed TNFa-induced expression of human IL-6 reporter 
constructs indicating an action at the level of transcription (Berghe et al., 1998). 
Although NF-kB plays an important role in the induction of EL-6 expression by TNFa, 
blocking the p38 MAPK pathway did not affect levels of NF-kB binding to DNA. 
Glucocorticoid inhibition of IL-6  expression was mediated at the level of transcription 
in FLSs, with no effect on the stability of IL-6 mRNA (Miyazawa et al., 1998c). This 
was dependent on de novo protein synthesis as exposure to cyclohexamide to block 
protein synthesis prevented dexamethasone inhibition of IL-6  expression. Levels of 
hcBa (a cytoplasmic inactivator of N F-kB, see section 1.3.2.1) were not altered by 
dexamethasone exposure of IL-1-stimulated FLSs.
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1.3.3. Polymorphisms in the 5’-flanking region of IL-6
Three single nucleotide polymorphisms (SNPs) have been described in the 5’-flanking 
region of the human IL-6 gene; a G to C at position -174 (Fishman et al., 1998, 
Olomolaiye et al., 1998), a G to C at position -572 (Nakajima et al., 1999, Osiri et al., 
1999) and a G to A at position -597 (Faulds et al., 1998, Jordanides et al., 2000). A 
variable length AT-tract polymorphism from -373 to -392 has also been described 
(Fishman et al., 1998, Nakajima et al., 1999, Terry et al., 2000). These polymorphisms 
had been identified prior to this thesis by the collaborative groups of Prof P Woo and 
Prof S Humphries at University College London.
1.3.3.1. SNPs in the 5’-flanking region of IL-6
The frequency of distribution of the -174, -572 and -597 alleles reported in this thesis 
for normal healthy individuals in various ethnic groups are in Hardy-Weinberg 
equilibrium (see table 1.2). There are clear ethnic differences between the frequency of 
distribution for these polymorphisms.
The -174C allele occurs significantly less frequently in Gujarati Indians, Southern 
Chinese, Afro-Carribeans and African-Americans compared to Caucasians. The lower 
frequency in retired Southern Chinese male coal miners is more difficult to interpret as 
a survival advantage of the -174G allele cannot be excluded. The -572 polymorphism 
has a similar reported frequency of distribution in Caucasians and African-Americas, 
though it is very interesting that in the Japanese population, the opposite allele 
frequency was reported with -572C being the most common allele. One should note 
that the Japanese study used PCR-RFLP with a different restriction enzyme, BsrBI, 
from the other studies. Though it recognises the same DNA sequence, it is possible 
that restriction digestion failure could have resulted in an over-estimation of the C- 
allele frequency for this SNP. In addition, the subjects in this study were all females 
selected as controls for a hypertension study. It would be of significant interest if  the 
results were replicated in an independent Japanese population. The allele frequency for 
the -597 polymorphism is similar in each ethnic group to that of the -174 
polymorphism. The -597A allele occurs in significantly lower frequency in African- 
Americans compared to Caucasians.
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Ethnic group Polymorphic site n Allele Frequency Reference
Caucasian -174 383 G 0.597 Fishman et al., 1998
C 0.403
Caucasian -174 73 G 0.555 Jordanides et al., 2000
C 0.445
Gujarati Indian -174 115 G 0.850 Fishman et al., 1998
C 0.150
Southern Chinese -174 259 G 0.998 TZhai et al., 2001
C 0.002
Korean -174 53 G 0.994 Lim et al., 2002
C 0.006
Afro-Caribbean -174 101 G 0.950 Fishman et al., 1998
C 0.050
African-American -174 63 G 0.960 Osiri et al., 1999
C 0.040
Caucasian -572 73 G 0.959 Jordanides et al., 2000
C 0.041
African-American -572 63 G 0.905 Osiri et al., 1999
C 0.095
Japanese -572 142 G 0.176 ♦Nakajima et al., 1999
C 0.824
Caucasian -597 73 G 0.568 Jordanides et al., 2000
A 0.432
African-American -597 63 G 0.952 Osiri et al., 1999
A 0.048
Table 1.2. The frequency of distribution of alleles at the -174, -572 and -597
SNPs of IL-6 in various ethnic groups.
n=number of individuals in the study group. 
TRetired male coal miners only 
♦Females only
1.3.3.2. SNPs can influence transcription
Single nucleotide polymorphisms in the regulatory region of a gene can influence 
levels of transcription and expression of the gene. This has been demonstrated and 
characterised for two SNPs in the 5’-flanking region of the cytokine gene TNFa. The 
G to A SNP at position -376 allows allele-specific binding of the transcription factor 
OCT-1 to this site of multiple protein occupancy (Knight et al., 1999). The OCT-1 
binding variant -376A was associated with higher TNFa-luciferase-reporter construct 
expression in primary human monocytes, Mono Mac cells. These in vitro findings 
appeared functionally significant as in a large case-control study of a West and East
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African population, possession of the -376A allele (present in approximately 5% of the 
population) was associated with a significantly increased susceptibility to cerebral 
malaria. In addition, the C to A polymorphism at position -863 of TNFa has been 
shown to alter NF-kB binding (Udalova et al., 2000). The -863A allele reduces 
binding of the p50/p50 homodimer compared to the -863C allele while still permitting 
the same p50/p65 heterodimer binding. Reduced p50/p50 binding was associated with 
higher levels of TNFa expression in COS-7 cells. In Mono Mac cells, higher TNFa 
expression occurred with transfected A-allele rather than C-allele constructs, however 
this was dependent on the presence of the TNFa 3’-untranslated region, located down­
stream of the reporter gene. This indicates that an allelic effect can be modified by 
factors influencing expression in other regions of the gene. Allelic associations can 
also be important. Within the same gene, this is illustrated by the effect of allelic 
association between the -863 polymorphism and another upstream SNP at position -  
1031. Concanavalin A stimulated peripheral blood monocuclear cells (PBMCs) from 
healthy donors possessing the -1031C-863A haplotype of TNFa produced 2-fold 
higher levels of TNFa expression than PBMCs from individuals possessing the 
dominant -1031T-863C haplotype (Higuchi et al., 1998). In contrast, transfection 
studies in the hepatocyte cell line HepG2, showed the -863A allele to be associated 
with lower levels of expression than -863C (Skoog et al., 1999). This corresponded 
with in vivo levels of expression in 254 healthy Swedish men in whom the -863A 
allele was associated with significantly lower levels of serum TNFa than the -863C 
allele. SNPs in the 5’-flanking region of a cytokine gene can influence transcription 
though the functional significance may vary depending on allelic associations and 
cellular context.
1.3.3.3. AT tract polymorphisms in the 5’-flanking region of IL-6
Several AT-tract polymorphisms between -373 and -392 have been described. The
majority maintain the length of the AT-tract at 20 bases however polymorphisms
varying the overall AT-tract length by one additional base have also been reported
(Fishman et al., 1998, Nakajima et al., 1999, Terry et al., 2000). Table 1.3 shows these
AT-tract variations and the frequency of distribution in the Caucasian and Japanese
population.
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Ethnic group n AT-tract allele Frequency Reference
Caucasian
Caucasian
57
78
A8/T12
A8/T12
0.421
0.370
♦Fishman et al., 1998 
Terry et al., 2000
Caucasian
Caucasian
57
78
A9/T11
A9/T11
0.211
0.190
♦Fishman et al., 1998 
Teny et al., 2000
Caucasian
Caucasian
Japanese
57
78
280
A10/T10
A10/T10
A10/T10
0.175
0.180
0.939
♦Fishman et al., 1998 
Terry et al., 2000 
♦♦Nakajima et al., 1999
Caucasian
Caucasian
Japanese
57
57
280
A10/T11
A10/T11
A10/T11
0.123
0.250
0.061
♦Fishman et al., 1998 
Terry et al., 2000 
♦♦Nakajima etal., 1999
Caucasian 57 A9/T10 0.053 ♦Fishman et al., 1998
Caucasian 57 A10/T9 0.017 ♦Fishman et al., 1998
Table 1.3. The frequency of distribution of alleles at the AT-tract of IL-6 in 
Caucasian and Japanese individuals.
n=number of individuals in the study group.
’normal controls and patients with SA 
*’females only
The frequency of distribution for each allele is similar in Caucasians between the two 
studies with A8/T12 the most common AT-allele. However, the frequency of alleles 
reported in the Japanese population is very different. Nakajima and co-workers (1999) 
used PCR-SSCP to identify the AT tract alleles, a technique that would not distinguish 
between allelic variations maintaining a constant length of AT-tract, but only variants 
of different lengths. The groups called ‘A10T10’ and ‘A10T11’ therefore probably 
represent a mixture of AT-alleles of 20 and 21 bp lengths, respectively. The other two 
papers used sequencing and/or the method of Bowcock et al., (1989) to distinguish 
each allelic variant.
No transcription factors have been reported to bind to such AT-tracts. However, this 
sequence has implications in the tertiary structure of the DNA helix and may influence 
ease of strand opening, a process essential for transcription to occur (Siebenlist, 1979). 
AT rich regions have been shown to induce a cruciform extrusion in vitro under certain 
conditions (Bowater et al., 1994), a similar effect may occur in vivo.
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1.3.4. Polymorphisms in other regions of the IL-6 gene
Variable region tandem repeats (VNTRs) of AT-rich sequences have been described in 
the 3’-flanking region of the IL-6 gene (Bowcock et al., 1989, Murray et al., 1997, 
Jordanides et al., 2000, Crilly et al., 2001). The functional relevance of these 
polymorphisms in the non-transcribed 3’-flanking region is unknown.
Single strand conformational polymorphism (SSCP) analysis revealed a G to A variant 
in exon 5 of IL-6 (Nakajima et al., 1999). Only heterozygotes for this variant were 
detected in 140 Japanese women with a frequency of 0.064. No other variants in the 
IL-6 intron or exon sequences have been reported.
1.3.5. Post-transcriptional regulation of IL-6 expression
Although the overall regulation of IL-6 expression is at the level of transcription, 
variations in mRNA stability and translation can modulate expression of the IL-6 
protein. Deletion of N-terminal untranslated regions (UTRs) including AU-rich 
sequences of IL-6 mRNA has been shown to increase mRNA stability and result in 
higher IL-6 expression in transfected mouse NIH3T2 cells (Tonouchi et al., 1989). 
Sequence and position specific AU-rich regions in the 3’UTRs of the proto-oncogene 
c-Jun act as RNA-destabilising elements (Peng et al., 1996), in TNFa these regions 
have been shown to bind RNA binding proteins (AUBPs) involved in repression of 
translation (Hel et al., 1998). No variations of the 3’-UTR of IL-6 have been reported.
The half-life of IL-6 mRNA in fibroblasts and monocytes is approximately 1-hour 
(Elias and Lentz, 1990, Brach et al., 1990). IL-6 mRNA stability has been shown to be 
influenced by a number of inflammatory modulators. IL-1 and TNFa act 
synergistically in the up-regulation of IL-6 expression in fibroblasts by a mechanism 
involving increased transcriptional activation, but also increased mRNA stability (Elias 
and Lentz, 1990). IL-1 p stabilises IL-6 mRNA induced by c-kit Ligand and IL-10 in 
mouse bone-marrow-derived mast cells via IL-lp inducible protein (Lu-kuo et al., 
1996). In human fibroblast-like synoviocytes IL-1 p stabilisation of IL-6 mRNA was 
via activation of the p38 MAPK pathway involving activation of MAPK-activated 
protein kinase 2 (MAPKAP kinase 2), (Miyazawa et al., 1998b, and see 1.3.2.10). The 
half-life of IL-6 was reduced by 10-fold in response to LPS, in MAPKAP kinase 2
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deficient macrophages from knockout mice (Neininger et al., 2002). The effects of 
MAPKAP kinase 2 seemed to be mediated via the 3’-UTR with AU-rich regions, as 
MAPKAP kinase 2 could stabilise a mRNA reporter construct carrying the human or 
mouse IL-6 3’-UTR (there is high homology for this region between the two species). 
Deletion of the AU-rich element of the 3’-UTR in TNFa-mRNA abrogated the effects 
of MAPKAP kinase 2 (Neininger et al., 2002). In human monocyte cell lines, IL-10 
stimulation was shown to reduce the half-life of IL-6  mRNA (Takeshita et al., 1996). 
Leukotriene B4 can result in stabilisation of IL-6 mRNA, possibly via up-regulation of 
AUBPs through its activity as a calcium ionophore (Rola-Pleszczynski and Stankova,
1992). The effect of TNFp (lymphotoxin) is contradictory. It has been reported to 
stabilise IL-6  mRNA in fibroblasts (Akashi et al., 1990), whereas to reduce IL-6 
mRNA half-life in monocytes (Brach et al., 1990). In both cases, a mechanism 
requiring protein synthesis was shown to be necessary.
Despite influences on mRNA stability, the over-riding influence of transcriptional 
regulation over these post-transcriptional modifications in the expression of IL-6  is 
shown by the stimulation of PBMCs with IL-1 in the presence of histamine. Over all 
there was an increase in the expression of IL-6  through increased transcription, though 
IL-6  mRNA half-life was reduced (Vannier and Dinarello, 1994). Post-translational 
modification of the IL-6  protein also occurs and includes N- and O-linked 
glycosylations and phosphorylations (May et al., 1988, Santhanam et al., 1989), which 
in turn may influence the half-life, distribution, binding capacity or actions of the 
protein. At sites of inflammation, IL-6  has been shown to induce release of elastase, 
proteinase 3 and cathepsin G (serine proteases) from neutrophils and results in 
degradation and inactivation of IL-6  (Bank et al., 1999), though sIL-6R was protective 
against IL-6  inactivation by cathepsin G. This may represent a feedback mechanism to 
regulate the availability and biological actions of IL-6 .
1.3.6. Hypothesis of this thesis
The hypothesis of this thesis was that over-expression of IL-6  contributes to disease 
susceptibility and phenotype of the systemic arthritis sub-type of JIA. As IL-6  is 
predominantly regulated at the level of transcription, genetic variations in the 5’- 
flanking region could influence IL-6  transcription and hence the pathophysiology of 
SA.
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1.3.7. Aims of this thesis 
The aims of this thesis were to:
i. Investigate the association of 5’-flanking region polymorphisms of the IL-6 
gene with SA compared to healthy controls.
ii. Assess the effect of polymorphisms in the 5’-flanking region of IL-6 on the 
regulation of IL-6 transcription using IL-6 variant-reporter constructs in 
transfection studies.
iii. Identify alterations in transcription factor(s) binding due to different alleles that 
may explain functional differences in IL-6 transcription.
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CHAPTER 2 
MATERIALS AND METHODS
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2.1. Source of patient and control genomic DNA samples
2.1.1. Patient samples
Fresh venous blood samples collected into sodium EDTA were obtained (with full 
patient and parental informed consent) from Caucasian patients attending paediatric 
rheumatology centres across the UK. This was facilitated through the British Paediatric 
Rheumatology Group. Blood was only taken from children when other blood samples 
were being collected for clinical reasons. Each patient had to have a confirmed 
diagnosis of juvenile idiopathic arthritis (JIA) by the International League against 
Rheumatism (ILAR) criteria (see section 1.2.10). Information was collected as to the 
age at onset of the disease, the sex of the patient, the classification and the pattern of 
the disease. Samples were sent for storage and HLA typing to the British Paediatric 
Rheumatology Group National DNA repository, Manchester University.
2.1.2. Control samples
Fresh venous blood samples collected into sodium EDTA were obtained from healthy 
individuals recruited from four independent sources as representative control samples 
of the UK Caucasian population. Healthy UK Caucasian adults aged 16-30 years, 
consecutively registered on a General Practice List from Nuneaton (Midlands) and 
North London, were invited to attend their general practitioner to donate a blood 
sample. There had to be no history of chronic illness or prior joint problems and the 
individual completely well at the time of sampling. Information on sex and age was 
collected. A third group was recruited from first time blood donors attending a blood- 
donor clinic in the West End of London. Individuals over the age of 18 years with no 
self-reported known illness were invited to allow an aliquot of blood to be taken for the 
study at the time of blood donation. Self-reported information on age, sex and ethnic 
origin was collected. Only samples from UK Caucasian individuals were used for the 
purposes of this study. First time donors were chosen to avoid sample duplication, as 
identification was anonymous. A fourth control group had been recruited prior to this 
thesis from North West London as UK healthy Caucasian men aged 50-61 years, as 
part of a study into cardiovascular risk factors (Miller et al., 1996). Permission was 
obtained to use these samples as a control group for the purposes of this study.
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2.2. Purification of genomic DNA
2.2.1. Purification of genomic DNA from blood
Fresh venous blood in sodium EDTA (300-1000^1) was purified in one of two ways; 
by the Nucleon biosciences DNA extraction kit or by phenol: chloroform extraction.
2.2.1.1. Nucleon biosciences extraction kit
Blood in sodium EDTA (300-600pl) was purified using Nucleon biosciences DNA 
extraction kit for blood and cell cultures following the manufacturer’s recommended 
instructions. In brief, the cells were lysed in SDS containing buffer and protein 
destroyed with sodium perchlorate (reagents supplied). The protein was extracted once 
with chloroform and once with Nucleon resin. The DNA was then precipitated with 
ethanol and re-suspended in 200|li1 of water or TE*.
2.2.1.2. Phenol: chloroform extraction
This method is based on that used by Kunkel et al. (1977).
Blood in sodium EDTA (1000-8000pl, best results with 6-7000pl) was diluted to 50ml 
with lysis buffer (320mM sucrose, lOmM tris-HCl, 5mM MgCb, 1% (v/v) triton) at 
4°C and gently mixed. The lysed cells were spun at 2,500rpm (Sigma 4K15 
refrigerated centrifuge) at 4°C for lOmin. The supernatant was discarded and the pellet 
re-suspended in 4.5ml NaCl/EDTA buffer (75mM NaCl, 24mM EDTA pH8). 250pl of 
10% SDS, lOOpl of proteinase K (lOpg/pl) and 150pl of sterile distilled water (SDW) 
were added and incubated at 37°C overnight. Protein was extracted with an equal 
volume of equilibrated phenol* (5ml), the phases separated by centrifugation at 
2000rpm for 5min. The upper aqueous phase was transferred to a clean tube (the lower 
phenol phase discarded into phenol waste). A further extraction was carried out on the 
aqueous phase with 2.5ml phenol and 2.5ml SEVAQ (chloroform: isopropanol 24:1), 
spun as before (2000rpm for 5min), retaining the upper phase and then a final 
extraction with 5ml SEVAQ. The upper aqueous phase was transferred to a clean tube, 
0.5ml of 3M sodium acetate was added followed by 12.5ml of ice-cold absolute 
ethanol and mixed by gentle inversion until the DNA threads could be seen to 
precipitate. For larger volumes of blood, the DNA could be hooked out with a glass 
pastette. For smaller volumes, the DNA was pelleted by centrifugation (13,000rpm for 
lmin). The DNA was air-dried before re-dissolving in 300-500pl of SDW or TE*.
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2.2.2. Purification of genomic DNA from cell lines
Cells were grown to confluencey in culture (see 2.10), harvested with trypsin/EDTA 
neutralised by DMEM* containing FCS, washed twice with PBS* and the cell count 
determined (see section 2.10.3). A cell pellet of 1 x 106 cells was gently re-suspended 
in 700pl of genomic-DNA buffer (50mM Tris, lOOmM EDTA pH8, lOOmM NaCl and 
1% SDS) using a lOOOpl pipette tip with the end cut off. 35pl of Proteinase K 
(lOmg/ml, Sigma) was added and the mix incubated overnight at 55°C. Protein was 
extracted using an equal volume of equilibrated phenol* which was mixed thoroughly, 
pulse centrifuged and the top aqueous phase containing the DNA removed into a fresh 
tube. This was repeated twice and followed by one extraction with an equal volume of 
chloroform: isopropanol (24:1). DNA was precipitated from the aqueous phase by 
adding an equal volume of cold propan-2-ol and gently mixing until threads of DNA 
precipitated. The DNA was either spooled out on a glass pastette or pelleted by 
centrifugation, washed twice in 70% ethanol, air dried and re-suspended in 300pl of 
TE*.
23. Electrophoretic separation of DNA molecules
2.3.1. Horizontal agarose gel electrophoresis
Typically a 1% (w/v) agarose suspension in lx  TAE* or TBE* buffer was boiled for 
lmin to dissolve the agarose, cooled to 40-50°C and 3pi of ethidium bromide 
(lOmg/ml) was added per 100ml. The mix was then poured into a gel slab mould 
(BioRad) and allowed to set for 40min before use. For separation of small fragments of 
DNA (<200bp) or to distinguish fragments that differed in length by a small amount 
(<50bp) separation was carried out on a 2-2.5% (w/v) agarose gel. Pre-loading, sample 
aliquots were mixed with 1/6* volume 6x blue/orange loading dye (0.4% orange G, 
0.03% bromophenol blue, 0.03% xylene cyanol FF, 15% Ficoll 400, lOmM Tris-HCl, 
50mM EDTA). Gels were run from cathode to anode in lx TAE or TBE (dependent on 
the buffer used to make up the gel), at 2-5 volts per cm, with a DNA molecular weight 
marker ladder (lOObp ladder, Promega ± lambda DNA HindHl digest, see figure 2.1) 
in one lane. The DNA bands were viewed under ultraviolet light and a photographic 
record taken.
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2.3.2. Vertical non-denaturing polyacrylamide gel electrophoresis 
For a 100ml gel, 10ml of lOx TBE* and 40% sequencing grade acrylamide (National 
Diagnostics) plus water was mixed according to the percentage gel required (see table 
2.1). Ammonium persulphate (AMPS, Sigma) was added and mixed, and then 
tetraethylmethylene diamine (TEMED, BDH) was added, thoroughly mixed and the 
gel solution immediately poured between glass plates (pre-washed and cleaned with 
ethanol). The gel was allowed to polymerise for 45min with 15% gel, to a minimum of 
2hours with 4% gel, before pre-running in lx  TBE. Samples were loaded in lx  
blue/orange loading dye (Promega).
2el % lOx TBE 40% h 2o AMPS TEMED Use
Acrylamide
4% 10ml 10ml 80ml O.lg 40pl EMSA
8% 10ml 20ml 69.6ml 350plT 35pl MADGE
15% 10ml 37.5ml 51.6ml 775plT 77pl Heteroduplex
Table 2.1. Polyacrylamide gel constituents.
Tfreshly prepared 10% (w/v) AMPS
2.4. Southern blotting and hybridisation
Typically, 20jug of purified genomic DNA (see sections 2.10.8 & 2.2.2) from stable 
cell transfectants was digested overnight with restriction enzyme (lU /pg of DNA). 
This was with Hindlll or Sphl (see section 2.7) as these enzymes have only one cut site 
in the transfected plasmid construct. The digested products were separated by 
electrophoresis on a 0.8% horizontal slab agarose gel containing 0.3mg/ml ethidium 
bromide in lxTBE* (section 2.3.1), for 16-20 hours at 2V/cm. Lambda DNA Hindlll 
digest and lOObp marker ladders (figure 2.1) were run along side for size reference. 
This lane was removed before blotting, after a photographic record of the gel had been 
taken on an ultraviolet light-box with a ruler scale.
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23,130
9,416
6,557
4,361
Figure 2.1. DNA molecular weight markers.
Combination of Lambda DNA digested with Hindlll and lOObp ladder (Promega), run on a 1% agarose 
gel at 2.5v/cm for 45min, stained with ethidium bromide and viewed under UV light.
2.4.1. Southern blotting
The electrophoresed gel was denatured in 1.5M NaCl with 0.5N NaOH for 45min on a 
slow rotating platform. This was followed by a rinse in deionised water and 
neutralisation in 1M Tris (pH7.4) with 1.5M NaCl for 40min. The blot was then set up 
as shown in figure 2.2. The membrane used was nylon Hybond-N+ nucleic acid 
transfer membrane (Amersham), the buffer used was concentrated Salt Sodium Citrate 
(20xSSC*). Blotting was carried out for 16-24 hours. After blotting, the DNA was 
fixed to the membrane by baking between two pieces of Whatman 3MM paper for 2 
hours at 80°C.
2.4.2. Hybridisation
The blotted membrane was prehybridised in hybridisation solution (6x SSC*, 5x 
Denhardt’s reagent*, 0.5% SDS and lOOmg/ml denatured, fragmented salmon sperm 
DNA*) for at least 2 hours at 68°C. This was carried out using roller bottles in a 
hybridisation oven (Hybaid) with 0.2ml hybridisation solution per cm2 of membrane. 
2-4ng of denatured radiolabelled probe (see 2.4.4) was added for hybridisation at 68°C 
for 12-18 hours.
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Figure 2.2. Southern blot set up.
2.4.3. Stringency washes
Following hybridisation, non-specifically bound probe was removed by stringency 
washes. This was carried out twice in 2x SSC* with 0.5% SDS, once in 2x SSC with 
0.1% SDS, each for 15min at room temperature, once in 0.1 x SSC with 0.5% SDS for 
30min at 37°C and once in O.lx SSC with 0.5% SDS for 60min at 65°C. The 
radioactive counts were read over the blot with a hand held monitor (Mini Instruments, 
Mini-Monitor GM Series 900) held 2cm above the blot, and if this was still above 10- 
20cps then the final wash was repeated. The blot was wrapped in Saran wrap (Dow 
Chemical Company) and exposed to x-ray film (X-OMAT, Kodak) for 16-24hours at -  
70°C. Longer exposures were carried out if required.
2.4.4. Preparation and random primer radiolabelling of DNA probe
For identification of the integration of IL-6-luciferase reporter constructs in the 
genomic DNA of stable transfectants, a 700bp fragment of the luciferase gene from 
PGL3 basic (Promega) was prepared. 15pg of plasmid DNA was digested with Sphl 
(see 2.7). The salt concentration of the reaction was then adjusted to high salt with 
NaCl for a second digestion with Hindlll (section 2.7). The resultant fragment was 
separated by horizontal agarose gel electrophoresis (see 2.3.1), visualised under UV 
light and cut out in slices of agarose gel. The DNA fragment was isolated from the 
agarose using the Qiagen Qiaex II kit as out-lined in section 2.5.4.
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The DNA was radiolabelled using the ‘ready-to-go’ system (Amersham). lOOng of 
DNA fragment in a final volume of 4 5 pi deionised water, was denatured by boiling for 
5min and then placed on ice. 5pi of a 32P-dCTP (3,000 Ci/mole) was added to the DNA 
and then this mix added to the lyophilised DNA polymerase and buffer mix from the 
kit. The labelling reaction was incubated for 30min at 37°C. Unincorporated radiolabel 
was removed by passing the incubated mix through a Sepharose 6CLB column 
(Clontech) to which <10bp fragments adhere and larger fragments pass through. The 
column was flushed with 150pl of TE. Labelled probes were required to have an 
activity of >100cps/ng (Mini-monitor GM series 900). Radiolabelled probe was 
denatured again immediately prior to hybridisation by boiling for 5min.
2.5. Polymerase chain reaction fPCR) amplification
2.5.1. Oligonucleotide primers
Oligonucleotide primers were synthesised to order by Genosys. The Tm value was 
calculated using the formula:
Tm in °C = 2(number of A+T residues) + 4(number of G+C residues)
This was used as a starting temperature for annealing. A series of PCR reactions was 
carried out to identify the optimum annealing temperature for each set of primers. 
Table 2.2 shows the identity of each primer pair, the sequence, the optimised annealing 
temperature and time, the product size and the PCR buffer conditions for all 
oligonucleotide primers used for PCR experiments. The PCR conditions for primers 
9A/10A and 5bF/6R were optimised by G Faulds and L Luong.
2.5.2. Standard PCR conditions
Target DNA used per reaction was a colony stab, lOng of plasmid DNA or 250ng of 
genomic DNA. 250ng of each oligonucleotide primer, 5 pi of lOx PCR buffer (see 
table 2.2), the optimised concentration of MgCL (see table 2.2), 0.2mM each dNTP, 
2.5U Thermus aquaticus (Taq) DNA polymerase (Promega) and SDW to a total 
volume of 50pl were added. Reactions in individual PCR tubes were overlaid with 
50pl of sterile mineral oil and run on a Perkin Elmer DNA Thermal Cycler 480 
Machine. Reactions carried out in 96 well PCR plates were run on a Perkin Elmer (oil 
free) GeneAmp PCR System 9700 Machine.
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Annealing Product PCR
Temp/time length buffer
Human EL-6
-174  polymorphism / M ain digestion
9A 5’-TGACTTCAGCTTTACTCTTTGT-3’ 55°C/60s 190bp
10A 5’-CTGATTGGAAACCTTATTAAG-3’
-174 & -597  polymorphism / SSOP & SfaNl digestion
DF20m 5’-agtcacacactccacctg-3’ 63°C/60s 858bp
DF21 5’-GTGACTGACAGCACAGCT-3’
NH4 polmix
MgCl2
ImM
Polmix
MgCl2
3mM
-174  polymorphism /  heteroduplex 
-174F 5’-GCTTCTTAGCGCTAGCCTCAATG-35 
-174R 5’-TGGGGCTGATTGGAAACCTTATTA-3 ’
60°C/30s 116bp Polmix
MgCl2
2.5mM
-572/—597 polymorphism / Mbil & Fokl digestion 
5bF 5’-GGAGACGCCTTGAAGTAACTGC-3’
6R 5’-GAGTTTCCTCTGACTCCATCGCAG-3’
55°C/40s 163bp Polmix
MgCl2
1.5mM
-572  polymorphism / heteroduplex 
-572F 5’-CGCCTTGAAGTAACTGCACG-3’ 
-572R  5’-GCCTGGGATTATGAAGAAGG-3’
54°C/45s 126bp Polmix
MgCl2
2.5mM
PGL3 basic plasmid
Verification o f IL-6 inserts in plasmid
RV3 5’-CTAGCAAAATAGGCTGTCCC-3’
GL2 5’-CTTTATGTTTTTGGCGTCTTCCA-3’
58°C/60s 147bp+ Polmix 
insert MgCh
length 2mM
cDNA primers
Actin
PW229 5’-ATGGATGATGATATCGCCGC-3’ 
PW230 5’-ATCTTCTCGCGGTTGGCCTT-3’
57°C/45s (xl), 320bp Polmix
55°C/45s (x29) (490bp MgCl2
gDNA) 2.5mM
IL-6
6-5’ 5’-ATGAACTCCTTCTCCACAAGC-3’
6-3’ 5’-CTACATTTGCCGAAGAGCCCTC...
.. AGGCTGGACTG-3 ’
62°C/45s (xl), 63gb
60°C/45s (x29) (43n f p
gDNA)
Polmix
MgCl2
3mM
Table 2.2. Oligonucleotide prim er pairs for PCR (made to order by Genosys). 
Showing the sequences, annealing temperatures and time, product length, PCR buffer conditions and 
purpose for which PCR product was used.
Polmix = lOx Taq DNA polymerase buffer without MgCl2 (Promega) containing lOOmM Tris-HCl 
(pH9), 500mM KC1,1.0% Triton X-100 (iso-Octylphenoxypoly-ethoxyethanol).
NH4 polmix lOx contained 160mM (NH4)2S04,670mM Tris (pH8.4), 0.00lv/v Tween.
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Reactions with genomic DNA template had a pre-cycling denaturation step of 4min at 
95°C. All reactions underwent a post-cycling extension step of lOmin at 72°C. Cycling 
was carried out at 95°C for 60sec, then the annealing temperature and length of time 
optimised for the individual primer set (see table 2.2), followed by 72°C for 90sec. 
Genomic DNA templates were cycled for 30-35 cycles, plasmid DNA templates for 25 
cycles.
Two PCR buffers were used dependent on the subsequent use of the PCR product. The 
enzyme N lalll was inhibited by KC1, therefore NH4 polymix (see table 2.2) was 
utilised as PCR buffer for amplifications to be digested with Nlalll.
2.5.3. Conditions for reverse transcription PCR CRT-PCR)
To generate cDNA from RNA, 0.5pl of cDNA random hexamer primers (500pg/pl, 
Promega) were added on ice to 11 pi of RNA preparation (section 2.6). These were 
annealed at 70°C for lOmin then placed immediately on ice again. A cocktail o f 4pl 5x 
First Strand Buffer (250Mm Tris-HCl pH8.3, 375mM KC1, 15mM MgCb, Gibco), 2pi 
lOOmM DTT (Promega) and 2pl 5mM dNTP mix in nuclease free water was added to 
the primer annealed RNA. This was incubated at 42°C for 2min, then lp l of 
Superscript II RNase H‘ reverse transcriptase (200u/pl, Gibco) was added, gently 
mixed and incubation continued at 42°C for 50min. The enzyme was inactivated by 
incubation at 70°C for lOmin and the final volume made up to 50pl with SDW. This 
sample preparation was then used in a standard PCR reaction (section 2.5.2). lpl of 
cDNA preparation was used with 30 rounds of amplification using primers specific for 
exonic regions of IL-6 and actin (see table 2.2). These primers were chosen to be 
located in two separate exons so that any genomic DNA contamination could be 
identified as a longer product length. The first cycle was carried out at a slightly higher 
annealing temperature to increase specificity of binding and amplification for this 
round and reduce primer dimmer formation. Actin is a cell structure protein, expressed 
in similar levels in all cell types and not induced. The strength of the actin band 
allowed standardisation of the cDNA quantities used in RT-PCR (figure 2.3).
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L 1 2 3 4 5 6 7 8
Figure 2.3. RT-PCR of HeLa cells for actin and IL-6.
cDNA was generated by RT-PCR using actin primers (PW229/230) and IL-6 primers (6-576-3’), (see 
table 2.2). L=DNA marker ladder, l&2=actin (320bp), 3, 5&7=IL-6 control (638bp), 4&6=IL-1- 
stimulated HeLa cells (638bp), 8=negative control.
2.5.4. PCR product and DNA fragment isolation
This was carried out using the Qiagen Qiaex II kit to isolate the DNA fragment from 
agarose gel. In brief, agarose slices containing the DNA fragment for purification were 
excised and placed in buffer QX1 (300pl buffer/lOOmg 0.8-1% gel), 20pl Qiaex 
suspension was added. The mix was incubated at 50°C for 5min to melt the agarose. 
Qiaex particles (to which the DNA binds) were pelleted by micro-centrifugation and 
washed once with QX1 buffer and twice with PE buffer. After air-drying the pellet, the 
DNA was eluted from the Qiaex particles with 40pl of water.
2.6. Purification of RNA
2.6.1. Purification of RNA from cell lines
Cell lines were grown over 48hours to 80% confluence in 6-well tissue culture plates 
seeded with 105 cells in 1ml DMEM/10%FCS (section 2.10). If required according to 
the experimental protocol, cells were stimulated with lOOu/ml IL-lp for 3-6 hours pre­
harvesting. Cells were harvested with trypsin/EDTA and pelleted (1200rpm at 4°C for 
5min), then washed twice with cold PBS before re-suspension in 800pl RNAzol 
(Biogenesis). If not used immediately, the lysate was stored at -70°C.
RNAse-free tubes & pipette tips (Sarstedt), DEPC treated water* and sterile DEPC 
water washed glassware, baked at 120°C for 2hrs, were used throughout. To 800pl of
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RNAzol/cell lysate, 80pl of RNAse free chloroform (BDH) was added, thoroughly 
mixed for 15sec and incubated on ice for 5min. The mix was then centrifuged at 
12,000g for 15min at 4°C to separate the two phases. The upper aqueous phase 
containing the RNA was transferred to a clean tube, an equal volume of ice-cold 
isopropanol (RNAse free) was added and the mix incubated on ice for 15min. The 
precipitated RNA was pelleted by centrifugation at 12,000g at 4°C for 15min and then 
the supernatant discarded. The RNA pellet was washed once with 700|l i 1 of 70% 
ethanol (RNAse free) and re-pelleted at 7,500g at 4°C for 8min. The pellet was air- 
dried and re-dissolved in 10- 20 j l x 1 of nuclease free water. The RNA was kept on ice. If 
not used immediately it was stored at -70°C.
2.6.2. Quantification of RNA
A 1:50 dilution of the RNA preparation in RNAse-free water was quantified by optical 
density at 260nm in a UV spectrophotometer (Hitachi U-1100) in RNAse free 
cuvettes:
RNA concentration (pg/ml) = 40(constant for ssRNA) x dilution factor x OD260
The quality of RNA was checked by running 5fil on a 1% agarose gel stained with 
ethidium bromide. Three distinct bands of ribosomal RNA (rRNA 28S, 18S and 5S) 
with a background smear of messenger RNA should be seen (figure 2.4).
28S
18S
5S
Figure 2.4. Electrophoretic separation of RNA on agarose gel.
RNA extracted from HeLa cells was separated on a 1% agarose gel by electrophoresis at lOOv for 
30min. Three bands o f ribosomal RNA are produced (28S, 18S & 5S) with a background smear of 
mRNA.
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2.7. Restriction enzyme digestion
To lpg of PCR product (see section 2.5.2), 1-2U of restriction enzyme and 2.5pl of 
specific buffer (see table 2.3) were added to a total volume of 25pl made up with 
sterile distilled water. The reaction was incubated overnight at 37°C and then placed on 
ice. For digestion with SfaNl however, the reaction was incubated for only 2 hours at 
37°C, then heated to 65°C for 5min and placed on ice. For the micro-titre array 
diagonal gel electrophoresis (MADGE) high throughput method (section 2.8.1.2), this 
was carried out in a 96-well PCR plate.
lug of plasmid DNA was digested in the same way. For double digests with enzymes 
requiring different salt conditions, digestion was carried out sequentially starting with 
the enzyme requiring the lowest salt concentration. The solution was then 
supplemented with additional salts and diluted as necessary to achieve the correct 
conditions for the second enzyme. For digestion of lpg of genomic DNA, 1-4U of 
restriction enzyme was added and incubated for 16-20 hours.
To distinguish digested products of >50bp length difference, a 2% agarose gel was 
used. For product size differences <50bp an 8% polyacrylamide gel was used (see 
section 2.3.2). DNA standard size markers were run along side the product on each gel 
(HindlU digested lambda DNA for products >1000bp and lOObp DNA ladder, 
Promega, for products <1000bp).
2.7.1. Analysis of sequences for restriction enzyme sites
The sequence of interest was analysed automatically for >400 restriction enzyme 
recognition sequences using the ‘Webcutter’ on-line programme available at 
http://www.medkem.gu.se/cutter. The programme scanned both positive and negative 
DNA strands in both directions and sequence data could be entered from the GenBank 
sequence file to avoid errors.
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Enzyme
Aatll
BglU
BamHl
Dpnl
Fokl
HindlU
Kpril
Mbil
Nhe I
Main
Notl
Amount Buffer
(per pg DNA) (lx)
1U J (50mM KC1,1 OmM Tris-HCl, 7mM
MgCl2, lmM DTT)
1U D (150mM NaCl, 6mM Tris-HCl, 6mM
MgCl2, ImMDTT)
0.5U E (6mM Tris-HCl, 6mM MgCl2, 1 OOmM
NaCl, lmM DDT, pH7.5)
0.5U Quikchange Site-directed mutagenesis kit
buffer
2U B (50mM NaCl, 6mM Tris-HCl, 6mM
MgCl2, lmM DTT, 5pg BSA)
1U E (6mM Tris-HCl, 6mM MgCl2, 1 OOmM
NaCl, lmM DDT, pH7.5)
0.5U J (50mM KC1,1 OmM Tris-HCl, 7mM
MgCl2, ImMDTT)
2U Y+Tango (33mM Tris-acetate pH 7.9,
lOmM Mg2+acetate, 66mM K acetate, 
0.1 mg/ml BSA)
0.5U B (50mM NaCl, 6mM Tris-HCl, 6mM
MgCl2, lmM DTT, 5pg BSA)
1U NEB4 (50mM KAc, 20mM Tris-acetate,
lOmM Mg2+ acetate, lmM DTT, pH7.9) 
supplemented with lOOpg/ml BSA 
1U D (150mM NaCl, 6mM Tris-HCl, 6mM
MgCl2, ImMDTT)
Table 2.3. Restriction enzymes
Manufacturer Restriction sequence Uses
Promega 5’,..GACGTVC...3’
3’...CTGCAC...3’
Promega 5 ’... AVGATCT.. .3 ’
3’...TCTAGVA...5’
Promega 5\..G''GATCC...3’
3’...CCTAGVG...5’
Stratagene 5 ’.. .GAmvTC.. .3 ’
3’...CTvAmG...5’
Promega S’^.GGATGCN)^..^’
3’...CCTAC(N)13v...5’
Promega 5’...AVAGCTT...3’
3’,..TTCGAVA...5’
Promega 5\..GGTACVC...3’
3’...CVCATGG...5’
Fermentas 5’...CCGVCTC...3’
3\..GGC'GAG...5’
Promega 5’...GVCTAGC...3’
3’...CGATCVG...5’
New England 5’...CATGV...3’
Biolab 3’...VGTAC...5’
Promega 5\..GCVGGCCGC...3’
3’.. .CGCCGGVCG.. .5’
Verification of IL-6 insert in pGL3 
plasmid (no cut site in pGL3 basic) 
Verification of IL-6 insert length in 
pGL3 plasmid (together with Notl cuts 
out insert + 203bp)
Together with Xhol to shuttle the 
1.17kb IL-6 fragment from pGEM to 
pBluescript
Removal of parental template DNA 
after site-directed mutagenesis PCR 
Identification of IL-6 -597 genotype 
(cuts with -597A allele but not -597G) 
Linearisation of IL-6/pGL3 constructs 
(one cut site in pGL3 basic vector, 
none in IL-6 insert)
Together with Xbal or Nhel to allow 
direction specific cloning of EL-6 
constructs into pGL3 basic 
Identification of IL-6 -572 genotype 
(cuts with -572G allele but not -572C)
Together with Kpril to allow direction 
specific cloning of IL-6 constructs into 
pGL3 basic
Identification of IL-6 -174 genotype 
(cuts with -174C allele but not -174G)
Verification of IL-6 insert length in 
PGL3 plasmid (together with BglU 
cuts out insert + 203bp)
Enzyme
Sad
Sail
SfaNl
Sphl
Sstn
Xbal
Xhol
Amount Buffer
(per fig DNA) (lx)
1U J (50mM KC1,1 OmM Tris-HCl, 7mM
MgCl2, lmM DTT)
5U D (15 OmM NaCl, 6mM Tris-HCl, 6mM
MgCl2, ImMDTT)
1U NEB3 (lOOmM NaCl, 50mM Tris-HCl,
lOmM MgCl2, lmM DTT)
1U K (lOmM Tris-HCl, lOmM MgCl2,
150mMKCl, pH7.4)
5U React 2 (50mM Tris-HCl, 1 OmM MgCl2,
50mM NaCl, pH8)
0.5U D (150mM NaCl, 6mM Tris-HCl, 6mM
MgCl2, lmM DTT)
0.5U D (150mM NaCl, 6mM Tris-HCl, 6mM
MgCl2, lmM DTT)
Table 2.3. Restriction enzymes, their buffers and uses.
v indicates the cut site of the endonuclease.
Manufacturer Restriction sequence Uses
Promega
Promega
New England 
Biolab 
Promega
Invitrogen
Promega
Promega
\..GAGCTC...3’
’...CTCGAG...5’
\..G VTCGAC...3’
\..CAGCTVG...5’
’...GCATC(N)5-...3’
’...CGTAG(N)9-...5’
\..GCATGVC...3’
\..C VGTACG...5’
\..CCGCVGG...3’
\..GGVCGCC...5’
\..rC TA G A ...3’
\..AGATCVT...5’
’...CTCGAG...3’
’...GAGCTC...5’
Together with Xhol, to shuttle the 
1.17kb IL-6 insert from pBluescript 
into pGL3 basic
Distinguishing and linearising parental 
plasmid in transformer site-directed 
mutagenesis
Identification of IL-6 -174 genotype 
(cuts with -174G allele but not -174C) 
Linearisation of IL-6/PGL3 constructs 
(one cut site in PGL3 basic vector, 
none in IL-6 insert)
Distinguishing and selecting parental 
plasmid in transformer site-directed 
mutagenesis
Together with Kpnl to allow direction 
specific cloning of <61 lbp EL-6 
construct into pGL3 basic 
Together with BamHl or Sad  to 
shuttle the 1.1 Tkb EL-6 insert from 
pGEM to pBluescript and pGL3 basic
2.8. Genotyping
2.8.1. Restriction fragment length polymorphism
This technique utilises restriction endonuclease digestion to distinguish between 
polymorphic sequences in a PCR amplified fragment of DNA containing the site of 
interest. It requires the base change of one allele to either form a restriction enzyme 
recognition site or abolish such a site, resulting in a different length of DNA fragment 
for each allele after exposure to the restriction enzyme.
2.8.1.1. MADGE high throughput method
This is based on the method used by Day and co-workers (1995). 
lpg of PCR product containing the amplified IL-6 region around the polymorphisms -  
174G/C (primers 9A & 10A), the -572G/C (primers 5bF & 6R) or the -597G/A 
(primers 5bF & 6R), (section 2.5.2) were digested in a 96 well PCR plate. A positive 
control for each genotype and a negative control were included per plate. The digest 
was carried out with 1-2U of restriction enzyme that would cut one allele but not the 
other, -174G/C (Malll), -572 (Mbil) and -597 (Fokl), (see section 2.7). After 
overnight digestion at 37°C, the products were resolved on 8% non-denaturing 
polyacrylamide gels (see section 2.3.2) pre-stained with ethidium bromide, using a 
matrix well lay out and ‘diagonal’ electrophoresis (as described by Day et al., 1995). 
The voltage, time of electrophoresis, and size of fragments obtained for each 
polymorphism are shown in table 2.4. A photographic record of the gel was made 
under UV light (see figure 2.5).
Polymorphism Digestion product Electrophoresis voltage Time of separation
size
-174 G allele 190bp 150V 45min
C allele 143,47bp
-572 G allele 101,62bp 150V 25min
C allele 163bp
-597 G allele 163bp 150V 35min
A allele 116,47bp
Table 2.4. Polyacrylamide gel electrophoresis conditions for MADGE genotype 
analysis of IL-6 polymorphisms.
Separation of restriction digest products was carried out by ‘diagonal’ electrophoresis on a horizontal 
8% non-denaturing polyacrylamide gel.
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Figure 2.5. Micro-titre array diagonal gel electrophoresis for the -597 
polymorphism of IL-6.
l|ig o f IL-6 PCR product using primers 5bF & 6R (table 2.2) was digested with 2u FokI (see 2.7). Fokl 
cuts with the A allele at position -597 but not the G allele. The products were resolved on an 8% non­
denaturing polyacrylamide gel (see 2.8.1). -597GG homozygotes produce a 163bp product, -597GA 
heterozygotes 163, 116 and 47bp products, and -597AA homozygotes produce 116 and 47bp products. 
The 163 & 116bp products can be seen within the centre of each grid.
2.8.2. Sequence specific oligonucleotide probing
The method was adapted from that of Turner et al. (1997).
Sequence specific oligonucleotide probing (SSOP) was used to determine the genotype 
of the -174 and -597 polymorphisms of IL-6. lpg of PCR product (primers DF20m & 
DF21, see 2.5.2) was dotted on to nylon nucleic acid transfer membrane (Hybond N+, 
Amersham), one membrane per allele to be probed. The double-stranded DNA was 
denatured by soaking the membrane for 5min in 0.5M NaOH with 1.5M NaCl, then 
neutralised for 1 min in 1.5M NaCl with 0.5M Tris. To cross-link the DNA to the 
membrane, the membrane was baked for lOmin at 80°C and then treated for 30sec with 
120,000pJ of ultraviolet energy (Stratagene UV Stratalinker 2400). The membrane was 
pre-hybridised in 15-25ml of hybridisation buffer (5x SSC*, 0.1% N-lauroylsarcosine, 
0.02% SDS, 0.5% dried skimmed milk [Marvel]) for 60min at 42.5°C, using roller
IB B E 9 9 B S a a
IB B B 9 B H 9 B
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bottles in a hybridisation oven (Hybaid). Biotinylated allele-specific oligonucleotide 
probe (see table 2.5) was added (20-40ng/ml of hybridisation buffer) and hybridised 
for 120min at 42.5°C. Following hybridisation, the membranes were washed in 5x SSC 
with 0.1% SDS for 5min at room temperature. Each membrane was stringency washed 
twice in lx  SSC with 0.1% SDS for 15min at the optimised stringency wash 
temperature the probe (table 2.5). All subsequent steps were carried out at room 
temperature. The membrane was then soaked for lmin in buffer 1 (0.15M NaCl, 0.1M 
Tris) before blocking for 30-45min in buffer 1 with 0.5% dried skimmed milk 
(Marvel), on a slow rotation platform. Streptavidin-horseradish peroxidase conjugate 
(Amersham) was diluted 1:10,000 with buffer 1 and the membrane soaked in this 
reagent for 30min on a slowly rotating platform. Streptavidin will bind with high 
affinity to the biotinylated probe. Washing was then performed twice in 0.4M NaCl 
with 0.1M Tris for lOmin. The membranes were blotted dry and covered in LumiGLO 
Substrate Kit for chemiluminescent detection of horseradish peroxidase-labelled 
reagents (Kirkegaard & Perry Laboratories). Substrate A and substrate B (LumiGLO 
kit) were mixed in equal volumes. After lmin, the membranes were exposed to x-ray 
film (Kodak X-OMAT) for lOmin and 2hour.
Oligo Allele Sequence Tm Stringency
ID detected wash temp
DF11 -174G 5 '  -GTGTCTTGCGATGCTAAAG-3' 56°C 54°C
DF12 -174C 5 ' -CTTTAGCATGGCAAGACAC-3' 56°C 54°C
PW268 -597A 5 ' -ATTTGAGGATGGCCAGGC-3' 56°C 54°C
PW269 -597G 5 ' -CCTGGCCACCCTCAAATT-3' 56°C 54°C
Table 2.5. Sequence specific oligonucleotide probes for detection of -174 and -597 
alleles of IL-6.
Oligonucleotides were synthesised to order with 5’ biotinylated ends (Genosys).
2.8.3. Heteroduplex
This was carried out using a modified protocol of Morse et al., (1999).
Heteroduplex was used to genotype the -174 and -572 polymorphisms of IL-6. It 
involves amplification of a ~100bp region around the polymorphic site and then 
anneals the PCR product with a universal heteroduplex generator (UHG) that is the 
same sequence as the PCR product apart from 3-4 artificially inserted adenosine 
residues adjacent to the site of the polymorphism. This forms a loop in the DNA
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structure at this site when PCR product is annealed, the exact conformation being 
influenced by the specific allele at the polymorphic site. With optimisation, the 
annealed products can be separated on a polyacrylamide gel to distinguish the alleles.
The sample DNA (200ng in lpl) was amplified by PCR using primers -174F & R for 
the -174 heteroduplex and primers -572F & R for the -572 heteroduplex (section
2.5.2). Thirty-five cycles of PCR amplification were performed using an Applied 
Biosystems PE9700 thermal cycler. Specific UHG oligonucleotide for each 
heteroduplex (-174UHG, -572UHG, table 2.6) was amplified by PCR. 25pmol of 
UHG oligonucleotide was mixed with 5pi lOx Taq DNA polymerase buffer without 
MgCb (lOOmM Tris pH9, 500mM KC1,1.0% Triton X-100, Promega), 1.5mM MgCk, 
0.2mM each dNTP, 250ng F & R primer, 0.5units Taq DNA polymerase (Promega), 
made up to 50pl with sterile distilled water. See table 2.6 for amplification cycle 
conditions for each UHG.
Oligo ID Sequence, amplification primers and conditions
-174UHG 5 ' -TGGGGCTGATTGGAAACCTTATTAAGATTGTGCAATGTGAC...
GTCCTTTAGCATCAAAAGCAAGACACAACTAGGGGGAAAAGTGC...
AGCTTAGGTCGTCATTGAGGCTAGCGCTAAGAAGC-3'
Primers: -174F & R (see table 2.2)
Cycles: 95°C/5min (xl), 95°C/30sec, 60°C/30sec, 72°C/30sec (x25), 
72°C/5min (xl)
-572UHG 5 '  -GCCTGGGATTATGAAGAAGGTAATACTACCAGTCATCTGAG...
TTCTTCTGTGTTCTGGCTCTCCCTGTGAGAAAACGGCTGTTGTA...
GAACTGCCTGGCCACCCTCAAATTTCGTGCAGTTACTTCAAGGC...
G - 3 '
Primers: -572F & R (see table 2.2)
Cycles: 95°C/5min (xl), 95°C/45sec, 54°C/45sec, 72°C/45sec (x25), 
72°C/5min (xl)
Table 2.6. Universal heteroduplex oligonucleotides for the -174 and -572 
polymorphisms of IL-6.
Oligonucleotides were obtained synthesised to order by MWG Biotech (high purity salt free). The 
artificially added adenosine bases are indicated in blue lettering, the polymorphic site is underlined in 
bold.
PCR and UHG products were run on 2.5% agarose gel (see 2.3.1) to ensure equal 
concentrations of each. For induction of the heteroduplex, 8pl UHG was mixed with
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8|il of PCR product, heated to 95°C for 5min and allowed to cool slowly to room 
temperature. 5pi of 6x blue/orange loading dye (Promega) was added and the samples 
loaded and run on a prepared 15% non-denaturing vertical polyacrylamide gel (37.5:1 
ratio) in lx TBE* (see 2.3.2). This was run using a Bio-Rad tank and gel plates at 
200V for 5-6 hours. The gel was then stained with ethidium bromide and photographed 
under UV light (see figure 2.6).
1
2
3
4
5
Figure 2.6. Optimised heteroduplex bands for the -174 polymorphism of IL-6.
-174UHG product (see text above) was mixed in equal volumes with PCR product using primers -  
174F&R (see section 2.5.2). This was heated to 95°C for 5min and cooled slowly. Separation was on a 
15% non-denaturing polyacrylamide gel (37.5:1 ratio), run in lxTBE at 200V for 5hours.
Band 1= -174G (1 strand) annealed to UHG, 2= -174C (1 strand) annealed to UHG, 3= UHG annealed 
to UHG, 4=-174C (2nd strand) annealed to UHG, 5=-174 (2nd strand) annealed to UHG.
2.8.4. DNA sequencing
2.8.4.1. Manual T7 sequenase sequencing
To confirm plasmid insert sequence and orientation in the PGL3 basic vector, manual 
sequencing was undertaken using the T7 Sequenase Sequencing Kit (Amersham Life 
Science). To prepare the DNA template, 2pg of test plasmid (from mini-prep or maxi- 
prep) in 16pl sterile distilled water was denatured with 4pl of lmM EDTA & 1M 
NaOH mix, incubated for 5min at room temperature. The solution was neutralised with 
2pi of 2M NH4Ac (pH 5.4) and precipitated by the addition of 55pi absolute ethanol, 
incubated on dry ice for 15min, then pelleted by micro-centrifugation. The pellet was 
washed twice in 70% ethanol, dried and re-suspended in 5.5pl of distilled water.
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For the annealing reaction, the re-suspended DNA was mixed with 5ng of sequencing 
primer (RV3 or GL2, table 2.2). 2pi of 5x T7 Sequenase Reaction Buffer was added 
and the mix incubated for at 65°C for 2min, then cooled slowly (over 20-30 min) to 
35°C before placing on ice.
For the labelling reaction, 0.5pl of 1% Nonidet P40, lp l of 0.1M DTT, 2pl of 
Labelling Mix (undiluted for >200bp sequencing, 1:5 dilution in water for shorter 
sequences), 0.5pl a 35S-dATP (lOOOCi/mmol, Amersham) and 2pl of T7 sequenase 
polymerase (1:8 dilution in sequenase dilution buffer) were added to the primer 
annealed template. The reaction was mixed and incubated at room temperature for 2- 
5min (2min for sequences <200bp, 3min for sequences 200-300bp & 5min for 
sequences >300bp). lp l of 0.1 M MnCh (in 0.15M sodium isocitrate) was added at the 
end of the incubation and 3.5pl of this mix was then added to each of four tubes 
containing 2.5pl of dideoxynucleotides ddGTP, ddATP, ddTTP and ddCTP 
respectively. This termination reaction was incubated at 37°C for 5min, after which 4pl 
of Stop Solution was added to each tube. Prior to running these on the sequencing gel, 
each mix was denatured by heating to 90°C for 2min.
The ‘G’, ‘A’, ‘T’ and ‘C’ reactions were run on a pre-prepared 6% polyacrylamide gel 
made with 40ml of SequaGel-6 acrylamide monomer (National Diagnostics) mixed 
with 10ml of SequaGel Complete Buffer Reagent (National Diagnostics). 400pl of 
fresh 10% ammonium persulphate (to initiate polymerisation) was added immediately 
prior to pouring the gel between glass plates (pre-washed with detergent and then 
ethanol) separated by 0.4mm spacers. The gel was allowed to polymerise for 45- 
90min, then pre-heated to 50°C by electrophoresis in lx  TBE* (1.5 volts per cm) on a 
Flowgen Sequencing Gel System, before the sequencing reactions were run. Longer 
sequencing reactions (>200bp) were loaded first and run for 4-6 hours compared to 
shorter sequencing reactions run for 2-4 hours. The gel was fixed for 5min in 40% 
glacial acetic acid with 40% ethanol, dried on a vacuum drier and exposed to x-ray 
film (X-OMAT, Kodak) for 1-2 days at room temperature. The sequence was read as a 
ladder produced by the random incorporation of termination dideoxynucleotides along 
the synthesised strand.
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2.8A.2. Automated thermocycle sequencing
The direct sequencing method of the Thermo Sequenase II Dye Terminator Cycle 
Sequencing Kit (Amersham Life Science) was used to sequence the IL-6 AT-tract 
from genomic DNA samples or plasmid constructs, and to sequence the 1.17kb insert 
of IL-6 in the pGEM vector and then in the pGL3 basic vector after site-directed 
mutagenesis. A list of the oligonucleotide primers used is shown in table 2.7.
800ng of plasmid DNA (mini- or maxi-prep) or lpg of gel purified PCR product (from 
genomic DNA) in 8pl sterile distilled water was mixed with 2pl of reagent mix A 
(containing Thermo Sequenase II DNA polymerase) and 2pi of reagent mix B 
(containing dNTPs in excess, and dye-labelled termination ddNTPs). There was a 
different fluorescing colour label for ddATP, ddTTP, ddGTP and ddCTP. 5pM of 
primer in distilled water (2.5pi) was added (see table 2.7) and the total reaction volume 
was made up to 20pl with sterile distilled water. The reaction was pulse spun in a 
micro-centrifuge before thermal cycling for 25 cycles at 96°C for 30sec, 50°C for 
15sec and 60°C for 60sec using an Applied Biosystems PE9700 thermal cycler. At the 
end of thermal cycling, 2pl of 1.5M NaAc pH>8 with 250mM EDTA was added and 
mixed to stop the reaction. 20pl of the mix was removed and DNA precipitated in 66pl 
of absolute ethanol on ice for 20min. Un-incorporated dNTPs and ddNTPs would 
remain in suspension. The DNA was pelleted by micro-centrifugation at 12,000rpm for 
20min at 4°C. The pellet was washed twice in 250pl of cold 70% ethanol and re­
pelleted at 12,000rpm for lOmin before air-drying and re-suspended in 4pl of 90% 
(v/v) formamide and loading dye (Amersham). Before loading, the sequencing reaction 
was denatured by heating to 70°C for 2min and then immediately stored on ice. 1.5pi 
o f sample was loaded onto a 6% polyacrylamide sequencing gel (see 2.8.4.1), pre-run 
in lx  TBE* using a Perkin-Elma ABI prism 377 DNA Sequencer. The samples were 
run over-night at lV/cm (filter set A). As the incorporated termination ddNTPs from 
the DNA fragments passed the laser beam of the automated sequencer, the fluorescent 
dye emissions detected by the photodiode array detector were recorded. An example of 
the type of chromatogram that was generated by this method is shown in figure 2.7.
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Primer ID Sequence
Sequencing IL-6 insert from pGL3 basic vector 
RV3 5'-CTAGCAAAATAGGCTGTCCC-3'
GL2 5'-CTTTATGTTTTTGGCGTCTTCCA-3'
Sequencing 1.17kb IL-6 construct
IL-6 Pro(l)F 5' - GGATCCTCCTGCAAGAGACACC-3'
IL-6 Pro(2)R 5' -CAGGGCAGAAAGGGGGAGATTAC-3'
IL-6 Pro(3)F 5 ' -CAAGGTCCTCCTTTGACATCCCC-3,
IL-6 Pro(4)R 5' -GTCTGCCATTTCTTCACCTGCTTC-3'
IL-6 Pro(5)F 5'-CCTACTGGAGATTCCAAGGGTCAC-3'
IL-6 Pro(6)R 5' -GAGTTTCCTCTGACTCCATCGCAG-3'
IL-6 Pro(7)F 5' -GAACTCAGATGACTGGTAGTATTACC-3'
IL-6 Pro(8)R 5' -CAGCACTTTGGCATGTCTTGAC-3 '
IL-6 Pro(5b)F 5' -GGAGACGCCTTGAAGTAACTGC-39
Sequencing IL-6 AT-tract
ATI F 5'-TCACAGGGAGAGCCAGAACA-3'
AT2 R 5' -TGCAGCTTAGGTCGTCATTG-3'
Table 2.7. Oligonucleotide primers used for sequencing.
Synthesised to order by Genosys. The F (forward) and R (reverse) suffix at the end o f each primer ID 
indicates sequencing of the sense and anti-sense DNA strands respectively.
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Figure 2.7. Automated sequencing chromatogram for the A9T11 allele of IL-6.
Sequencing was carried out using the Thermo Sequenase II Dye Terminator Cycle Sequencing Kit 
(Amersham Life Science) and run on a Perkin-Elma ABI prism 377 DNA Sequencer (6% 
polyacrylamide sequencing gel). See above text for details.
Later samples were sent for commercial sequencing by MWG Biotech.
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2.9. Plasmid manipulation
2.9.1. Generation of 61 lbp and deletion mutant IL-6 reporter constructs 
This had been carried out by D. Fishman prior to this study (Fishman et al., 1998). In 
brief, the IL-6 sequence from known -174GG and -174CC homozygous individuals 
(otherwise identical in IL-6 sequence from +70 to -560 as determined by automated 
sequencing) were amplified using PCR primers 5/2 (5’-CAGAAGAACTCAGATGAC
TGG-3’) and 3/2 (5’-GCTGGGCTCCTGGAGGGG-3’). Fresh PCR product was sub­
cloned into the pCRII vector (TA cloning kit, Invitrogen) utilising the single stranded 
deoxyadenosine residues at the 3’-end of the Taq polymerase synthesized PCR product 
and the single stranded deoxythymidine residue overhang in the linear vector. 4U of 
T4 DNA ligase was used with a 1:1 molar ratio of PCR product (lpl) to vector, 2pi 
lOx buffer L (500mM Tris pH7.8, lOOmM MgCl2, 200mM DTT), 4pl lOmM ATP and 
3pi water, at 14°C overnight (~15hrs). Successful cloning was confirmed by X-gal and 
ampicillin selection on agar plates after transformation into ‘One-Shot’ E. coli (see 
sections 2.9.8.5&7). The clone was isolated and purified by mini-prep plasmid 
preparation (see 2.9.6.1) and provided a high quality PCR template for further 
manipulations. The inserted sequence was confirmed by automated sequencing.
In a second step, the IL-6 insert was amplified from pCRII containing the -174G or -  
174C allele using primers DF5/2D (5 ’ -TATGCGAGGTACVCAGAAGAACTCAGAT 
GACTGG-3’) and DF3/2D (5’-AGTTAATXTAGATATGCTGGGCTCCTGGAGG 
GG-3’). This generated PCR fragment from +61 to -550 of the IL-6 sequence, 
constructs AG and AC (see figure 4.1). The primers had been designed to contain the 
restriction site sequence for Kpnl at the 5’-end (DF5/2D) and for Xbal at the 3’-end 
(DF3/2D), (extra sequence shown in purple, v indicates cut site). This facilitated 
direction specific cloning into the PGL3 basic vector between the Kpnl and Nhel 
cloning sites (figure 4.1). Ends generated by Xbal can be directly ligated to ends 
generated by Nhel, though the recognition sites are lost in the product. The IL-6 PCR 
product was digested with Kpnl and Xbal, separated from the plasmid on a 1% agarose 
gel (see 2.3.1), isolated and purified using the Qiagen Qiaex II kit (see 2.5.4) and 
ligated with T4 DNA ligase as above into the PGL3 basic vector that had been 
linearised with Kpnl and Nhel digestion.
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For the shorter deletion mutant constructs, the same method was used with 3’-end 
primer DF3/2D and alternative 5’-end primers. For constructs AGD and ACD (IL-6 
region +61 to -310) the 5’-end primer DFAAT (5 ’ - ACT GGT GGT A C T  AAG AC AT G 
CCAAAGTG-3’) was used, while for constructs AGDS and ACDS (IL-6 region +61 to 
-219) the 5’-end primer DF5/2DS (5’-GACCTGTAGGTACTTCAATGACGACCT 
AAGCTG-3’) was used. Each 5’-end primer contained the Kpnl recognition sequence 
(shown in purple, " indicates the cut site).
2.9.2. Confirmation of successful cloning and plasmid construct identity 
Clones were selected from agar plate colonies, isolated and purified by the mini-prep 
method (see 2.5.4). Confirmation of cloning success into PGL3 basic was carried out 
by insert removal and size determination with Notl and Bglll digestion (cut sites on 
either side of where the insert should be), linearisation of the plasmid with AatTL 
digestion (cuts once only within the IL-6 insert) and by automated sequencing across 
the insert (figure 2.8a&b). The region was also amplified by PCR using primers RV3 
and GL2 for regions of the pGL3 basic vector on either side of the insert (see section
2.5.2). This allowed digestion of the PCR product with M ain or SfaNl to confirm the -  
174 allele (figure 2.8c&d), providing a quicker method than repeat sequencing after 
each amplification step. Large quantities of transfection grade plasmid were amplified 
using the standard alkaline-lysis maxi-prep method with caesium chloride purification 
(see 2.9.6.2 & 2.9.7) followed by repeat verification of the construct identity as 
outlined above.
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Figure 2.8. Confirmation of construct identity in PGL3 basic vector
(a) plasmid digested with Aatll (see 2.7).
Lane 1, 3 &5=undigested product; 2, 4 & 6=digested product (5.3kb, Aatll cuts only if IL-6 insert present).
(b) insert digested out with BglII & Notl restriction endonucleases (see section 2.7).
Lane 1, 3&5=AG, 2&4=AC (814bp).
(c) PCR amplification of insert using RV3 & GL2 primers (see section 2.5.2).
Lane 1&2=AGDS construct (427bp), 3&4=ACDS (427bp), 5&6=AGD (518bp), 7&8=ACD (518bp).
(d) PCR amplification of IL-6 insert in PGL3 basic vector, (primers RV3&GL2), followed 
by SfaNl digestion (see 2.7).
Lane 1&5=AG (undigested, 758bp), 2&6=AG (digested, 427&331bp), 3&7=AC (undigested, 758bp), 
4&8=AC (digested, 758bp). L=100bp DNA ladder (Promega).
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2.9.3. Quantification of plasmid DNA
The concentration of serial dilutions of purified plasmid DNA in water was determined 
by optical density at 260nm and 280nm (Hitachi U-1100 Tungsten UV 
spectrophotometer with 10mm path length quartz cuvettes) against a reference sample 
of diluted buffer. The concentration of nucleic acid can be calculated from the 
equation:
ds-DNA concentration (pg/ml) = 50(constant for dsDNA) x dilution factor x OD260 
That is, an OD260 of 1 is equal to approximately 50pg/ml for double-stranded DNA 
(40pg/ml for single-stranded DNA). The purity of the DNA sample can be calculated 
from the OD260/OD280 ratio. A pure sample of DNA has an absorbance ratio of 1.8, 
while the absorbance ratio for pure RNA is 2.0. A purity ratio of 1.65-1.85 was 
required. Plasmid stocks were diluted to lpg/pl with water and repeat 
spectrophotometry performed at 260nm. In addition, aliquots of diluted plasmid, and 
Aatll digested, linearised plasmid were run on a 0.8% agarose gel and photographed 
under UV light to ensure dilutions were equivalent. Diluted stocks were stored at -  
20°C.
2.9.4. Generation of the 1.17kb IL-6 reporter constructs
A 3kb IL-6 construct from +2000 to -1170 with flanking BamHl sites inserted into the 
pGEM vector (Promega, see figure 2.9) was a kind gift from S. Akira and T. 
Kishimoto of the Institute of Molecular and Cellular Biology, Osaka University, Japan. 
The sequence was verified by automated sequencing using the primers shown in table
2.7. A 1.17kb portion of the construct from +8 to -1170 was removed from pGEM by 
digestion with BamHl 8c Xhol and sub-cloned into pBluescript.SK phagemid 
(Stratagene). This allowed selection of the Sacl digestion site, not available from 
pGEM, for cloning into the pGL3basic vector (Promega). The construct was cut from 
pBluescript with restriction enzymes Xhol 8c Sad  and ligated into pGL3 basic between 
the Xhol 8c Sad  cloning sites (figure 2.9), using equal molar ratios of insert to vector 
with T4 DNA ligase as for the short constructs (see 2.9.1). Successful cloning was 
verified as outlined in section 2.9.2. PCR products were digested with Mbil, Fokl, 
Main or SfaNl to confirm the allelic identities (see 2.7).
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Fig 2.9. Transfer of a 1.17kb construct of the 5’-flanking region of IL-6 from pGEM 
to pGL3 basic via pBluescript.
A 1.17kb fragment of the 5’-flanking region of the IL-6 gene was cut from the 3kb construct in pGEM by digestion with BamHl & Xhol. 
This fragment was cloned into pBluescript between the BamHl and Xhol sites of the polycloning region. The fragment was removed from 
pBluescript by digestion with Xhol & Sacl and cloned into pGL3 basic between the Xhol & Sad  sites (for plasmid map see figure 4.1).
Automated sequencing across the insert was carried out to ensure no additional 
mutations had been introduced and to confirm orientation. Transfection-grade 
amplification and quantification of the plasmid was as for the short constructs.
2.9.5. Site-directed mutagenesis
To generate different -174/-572/-597 haplotypes from the 1.17kb clone obtained from 
S. Akira and T. Kishimoto, which was -174G[A9T11]-572G-597G, site-directed 
mutagenesis was carried out on the purified construct in pGL3 basic.
2.9.5.1. Ouikchange
For the -174, -572 and -597 point mutations, the Quikchange site-directed 
mutagenesis kit (Stratagene) was used and is based on PCR with mutation primers to 
introduce the base change. Manufacturers instructions were followed and carried out 
directly on the supercoiled double-stranded DNA plasmid. Primers were designed to 
contain the desired base change for each site in the forward and reverse strand 
sequence (see table 2.8). The primers were incorporated in the PCR reaction one pair 
at a time, dependent on what haplotype combination was required. Extension of the 
primers was carried out with Pfu DNA polymerase. Following PCR, the parental DNA 
template was removed by digestion with Dpnl endonuclease that is specific for 
methylated and hemi-methylated DNA. The parental DNA, isolated from E. coli would 
be dam methylated and susceptible to digestion whereas the freshly synthesised 
mutated DNA would not. The synthesised, mutated DNA was transformed into XL1- 
Blue supercompetent cells and selected on LB-plates containing ampicillin (see 
2.9.8.6). Positive colonies were picked and the plasmid isolated and purified by mini- 
prep (see 2.9.6.1). Confirmation of successful mutation without introduction of other 
changes was carried out by automated sequencing across the region (see 2.4.8.2). 
Repeat PCR mutation steps were carried out for haplotypes requiring mutation at more 
than one site. This was carried out in collaboration with L. Luong in the department of 
Cardiovascular Genetics at University College London to obtain the three additional 
haplotypes, -174G-572G-597A, -174C-572G-597A and -174G-572C-597G. For 
some reason the haplotype -174C-572G-597G could not be generated on repeated 
attempts. The -174C-572G-597A haplotype was generated by first mutating the -597 
allele and then mutating the -174 allele.
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Primer ID
DL-6-174C MutF 
IL-6-174C MutR 
IL-6 -572C MutF 
IL-6-572C MutR 
IL-6-597A MutF 
IL-6-597A MutR
Sequence
5 ' -CTAGTTGTGTCTTGCCATGCTAAAGGACGT-3'
5 ' -ACGTCCTTTAGCATGGCAAGACACAACTAG- 3 '
5 ' -GTTCTACAACAGCCCCTCACAGGGAGAGCC-3'
5 ' -GGCTCTCCCTGTGAGGGGCTGTTGTAGAAC-3'
5 ' -ACTGCACGAAATTTGAGGATGGCCAGGCAGTTCTAC-3' 
5 ' -GTAGAACTGCCTGGCCATCCTCAAATTTCGTGCAGT-3'
Table 2.8. Site-directed mutagenesis primer pairs for the -174, -572 and -597 
polymorphisms.
Primers were synthesised to order by Genosys. The introduced mutagenic nucleotide bases are 
underlined in bold.
2.9.5.2. Transformer site-directed mutagenesis
Site-directed mutagenesis and amplification based on the Quikchange PCR technique 
could not be used for single base changes in the AT-tract because this low GC residue 
region did not allow for a primer design with a high enough Tm to allow cyclical 
annealing and extension. A transformer site-directed mutagenesis system was therefore 
designed based on the Clontech Transformer Site-Directed Mutagenesis kit using a 
protocol adapted from Deng and Nickoloff (1992). In this method, two oligonucleotide 
primers were simultaneously annealed to denatured plasmid construct DNA. The 
mutagenic primer (AT601F) contained the desired AT-tract mutation, while the 
selection primer (PGB1F) introduced a mutation to a unique restriction site in the 
plasmid, (see table 2.9 for primer sequences). A 200-fold excess molar ratio of primer 
to plasmid was used, with the amounts required calculated from the equation: 
pmoles DNA = (pg DNAxl06)/(330 x primer length in bp)
Mutation of the restriction site from Sail to Sstll allowed selection of the mutated 
plasmid strand. A series of transformations and digestions allowed selection and 
isolation of mutated plasmid. Transformation efficiency is lost with linearised parental 
plasmid on digestion with Sail. The primer/plasmid mix was denatured by boiling in 
annealing buffer (20mM Tris-HCl pH7.5, lOmM MgCl2, 50mM NaCl) then annealed 
on ice. Synthesis of the mutant strand was as per manufacturers instructions (Clontech 
Transformer Site-Directed Mutagenesis kit), 2-4U T4 DNA polymerase and 4-6U T4 
DNA ligase were used. The synthesis reaction contained a mixture of parental 
homozygous plasmid and heterozygous parental/mutant synthesised plasmid. This was 
in a 30pi volume of >6mM Tris-HCl, 6.7mM MgCl2 and 33.3mM NaCl. 3.lp l of 10 x 
buffer D (see table 2.3), 6.4pl water and 5U Sail were added and digestion allowed to
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proceed for 2 hours at 37°C. This would linearise the parental DNA and reduce 
efficiency of transformation to < 1% of the non-linearised plasmid (pre-determined). 
Transformation was into BMH 71-18 mutS cells (see section 2.9.8.4). Transformed 
plasmid was then isolated and purified by mini-prep (see 2.9.6.1). The synthesis step 
was repeated using the complementary mutation and selection primers (AT601R & 
PGB1R, table 2.9) and then a second Sail digestion with 10U of endonuclease was 
carried out to yield homozygous mutant plasmids and nicked or linearised parental 
DNA. This was transformed into ‘One Shot’ competent E. coli and selected on 
ampicillin-containing agar plates (see 2.9.8.5). Mini-preps of isolated colonies were 
digested with SstU and successful mutation to incorporate this new restriction site was 
detected on 1% agarose gel separation. Preparations that were identified as 
successfully mutated for the &/II selection site were sequenced for the AT-tract using 
automated sequencing (see 2.4.8.2).
Primer ID Sequence 5’ to 3*
AT601F P-ATCTGGTCACTGAAAAAAAATTT...
TTTTTTTTTCAAAAAACATAGC  
AT601R P-GCTATGTTTTTTGAAAAAAAAAA...
..AATTTTTTTTCAGTGACCAGAT 
PGB1F P-GATAAGGATCCGCGGACCGATGCCCT
PGB1R P-AGGGCATCGGTCCGCGGATCCTTATC
Desired change
A9T11 to A8T12
Generation o f second strand 
for A8T12 mutated strands 
Sail site (GTCGAC) to 
SstU site (CCGCGG) 
Generation of second strand 
for & /n  mutated strand
Table 2.9. Mutation and selection primers for AT-tract site-directed mutagenesis.
Primers were synthesised to order by Genosys with phosphorylated 5’-ends. The introduced mutated 
nucleotide bases are underlined in bold.
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2.9.6. Isolation of plasmid DNA by the alkaline lysis method
These methods were modified from the procedure of Bimboim and Doly (1979).
2.9.6.1. Small scale purification of plasmid DNA (mini-prep)
Small scale sequencing grade plasmid DNA was prepared using the Wizard plus mini- 
prep DNA purification system (Promega) according to Manufacturer’s instructions. A 
single transformed bacterial colony was picked and inoculated into 5ml of LB media* 
containing lOOpg/ml ampicillin* and incubated (at 37°C), whilst shaking for 6-8 hours 
to a cell density of ~ 1 x 109 cells/ml (determined by optical density at 600nm, see 
section 2.9.8.3). 1.5ml of this culture was transferred to an eppendorf tube and pelleted 
by centrifugation at l,200g for 5min at room temperature. This was re-suspended in 
200pl of re-suspension solution (50mM Tris-HCl pH8.0, lOmM EDTA pH8.0 & 
lOOpl/ml RNAse A) then 200pl of alkaline cell lysis solution (200mM NaOH, 1% 
SDS) was added and thoroughly mixed until the solution became clear. 200pl of 
neutralisation solution (3M KAc pH5.5) was added, precipitating the bacterial cell 
debris that was then pelleted by centrifugation at 10,000g for 5min. The resultant 
supernatant was applied to a Wizard mini-prep column containing 1ml of DNA 
binding resin (Promega kit). The solution was drawn through the column by means of 
a vacuum pump and washed with 2ml of ethanol based column wash (200mM NaCl, 
20mM Tris-HCl pH7.5, 5mM EDTA & 55% ethanol) to remove RNA, proteins and 
low molecular weight impurities. The plasmid DNA was eluted from the column with 
50pl of TE buffer pre-heated to 70°C and collected into a fresh eppendorf tube by 
centrifugation of the column at 10,000g for 20sec.
2.9.6.2. Large scale purification of plasmid DNA (maxi-prep)
Large scale, transfection grade (endotoxin-free) plasmid DNA was prepared using an 
in-house protocol. Transformed E. coli from a glycerol stock or a single bacterial 
colony grown on LB agar* containing 50pg/ml ampicillin (± X-gal/IPTG if  blue/white 
selection was required, see 2.9.8.7) were inoculated into 7-10ml of LB media 
containing lOOpg/ml ampicillin and incubated (at 37°C), shaking for 8-10 hours (until 
turbid). This starter culture was transferred to 500ml of Terrific-broth* containing 
1 OOpg/ml ampicillin, in a 2 litre conical flask. This was cultured for 12-16 hours at 
37°C in the shaking incubator.
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The 500ml culture was transferred to a 500ml centrifuge bottle and centrifuged in GS3 
rotor (Sorvall) at 8000rpm for 5min at 4°C to pellet the bacteria. The supernatant was 
decanted and the bacterial pellet re-suspended and washed in 100ml cold STE (lOOmM 
NaCI, lOmM Tris pH8.0 & ImM EDTA pH8.0). The suspension was re-centrifuged at 
8000rpm for 5min at 4°C. The bacterial pellet was re-suspended in 18ml cold solution I 
(50mM glucose, 25mM Tris pH8.0 & lOmM EDTA pH8.0), gently mixed using a 5ml 
disposable pipette and transferred to a 250ml centrifuge bottle. 36ml of freshly made 
solution II (0.2M NaOH, 1% SDS) was added and after thorough mixing, was 
incubated for lOmin at room temperature. Next 20ml cold solution HI (3M KAc & 
11.5% acetic acid) was added, vigorously mixed and incubated for 20min on ice. 
These steps lyse the bacterial cells and release the DNA plasmid into suspension. The 
flocculant suspension of plasmid and precipitated cell debris was centrifuged in SLA- 
1500 rotor (Sorvall) at 8000rpm for 15min at 4°C. The supernatant was carefully 
removed, filtered into clean 250ml centrifuge bottles, through fine nylon mesh to 
remove any remaining cellular debris. To the filtered plasmid suspension 0.6 volumes 
of propan-2-ol was added and incubated for lOmin at room temperature. The mix was 
centrifuged at 10,000rpm for 15min at room temperature. The pellet of plasmid DNA 
was carefully rinsed twice with 70% ethanol and then air-dried before re-suspending in 
8ml cold TE (lOmM Tris pH8.0, ImM EDTA pH8.0) overnight at 4°C. For 
transfection grade plasmid, very low in RNase and LPS content, the plasmid DNA was 
purified twice by caesium chloride gradient (see below).
2.9.7. Caesium chloride purification of plasmid DNA
8g of caesium chloride (CsCl, lg/ml) was dissolved in the 8ml plasmid-DNA in TE 
buffer preparation, prepared by maxi-prep (see above). 150ml of ethidium bromide 
(lOmg/ml) was added to label the DNA and complex with remaining bacterial proteins. 
The solution was gently transferred to Quickseal centrifuge tubes (Beckman) using a 
syringe (no plunger) and wide bore needle to avoid shearing of the plasmid DNA. The 
tubes were precision balanced and heat-sealed before ultracentrifugation in a 70.1Vti 
rotor (Beckman) at 60,000rpm for 20 hours at 20°C. Normally after centrifugation, two 
bands were visible under normal light. The thinner, upper band consisted of nicked 
circular plasmid DNA and linear bacterial (chromosomal) DNA, while the lower band 
consisted of closed circular plasmid DNA. A red pellet along the side or bottom of the 
tube consisted of ethidium bromide-RNA/protein precipitates. A 21-guage hypodermic
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needle was inserted into the top of the tube to allow air to enter and then the lower 
band of circularised plasmid was removed with a 21-guage hypodermic needle and 
lml syringe (figure 2.10). This DNA was transferred to a clean Quickseal tube, made 
up with 1 mg/ml CsCl in TE and ultracentrifuged for a second time as above. Often 
after this second purification, only one band of DNA (circularised) would be visible. 
The double purified, circularised plasmid DNA was removed from the Quickseal tube 
as before and the ethidium bromide extracted using TE-saturated butanol. 6-8 times 
volume of TE-saturated butanol was added to the DNA solution, the two phases mixed 
and the organic phase removed from the top. This was repeated >6 times until the pink 
colour had disappeared completely from the aqueous and organic phases. To 
precipitate the DNA from the CsCl solution, an equal volume of water was added 
followed by 2 volumes of 4M ammonium acetate (pH5.4) and cold ethanol to a 
volume of 70%. The DNA was precipitated on ice for at least 15min and then 
recovered by centrifugation in a Corex tube using the HB4 rotor (Sorvall) at 
10,000rpm for lhour at 4°C. The pellet was washed twice with cold 70% ethanol and 
air-dried before re-suspension in TE* and the DNA concentration determined by 
optical density at 260nm (see 2.9.3). Plasmid identity was verified by PCR and 
restriction enzyme digestion (see 2.9.2). Purified plasmid was stored at -20°C.
Nicked plasmid and linear 
bacterial genomic DNA
Circularised 
plasmid DNA
Ethidium-bromide- 
RNA/protein precipitates
Figure 2.10. Isolating purified circularised plasmid DNA by CsCl ultra­
centrifugation.
The plasmid prep in 1 mg/ml CsCl/TE was ultra-centrifuged at 60,000rpm for 20hours at 20°C. The 
circularised plasmid DNA band was carefully aspirated using a 21-guage hypodermic needle.
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2.9.8. Bacterial cell culture and transformation
2.9.8.1. Escherichia coli strains
Three strains of E. coli were used for transformations involved in genetic manipulation 
experiments. BMH 71-18 mutS E. coli (Clontech) were used for the transformer site- 
directed mutagenesis of the AT-tract. This strain has a TnlO transposon carrying a 
tetracycline resistance gene inserted in its DNA mismatch repair gene, rendering it 
recombinase deficient so that induced mis-match mutations in the plasmid are not 
‘repaired’ during transformation. These cells were received as non-competent and were 
made competent before transformation. The other two strains of E. coli were obtained 
already competent. The INVaF’ E. coli strain (OneShot cells, Invitrogen) was used for 
sub-cloning and the XL-1 Blue E. coli strain (Stratagene) was used following PCR- 
based site-directed mutagenesis.
2.9.8.2. Culture medium and plates
Luria-Bertani (LB) medium (10g/l bactotryptone, 5g/l bacto-yeast extract, 10g/l NaCl 
in water, pH7.0, autoclaved to sterilise) was used to culture all three strains except for 
the maxi-prep method where high yield was required and Terrific-broth (48g/l EzMix 
Terrific broth base [Sigma], 0.8% glycerol in water, autoclaved to sterilise) was used. 
To culture single colonies, 20g/l of agar was added to the LB medium and autoclaved 
to sterilise. Approximately 25ml per 100mm petri dish was poured. For plasmid 
selection, once the mix had cooled to 50°C before pouring, the appropriate antibiotic 
(ampicillin 50pg/ml, tetracycline 50pg/ml, filter sterilised) was added, and X-gal plus 
IPTG (see 2.9.8.7) were added where blue/white selection was required. Bacterial 
cultures were streaked on to the agar plate and grown overnight, incubated at 37°C.
2.9.8.3. Preparation of competent BMH 71-18 mutS cells
BMH 71-18 mutS E. coli cells were made competent using a modified protocol o f 
Chung and co-workers (1989). The supplied cells (Clontech) were cultured on an agar 
plate containing tetracycline (see above) to obtain single colonies. A single colony was 
picked and inoculated into 5ml LB* media containing tetracycline* (50pg/ml) and 
grown overnight at 37°C, shaking at 220rpm. 1ml of the overnight culture was 
transferred to 100ml LB media in a 500ml flask and incubated at 37°C for 2-3hours, 
whilst shaking. Serial aliquots were removed from 2 hours incubation and the optic
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density determined at 600nm (Hitachi U-1100 Spectrophotometer). When the OD600 
reached 0.45-0.50 (indicating optimal exponential cell growth), the culture was chilled 
on ice for 20min. The cells were then pelleted by centrifugation at l,200g for 5min, at 
4°C and the pellet re-suspended in 10ml cold transformation and storage solution (85% 
LB medium, 10% polyethylene glycol, 5% dimethyl sulphoxide and 50mM MgCL, 
filter sterilised). Aliquots of competent cells were stored at -80°C or used immediately 
for chemical transformation.
2.9.8.4. Transformation of competent BMH 71-18 mutS E.coli
lOpl of plasmid DNA was gently mixed with lOOpl of competent BMH 71-18 mutS 
cells (see above) and incubated on ice for 20min. This was followed by incubation at 
42°C for 60sec before storage back on ice. 1ml of LB medium was added and cultured 
for lhour at 37°C in the shaking incubator (220rpm) to allow expression of the 
antibiotic resistance gene. Transformation was confirmed by culture on LB-agar plate 
containing ampicillin (see 2.9.8.2) as the transformed plasmids contained an ampicillin 
resistance gene.
2.9.8.5. Transformation of INVaF’ competent E. coli
2pi of 0.5M P-mercaptoethanol was added and gently mixed with a 50pl vial o f 
OneShot (INVaF’ E. coli, Invitrogen) cells thawed on ice. Plasmid DNA (l-25ng) was 
added and gently mixed, followed by incubation on ice for 30min, incubation at 42°C 
for 30sec and then incubation on ice again for 2min. 450ml of SOC medium (LB* 
media plus freshly added 1/100* volume 1M MgSC>4, 1M MgCh & 2M glucose, filter 
sterilised) at room temperature was added and incubated at 37°C for lhour, whilst 
shaking. Controls were included to estimate the transformation efficiency (0.1 ng of 
supercoiled pUC test plasmid, supplied with the competent cells) and negative controls 
to check for contamination (‘no DNA’). lx, O.lx and 0.0 lx  dilutions were plated onto 
LB-agar plates containing ampicillin (see 2.9.8.2) and cultured overnight, up side 
down at 37°C to confirm transformation. The cells had a transformation efficiency o f
o
>10 transformants per pg of supercoiled plasmid. The transformed cells were stored 
as glycerol stocks (see 2.9.8.8), plasmid DNA was isolated and purified by one of the 
alkaline lysis methods (see 2.9.6).
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2.9.8.6. Transformation of XL-1 Blue competent E. coli
lfj.1 of Dpnl-treated DNA from the Quikchange Site-Directed Mutagenesis protocol 
(see 2.9.5.1) was added and gently mixed with 50pl of XL-1 Blue Supercompetent E. 
coli cells (Stratagene), thawed and incubated on ice for 30min. Transformation 
efficiency was determined by adding 0.1 ng of pUC18 to a 50pl aliquot of cells. The 
reaction was heated to 42°C for 45secs and then incubated on ice for 2min. 500ml of 
NZY broth (5g/l bacto-yeast extract, 10g/l NZ amine (casein hydrolysate), freshly 
added 12.5ml 1M MgCh, 12.5ml 1M MgS04 & 20ml/l 20% glucose (w/v), pH7.5) 
was added and incubated for lhour at 37°C, shaking (220rpm). Transformation was 
confirmed by plating 250pl of the transformation culture on an LB-agar plate
Q
containing ampicillin (see 2.9.8.2). Transformation efficiency was >10 cfu/pg of 
pUC18 (5pi of transformation culture was applied to the agar plate) with >98% blue 
phenotype colonies when plated on agar plates containing X-gal and IPTG (see below).
2.9.8 .7. Blue/white colony selection with X-gal and IPTG
For plasmid selection, where cloning resulted in disruption of the LacL gene and 
promoter association (such as construct ligation into the multi-cloning site of pCRII, 
see 2.9.1) loss of (3-galactosidase activity from the plasmid indicated successful 
cloning. This was detected on LB-agar plates (see 2.9.8.2) containing X-gal (20pl of 
10% (w/v) 5-bromo-4-chloro-3-indolyl-p-D-galactopyranoside in dimethylformamide) 
and IPTG (20pl of lOOmM isopropyl-P-thiogalactopyranoside in water), filter 
sterilised. Colonies of bacteria that contain successful construct insertion appear white.
2.9.8.8. Glycerol stocks
For long-term storage of manipulated plasmids, glycerol stocks were made by addition 
o f 20% sterile glycerol to transformed bacteria stock and stored at -80°C.
2.10. Mammalian cell culture and transfection
Mammalian cell culture used full sterile technique in a dedicated class I tissue culture 
hood. Cells were grown in Falcon tissue culture flasks (T25, T75 or T175) at 37°C 
under 5% CO2: 95% air, in high humidity in a humidified incubator dedicated to 
mycoplasma-free tissue culture. HeLa cells (human cervical epithelioid carcinoma cell 
line) and Huh7 cells (human hepatoma cell line) were obtained from the European cell
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bank and stocks maintained at fewer than 30 passages for transfection. Cells were 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM -  high glucose, Gibco) 
supplemented with 10% (v/v) heat inactivated foetal calf serum (FCS, Globepharm), 
2mM glutamine, lOOIU/ml penicillin V, lOOpg/ml streptomycin & gentamicin 
(Gibco), and ImM non-essential amino acids (Sigma). Each additive was filter 
sterilised. When near confluent, the adherent cells were passaged by washing with 
warmed Hanks’ balanced salt solution (0.185g/l CaCl2, 0.4g/l KC1, 0.06g/l KH2PO4, 
0.1g/l MgCl2, 0.1g/l M gS04, 8g/l NaCl, 0.35g/l NaHC03, 0.048g/l Na2HP04, lg/1 D- 
glucose, pH7.4 from Gibco) to remove the media. The cells were then covered with 3- 
5ml trypsin-EDTA (2.5g/l trypsin in Versene [0.015% phenol red, 140mM NaCl, 
2.6mM KC1, 1.5mM KH2P 0 4, 9mM Na2HP04, 600pM EDTA & 20mM HEPES, 
pH7.2] from Gibco) and incubated for 2-3min until the cells de-adhered. The cells 
were transferred to a 50ml Falcon tube, 2x volume of DMEM media containing FCS 
was added to neutralise the trypsin and the cells harvested by centrifugation at 
1200rpm for 5min. The cell pellet was re-suspended in the required volume of warmed 
media and seeded into fresh culture flasks. A one in five cell split was usually required 
every 3-4 days to prevent cell overgrowth.
Frozen stocks were regularly prepared to ensure availability of low passage cells for 
transfection studies. The cells were grown to 80% confluency and harvested as 
described above. The cell pellet was then re-suspended in cold DMEM media 
containing 20% heat inactivated FCS and 10% dimethyl sulphoxide (DMSO, Sigma), 
lm l aliquots were transferred to cryotubes (NUNC) and slowly cooled to -80°C over 
propan-2-ol. After 24 hours, these were transferred to liquid nitrogen for long-term 
storage. To revive cells, a vial was removed from liquid nitrogen storage, warmed for 
lmin at room temperature and then a further lmin at 37°C in a water bath after 
loosening and re-tightening the lid to prevent explosion of the vial on warming. The 
thawed contents were mixed with 10ml of pre-warmed DMEM media containing 10% 
FCS in a falcon tube, pelleted at 1200rpm for 5min, re-suspended in media and seeded 
into a 80cm2 culture flask. The cells were grown at 37°C, 5% CO2: 95% air, high 
humidity in a dedicated tissue culture incubator.
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2.10.1. Transfection of HeLa and Huh7 cells
Cultured cells, of less than 30 passage, grown to 80-90% confluence in 80cm2 flasks, 
were detached by trypsin-EDTA, pelleted, washed once with media and re-suspended 
in DMEM with 10% FCS to achieve a concentration of 105 viable cells per ml (see 
2.10.3 for trypan blue stain for viability). The cells were seeded into 6-well (1ml per 
well) or 24-well (0.5ml per well) tissue culture plates (NUNC) and grown for 48hrs 
until ~80% confluent. The media was removed and replaced with fresh DMEM media 
containing 10% FCS. 2-3 hours later, the DNA-calcium phosphate precipitate in Hepes 
buffered saline (see 2.10.1.1) was applied drop-wise to each well. Incubation was 
continued for 18hrs. At this time, the media was removed and the adherent cells 
washed twice with warmed Hanks buffered salt solution (Gibco) to remove remaining 
precipitate debris and non-dead adherent cells. Fresh DMEM media containing 2% 
FCS was applied, this was considered as time zero for stimulation (where stripped FCS 
was used see preparation protocol section 2.10.2). If cytokine stimulation or 
dexamethasone inhibition was required, it was added in this change of media. The 
cytokines used were recombinant human IL-ip (800units/pl in sterile PBS with 0.1%
o
BSA stabiliser; specific activity 2 x 10 units/mg, Genzyme) and recombinant human 
TNFa (lyophilised from sterile PBS with BSA, reconstituted in sterile distilled water
O Q
to 1.1 x 10 units/pl; specific activity 1.1 x 10 units/mg, R & D Systems). Cytokine 
aliquots were stored at -80°C for <6 months (with only one freeze-thaw). 
Dexamethasone was obtained in crystalline form (Sigma) and dissolved in ethanol to a 
10'3M stock solution (stored at -20°C for <1 month in aliquots used only once). In 
experiments with ethanol-dissolved dexamethasone, the presence of ethanol was 
controlled for by adding the equivalent volume of 100% ethanol to the media of cells 
in other wells.
After addition of media ± cytokine/dexamethasone, the cells were incubated for set 
lengths of time, variant from 2-24hrs. For time point zero samples, wells were 
harvested without the addition of media. At the set time point, cells were washed twice 
with cold Hank’s buffered salt solution and harvested into 1 x lysis buffer (lOOpl, 
Promega), then stored at -80°C. Prior to assaying the lysed cellular contents for 
luciferase and p-galactosidase levels (see 2.10.4&5), the plates were thawed (freezing 
helped to ensure 100% cell lysis was achieved), cells scraped from the bottom of each
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well, transferred to an eppendorf tube and cellular debris pelleted by pulse micro­
centrifugation. The supernatant was assayed immediately.
2.10.1.1. Calcium phosphate precipitation of DNA for transfection
The technique was based on a modified protocol from Graham and van de Eb (1973)
and Wigler et al. (1977).
8pg (lpg/pl stock) of test plasmid DNA and 2fig (lpg/pl stock) of RSV-P-gal plasmid 
was dissolved in 165pl TE (ImM Tris, O.lmM EDTA) pH8.0. 25ml of 2M CaCh was 
added, mixed thoroughly and this solution added drop-wise into 200pl of 2 x Hepes 
buffered saline (HBS, pH7.12) diluted from a stock of lOx HBS*, pH adjusted with 
NaOH. Precipitate formation and mixing was assisted by bubbling air through the 
solution. A fine opaque suspension should be obtained rather than large clumps of 
precipitate forming out of suspension. This was incubated for 30min at room 
temperature before applying drop-wise to the cells (250pl per well for 6-well plates, 
120pl per well for 24-well plates).
2.10.2. Preparation of stripped FCS
This method used a protocol described by Fenske (1991).
For 500ml of heat inactivated FCS (Globepharm, from the same batch as the 
unstripped FCS) 500mg of activated charcoal and 50mg of dextran T70 were added, 
stirred for 30min, centrifuged at l,500g for 15min to pellet the charcoal with bound 
dextran and the supernatant filter sterilised through a 0 .22pm filter before use. 
Aliquots of the stripped FCS were stored at -20°C.
2.10.3. Determining cell viability
0 .2% trypan blue solution was mixed in a 1:2 ratio with cells in media (up to 106 cells 
per ml), incubated at room temperature for 5min and then the number of cells counted 
in an improved Neubauer cell counting chamber (Hausser Scientific) under light 
microscope. Only dead cells take up the trypan blue dye over 5min incubation, so the 
ratio of dead (blue stained cells) to total cells can be determined. Only cell stocks 
>95% viable were used in experiments. The concentration of viable cells was
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calculated as the average number of unstained cells per square of the counting chamber 
x dilution x 104 per ml.
2.10.4. Assay for luciferase expression
Luciferase levels were measured using luciferase assay system (Promega). 20pl of 
transfected cell lysate (section 2.10.1) was mixed with lOOpl of luciferase assay 
substrate (reconstituted in luciferase assay buffer) and the luminescence produced was 
measured over 15sec intervals in a luminometer (BioOrbit 1253) using Stingray 
software (DazDaq) to record the results. This produced results in luminescent emission 
units for luciferase. The results were controlled for variation in transfection efficiency 
by dividing the luciferase luminescent emission units for luciferase by the p- 
galactosidase luminescent emission units (see below) for each sample. An average of 
these ratios was then calculated for replica wells and the standard deviation was 
determined (using Microsoft Excel). Results more than 2 standard deviations from the 
mean were excluded.
2.10.5. Assay for p-galactosidase expression
p-galactosidase expression from co-transfected plasmid was used as an internal control 
for transfection efficiency and level of cell activity. The background level of P-gal 
expression in un-transfected cells was negligible, p-galactosidase activity was assayed 
using Galacto-light Plus reporter gene assay for p-gal (Tropix). 20pl of cell lysate 
(2.10.1) was incubated for 1 hour at room temperature with 200pl of Galacton-Plus 
reagent (diluted 1:100 in Galacton reaction buffer diluent). 300pl of accelerator II was 
then added and the luminescence produced measured over 5sec intervals in a 
luminometer (BioOrbit 1253) with Stingray software (DazDaq). This produced 
luminescent emission units for p-galactosidase that were used to control luciferase 
luminescent emission units as described above.
2.10.6. In situ B-galactosidase activity assay
The efficiency of transfection was calculated by determination of the proportion of 
cells positive for p-galactosidase activity post-transfection with the plasmid RSV-P-gal 
(see 2.10.1). After transfection by calcium phosphate precipitation, the cells were 
washed 5x with phosphate buffered saline (PBS*) to remove untransfected precipitate.
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The cells were then covered with 2% gluteraldehyde and fixed for 40min. The fix 
solution was removed and the cells covered with fresh stain solution (0.2% X-gal, 
lOmM sodium phosphate pH7.0, ImM MgCk, 150mM NaCl, 3.3mM K4Fe(CN)63H20 
and 3.3mM K4Fe(CN)6). The cells were incubated for lhour at 37°C, the stain removed 
and the cells covered in 70% glycerol solution. The number of stained (p-galactosidase 
positive) cells per 100 cells present was counted under light microscope.
2.10.7. Fluorescence-activated cell sorter (FACS)
2.10.7.1. Carboxvfluorescein succinimidvl ester (CFSE) staining 
To determine the rate of cell division of cell lines and to ensure that the cells were in 
log phase when being transfected, cells were stained with CFSE. 5-(and-6)- 
carboxyfluorescein diacetate, succinimidyl ester (CFDA SE) is colourless and 
nonfluorescent and diffuses passively into cells. Once in the cell, CFDA SE forms an 
amine-reactive carboxyfluorescein succinimidyl ester (CFSE) as its acetate groups are 
cleaved by intra-cellular esterases. The succinimidyl ester group of CFSE reacts with 
intracellular amines, to form a fluorescent conjugate that is well retained (up to 8 
weeks in lymphocytes and for at least 20 days in hepatocytes). The label is inherited in 
a 1:1 ratio by daughter cells on division. The time for each division can therefore be 
calculated from the time taken for mean cell fluorescent intensity to halve (Lyons and 
Parish, 1994, Graziano et al., 1998).
CFDA SE (Molecular Probes) was reconstituted to a concentration of 5mM in DMSO. 
Adherent HeLa cells cultured in 6-well or 24-well plates were washed 3x in warmed 
PBS* to remove any traces of FCS remaining from the media. 2.5pM CFDA SE in 
warmed PBS (5pi of 5mM stock in DMSO per 10ml PBS) was applied to cover the 
cells and incubated at 37°C for 15min. The CFDA SE solution was removed and the 
cells washed 3x in warmed DMEM media containing 10% FCS. Incubation was then 
continued in DMEM media with 10% FCS. At the required time point post-staining, 
cells were harvested with trypsin/EDTA, pelleted by centrifugation at 1200rpm at 4°C 
for 5min and washed 2x in 5ml FACS buffer (lx  PBS, 0.1% azide, 1% FCS). The cells 
were re-suspended in lOOpl of fix buffer (FACS buffer with 0.1% formaldehyde). It 
had previously been established that cell fluorescence was not affected by fix buffer 
compared to FACS buffer and that fix buffer allowed the cells to be stored for up to
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72hours at 4°C. Detection and analysis of percentage stained cells was carried out 
using a fluorescence-activated cell sorter (see 2.10.7.3).
2.10.7.2. Surface labelling of IL-1RI on HeLa and Huh7 cells
IL-1RI (CD121a) is the signal transduction molecule of the IL-1 receptor complex. 
HeLa and Huh7 cells were seeded into 24-well culture plates and grown to -80% 
confluence as for transfection (see 2.10.1). The DMEM media was changed at Ohrs and 
contained either 2% FCS (unstripped) or 2% stripped FCS (see 2.10.2) ± IL-1 p 
(100units/ml) ± dexamethasone (10' M) and incubation continued to the set tune point. 
At this time, cells were washed with cold Hanks buffered salt solution to remove 
residual media and harvested into 1ml cold 0.2% EDTA with lOmin incubation at 4°C. 
Cells were transferred to 15ml falcon tubes, pelleted at lOOOrpm for 5min at 4°C and 
washed once in cold FACS buffer*. They were then transferred to the wells of a 
microtitre plate (~106cells per well) and pelleted at 1500rpm for 4min at 4°C. The cells 
were re-suspended in lOOpl FACS buffer containing a 1:1, 1:2, 1:5 or 1:10 dilution of 
biotinylated rat anti-human IL-1R1 monoclonal antibody (anti-CD121a, Pharmingen) 
and were then incubated on ice for 30min. For secondary labelling with quantum red 
(QR) for fluorescent detection, the cells were pelleted again by centrifugation, washed 
3x with FACS buffer and re-suspended in lOOpl of FACS buffer containing a 1:40 
dilution of QR-labelled avidin (Pharmingen), then incubated for 30min on ice (with 
light excluded). Cells were pelleted and washed 3x with FACS buffer, then re­
suspended in lOOpl of fix buffer (FACS buffer with 0.1% formaldehyde). Freshly 
isolated B-cells and monocytes from peripheral blood of healthy volunteers, with or 
without LPS stimulation (lpg/ml in RPMI media), were used as positive controls with 
anti-CD19PE (Phycoeiythrin, Pharmingen) labelling of B-cells and anti-CD14FITC 
(Fluorescein isothiocynate, Pharmingen) labelling of monocytes/macrophages carried 
out (as above) before IL-1RI staining. Unstimulated T-cells, freshly isolated from the 
peripheral blood of healthy volunteers were used as ‘negative’ (low expressing) 
controls and were labelled with anti-CD3FITC (Pharmingen). Detection and analysis 
of percentage stained cells was carried out using a flow analyser cell sorter (figure 2.11 
and section 2.10.7.3).
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Figure 2.11. Constitutive levels of IL-1RI expression on freshly isolated 
peripheral blood (a) B-cells, (b) T-cells and (c) monocytes/macrophages compared 
to (d) HeLa and (e) Huh7 cells.
B-cells were labelled with anti-CD 19PE, T-cells with anti-CD3FITC and monocytes/macrophages with 
anti-CD 14FITC. All cells were labelled with biotin-conjugated rat anti-human IL-1RI (CD121a) mAb 
and avidin-quantum red (see 2.10.7.2). The cells were analysed by FACS (see 2.10.7.3). The percentage 
of gated cells positive for IL-1RI (quantum red) is shown on dot plot graph. The proportion of cells 
constitutively expressing IL-1RJ was similar for cultured HeLa and Huh7 cells, 6.5% and 6.7% 
respectively. The proportion of B-cells and monocytes/macrophages constitutively expressing IL-1RI 
was 77.5% and 77.6% respectively. Only 0.03% of T-cells constitutively expressed detectable levels of 
IL-1R1.
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2.10.7.3. FACS acquisition and analysis
Cell analysis and fluorescence detection of CFSE (see 2.10.7.1) and quantum red- 
tagged IL-1RI (see 2.10.7.2) labelled cells was carried out on a Becton-Dickinson 
FACSCAN with CellQuest software. The cells were analysed for size versus 
granularity (forward and side scatter properties) and the main cell population gated, 
this gate being maintained throughout the acquisition and analysis. The 
detector/amplifier settings were optimised for unstained HeLa cells and Ohr stained 
cells, and kept constant throughout. Up to 50,000 events were collected for each time 
point. Cells labelled in the same way, but finally re-suspended in FACS buffer* rather 
than fix, were incubated with a 1:20 ratio of propidium iodide (500pg/ml) to cell 
suspension for 5min at room temperature. This enabled confirmation that the gated 
cells were all viable and that the majority of outliers were dead cells as propidium 
iodide is taken up by dead cells.
2.10.8. Generation of stable transfected cell lines
Transfections were set up for HeLa cells as described in section 2.10.1. lOjig of test 
plasmid DNA and 0.5pg of antibiotic resistance expressing plasmid PSVneo (gift of 
Dr Fellowes, UCL) conferring resistance to G418 (a neomycin analogue) to allow 
selection of transfected cells, were transfected using the calcium phosphate 
precipitation method (2.10.1.1). The cells were transfected for 24 hours, washed with 
Hanks buffered salt solution and fresh DMEM media with 10% FCS applied. 
Incubation was continued for 12-18 hours to allow expression of the G418 resistance 
gene. The media was then changed to contain 800pg/pl G418, the optimum 
concentration determined to ensure 100% killing of HeLa cells without PSVneo 
transfection. The transfected HeLa cells were cultured in this G418 selection media 
until individual colonies started to re-appear. Individual colonies were picked using a 
pipette tip, transferred to individual wells and grown up in G418 selection media. Once 
adequate cell numbers from each colony were obtained, a sample of cells was tested 
for luciferase expression using the luciferase assay system (2.10.4) to ensure that the 
test plasmid and not just the antibiotic resistance plasmid had inserted into the cell line 
genome. Once established, stable transfectants were maintained in media containing 
400pg/inl G418 or stored frozen in liquid nitrogen (see 2.10). Genomic DNA was 
isolated (see 2.2.2) from a sample of each luciferase-expressing colony and Southern
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blot analysis was carried out (see 2.4). This allowed determination of the copy number 
of luciferase genes (and hence test construct) inserted into the genome of each clone.
For experiments with stable transfectants, an individual clone or ‘pool’ of clones 
(combined equal quantities of individual clones for one plasmid-construct type) were 
seeded at 105 cells/ml into 6-well tissue culture plates and grown in maintenance media 
(DMEM with 10% FCS and 400pg/ml G418). These were incubated over 48hrs to 80- 
90% confluence and then harvested or stimulated with cytokines or dexamethasone for 
set time-periods before harvesting into trypsin/EDTA as for transient transfections (see 
2.10.1). The cytokines used were recombinant human IL-ip and TNFa (see 2.10.1), 
and recombinant human IL-6  up to lOOOu/ml (obtained as lyophilised product from 
sterile PBS with BSA, reconstituted in sterile distilled water to 1.25 x 10 units/pl; 
specific activity 1.1 x 108 units/mg, R & D Systems). Lipopolysaccharide up to 
lOpg/ml (from 1 mg/ml reconstituted in sterile DMEM, Sigma) and crystalline 
dexamethasone 10'7M (see 2.10.1) were used.
2.11. Electrophoretic mobility shift assays
This technique was based on the methods of Fried and Crothers (1981), Gamer and 
Revzin (1981).
2.11.1. Preparation of protein nuclear extracts
This used a method adapted from Dignam et al., (1983). HeLa cells were grown to 
80% confluence in 175cm2 tissue culture flasks (Gibco), washed twice with PBS* 
(calcium/magnesium free), then gently scraped from the flask with a rubber scrapper 
into ice cold PBS. The cells were pelleted by centrifugation at 1,200 rpm for 5 min at 
4°C (Heraeus Instruments, Megafuge 2.0R) followed by a second wash in cold PBS. 
The pelleted cells were re-suspended in 5 times volume of ice cold buffer A containing 
freshly added protease inhibitors (lOmM Hepes pH 7.8, 1.5mM MgCL, 60mM KC1, 
lOmM NaCl, 0.5mM EDTA, 0.5mM DTT, 50pg/ml AEBSF (4-[2- 
aminoethyljbenzenesulfonylfluoride HC1, CalBioChem), 1 tablet/50ml Complete 
Protease Inhibitor Cocktail (EDTA-free, Boehringer)), incubated for lOmin on ice and 
then re-pelleted at 2,000rpm for 5 min at 4°C. The pelleted cells were re-suspended in 
3 times volume of buffer A/protease inhibitors with 0.05% TritonX-100 (iso-
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octylphenoxy polyethoxyethanol molecular biology grade, BDH) and kept on ice, 
while mechanically lysed using a Dounce A homogeniser (tight fitting pestle, 
Wheaton, USA). 90% cell lysis without nucleosome rupture was required 
(approximately 80-100 strokes), and checked for under light microscopy. The nuclear 
fraction of lysed cells was separated from the cytosol by centrifugation at 2,000rpm for 
lOmin at 4°C. The nuclear pellet was re-suspended in an equal volume of buffer B 
containing freshly added protease inhibitors (40mM Hepes pH 7.8, 3mM MgCk, 
0.5mM EDTA, 50% glycerol, ImM DTT, 50jag/ml AEBSF, 1 tablet/50ml Complete 
Protease Inhibitor Cocktail). NaCl from a 5M stock was added to the desired final 
concentration (low salt extracts lOmM NaCl, medium salt extracts 150mM NaCl, high 
salt extracts 300mM NaCl). This was gently mixed on a rotary mixer at 4°C for 30min, 
then cellular debris removed by centrifugation at 14,000 rpm for 30min at 4°C in a 
bench-microfuge (eppendorf 5415C). The supernatant containing the nuclear proteins 
was carefully removed, snap frozen in liquid nitrogen in small aliquots and stored at - 
70°C. Each aliquot was only thawed once for use. Protein concentration was 
determined by BCA/copper sulphate reaction, read by spectrophotometer with a BSA 
standard (see 2.12.2).
2.11.2. Preparation of radiolabelled DNA probes
2.11.2.1. 5’-end labelling DNA probes
Sequence complementary, single-strand oligonucleotide probes were synthesised to 
order (see table 2.10). 40pM of single-stranded oligonucleotide was dissolved in 29pl 
of water, and mixed with 4pl of lOx kinase buffer (Promega; 700mM Tris-HCl pH 7.6, 
lOOmM MgCb, 50mM DTT), 4pi of T4 polynucleotide kinase (Promega), and 3pi o fY'
'y'y
P-ATP (3000 Ci/mmol specific activity, Amersham). The mix was incubated for 40 
min at 37°C, for 5 min at 65°C and stored on ice. 40pl of each complementary, end- 
labelled oligonucleotide was mixed with 20pl of SDW in an eppendorf, sealed and 
floated in a beaker of water pre-heated to 95°C, allowed slowly to cool to room 
temperature overnight to promote DNA annealing into double-stranded probes. 
Unincorporated radiolabel was removed by passing the annealed probe mix through a 
Sepharose 6CLB column-10 (Clontech) that retards <10bp particles. Purified probe 
was collected by centrifugation of the loaded column (3,000g for 3min). A specific 
activity of >500cpm/pl of probe was required.
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2.11.2.2. Integrated second-strand labelling of DNA probes
DNA probes >30bp in length were radiolabelled by Klenow synthesis of a second 
strand to a DNA template sequence to obtain adequate specific activity for EMSA. 
64pmol of single-stranded DNA template was annealed with 180pmol of a short 
complementary primer sequence (see table 2.10) by boiling together in a sealed tube 
for 3min, then cooling slowly to room temperature to allow annealing. In a microtube 
on ice, a mix was prepared of 2pi 20mM DTT, 5 pi 2mM dATP/dTTP/dGTP mix, 2pi 
10x RP buffer (900mM Hepes pH 6.6, lOOmM MgCl2), 3.5pl SDW and 5pl a32P- 
dCTP (>3000Ci/mmol specific activity, Amersham). 1.5pl (64pmol) of annealed 
template/primer was added, followed by lp l (5 units) of DNA polymerase I large 
(Klenow) fragment (Promega) and incubated at room temperature for 16 hours. 2.5pl 
of 2mM unlabelled-dCTP was subsequently added as a cold chase and incubated for 2 
hours to ensure complete double-strand synthesis. The Klenow was deactivated by 
heating to 75°C for lOmin before storing on ice. The probe mix was diluted in lOOpl of 
TE* and purified by TE-30 Sepharose spin column (Clontech) to remove 
unincorporated primer and dNTPs, centrifugation at 3,000g for 3min.
Cold probes for competition studies were generated using the same method. In the 
initial incubation mix, 5pl of 2mM unlabelled dCTP was substituted for the 
radiolabelled dCTP and incubated as above. No cold chase was required but otherwise 
preparation was the same as for hot probes. Pre-purification, unlabelled probes were 
diluted in TE to obtain 3.33x concentration of radiolabelled probe.
2.11.3. Binding reaction
The binding reaction was carried out with lOpg of nuclear extract pre-incubated for 
lOmins at room temperature with 10pg of poly dl.dC (Amersham, lOpg/pl in dl.dC 
buffer*) in lOpl 2x Parker Buffer (16% Ficoll, 40mM Hepes pH 7.9, lOOmM KC1, 
2mM EDTA pH 8, ImM DTT) made up to 19.5pi with SDW. 5pmol of radiolabelled 
probe in 0.5pl TE was added and incubated with the nuclear extract mix for 20min at 
21°C. The binding reaction temperature was initially room temperature but as this was 
found to vary over a range o f 5°C with effects on non-specific protein binding to the 
probe (see 5.2.1), the temperature was subsequently fixed at 21 °C in a water bath.
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Probe identity Region of IL-6 gene / length Allele(s)
1G -189 to -164 / 26bp -174G
5 ' -CTAGTTGTGTCTTGCGATGCTAAAGG-3'
3 ' -GATCAACACAGAACGCTACGATTTCC-5'
1C -189 to -164 / 26bp -174C
5 ' -CTAGTTGTGTCTTGCCATGCTAAAGG-3'
3 ' -GATCAACACAGAACGGTACGATTTCC-5'
2G -184 to -1 3 4 /5  lbp -174G
5 ' -TGTGTCTTGCGATGCTAAAGGACGTCACATTGCACAATCTTAATAAGGTTT-3'
3 ' - ACACAGAACGCTACGATTTCCTGCAGTGTAACGTGTTAGAATTATTCCAAA-5y
2C -184 to -134 / 5 lbp -174C
5 ' -TGTGTCTTGCCATGCTAAAGGACGTCACATTGCACAATCTTAATAAGGTTT-3'
3 ' - ACACAGAACGGTACGATTTCCTGCAGTGTAACGTGTTAGAATTATTCCAAA-5'
3G -235 to -161 / 75bp -174G
5 ' -CTTCTTAGCGCTAGCCTCAATGACGACCTAAGCTGCACTTTT...
3 ' - GAAGAATCGCGATCGGAGTTACTGCTGGATTCGACCTGAAAA...
...CCCCCTAGTTGTGTCTTGCGATGCTAAAGGACG-3' 
...GGGGGAT CAAC AC AGAAC G C T AC GAT TTCCTGC -  5 '
3C -235 to -161 / 75bp -174C
5 '  -CTTCTTAGCGCTAGCCTCAATGACGACCTAAGCTGCACTTTT...
3 # - GAAGAATCGCGATCGGAGTTACTGCTGGATTCGACCTGAAAA..
...CCCCCTAGTTGTGTCTTGCCATGCTAAAGGACG-3' 
...GGGGGATCAACACAGAACGGTACGATTTCCTGC- 5 '
4G -613 to -539 / 71bp -597G/-572G
5 '  -GCACGAAATTTGAGGGTGGCCAGGCAGTTCTACAACAGCCGC...
3 '  - CGTGCTTTAAACTCCCACCGGTCCGTCAAGATGTTGTCGGCG...
...TCACAGGGAGAGCCAGAACACAGAAGAAC- 3 '  
...AG TGTCCCTCTCG GTCTTGTGTCTTCTTG -5'
4A -613 to -539 / 7lbp -597A/-572G
5 '  -GCACGAAATTTGAGGATGGCCAGGCAGTTCTACAACAGCCGC...
3 '  - CGTGCTTTAAACTCCTACCGGTCCGTCAAGATGTTGTCGGCG...
...TCACAGGGAGAGCCAGAACACAGAAGAAC- 3 '  
..A G TG TCCC TCTCG G TCTTG TG TCTTC TTG -5'
Table 2.10. The IL-6 5’-flanking region probes used for EMSA studies.
Red lettering = polymorphic alleles. Blue lettering = oligonucleotide primer sequences used for second 
strand synthesis. Underlined lettering = synthesised second strand.
Single-strand oligonucleotides and primers were synthesised to order by Genosys.
In the optimization process, different concentrations of poly (dl.dC).poly (dl.dC) were 
tried by varying the quantity at pre-incubation. Poly (dl.dC).poly (dl.dC) is a synthetic 
double-stranded polymer of inosine and cytosine (abbreviated to poly dl.dC, obtained 
from Amersham as a sodium salt) and will bind non-specifically to nuclear proteins 
such as histones. For probes 1G and 1C (table 2.10), an NF1 specific binding buffer
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(final concentration 10% glycerol, lOmM Tris HC1, 0.5mM EDTA, 5mM MgCh, 
50mM NaCl) was used in place of Parker buffer.
2.11.4. Cold competition and supershift studies
For cold-competition studies, unlabelled probe (see section 2.11.2.2) was used at 3.33x 
concentration of radiolabelled probe. Double-stranded, purified oligonucleotides of 
transcription factor consensus binding site sequences were obtained to order from 
Santa Cruz (20ng/pl) or MWG Biotech (lpg/pl), (table 2.11). These were used 
unlabelled in competition studies. 5pmol (0.5pi) of radiolabelled probe was mixed 
with unlabelled probe/oligonucleotide in TE to the required ratio, total volume 8pl. 
The ratios used were 1:0, 1:2, 1:5,1:10, 1:20 and 1:50 radiolabelled (hot) to unlabelled 
(cold) probe. This mix was added in place of radiolabelled probe alone in the binding 
reaction (see 2.11.3) and incubated at 21°C for 20min. The total volume of the pre­
incubation reaction was 20pl.
For supershift studies, 1.5pl of specific antibody (2pg/pl in PBS containing 0.1% 
sodium azide, Santa Cruz, see table 2.12) was added either ‘before’ or ‘after’ the 
binding reaction (total volume 20pl, see 2.11.3). If added ‘before’, it was added to the 
pre-incubation mix after the lOmin incubation of nuclear extracts with polydl.dC and 
incubated at 21°C for 20min before addition of the radiolabelled probe. If antibody was 
added ‘after’, it was added after the addition and incubation of radiolabelled probe 
with nuclear extracts, and incubated for a further 20min at 21°C. The volume of SDW 
was altered to keep the total volume of the reaction at 20pl. During optimization 
antibody concentrations of 100-300ng/pl of reaction, an incubation temperature of 4°C 
instead of 21°C and lengths of incubation up to 60mins were also tried.
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Probe identity Transcription factor identified to bind Probe length
C/EBP1 C/EBP family members 20bp
5 ' -TGCAGATTGCGCAATCTGCA-3'
3 ' -ACGTCTAACGCGTTAGACGT-57
CREBX CREB/ATF family members 27bp
5 ' - AGAGATTGCCTGACCTCAGAGAGCTAG- 3 '
3 ' -TCTCTAACGGACTGGAGTCTCTCGATC-57
Glucocorticoid receptor1 GR
5 ' -AGAGGATCTGTACAGGATGTTCTAGAT-37 
3 7-GCTCCTAGACATGTCCTACAAGATCTA-5'
NF1 controlT NF1
5 ' -AAGGGATGGCTGCCAGCCAAGCATGA-3'
3 7-TTCCCTACCGACGGTCGGTTCGTACT-57
NF1 consensus 1 (N F l-l)-1 NF1 family members
5 7-TTTTGGATTGAAGCCAATATGATAA-37 
3 7-AAAACCTAACTTCGGTTATACTATT-57
NF1 consensus 2 (NF1-2)T NF1 family members
5 ' -TTTTGGATTGATGCCATTATGATAA-37 
3 ' -AAAACCTAACTACGGTAATACTATT-5'
NFlmutlx notNFl
5 7- TTTTGGATTGAATAAAATATGATAA-3 7 
3 ' -AAAACCTAACTTATTTTATACTATT-5'
NFlmut2r notNFl
5 7 - TTTTGGAT TG ATTAA ATTA TG A TAA-3 7 
3 7 -A A A A C C T A A C T A A T T T A A T A C T A T T -57
NF-kB1 NF-kB family members 22bp
5 f -AG TTG AG GG G ACTTTCCCAG GC-3'
3 7 -TCA ACTC CCC TG A AAG G G TC CG -57
Random probeT (a universal heteroduplex generator for an exonic 93bp
portion of the IL-4 receptor gene around Q 576)
5 ’ -CAGCTGCAGCCCCCGTCTCGGCCCCCACCAGTGGCTATCATTTGTACA..
3 '  -GTCGACGTCGGGGGCAGAGCCGGGGGTGGTCACCGTATGTAAACATGT...
...TGCGGTGGAGCAGGGTGGCACCCAGGCCAGTGCGGTGGTGGGCTT-3'
.. A.CGCCACCTCGTCCCACCGTGGGTCCGGTCACGCCTCCACCCGAA- 5 '
Spl1 Spl 22bp
5'-ATTCGATCGGGGCGGGGCGAGC-3,
3 f -TAA G C TAG CCC CG CCC CG CTCG -5r
YY11 YY1 27bp
5 f -CGCTCCGCGGCCATCTTGGCGGCTGGT-37 
3 7 -GCGAGGCGCCGGTAGAACCGCCGACCA-57
Table 2.11. The transcription factor consensus site and mutant oligonucleotide 
sequences used as competitors and controls for EMSA studies.
Purple lettering denotes binding bases in sequence. Underlined lettering denotes mutated bases.
1 oligonucleotides obtained from Santa Cruz Biotechnology.
T oligonucleotides designed in this study and obtained pre-synthesised from MWG Biotech.
27bp
26bp
25bp
25bp
25bp
25bp
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Identity Specificity Epitope Cross-reactivity Species 
raised in
sc-150X a-C/EBPp C-terminus rat 
CEBPp
human reactive 
non cross-reactive with 
other C/EBP members
Rabbit
(polyclonal
IgG)
sc-746X a-C/EBP C-terminus 
human C/EBPp
cross-reactive with 
C/EBPa, 8 and e
Rabbit
(polyclonal
IgG)
sc-186X a-CREB-F C-terminus
human
CREB-1
cross-reactive with CREB- 
lp43, ATF-1 and CREM-1
Rabbit
(polyclonal
IgG)
sc-27 IX a-CREB-l“ DNA binding/ 
dimerisation 
domain human 
CREB-1
specific for CREB-1 p43 Mouse
(monoclonal
IgG2b)
sc-1002X a-GRa
sc-1003X a-GR
sc-870X a-NFl
sc-28 IX a-YYl
sc-734 IX a-YYl
C-terminus 
human GRa
N-terminus 
human GRa
N-terminus 
human NF1
C-terminus 
human YY1
human YY1 
a a  1-414
non cross-reactive GRp Rabbit
(polyclonal
IgG)
cross-reactive GRp, Rabbit
not other steroid receptors (polyclonal
IgG)
Rabbit 
(polyclonal 
IgG)
Rabbit 
(polyclonal 
IgG)
Mouse 
(monoclonal 
IgGl)
reactive with all NF1 
isoforms
specific
specific
Table 2.12. Specific antibodies used for EMSA supershift studies and as primary 
detection antibodies for Western blots, obtained from Santa Cruz Biotechnology 
(2mg/ml).
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2.11.5. Gel resolution of EMSA bands
EMSA bands were resolved after the binding reaction on a 4% non-denaturing 
polyacrylamide gel with 0.5x TBE* (see section 2.3.2); gel plates were 12cm long, 
separated by 1mm spacers with a 14 x 1cm well comb. The gel was pre-run in 0.5x 
TBE at lOvolts/cm until the current and temperature stabilised (about 4 hours). The 
full 20pl of binding reaction was loaded per well and could be seen to sink into the 
well because of the glycerol in the binding buffer. Loading dye* was used only in an 
empty or probe only lane. The gel was run at lOvolts/cm until unbound radiolabelled 
probe began to come off into the lower reservoir, 2.5-4.5 hours dependent on the probe 
size. For each set of probes, the length of run was kept constant. The gel was 
transferred to Whatman 3MM paper and dried for 1 hour at 80°C on a vacuum pump 
gel drier. The bands were then detected on x-ray film (BIOMAX, Kodak) and put 
down for 4 - 8 hours at -80°C (see figure 2.12).
Introduced
factor
binding
Figure 2.12. EMSA for NF1 consensus probe and NF1 mutant probe with HeLa 
cell nuclear extracts.
5pmol of NF1 consensus 1 (NF1-1) or NF1 mutant 1 (NFl-mutl) probe (see table 2.11) was 5’-end 
labelled (see 2.11.2.1) and incubated with 10pg of unstimulated HeLa cell nuclear extracts in a binding 
reaction containing Parker buffer (see 2.11.3). The products were separated by electrophoresis on a 4% 
non-denaturing polyacrylamide gel run for 2.5hrs at 4°C. Lanes 1&2=NF1-1 probe, lanes 3&4=NF1- 
mutl probe. The NFl-mutl sequence abolished NF1 binding but permitted another nuclear factor to 
bind.
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2.12. Protein detection and quantification
2.12.1. Enzyme-linked immunosorbent assays (ELISA)
Standardised ELISA kits from R & D Systems were used to detect IL-la, IL-lp, 
TNFa and IL-6 in culture media and serum. These were used according to 
manufacturers instructions. 50pl of cell culture medium or serum was added to the 
microtitre-plate wells pre-coated with antibody and then incubated at 37°C for lhr. All 
samples and standards were loaded in duplicate. Unbound protein was washed away 
using lx PBS* with 0.05% Tween (polyoxyethelenesorbitan monolaurate, Sigma). A 
second antibody, conjugated to horseradish peroxidase, was added to each well. This 
was incubated at 37°C for lhr before unbound antibody was washed away 
(PBS/Tween) and detection substrate added to produce the chemiluminescent reaction 
when hydrolysed by the horseradish peroxidase. The plates were read at an absorbance 
of 450nm (Anthos II plate reader, Stingray (DazDaq) software package). A standard 
curve was plotted from which the cytokine concentration of the sample was calculated.
2.12.2. Determining total protein concentration
Total protein concentrations from cell lysates or nuclear extracts were determined 
using a Bicinchoninic acid (BCA) protein assay system. lOpl aliquots of cell or nuclear 
extracts (diluted 1:0, 1:5, 1:10) were loaded onto a micro-titre plate (NUNC) in 
duplicate alongside lOpl aliquots of bovine serum albumin (BSA) standards covering 
the range 0.1, 0.2, 0.5, 0.8 & lmg/ml. Samples and standards were loaded in duplicate 
together with two control reference samples containing water or cell lysis buffer. 200pl 
of BCA reagent (196pl BCA and 4pl copper(II) sulphate solution mixed immediately 
prior to use) was added to each well. The plate was covered and incubated for 30min at 
37°C, before cooling to room temperature again for 5min. The alkaline medium allows 
the proteins to reduce Cu to Cu resulting in a colour change that was read at an 
absorbance of 562nm, using an Anthos II plate reader. Using Stingray (DazDaq) 
software, a standard curve was plotted from which the protein concentration of the 
samples could be calculated.
2.12.3. Polyacrylamide gel electrophoresis (PAGE)
SDS-PAGE gels were used based on the method of Laemmli (1970) and run using the 
Mini-PROTAN II gel electrophoresis system (BioRad). A 6cm x 8cm x 1mm gel cell
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was assembled according to manufacturer’s instructions. A 4cm resolving gel of 12% 
polyacrylamide was poured (for 10ml, 4.85ml SDW, 3ml 37.5:1
acrylamide:bisacrylamide at 40% [National Diagnostics], 2ml 1.5M Tris-HCl pH 8.8, 
lOOpl 10% (w/v) SDS, 6pl TEMED (electrophoresis grade, BDH), 60pl 10% (w/v) 
AMPS (Sigma) and allowed to polymerise for 30min over-layed with a few drops of 
water. The over-layed water was poured off and a 1.5cm stacking gel of 3% 
polyacrylamide poured on top with an 8 x 0.5cm well comb inserted (for 2.5ml, 1.4ml 
SDW, 750pl 37.5:1 acrylamide:bisacrylamide at 40%, 300pl 1M Tris-HCl pH 6.8, 
25pi 10% (w/v) SDS, 2pl TEMED, 20pl 10% AMPS) and allowed to polymerise for 
30min. lOOng of pure protein or lOpg of nuclear extract was mixed with equal 
volumes of 2x Novex Tris-Glycine SDS Sample Buffer (Gibco), boiled for 2min to 
denature the protein, microcentrifuged at 13,000rpm for lmin to remove insoluble 
debris and loaded into the wells set in the gel. Electrophoresis was carried out in SDS 
running buffer (25mM Tris pH8.3, 200mM glycine (electrophoresis grade, pH8.3), 
0.1% (w/v) SDS) from cathode to anode at a constant 150V (~35mA) for 1 hour, until 
the bromophenol blue tracking dye reached the bottom of the gel. In all cases, 5pl of 
Benchmark Pre-stained Protein Ladder (Gibco) was run alongside the protein sample 
to enable estimation of the molecular weights of protein bands detected by Western 
blotting (figure 2.13).
kDa
190
120
Figure 2.13. Pre-stained Protein Molecular Weight M arker (Benchmark, Gibco). 
Approximate molecular weights (kDa) shown on SDS-PAGE denaturing gel (3% polyacrylamide 
stacking gel, 12% polyacrylamide resolving gel, see above).
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2.12.3.1. Western blotting
This is a based on a modified method of Towbin et al., (1979). Proteins were 
transferred from the polyacrylamide gel by wet transfer to a polyvinylidene difluoride 
(PVDF) membrane (Hybond P membrane, Amersham). A 6.5cm x 8.5cm PVDF 
membrane was cut with a notch in one comer to identify lane 1 of the gel. The 
membrane was pre-soaked briefly in methanol (Sigma) followed by a rinse in SDW, 
before soaking for 2min in transfer buffer (25mM Tris pH 8.3, 200mM glycine, 5% 
(v/v) methanol). Whatman 3MM paper cut to size and the blotting cassette porous 
nylon pads were also soaked in transfer buffer. The pre-soaked PVDF membrane was 
placed over the polyacrylamide gel with the exclusion of air bubbles and sandwiched 
between 4 pieces of pre-soaked Whatman 3MM paper, 2 nylon pads and 2 plastic 
supports, before immersion in the blotting tank filled with transfer buffer (BioRad 
Minitransblot System, figure 2.14). Ensuring that the membrane was on the anode side, 
transfer was carried out with a constant 60V (195mA) for 45min.
+
Reservoir containing 
transfer buffer
Cathode
Plastic support Porous nylon pad
Whatman 3MM paper
membrane
Figure 2.14. Western blot set up.
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2.12.3.2. Immunological detection of proteins following transfer 
The nitrocellulose membrane was ‘blocked’ with 5% (w/v) Marvel milk (Premier 
Brands) in PBS* for 45min at room temperature on a slow rotating platform. This was 
to prevent non-specific binding of antibodies to protein-free sites. The membrane was 
then incubated with the primary detection antibody (1:2000 dilution, see table 2.12) in 
PBS containing 0.1% (v/v) Tween overnight at 4°C on a slow rotating platform. This 
was followed by five washes in PBS/0.1% Tween for 5min each at room temperature. 
The membrane was then incubated for 2 hours at room temperature with secondary 
detection horseradish peroxidase (HRP)-conjugated antibody specific to the species of 
the primary antibody (1:1000 dilution, see table 2.13). This was also followed by 5x 
5min washes in PBS/Tween at room temperature.
Immunoglobulin specificity Cone./
(peroxidase-conjugated) dilution
used
Supplier Primary antibodies
(table 2.12)
Swine anti-rabbit 1.3mg/ml
immunoglobulin 1:1000
(polyclonal, mainly to IgG)
DAKO a-C/EBPp sc-150 
a-C/EBP sc-746 
a-CREB-P sc-186 
a-GRa sc-1002 
a-GR sc-1003 
a-NFl sc-870 
a-YYl sc-281
Sheep anti-mouse 
immunoglobulin 
(polyclonal, whole antibody)
1:1000 Amersham a-CREB-lu sc-271 
a-YYl sc-7341
Table 2.13. Secondary detection horseradish peroxidase (HRP)-conjugated 
antibodies used for immunological detection of Western blots.
The membranes were developed using enhanced chemiluminescence (ECL) Western 
Blotting Detection Reagents (ECL Plus, Amersham), according to manufacturers 
instructions. In brief, 5ml of substrate A (supplied) was mixed with 125 pi of substrate 
B (supplied). This was poured onto the membrane and incubated at room temperature 
for 5min. Membrane bound HRP and added H2O2 (in applied reagents) catalyse the 
oxidation of an acridan-based substrate in the applied reagent to release a high level, 
sustained output of light, detectable on film. Excess reagent was drained off and the
Chapter 2. Material and Methods 148 *see appendix R Jeffery
membrane wrapped in transparent cling-film with air bubbles excluded, placed protein 
side up in an autoradiograph cassette and exposed to X-ray film (BIOMAX, Kodak) 
for 5-60sec (figure 2.15). Longer exposures were carried out so that the edges of the 
membrane could be clearly seen and marked on the developed radiograph. This 
enabled the positions of the protein molecular weight marker bands to be traced onto 
the radiograph for estimation of the molecular weight of detected sample bands.
1 2 3 L
87k 
64k
52k 
26k
9k
Figure 2.15. Western blot for CREB in HeLa cell nuclear extracts.
CREB was detected using Sc-271 mouse monoclonal anti-CREB antibody (table 2.11) followed by 
HRP-conjugated rabbit anti-mouse polyclonal antibody (table 2.12), (see 2.12.3 for method).
Lane 1 =unstimulated HeLa cell nuclear extracts, lanes 2&3=IL-l|3-stimulated HeLa cell nuclear 
extracts, L=protein size marker ladder.
2.13. Statistical methodology
Advice on statistical analysis was obtained from Dr Cathryn Lewis, Lecturer in 
Statistics, Guy’s, Kings and St. Thomas’ School of Medicine, London, UK. All 
methods except the EH programme were carried out in Microsoft Excel (for PC) and 
used raw data.
CREB
43kD
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2.13.1. Power calculations
Calculation of the power of the study and numbers needed to achieve a pre-determined 
level of significance were calculated using the formula
n > 4[pi(l-pi)+p2(l-p2)]/e2
pi and P2 are the proportions in the two groups being studied, e is the estimate of what 
would be considered a significant difference (Fleiss et al., 1980).
2.13.2. Determination of genotype association
The chi-square test was used to compare genotype distribution between cases and 
controls and to confirm populations were in Hardy Weinberg Equilibrium. This test 
determines whether an observed distribution differs from an expected distribution. 
x2= ( 0 , - e ,)2 / e ,
Oi is the observed frequency distribution and Ei is the expected frequency distribution. 
From x2 the probability value (p) was determined from %2 tables, a p-value <0.05 (95% 
confidence) was considered significant.
The Hardy Weinberg equilibrium equation tests for stability of a mutation or allele 
within the gene pool of a population. 
p2 + 2pq + q2 = 1
p is the frequency of the dominant allele in the population and q is the frequency of the 
recessive allele.
The Fisher Exact test was used to compare genotype distribution between cases and 
controls where there was a small expectation value due to the rarity of the -572 CC 
homozygote genotype of IL-6. The exact method calculates the probability of the 
contingency table for the genotype frequency distribution found in cases and controls 
with that of similar tables.
To investigate association between allelic carriage and disease, the odds ratio (OR) 
was determined from a 2 x 2 cross-classification table (see below) comparing 
distribution in cases and controls.
Chapter 2. Material and Methods 150 R Jeffery
Disease
+
Allelic carriage
OR = ad / be
2.13.3. Estimation of haplotype frequency and association
Haplotype frequencies were estimated from the genotype frequencies in controls and 
cases using the estimation of haplotype (EH) programme available through the human 
genome mapping project (www.hgmp.mrc.ac.uk). This programme was also used to 
compare haplotype frequency distribution between cases and controls using the chi- 
square test. It calculated the log likelihood values for the null hypothesis and 
determined the linkage disequilibrium measure Delta (A) between loci.
2.13.4. Comparing transfection results
The standard deviation was calculated for each set of experiments as a measure of the 
spread around the mean. This is the square root of the variance, where variance is 
s2= E ( X - M ) 2/N-1
X is the individual sample value, M is the mean of the sample values and N is the 
number of samples.
The T-test was used to compare transfection results. This uses the formula 
t = (Xi -  X2) / V A x B
A = (ni + n2) / nin2
B = [(ni - l ) s i2 + (n2 -  l)s22] / [ni + n2 -  2]
X is the sample mean, s is the standard deviation and n is the number of values within 
the sample. The denominator is a measure of experimental error, thus the higher the 
value of t, the greater the confidence that there is a difference between the samples. 
From t, the probability value (p) was determined from tables, a p-value <0.05 (95% 
confidence) was considered significant.
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Methods appendix
Antibiotics
50x Denhardt’s Solution
DEPC treated water
dl.dC buffer
DMEM media
FACS buffer 
lOx HBS 
LB agar 
LB media
Loading dye 
lOx blue
6x blue/orange
PBS
Equilibrated phenol
These were added to media just prior to use from stock
solutions that had been filter sterilised
Ampicillin: lOOmg/ml in water
Tetracycline: 12.5mg/ml in 50% ethanol (stored in dark)
l%(w/v) BSA, l%(w/v) Ficoll, 2%(w/v) polyvinyl-
pyrollidine
0.1% DEPC left over-night and then sterilised by 
autoclave
ImM EDTA, 40mM KC1, 5mM MgCl2, 5mM MgCl2, 
2.5mM DTT (lyophilised poly.(dI-dC).(dI-dC) added and 
heated to 65°C for 5min)
Dulbecco’s modified essential media (high glucose,
Gibco) supplemented with FCS, 2mM glutamine,
lOOIU/ml penicillin, 1 OOpg/ml streptomycin &
gentamicin, ImM non-essential amino acids
lx  PBS, 0.1% azide, 1% FCS
8.18% NaCl, 5.94% HEPES, 0.2% Na2HP04
1.5g agar per 100ml LB media
1% bacto-tryptone, 0.5% bacto-yeast extract, 170mM 
NaCl, pH7.5
0.25% bromophenol blue, 0.25% xylene cyanol FF, 15%
Ficoll, lOmM Tris-HCl, 50mM EDTA
0.4% orange G, 0.03% bromophenol blue, 0.03% xylene
cyanol FF, 15% Ficoll 400, lOmM Tris-HCl, 50mM
EDTA
0.01M Phosphate buffer, 2.7M KC1,137mM NaCl 
Phenol solution with 0.1%(w/v) 8-hydroxyquinoline, 
equilibrated xl with equal volume 1M Tris-HCl (pH8.0), 
x2 with equal volume lOOmM Tris-HCl (pH8.0)
Fragmented salmon sperm lOmg/ml dH20 , sheared using an 18 gauge needle and
boiled for lOmin 
20x SSC 3M NaCl, 0.3M Na3citrate, pH7.0
50x TAE 2M Tris, 1M Acetic acid, 50mM EDTA (pH8.0)
lOx TBE 0.89M Tris, 0.89M Boric acid, 25mM EDTA (pH8.0)
TE lOmM Tris-HCl pH8.0, ImM EDTA, pH7.5
(1:10 dilution was used for transfection calcium 
phosphate precipitation protocol)
Terrific broth 48g EzMix terrific broth base (Sigma), 8ml glycerol per
1000ml dH20
Solutions and media were sterilised by autoclaving or filtration through a Supore® 
Acrodisc™ 13 (0.2pm) syringe filter.
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CHAPTER 3 
RESULTS:
The association of 5’-flanking region 
polymorphisms of IL-6 with SA
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3.1 Recruitment of case and control populations
At the start of this study, power calculations were carried out to determine the numbers 
of samples needed for control and patient groups. The calculation was based on the 
formula n > 4[pi(l-pi)+p2(l-p2)]/e , where pi and p2 are the proportions in the two 
groups and e is the estimate of what would be considered a significant difference 
(Fleiss et al., 1980). To have 80% power for determining allelic, genotype or haplotype 
frequency in a control population with 95% confidence limits, a minimum of 385, 113 
and 381 individuals would be required for the -174, -572 and -597 polymorphisms 
respectively (based on the estimated common-allele frequency for each polymorphism 
from preliminary studies 0.55, 0.95 and 0.56 respectively). As the systemic arthritis 
(SA) from of juvenile idiopathic arthritis (JIA) has a relatively low incidence 
(1:100,000 in the UK), it was considered feasible to obtain approximately 100 SA 
patient samples, therefore unequal group size comparison with controls was going to 
be necessary to achieve a power of 80%. For detection of a 10% difference in 
common-allele carriers between cases and controls it was calculated that numbers 
needed for the -174 polymorphism were 129 cases and 774 controls, for the -572 
polymorphism 65 cases and 388 controls and for the -597 polymorphism 121 cases 
and 728 controls. These numbers were considered feasible to recruit.
Independent representative groups (control samples) were recruited from the healthy 
adult Caucasian population of the UK. Two groups were recruited from consecutively 
registered individuals on a General Practice List, one from Nuneaton in the Midlands, 
the Nuneaton samples (n=225), and one from North London, the Goodinge samples 
(n=238). Individuals were UK Caucasians, had no known illness and specifically had 
no history of joint problems. They were aged 16-30 years for the Nuneaton Group and 
>16 years for the Goodinge group. A third group, the WEDC samples (n=253) were 
recruited from first time blood donors attending a blood-donor clinic in the West End 
of London. These individuals were Caucasian, >18 years and had no know illnesses or 
joint problems as self-reported. A fourth group, the NPH samples (n=385) had been 
recruited prior to this study from North West London, through Northwick Park 
Hospital, as healthy Caucasian males with no history of medical or joint problems, 
aged 50-61 years, for a prospective study of cardiovascular risk factors (Miller et al., 
1996). Permission was obtained to use these samples for this study. Control sample 
groups were chosen from London and the Midlands, as the majority of patients with
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JIA were recruited from these areas (see below). A fresh venous blood sample was 
obtained in EDTA from each recruit (with informed consent & ethical approval) and 
genomic DNA isolated (see section 2.2.1). Samples from the Northwick Park Hospital 
controls were kindly provided as aliquots of pre-isolated genomic DNA (stored at -  
20°C) by our collaborator S. Humphries.
UK Caucasian patients with JIA were recruited through the British Paediatric 
Rheumatology Group (BPRG). A national DNA repository has been set up at 
Manchester University to store these samples (under the supervision of W. Thompson, 
R. Donn and P. Woo). Patients attending paediatric and adolescent rheumatology units 
across the UK were asked to donate a fresh venous blood sample (with full patient and 
parental informed consent) at the time of a blood test for clinical reasons. The patients 
had a confirmed diagnosis and sub-classified type of JIA by ILAR criteria (see table 
1.1). Information was collected as to the age at onset of disease, gender of patient and 
pattern of disease. One hundred and eighteen Caucasian patients with SA were 
recruited, 75% through our own hospitals and tertiary referral centres in London (Great 
Ormond Street and University College London hospitals), 10% from Birmingham, 8% 
from Manchester and the remainder from other UK centres. Genomic DNA was 
isolated from each fresh blood sample (see 2.2.1).
3.2. Genotype analysis
There are many techniques for genotype analysis. The methods chosen need to be 
accurate, fast and allow high-throughput if  large numbers of samples are to be 
analysed in a population study. Three techniques were chosen and compared for this 
thesis, restriction fragment length polymorphism (RFLP), sequence specific 
oligonucleotide probing (SSOP) and heteroduplex analysis. All three techniques 
require the prior knowledge of polymorphisms of interest and of the surrounding DNA 
sequences of the gene, and depend on successful generation of a PCR product, but are 
then amenable to large-scale sample analysis.
Prior to this thesis, single-strand conformational polymorphism (SSCP) analysis had 
been carried out for 1.2kb of the 5’-flanking region, the five exons and four introns of 
the IL-6 gene (D Fishman, L Luong, personal communication). This had identified 
four SNPs and a variable AT-tract length polymorphism in the 5’-flanking region and a
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single SNP in exon 5. The SNP in exon 5, a base transition from T to C, was a silent 
polymorphism (Tn>TTC), conserving the phenylalanine residue at position 201 of 
the IL-6 protein. The C to A SNP at position -627 was found to occur in <1% of the 
Caucasian population (preliminary studies, L. Luong, personal communication). The G 
to C SNP at position -174, G to C SNP at position -572, G to A SNP at position -597 
and variable AT-tract length polymorphisms between -373 and -392 occurred more 
frequently (Fishman et al., 1998, Nakajima et al., 1999, Osiri et al., 1999, Jordanides et 
al., 2000, Terry et al., 2000).
IL-6 plays an important pathogenic role in SA (see section 1.2.10). It is predominantly 
regulated at the level of transcription. The 5’-flanking region polymorphisms of IL-6 
occur within the main regulatory region for EL-6 transcription and so their possible 
association with SA was investigated. The distribution of the SNPs -174G/C, -572G/C 
and -597G/A was determined in the healthy Caucasian population and compared to 
SA.
RFLP analysis relies on a restriction endonuclease that will recognise the DNA 
sequence of one allele but not the other. Cleaved products of one allele can be 
distinguished from uncleaved products of the other allele by electrophoretic resolution 
on an agarose or acrylamide gel. This is a quick and relatively cost efficient method, 
widely used in genotyping (Holloway et al., 1999). It can be carried out in a 96-well 
micro-titre plate allowing reasonably high throughput. The technique is generally 
considered 95-96% accurate for genotype determination when appropriate positive and 
negative controls are used. A very low or very high frequency of the allele that will 
cut, is more likely to result in skewing of results if there is a problem with the 
efficiency of the digestion stage of the technique and RFLP conditions have to be 
carefully optimised to minimise over- or under-digestion with appropriate controls for 
each experiment. The cut site in the PCR product needs to generate sufficiently 
different product lengths to enable clear size distinction by gel electrophoresis. Micro- 
titre array diagonal gel electrophoresis (MADGE) employs acrylamide gel 
electrophoresis from 96-wells to allow digestion products differing by only a few bases 
to be clearly distinguished (Day et al., 1995). RFLP was optimised for three 5’- 
flanking region polymorphisms of EL-6, the -174 G/C polymorphism, the -572 G/C
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polymorphism and the -597 G/A polymorphism. The restriction enzyme Nlalll 
(Hsp92U) will recognise and digest the sequence 5 \..C A T G \..3 ’
3’...''GTAC...5’ from -171 to -174 
of IL-6 when the -174 C allele is present but not the G allele (see figure 1.9). Mbil will 
recognise and digest the sequence 5’.. .CCGVCTC.. .3’
3’...GGCVGAG...5’ from -569 to -574 of IL-6 
when the -572 G allele is present but not the C allele, and Fokl will recognise and 
digest the IL-6 sequence 5’.. .GGATG(N)9V.. .3’
3’...CCTAC(N)i3w...5 ’ from-582 to -599 with the A allele at 
-597 but not the G allele (figure 1.9).
Figure 3.1 shows the optimised products separated on 8% polyacrylamide gels for a 
190bp PCR product from -128 to -318 of IL-6 for the -174 polymorphism and a 
163bp PCR product from -468 to -632 for the -572 and -597 polymorphisms (see
2.8.1.1 for the methods).
SSOP uses a variant of the Southern blot technique. PCR product of the region of 
interest is applied to nylon nucleic acid transfer membrane (Hybond N+), denatured 
and probed by complementary single-stranded allelic probes for the polymorphism to 
be detected. The probe was biotinylated to allow detection with streptavidin-bound- 
horseradish peroxidase and substrate addition to produce a chemiluminescent reaction 
detected on radiograph (see 2.8.2 for the method and allelic probe sequences). The 
method allows a relatively high throughput, though the procedure is more labour 
intensive than for RFLP. The technique is very sensitive to the temperature and salt 
concentration of stringency washes, which need to be carefully optimised for each set 
of probes. Even with optimisation, one allelic probe will often bind more efficiently, 
resulting in potential false positives. Inclusion of positive and negative controls on 
each membrane is essential.
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Figure 3.1. RFLP-MADGE of the (i) -174 G/C, (ii) -572 G/C and (iii) -597 G/A 
polymorphisms of IL-6.
200ng o f genomic DNA, amplified by PCR for the IL-6 5’-flanking region (primers IL-6 9A&10A for -  
174 region, primers IL-6 5bF&6R for -572&-597), made up to a volume of 25pl with specific 
restriction endonuclease buffer was digested over-night with (i) 1U M alll, (ii) 2U Mbi\ or (iii) 1U Fok\, 
then resolved by electrophoresis on an 8% polyacrylamide gel pre-stained with ethidium bromide and 
visualised under UV light (see 2.8.1.1. for methods and PCR primers).
(i) -174: Nlalll digestion o f 190bp PCR product cuts the -174 C allele (143/47bp) but not the G allele 
(190bp). Genotype results: sample la=CC, lb=GG, lc=GG, ld=GC, le=GC, lfK iC, lg=GC, lh=GC, 
2a=GG, 2b=GG, 2c=GC, 2d=CC, 2e=CC, 2f=GC, 2g=GC, 2h=GC.
(ii) -572:M>/I digestion of 163bp PCR product cuts the -572 G allele (101/62bp) but not the C allele 
(163bp). Genotype results: sample la=GG, lb=GG, lc=GG, ld=GG, le=GC, lf=GG, 2a=GG, 2b=GG, 
2C=CC, 2d=GG, 2e&2f=inadequate PCR product.
(iii) -597Fok\ digestion of 163bp PCR product cuts the -597 A allele (116/47bp) but not the G allele 
(163bp). Genotype results: sample la=GA, lb=GG, lc=GA, ld^GG, le=AA, lf^GA, lg=GA, 2a=AA, 
2b=AA, 2c=GG, 2d=GA, 2e=GG, 2f=GG, 2g=GG.
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Figure 3.2. SSOP of the (i) -174 G/C and (ii) -597 G/A polymorphisms of IL-6.
l(ig o f IL-6 5’-fIanking region PCR product (primers IL-6 DF20mod&DF21) was applied to nylon 
nucleic acid transfer membrane (Hybond N+, Amersham), denatured with 0.5M NaOH/1.5M NaCl, 
baked for lOmin at 80°C before probing with biotinylated allele specific probe (i) -174G probe DF11, -  
174C probe DF12, stringency wash temp. 54°C or (ii) -597G probe PW269, -597A probe PW268, 
stringency wash temp. 54°C (see 2.8.2 for methods, primer and probe sequences). The probes were 
detected with streptavidin-horseradish peroxidase and substrate addition to produce a chemiluminescent 
reaction exposed to radiograph.
(i) -174: Sample la=GG, lb=CC, lc=GC, ld=GG, le=GC, 2a=GC, 2b=GG, 2c=CC, 2d=GG, 2e=GC, 
3a=GG, 3b=GC, 3c=GC, 3d=GC, 3e=GG.
(ii) -597: Sample la=GG, lb=GG, lc=GA, ld=GG, le=GA, 2a=AA, 2b=GA, 2c=AA, 2d=GG, 2e=GA, 
3a=GA, 3b=GA, 3c=GG, 3d=GA, 3e=GA.
Heteroduplex analysis uses PCR product of the region of interest to anneal a universal 
heteroduplex generator (UHG) specific for each polymorphism. A UHG is a 
complementary sequence of the full length of the PCR product (usually 100-125bp in 
length) with several base insertions adjacent to the polymorphic site to produce a 
structural loop that varies with the allele. These structural variants can be separated by 
electrophoresis on a high-percentage polyacrylamide gel. Heteroduplex is generally 
considered the most accurate of the three techniques. However, it is dependent on the 
quality of the PCR product obtained and the design of the UHG to achieve clear 
separation of the allelic bands. The UHG itself can form homodimers that need to be
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optimised to run separately from the heteroduplex bands. Compared to RFLP or SSOP, 
heteroduplex is more expensive and more labour intensive, allowing only moderate 
throughput of samples (20-40 per gel). It has the advantage however that PCR products 
can be multiplexed for more than one polymorphism per lane, if the UHG design is 
such that the different allelic bands run in different positions on the gel.
Figure 3.3 shows the optimised heteroduplex banding patterns using a 116bp PCR 
product & 120bp UHG for the -174 G/C polymorphism, and a 126bp PCR product & 
130bp UHG for the -572 G/C polymorphism, separated by electrophoresis on a 15% 
polyacrylamide gel (see section 2.8.3. for the method and UHG sequences).
All samples were analysed by RFLP for each genotype. All SA samples and 50% of 
control samples were additionally genotyped by a second method. Each result was 
analysed by two independent observers. If there was observer disagreement for any 
results, these were repeated until agreement was reached. If there were disagreements 
in results between techniques, then samples were analysed by a third method if 
available, or by automated sequencing (commercially by MWG Biotech). If none of 
these options were possible, the sample was discounted. Direct sequencing is 
considered the gold standard for genotype analysis with modem automated sequencing 
techniques allowing increased speed and throughput of samples, however it is 
expensive and labour intensive to do on a large scale, and considered unnecessary for 
every sample.
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Figure 3.3. Heteroduplex of the (i) -174 G/C and (ii) -572 G/C polymorphisms of 
IL-6.
200ng of genomic DNA was amplified by PCR (i) primers IL-6 -174F&R or (ii) primers IL-6 -572F&R 
and UHG for each sequence was amplified in the same way. Equal amounts o f PCR product and UHG 
were mixed, melted at 95°C and cooled to anneal, products were resolved on a 15% polyarcylamide gel, 
stained with ethidium bromide and visualised under UV light (see 2.8.3. for method, primer and UHG 
sequences).
G/UHG’= one strand of the G allele PCR product annealed to the complementary UHG strand, 
C/UHG’= one strand of the C allele PCR product annealed to the complementary UHG strand. G’/UHG 
and C’/UHG= the other strand of the gene PCR product annealed to the complementary strand o f UHG. 
UHG/UHG’= the two UHG strands annealed to each other. G/G’ and C/C’ products had a higher 
electrophoretic mobility and ran faster through the gel.
» m w
m  »
CC GC GC GC GG GC GC GC GG CC
Chapter 3. Results. 161 R Jeffery
3.2.1. Comparison of techniques
For samples that were genotyped by more than one method, comparisons could be 
made as to the accuracy and efficiency of each technique for determining the IL-6 
polymorphisms. Table 3.1 shows the number of samples from those analysed that were 
considered to be correctly genotyped by a technique, that is to say, those results that 
agreed between two techniques, or agreed with the automated sequence result. This 
allowed the positive predictive value for the technique to be determined. The table also 
shows the number of samples that could not be genotyped by that technique, indicating 
the efficiency of the method, the negative predictive value. For both the -174 and -572 
polymorphisms, heteroduplex analysis was 100% accurate in genotype determination. 
The accuracy of RFLP for these polymorphisms was 96%, within the accepted level of 
accuracy for this technique. For the -174 polymorphism, the efficiency of RFLP was 
higher than for heteroduplex (90% compared to 79%). This resulted in statistically 
better results overall by RFLP than heteroduplex, a trade-off of the efficiency of RFLP 
for the accuracy of heteroduplex. For the -572 polymorphism, there was no significant 
difference between the efficiency or overall statistical results obtained by RFLP or 
heteroduplex, though heteroduplex gave no incorrectly identified genotypes. Despite 
the higher accuracy of heteroduplex, it is possible for this technique to skew results if 
it fails to produce results for one genotype more frequently than for another. RFLP 
may produce an over-representation of one genotype by over- or under-enzyme 
digestion. The incorrectly genotyped samples in this study were generally due to 
under-cutting of the enzyme despite careful optimization and the presence of control 
samples. The accuracy of both techniques may have been over-estimated if both 
techniques incorrectly identified the genotype in the same way. If both techniques 
agreed on the genotype of a sample, further analysis such as sequencing was rarely 
carried out, however, when it was, the sequencing genotype agreed with the genotype 
determined by the other two methods. For the -597 polymorphism, RFLP and SSOP 
appeared equally accurate at 98% (table 3.1). Again, this may have been an over­
estimation for the same reasons as above. A number of randomly chosen samples were 
sequenced and agreed with the genotypes determined by RFLP/SSOP. Taking into 
consideration accuracy and efficiency of RFLP and SSOP for this polymorphism, there 
was no significant difference between the two techniques. Based on these results, 
RFLP was considered the most appropriate technique in this study for large-scale 
genotype determination, with heteroduplex analysis to confirm the results where
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possible. This was considered particularly important for the patient groups where the 
smaller number of samples compared to controls would result in a more significant 
skewing of results if even a few genotypes were incorrectly identified.
(a) -174 G/C polymorphism Hetcroduplex RFLP
Number of samples genotyped 262 262
Number of samples clear results obtained 206 246
Number of samples results obtained which agreed 
with finally determined genotype
206 237
Positive predictive value 1.0 0.96
Observed difference 0.12, p-value <0.002, 95% confidence limits 0.061, 0.179
(b) -572 G/C polymorphism Heteroduplex RFLP
Number of samples genotyped 181 181
Number of samples clear results obtained 167 166
Number of samples results obtained which agreed 
with finally determined genotype
167 159
Positive predictive value 1.0 0.96
Observed difference 0.04, p-value 0.1 < p < 0.2, 95% confidence limits -0.019, 0.099
(c) -597 G/A polymorphism RFLP SSOP
Number of samples genotyped 263 263
Number of samples clear results obtained 256 250
Number of samples results obtained which agreed 
with finally determined genotype
251 244
Positive predictive value 0.98 0.98
Observed difference 0.03, p-value 0.1 < p < 0.2, 95% confidence limits -0.003, 0.069
Table 3.1. Comparison of the accuracy & efficiency of genotyping techniques for 
the -174, -572 and -597 SNPs of IL-6.
The techniques for each polymorphism were compared by proportions testing to 95% confidence 
(shown under each table).
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3.3. The -174 polymorphism of IL-6
3.3.1. The -174 genotype is associated with susceptibility to SA 
Genomic DNA was isolated from venous blood samples donated by each control 
subject. Each sample was genotyped for the -174 polymorphism using RFLP with 
Nlalll (see 2.8.1.1). The NPH controls were genotyped in S. Humphries laboratory by 
G. Faulds, using the same RFLP technique (Main MADGE). Twelve of these samples 
and 80 other samples were genotyped by both laboratories for comparison and no 
differences were obtained (no further NPH DNA was available for complete repetition 
of the genotype analysis). The WEDC and Nuneaton controls were also genotyped by 
heteroduplex (see 2.8.3). Table 3.2 shows the -174 genotype distribution analysed 
using the chi-square test. All four control-groups were in Hardy-Weinberg (H-W) 
equilibrium and there was no significant difference between the genotype distributions 
(95% confidence, 2 degrees of freedom, df). The results were therefore combined to 
give a representative genotype distribution for the UK Caucasian population. GC was 
the most common genotype with a frequency of 0.470. GG had a frequency of 0.363 
and CC was the least common genotype with a frequency of 0.168. The C allele 
frequency was 0.402.
Genotyping for the -174 polymorphism was carried out on the SA samples by RFLP 
with Main and heteroduplex. Genotype results could only be obtained for 107 of the 
118 SA samples, mainly because PCR products could not be generated, despite 
attempts with different PCR primers. The 11 patients for which -174 genotype results 
could not be obtained were not significantly different in terms of distribution of gender 
(p=0.82) or age at onset (p=0.09) from those for which -174 genotype results could be 
obtained (chi-square test, 95% confidence, 2df). The genotyping success rate of 91% 
for the SA samples was equivalent to the overall success rate for the control groups, 
90%. Different methods of DNA preparation were employed during the course of 
sample collection. The first samples collected were prepared using the Nucleon resin 
kit (see section 2.2.1.1). This method yielded genomic DNA of poor quality and 
reduced stability than conventional phenol-extraction methods, and phenol-extraction 
was soon adopted as the preferred method of preparation for the rest of the samples.
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Control group GG GC CC n C-allele frequency
Nuneaton 0.364 0.461 0.175 206 0.405
Goodinge 0.387 0.464 0.149 194 0.381
WEDC 0.321 0.527 0.152 237 0.416
NPH 0.376 0.441 0.183 383 0.403
Combined
NUN/GOOD/WEDC/NPH
0.363 0.470 0.168 1020 0.402
Table 3.2. The genotype distribution for the -174 polymorphism of IL-6 in 
healthy UK Caucasian controls.
Each group is in H-W equilibrium by chi-square test (with 95% confidence, ldf), with no significant 
difference between the groups (chi-square test, 95% confidence, 2df, p>0.1). n=number of samples.
In the SA group, the GC genotype was most common with frequency 0.598. The GG 
frequency was 0.280 and the CC frequency 0.121 (C-allele frequency 0.421). These 
results were not in H-W equilibrium (p=0.019) and comparison with the control 
population using the chi-square test (95% confidence, 2 df) revealed a significant 
difference in genotype distribution (x2=6.435, p=0.040), (figure 3.4). There were 
significantly fewer CC homozygous individuals in the SA group and significantly 
more GC heterozygotes than the control population. The allele frequency was not 
statistically significantly different between the two groups, probably due to the 
relatively small numbers in the SA group. However, the magnitude of the association 
between allele carriage and disease can be seen from the odds ratio (OR, see 2.13.2 for 
method). This indicates the ‘odds’ of having disease with carriage of one allele, 
compared to the ‘odds’ with carriage of the other allele. If there was no association 
between allele carriage and disease then OR would be 1.0. The OR for SA with 
carriage of the G-allele was 1.46, indicating a significant association.
To ensure that the -174 genotype association was specific for SA and not just 
associated with JIA, other sub-types of JIA were compared. These UK Caucasian 
patients had been recruited in the same way as the SA patients, though recruitment 
started after SA recruitment and consequently fewer samples were available; 
oligoarticular (n=64), extended-oligoarticular (n=69), polyarticular (n=60), (see table
1.1 for classification). Genotyping was carried out by RFLP with A7aIII and 
heteroduplex. The results confirmed a specific association with SA, but not other sub- 
types of JIA (table 3.3). There was no significant difference between oligoarticular,
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extended-oligoarticular or polyarticular JIA compared to the control population
(p>0.08).
091
Controls
Figure 3.4. The genotype distribution for the -174 polymorphism of IL-6 in SA 
compared to controls.
The -174 genotype was determined by RFLP with AValll and heteroduplex analysis (see 2.8.1.1&2.8.3) 
for 1020 UK Caucasian healthy controls and 107 UK Caucasian SA patients (data values shown). The 
control but not the SA group was in H-W equilibrium (chi-square test). Controls were compared to SA 
by chi-square test and were significantly different (95% confidence, 2df), X2 and p-value shown.
JIA sub-type GG GC CC n r p-value
SA 0.280 0.598 0.121 107 6.435 *0.040
Oligoarticular 0.263 0.526 0.211 57 2.449 0.294
Extended-oligoarticular 0.339 0.500 0.161 62 0.222 0.895
Polyarticular 0.232 0.518 0.250 56 4.900 0.086
Control population 0.363 0.470 0.168 1020 - -
Table 3.3. The genotype distribution for the -174 polymorphism of IL-6 in 
different sub-types of JIA compared to healthy controls.
All except the SA group were in H-W equilibrium by chi-square test (95% confidence, 1 df). Each JIA 
sub-type was compared to the healthy Caucasian control population using the chi-square test, results 
shown (95% confidence, 2df). *denotes statistical significance within these limits. n=number of 
samples.
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3.3.2. The -174 genotype is associated with early-onset SA
The peak age at onset for SA is 2-4 years of age. Children with early onset disease (<5 
years of age) tend to have more severe disease with a poorer prognosis (Modesto et al., 
2001). Figure 3.5 shows the distribution of age at onset for 96 of the 107-SA patients 
for which age at disease-onset information was available.
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Age at onset (yrs)
Figure 3.5. The distribution of age at onset for SA in 96 patients.
Age at onset was known for 96 o f the 107 SA patients that were genotyped for the -174 polymorphism 
of IL-6. The median age at onset was 4.5 years, modal age at onset 5 years.
This sub-group of patients was not significantly different from the total group of SA 
patients when compared by chi-square analysis (95% confidence, 2df, p=0.102). The 
median age at onset was 4.5 years, modal age at onset 5 years, with 69% of patients <5 
years at onset. The -174 genotype distribution was compared to the control population 
for early onset SA (<5 years at onset) and late onset SA (>6 years at onset). The 
differences in genotype distribution in the total SA group were attributable to 
differences in genotype distribution in children with disease onset <5 years of age and 
not in the older age at onset group (table 3.4).
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SA group GG GC CC n X p-value
Any age at onset 0.292 0.594 0.115 96 4.901 *0.027
< 5 years at onset 0.258 0.652 0.091 66 8.431 *0.015
> 6 years at onset 0.367 0.467 0.167 30 0.002 0.999
Table 3.4. The genotype distribution for the -174 polymorphism of IL-6 in SA by 
age of onset.
Only the late age at onset group (> 6 years) was in H-W equilibrium by chi-square test (95% confidence, 
ldf). Each group was compared to the healthy Caucasian control population using the chi-square test, 
results shown (95% confidence, 2df). ♦denotes statistical significance within these limits. n=number of 
samples.
The CC genotype was under-represented in the early-onset group raising the possibility 
that the CC genotype may be protective against SA, or at least against the more severe, 
early-onset form of the disease. Indeed, the odds ratio (OR) for SA in individuals 
carrying the -174 G-allele was 2.01 for onset of disease <5 years of age, compared to 
1.46 for SA onset at all ages, and 1.01 for onset of disease >6 years of age. This 
suggests that the -174 polymorphism may be a severity as well as a susceptibility 
marker for SA.
The course of SA can be heterogeneous despite the unifying ILAR classification 
criteria (table 1.1). The predominant disease course following onset can be sub-divided 
into persistent or relapsing arthritis, or persistent or relapsing systemic features, though 
these may overlap and vary with time for each individual making clear sub­
classification difficult. Of those patients for which information on disease course was 
available, only 41, 78% had persistent arthritis and 22% on-going systemic features 
(12% of relapsing, 10% persisting). Though the group with disease course information 
was small, the chi-square test showed no significant difference between this group and 
the total SA group (95% confidence, 2df, p=0.292). Comparison of the -174 genotype 
distribution between the group with ongoing arthritis and the group with ongoing 
systemic features revealed no significant difference (chi-square test, 95% confidence, 
2df, p=0.219). It is difficult to draw any conclusion however with small numbers and 
resultant low power.
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3.3.3. The -174 genotype distribution is not influenced by gender
The gender distribution for 106 of the SA patients for which information was available 
was 54% female. This reflects the equal susceptibility for SA of males and females. 
Sixty percent of controls were female. There was no significant difference between the 
-174 genotype distribution in males and females for SA (p=0.320) or controls 
(p=0.233) by the chi-square test (95% confidence, 2df).
3.3.4. HLA association studies with the -174 genotype
No HLA associations have been consistently reported for SA. Those that have been 
reported have been with Class II genes but data are either conflicting or restricted to 
limited numbers of patients. HLA-DR4 was reported to be associated with SA in a UK 
study of 51 and a US study of 81 Caucasian patients respectively (Bedford et al., 1992, 
Miller et al., 1985). However, a larger European study (including 108 SA patients) 
found no association with HLA-DR4, nor any other Class II loci (Desaymard et al., 
1996). More recently, a UK based study of 521 JIA patients found association of 
DRB1*11 and DQA1*05 with SA (Thomson et al., 2002). R. Donn (Manchester 
University) kindly provided HLA typing information on the SA patients in this study, 
from the National BPRG project on HLA associations with childhood arthritides 
(Arthritis Research Campaign funded). The number of individuals in each HLA sub­
group was small (DR4 and DR11 14-18%, other sub-types <10%). No statistically 
significant association between the -174 and HLA genotypes could be identified but 
the power was low and so no conclusions could be drawn.
3.4. The -572 polymorphism of IL-6
3.4.1. The -572 genotype is not associated with SA
Samples from the Nuneaton, Goodinge and WEDC control groups were genotyped for 
the -572 polymorphism of IL-6 using RFLP with A/M, the Nuneaton and WEDC 
controls were also analysed by heteroduplex (see 2.8.1.1 & 2.8.3). No samples from 
the NPH control group were available for -572 genotyping. The Nuneaton, Goodinge 
and WEDC control groups were in H-W equilibrium for the -572 polymorphism, with 
no significant difference in genotype distribution between the groups (Fisher’s exact 
test, p>0.7), (table 3.5). An exact test was used because of small ‘expected’ numbers 
with the rare allele making the chi-square test formulation inappropriate (Weir, 1996). 
The groups were combined as a representative UK Caucasian control population. The
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GG genotype was by far the most common genotype with a frequency of 0.856. The 
GC genotype occurred at a frequency of 0.137, the CC genotype extremely rare at 
frequency of 0.007. C allele frequency was 0.076.
Control group GG GC CC n C-allele frequency
Nuneaton 0.836 0.154 0.010 201 0.087
Goodinge 0.852 0.143 0.004 230 0.076
WEDC 0.876 0.116 0.008 241 0.066
Combined
Nun/Good/WEDC
0.856 0.137 0.007 672 0.076
Table 3.5. The genotype distribution for the -572 polymorphism of IL-6 in 
healthy UK Caucasian controls.
Each group is in H-W equilibrium by Fisher’s exact test, with no significant difference between groups 
(Fisher’s exact test, p>0.7). n=number of samples.
Genotyping for the -572 polymorphism was similarly carried out on the SA samples 
by RFLP with Mbil and by heteroduplex. PCR product for the region surrounding the 
-572 and -597 polymorphisms of IL-6 could only be generated for 85 of the 118 
stored samples and genotype results for the -572 polymorphism could only be 
obtained for 52. This low success rate reflected the quality of the samples for which 
genomic DNA had been prepared using the Nucleon resin extraction method rather 
than phenol-extraction (see 2.2.1). Nucleases must have remained in the samples as 
many of them had become degraded with time. It was not possible to obtain fresh 
samples. The PCR technique was proven effective on the samples isolated by phenol- 
extraction from the control subjects (94% success rate). Comparison of the distribution 
of gender and age at onset for the SA patients with and without -572 genotype results, 
revealed no significant difference (chi-square test, 95% confidence, 2df, p=0.945 and 
0.994 respectively). The genotype results obtained were in H-W equilibrium by 
Fisher’s exact test. The GG genotype was most frequent at 0.904, with GC frequency 
0.096 and CC genotype frequency 0.000 (reflecting the small sample number and the 
low frequency of this genotype in the Caucasian population), (figure 3.6). There was 
no significant difference between the -572 genotype distribution for SA and controls 
(Fisher’s exact test, p=0.675), though the power of the study was reduced by only 
obtaining genotype results for 44% of the SA samples.
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Figure 3.6. The genotype distribution for the -572 polymorphism of IL-6 in SA 
and controls.
The -5 7 2  genotype was determined by RFLP with Mbil and heteroduplex analysis (see 2.8.1.1 & 2.8.3) 
for 672 UK Caucasian healthy controls and 52 UK Caucasian SA patients (data values shown). Both the 
control and SA group were in H-W equilibrium (exact test). Controls were compared to SA by exact test 
and were not significantly different, p-value shown.
3.5 The -597 polymorphism of IL-6
3.5.1 The -597 genotype is not associated with SA
The Nuneaton, Goodinge and WEDC controls were genotyped for the -597 
polymorphism using RFLP with FokI, the Nuneaton and WEDC samples were also 
genotyped by SSOP (see 2.8.1.1 & 2.8.2). The Nuneaton and Goodinge controls were 
in H-W equilibrium using the chi-squared test (95% confidence), (table 3.6). However, 
the WEDC control group was just out-with H-W equilibrium for 95% confidence 
limits (p=0.043), but well within H-W equilibrium for 90% confidence limits (chi- 
square test) and there was no significant difference between the Nuneaton, Goodinge 
or WEDC groups (chi-square test, 95% confidence, 2df, p>0.1). The groups were 
therefore combined as a representative control population. The combined group was in 
H-W equilibrium (chi-square test, 95% confidence). The GA genotype was most 
common (frequency 0.471), with the GG homozygote genotype (frequency 0.374) 
more common that the AA genotype (frequency 0.156). The A allele frequency was 
0.391.
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Control group GG GA AA n A-allele frequency
Nuneaton 0.374 0.455 0.171 211 0.398
Goodinge 0.422 0.409 0.168 232 0.373
WEDC 0.325 0.544 0.131 237 0.403
Combined
Nun/Good/WEDC
0.374 0.471 0.156 680 0.391
Table 3.6. The genotype distribution for the -597 polymorphism of IL-6 in 
healthy UK Caucasian controls.
The Nuneaton and Goodinge groups, but not the WEDC group, were in H-W equilibrium by chi-square 
test (95% confidence). The WEDC group was in H-W equilibrium by chi-square test for 90% 
confidence limits. There was no significant difference between the Nuneaton, Goodinge or WEDC 
groups (chi-square test, 95% confidence, p>0.1). n=number of samples.
Genotyping the -597 polymorphism by RFLP with Fokl and SSOP obtained results for 
85 of the 118 SA samples. Incomplete typing was again due to problems generating 
PCR product from many stored genomic DNA samples. Comparison of distribution of 
gender and age at onset was not significantly different (p=0.998 and 0.443 respectively 
by chi-square test, 95% confidence, 2df) for the group for which -597 genotyping was 
obtained and for those genotyping could not be done. The genotype distribution was in 
H-W equilibrium (chi-square test, 95% confidence), GA frequency 0.471, GG 
genotype frequency 0.412 and AA genotype frequency 0.118 (figure 3.7). There was 
no significant difference between this distribution and that of the control population 
(chi-square test, 95% confidence, 2df, p=0.600). This was also the case if the WEDC 
control group was omitted (p=0.431). It should be remembered that the power of the 
study to exclude an association with SA is lowered by the reduced number of samples 
for which genotyping results were obtained.
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Figure 3.7. The genotype distribution for the -597 polymorphism of IL-6 in SA 
and controls.
The -5 9 7  genotype was determined by RFLP with FokI and SSOP (see 2.8.1.1 & 2.8.2) for 680 UK 
Caucasian healthy controls and 85 UK Caucasian SA patients (data values shown). Results were 
compared by chi-square test (2df), with p-value shown.
3.6. Allelic associations with the -174 polymorphism
3.6.1. The -174 polymorphism is in strong allelic association with -597 and weak 
allelic association with -572
To investigate whether allelic association occurred between the -174, -572 and -597 
SNPs, the genotype information for 600 controls with 2- or 3-loci genotype 
information was analysed using the EH linkage-utility program (available through 
HGMP, www.hgmp.mrc.ac.uk). This programme calculated the gene frequency from 
the genotype data for cases and controls, and then estimated the 2- and 3-loci 
haplotype frequencies under the assumption of either allelic association (associated 
model) or of no allelic association (independent model), (Terwilliger and Ott, 1994). 
The EH program uses the Expectation-maximisation algorithm to obtain accurate and 
fast estimates of haplotype frequencies from genotype data and can be used to test 
differences between haplotype frequencies. By performing the analysis on cases,
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controls and the combined cases and controls, a likelihood ratio test can be used to test 
for a difference in haplotype frequencies between cases and controls. The chi-square 
test for the independent inheritance model (assumption of no allelic association) versus 
the associated inheritance model (assumption of allelic association), for each set of 
loci, revealed a significant difference (p<0.0001, table 3.7). This indicated that there 
was allelic association between the SNPs. Allelic frequency tables generated from 
these estimated haplotype frequencies allowed determination of the linkage 
disequilibrium co-efficient A for the -174 & -572 alleles, and the -174 & -597 alleles.
(a) n=617_________   Haplotype frequency
-174 allele -597 allele Independent model Associated model
G G 0.366 0.595
G A 0.232 0.003
C G 0.246 0.018
C A 0.156 0.384
X 2 = 1022.76, p<0.00001, Ln(L) = -732.11 
A=0.956
(b) n=612_________   Haplotype frequency
-174 allele -572 allele Independent model Associated model
G G 0.555 0.531
G C 0.045 0.069
C G 0.369 0.394
C C 0.030 0.006
x2 = 31.19, p<0.0001, Ln(L) = -871.78 
A=0.188
(c) n=660_________   Haplotype frequency
-572 allele -597 allele Independent model Associated model
G G 0.561 0.539
G A 0.363 0.386
C G 0.046 0.068
C A 0.030 0.007
X 2 = 29.57, pO.OOOl, Ln(L) = -945.99 
A=0.176
Table 3.7. Estimated 2-loci haplotype frequencies for the SNPs (a) -174/-597, (b) 
-174/-572, (c) -572/-597 of IL-6 in healthy UK Caucasian controls.
Haplotype frequencies were estimated from the genotype frequency using the EH linkage-utility 
program for independent (assumption of no allelic association) and associated (assumption of allelic 
association) models of inheritance. If alleles were not associated then the results from die two models 
would be similar. The likelihood of the models was compared by chi-square test (95% confidence, ldf). 
Ln(L)=log likelihood of allelic association, A=linkage disequilibrium co-efficient, n=number of 
samples.
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The -174G was in strong allelic association with -597G, -174C with -597A (A=0.956). 
The -174G was in weak allelic association with -572C, -174C with -572G (A=0.188). 
Consistent with the strong allelic association between the -174 and -597 SNPs, the -  
597G was in weak allelic association with -572C, -597A with -572G (A=0.176).
3.6.2. The -1747-597 haplotype frequency was significantly different in SA 
Interestingly, when the estimated haplotype frequencies for the -174 and -597 SNPs 
were determined for the SA group, the allelic association between these 
polymorphisms was significantly less (A=0.871) than for the healthy control group 
(A=0.956), (p<0.02, table 3.8).
(a) n=81__________   Haplotype frequency
-174 allele -597 allele Independent model Associated model
G G 0.381 0.585
G A 0.249 0.044
C G 0.224 0.019
C A 0.146 0.351
X2 = 90.18, p<0.0001, Ln(L) = -110.78 
A=0.871
Ln(L)
SA
Ln(L)
controls
Ln(L)
all
Difference X2 p-value
-110.78 -732.11 -847.11 4.22 8.44 0.02<p<0.05
Table 3.8. Estimated 2-loci haplotype frequencies for the SNPs -174 and -597 of 
IL-6 in (a) Caucasian SA patients, (b) compared to healthy Caucasian controls.
(a) Haplotype frequencies were estimated from the genotype frequency using the EH linkage-utility 
program for independent (assumption of no allelic association) and associated (assumption of allelic 
association) models of inheritance. The likelihood of the models was compared by chi-square test (95% 
confidence, ldf). Ln(L)=log likelihood of allelic association, A=linkage disequilibrium co-efficient, 
n=number of samples, (b) the Ln(L) was compared for the genotype distribution in SA and healthy 
controls (see table 3.7) by chi-square test (95% confidence, 3df).
The difference was due to a significantly higher frequency of-597A-174G individuals 
and lower frequency of -597A-174C individuals in the SA group, suggesting that 
carriage of the -174G allele was associated with an increased susceptibility to SA, 
independent of the allele at position -597.
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3.6.3. The -597G-572G-174G and -597A-572G-174C haplotypes were most
common
In the same way, using the EH linkage-utility program, the 3-loci haplotype 
frequencies for the -174, -572 and -597 polymorphisms could be estimated and 
compared for the control and SA group. This showed that the most common naturally 
occurring haplotype was the -597G-572G-174G with a frequency of 0.524, followed 
by the -597A-572G-174C with a frequency of 0.372 (table 3.9). The -597G-572C- 
174G haplotype was the next common with a frequency of 0.070, while other 
haplotypes occurred more rarely with a frequency of <0.018. The order of haplotype 
frequency was similar for the SA group though 3-loci haplotype data could only be 
calculated on 35 of the SA patients.
Haplotype frequency
-597 allele -572 allele -174 allele Controls (n=610) SA (n=35)
G G G 0.524 0.570
A G C 0.374 0.313
G C G 0.070 0.057
G G C 0.018 0.030
A C C 0.007 <0.001
A G G 0.005 0.030
A C G 0.001 0.000
G C C <0.001 0.000
X2=1005.06 x2=37.46
p<0.00001 p<0.0001
Ln(L)=-l 003.13 Ln(L)=-56.11
Table 3.9. Estimated 3-loci haplotype frequencies for the SNPs -597, -572 and 
-174 of IL-6 in Caucasian controls and SA patients.
Haplotype frequencies were estimated from the genotype frequency using the EH linkage-utility 
program for independent (assumption of no allelic association) and associated (assumption of allelic 
association) models of inheritance. The values for the associated model are shown as the results showed 
a high significance of allelic association when compared by chi-square test (95% confidence, 7df), 
shown under the table. Ln(L)=log likelihood of allelic association, n=number of samples.
3.7. Power calculations
Retrospectively, the observed difference in the frequency of G-allele carriers between 
controls and cases was less than the estimated 10% taken at the start of this study. The 
observed differences were 4.7% for the -174,2.8%  for the -572 and 3.8% for the -597 
polymorphism. The power of this study to exclude a polymorphic association with
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disease was therefore significantly less than 80%. Given this low power it is fortunate 
that the -174 polymorphism association with SA was detected. Four independently 
recruited control groups of adequate numbers to have 80% power in comparing groups 
of equal sizes were not significantly different from one another. It is therefore unlikely 
that population stratification was present, making it less likely that the difference seen 
between the controls and SA group for the -174 polymorphism occurred by chance 
alone.
3.8. Summary of genotype results
The -174 polymorphism of IL-6 was associated with SA, with the CC genotype 
occurring in significantly lower frequency in SA compared to healthy controls. The -  
174 polymorphism appeared to be a severity, as well as susceptibility marker, with the 
lower frequency of -174CC occurring in the early disease onset group (<5 years of 
age) who tend to have a poorer disease prognosis. The odds ratio for SA was higher for 
carriers of the -174G-allele and from the allelic association studies this appeared to be 
independent of the allele at position -597. The -597 polymorphism was in strong 
allelic association with -174 and the -572 polymorphism in weak allelic association 
with -174 and -597. The haplotype -597G-572G-174G was the most common, 
followed by -597A-572G-174C and -597G-572C-174G, other haplotypes were rare.
Chapter 3. Results. 177 R Jeffery
CHAPTER 4 
RESULTS:
The influence of IL-6 5’-flanking region 
polymorphisms on transcriptional activity
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4.1. Transfection studies
Transient and stable transfection studies were used to investigate the potential 
influence of the 5’-flanking region polymorphisms of IL-6 on the levels of IL-6 gene 
transcription. This was first carried out in HeLa cells, a transformed human epithelial 
cell line derived from a cervical carcinoma. These epithelial cells are robust, relatively 
easy to culture and transfect efficiently. They express endogenous IL-6 (confirmed by 
RT-PCR) that is inducible with pro-inflammatory cytokine stimulation (IL-ip & 
TNFa), and therefore have constitutive and induced expression of relevant 
transcription factors required for IL-6 transcription. The HeLa cells provided an ex 
vivo model of human cells for comparison of the allelic effects of IL-6 polymorphisms. 
Huh7 cells, a transformed human hepatocyte cell line derived from a hepatocellular 
carcinoma, were chosen as a second cell type for investigation. In terms of volume of 
IL-6 production in vivo and responsiveness to acute inflammatory stimuli, hepatocytes 
were considered the largest producers of IL-6. RT-PCR studies confirmed that Huh 7 
cells expressed endogenous IL-6 and that the gene was inducible with IL-1 stimulation.
Luciferase was chosen as the reporter gene as it fulfilled the criteria for an ideal 
reporter, not undergoing any post-transcriptional or post-translational modification, 
remaining intra-cellular and producing a gene product easily detectable on assay. In 
addition, the intracellular half-life of luciferase is three hours making it a sensitive 
indicator to changing levels of promoter activity over time (Bronstein et al., 1994). The 
P-galactosidase (P-gal) gene driven by the respiratory syncytial virus (RSV) promoter 
was chosen as a control plasmid as this gene has a long half-life, does not undergo 
post-transcriptional or post-translational modification and the RSV promoter is non- 
responsive to cytokine stimulation with IL-1 and TNFa (confirmed in transfection 
studies). P-gal remains as an intra-cellular protein and is easily detected with substrate 
assay. Transfected p-gal was expressed in HeLa and Huh7 cells with negligible 
endogenous levels detected. The pro-inflammatory cytokines IL-1 p and TNFa were 
chosen as inducers of IL-6 transcription to model an acute inflammatory response. 
These cytokines, particularly IL-1, are the main inducers of IL-6 and act via the NF-kB 
and C/EBP transcription factor sites, with a lesser involvement of the cAMP response 
element (see section 1.3.2). Glucocorticoids were investigated as a known repressor of 
IL-6 transcription (see 1.3.2.5).
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4.1.1. Generation of plasmid constructs
The genotype associations identified between the -174 G/C polymorphism of IL-6 and 
systemic arthritis (SA, see chapter 3), were examined. Constructs of 61 lbp of the 5’- 
regulatory region of IL-6 from +61 to -550 were initially used to investigate the -174 
allelic effects. These constructs were generated by PCR of individuals of known 
sequence, with either the homozygote G or the C allele at position -174. The fragment 
was cloned into the luciferase-reporter plasmid PGL3-basic between the Kpnl and 
Nhel restriction sites (figure 4.1 & section 2.9.1). The constructs were named AG for 
the -174G allele and AC for the -174C allele. Automated sequencing confirmed that 
the constructs differed only by the allele at position -174. The AT-tract sequence 
between -373 and -392 was a constant A8/T12 for both constructs. To investigate the 
influence of IL-6 5’-flanking regions up-stream of the -174 polymorphism, including 
the AT-tract and surrounding region, deletion mutants of constructs AG and AC 
(61 lbp) were generated by PCR and cloned into the same sites of PGL3-basic (see 
section 2.9.1). Constructs designated AGD (-174G) & ACD (-174C) were 37lbp in 
length from +61 to -310 (figure 4.1). Constructs designated AGDS (-174G) & ACDS 
(-174C) were 280bp in length from +61 to -219 (figure 4.1). AGD/ACD lacked the 
AT-tract and surrounding regions from -311 to -550 and AGDS/ACDS in addition 
lacked the API site and surrounding regions from -220 to -310. To investigate the 
potential influence of AT-tract polymorphisms on IL-6 transcription, construct AG9/11 
(-174G) was generated by PCR of genomic DNA from an individual with known AT- 
tract sequence A9T11 instead of A8T12. This construct was otherwise identical to AG 
as confirmed by automated sequencing. Each construct was checked for correct 
orientation and sequence of the insert by manual and automated-sequencing (see 
section 2.8.4). The length of each insert was verified by agarose gel electrophoresis of 
Notl and BglU restriction digest products or by PCR amplification (see section 2.9.2). 
The PCR product was digested with SfaNl (cuts -174G sequence but not -174C) to 
allow quick verification of the allele at position -174 (see 2.9.2 & 2.7).
The PGL3-basic plasmid vector was selected for this study as it does not contain any 
other promoter sequences. The 5’-flanking region of IL-6 therefore directly regulates 
all cellular levels of luciferase in this system.
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Figure 4.1. The AG/AC (61 lbp), AGD/ACD (371bp) and AGDS/ACDS (280bp) IL-6 5’-flanking region constructs cloned into PGL3-basic.
Known 5’-flanking region sequences of IL-6 were amplified by PCR and cloned into the PGL3-basic luciferase reporter vector (Promega) between restriction sites Kpnl and 
NheI (see section 2.9.1 for method). The -174G/C polymorphism site and main transcription factor sites are indicated (see 1.3.2 for more detail).
Luc+=luciferase gene (arrow indicates direction of read frame), Amp’=ampicillin resistance gene.
To investigate the influence of the -174 polymorphism in the context of naturally 
occurring haplotypes of the 5’-flanking region polymorphisms, a 1.17kb IL-6 construct 
from +8 to -1170 (in pGEM) was kindly provided by S. Akira and T. Kishimoto 
(Institute of Molecular and Cellular Biology, Osaka University, Japan). Automated 
sequencing confirmed the sequence to have the common allele at each polymorphic 
site corresponding to Yasukawa et al. (1987), GenBank accession number Y00081 ( -  
174G'373A9/T11'392-572G-597G-627C). The 1.17kb IL-6 sequence was sub-cloned 
from the pGEM vector into pBluescript phagemid (Stratagene) and then cloned into 
the PGL3-basic plasmid between Sad  and Xhol (see 2.9.4). Confirmation of 
orientation of the insert was established by automated sequencing. This construct was 
designated GGG (-597G-572G-174G). The -627 polymorphism was kept constant at 
-627C as the frequency of the other allele had been shown to be extremely rare in the 
UK Caucasian population (frequency <0.010, see 3.2). Genotype studies in the healthy 
UK Caucasian population revealed the most common naturally occurring haplotype to 
be -597G-572G-174G at frequency 0.524, the next most common haplotype was -  
597A-572G-174C at frequency 0.372, followed by -597G-572C-174G at frequency 
0.070 (section 3.6.3). The additional haplotypes were generated by site-directed 
mutagenesis from the GGG construct and designated AGC (-597A-572G-174C) and 
GCG (-597G-572C-174) respectively. The GCG construct allowed comparison with 
GGG to investigate the effect of the -572 polymorphism on transcription. To 
determine if the -597 polymorphism had an independent functional influence on 
transcription despite strong allelic association with -174 a fourth construct was 
generated with -597A-572G-174G, designated AGG. This haplotype occurred only 
rarely in the UK Caucasian population with a frequency of 0.005 (section 3.6.3). 
Successful mutation for each allele was preliminarily confirmed by PCR and RFLP 
with SfaNl for the -174 polymorphism, Mbil for the -572 polymorphism and FokI for 
the -597 polymorphism (see 2.7). Each haplotype construct was then sequenced by 
automated sequencing (MWG Biotech) to verify the haplotype and to ensure no other 
mutations had been introduced. The AT-tract was kept constant at A9/T11.
A sequence identical to the GGG construct from Akira and Kishimoto but with an AT- 
tract of A8T12 instead of A9T11 was not available. Attempts to mutate the A9T11 AT- 
tract of the 1.17kb construct by transformer site-directed mutagenesis (see 2.9.5.2) 
were repeatedly unsuccessful. This was probably because of A to T binding within the
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AT-tract of the mutation primer to form a hairpin-like structure and thereby preventing 
binding to the template DNA. This occurred despite high annealing temperatures and 
extended end sequences on the primers. Mutation of a restriction digest site (Sail) 
within the plasmid vector to allow selection was successful by this technique (see 
2.9.52). The potential influence of the AT-tract polymorphism was therefore only 
investigated in the 61 lbp constructs.
The EL-6 plasmid DNA constructs were purified for transfection by double caesium 
chloride gradients (see 2.9.7). This ensured a high level of purity, with negligible 
levels of endotoxin or nicked, degraded or truncated plasmid. PCR and RFLP were 
used to verify the polymorphism of each preparation. The concentration of plasmid 
DNA was determined by optical density at 260nm; 1 pg/pl stocks were then prepared 
and the OD260 rechecked (see 2.9.3).
4.1.2. Optimization of transfection conditions
Transfection was carried out in 24 well plates. 5xl04 viable cells were seeded per well 
and grown for 48 hours until 80-90% confluence was reached. The IL-6 constructs 
were co-transfected by the calcium phosphate precipitation method with RSV-P-gal 
control plasmid (see 2.10.1 for method). Transfection efficiency was found to be 70- 
75% by p-galactosidase staining (see 2.10.6). Cell viability post-transfection was 
reduced by 20%. After 18 hours of transfection in media containing 10% foetal calf 
serum (FCS), the cells were washed and stimulated with fresh media (2% FCS) with or 
without added cytokine. The IL-6 promoter but not the RSV-promoter was sensitive to 
cell exposure to FCS or IL-1. The optimal concentration of FCS to maintain cell 
viability but with minimal IL-6 stimulation was found to be 2%. Enzyme-linked 
immunosorbent assay (ELISA, see 2.12.1) was used to confirm the absence of 
cytokines IL-1, TNF, and IL-6 from the media or heat inactivated FCS batches used. A 
commercial assay for lipopolysaccaride (LPS) confirmed <0.1 units/ml of LPS in the 
media or FCS. After the required stimulation time, cells were washed, harvested, and 
light emission units for luciferase and p-galactosidase were determined (see 2.10.5&6).
The results presented in this chapter represent repeat experiments with at least two 
separate preparations of construct DNA. Any individual results greater than two
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standard deviations from the mean were excluded. Luciferase light-emission units were 
corrected for p-galactosidase activity to standardise for variation in transfection 
efficiency between experiments.
Standardised result = luciferase light emission units (units/min)
p-galactosidase light emission units (units/min)
The results are presented as fold-change compared to baseline (Ohrs) unless stated 
otherwise and shown graphically as the mean ± standard deviation. Statistical 
significance was determined using the paired T-test with 95% confidence limits.
4.1.3. The -174 polymorphism influences levels of IL-6 transcription
Basal and IL-lp-induced levels of IL-6 transcription were compared for the 61 lbp
constructs AG (-174G) and AC (-174C) co-transfected with RSV-P-gal into HeLa
cells for 18 hours. The cells were washed and stimulated with fresh media (2% FCS)
alone or containing lOOunits/ml of IL-1 p (Genzyme Diagnostics). At set time intervals
post stimulation, the cells were harvested and assayed for levels of luciferase and p-
galactosidase.
There was a small, but significant increase in levels of IL-6 transcription from baseline 
with media change alone (AG 2.8-fold, p=0.028, AC 2.2-fold, p=0.012) but no 
significant difference between AG and AC in unstimulated cells (p>0.1, figure 4.2). IL- 
ip  stimulation resulted in increased IL-6 transcription for both AG and AC with 
maximum expression occurring within 6 hours of IL-1 stimulation. There was a 
significant difference in the magnitude of response to IL-1 p for AG (32-fold) and AC 
(18-fold) with -174G resulting in an approximately 2-fold higher level of expression 
than -174C at maximal stimulation (p=0.002, figure 4.2).
A dose response curve was determined for the constructs with 6-hours of IL-1 p 
stimulation. Maximum stimulation for both alleles was reached at lOOunits/ml IL-1 p 
above which the dose response reached a plateau (figure 4.3). The G-allele reached a 
significantly higher level of expression than the C-allele at lOOunits/ml IL-lp 
stimulation (p=0.024). lOOunits/ml IL-lp was chosen for subsequent experiments as 
the optimal dose to achieve maximal stimulation of both alleles. This equates to 2.9nM 
of IL-1 p; within the physiological pico- to nano-molar range of IL-1 in vivo.
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Figure 4.2. Time course for AG and AC constructs transfected into HeLa cells, 
unstimulated and with IL-lp stimulation.
HeLa cells in 24-well plates were co-transfected with the IL-6-luciferase constructs AG or AC and 
control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS and 1ml of 2%FCS medium ± 
100U IL-ip was added to each well. At the allocated time point, cells were harvested and luciferase 
and P-galactosidase assays carried out (see section 2.10.1). Luciferase light-emission units were 
standardised for P-gal levels. Results show fold change in levels o f expression compared to baseline 
(Ohrs). Results represent eight repeat experiments with duplicate wells, y-error bars= standard 
deviation. The table shows comparison of values by paired T-test, *denotes a significant difference 
within 95% confidence limits.
AG produced approximately 2-fold higher levels o f  reporter gene expression than AC at 
maximal stimulation. At all time points, IL-1 P significantly increased the level o f expression 
for AG and AC (p<0.04). 2% FCS medium alone (unstimulated conditions) significantly 
increased AG and AC expression at 6-hours only (p<0.03).
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Figure 4.3. Dose response curve for IL-ip stimulation of AG and AC constructs 
transfected into HeLa cells.
HeLa cells in 24-well plates were co-transfected with the IL-6-luciferase constructs AG or AC and 
control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS and 1ml of2%FCS medium + 1, 
10, 50, 100 or 200U of IL-1 P (shown as log of the dose) was added to each well. After 6 hours, the 
cells were harvested and luciferase and P-galactosidase assays carried out (see section 2.10.1). 
Luciferase light-emission units were standardised for p-gal levels. Results show fold change in levels 
of expression compared to baseline (Ohrs), representing two repeat experiments with duplicate wells, 
y-error bars= standard deviation. The table shows comparison of values by paired T-test, *denotes a 
significant difference within 95% confidence limits.
Maximal stimulation for AG and AC occurred with lOOU/ml IL-lp with AG showing 
significantly higher levels of expression.
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4.1.4. Regions up-stream of the -174 polymorphism modulate the -174 allelic effect
Deletion mutants of constructs AG and AC were used to investigate the possible 
influence of up-stream regions of IL-6 on the -174 allelic effect in HeLa cells. Specific 
AT-tract polymorphisms at -373 to -392 have been reported to be associated with the 
-174 G and C alleles (Fishman et al., 1998). Deletion mutants lacking the AT-tract and 
surrounding region to -310 (AGD and ACD) were studied as well as mutants lacking 
the API site (-277 to -283) and surrounding regions to -219 (AGDS and ACDS), 
(figure 4.1). A time course of IL-1 p stimulation (lOOU/ml) for the deletion mutants in 
HeLa cells revealed maximal stimulation of transcription to occur at 6-hours, as for the 
61 lbp constructs AG and AC. The constructs were therefore compared in unstimulated 
and IL-lp-stimulated conditions at this time point.
Significantly higher expression was obtained for AG compared to AC with DL-ip 
stimulation (p=0.018), but not when unstimulated (p=0.051), (figure 4.4). Constructs 
AGD and ACD resulted in significantly lower levels of unstimulated and IL-lp- 
stimulated expression (2 .8-fold reduction, p<0 .001) indicating that the deleted region 
from -311 to -550 contains an enhancer element(s) for constitutive and EL-ip-induced 
IL-6  transcription.
AGD showed significantly higher levels of transcription than ACD with IL-ip 
stimulation (p=0.032), but not when unstimulated (p=0.077). Constructs AGDS and 
ACDS resulted in a further small, but significant reduction in the level of unstimulated 
and IL-1-stimulated transcription, with the reduction being least for AGDS when 
stimulated with IL-ip (1.13-fold, p=0.045) compared to unstimulated AGDS 
(reduction 1.52-fold, p=0.0002), unstimulated ACDS (reduction 1.36-fold, p<0.0001) 
and IL-1-stimulated ACDS (reduction 1.42-fold, p<0.0001). This indicated that the 
deleted region from -220 to -310 also acts as an enhancer for constitutive and IL-lp 
induced expression of IL-6 . However, the fact that the G-allele is able to partially over­
come the effect of removal of this enhancer region when stimulated with IL-lp 
suggests that an element in this region may be interacting with the -174 
polymorphism.
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AG AC 0.310 0.051 1.958 0.018*
AG AGD 1.745 <0.001* 9.323 <0.001*
AGD AGDS 0.252 <0.001* 0.623 0.045*
AC ACD 1.568 <0.001* 8.196 <0.001*
ACD ACDS 0.285 <0.001* 1.411 <0.001*
AGD ACD 0.133 0.077 0.791 0.032*
AGDS ACDS 0.165 0.007* 1.582 <0.001*
Figure 4.4. Comparison of deletion mutant constructs AG/AC, AGD/ACD and 
AGDS/ACDS transfected into HeLa cells.
HeLa cells in 24-well plates were co-transfected with the IL-6-luciferase constructs AG or AC, AGD 
or ACD, AGDS or ACDS and control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS 
and 1ml of 2%FCS medium ± 100U of IL-1 P was added to each well. After 6 hours, the cells were 
harvested and luciferase and P-galactosidase assays carried out (see section 2.10.1). Luciferase light- 
emission units were standardised for P-gal levels. Results show fold change in levels of expression 
compared to baseline (Ohrs), representing three repeat experiments with 8 replica wells, y-error bars= 
standard deviation. The table shows comparison of values by paired T-test, *denotes a significant 
difference within 95% confidence limits.
Deletion of region -311 to -550 (AGD & ACD) and -220 to -310 (AGDS & ACDS) resulted 
in sequential reductions in the level of transcription with both alleles. Deletion of region — 
220 to -310 had differential effects on AGDS compared to ACDS.
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This could be an enhancer element facilitating down-stream factor binding when the -  
174C allele is present, or an inhibitory element facilitating down-stream factor binding 
when the -174G allele is present. Either way, it suggests that factor(s) bound around 
the -174 site are differentially stabilized or facilitated by a factor(s) in the region -220 
to -310. Interestingly, AGDS showed significantly higher levels of transcription than 
ACDS when unstimulated (p=0.007) as well as with IL-ip stimulation (p<0.001), 
which had not been seen with the longer constructs AGD/ACD and AG/AC. Again this 
supports an interaction between factor(s) in the region -220 to -310 with factor(s) 
binding around the -174 polymorphism, with differential modulation for the G and the 
C allele. This could be an inhibitory element acting more strongly on -174G or an 
enhancer element acting more strongly on -174C.
4.1.5. AT-tract polymorphisms influence levels of IL-6 transcription 
A number of AT-tract polymorphisms have been described (see section 1.3.3.3). In the 
Caucasian population, the most common polymorphism has been shown to be A8T12 
with a frequency of 0.370 (Terry et al., 2000) to 0.421 (Fishman et al., 1998). The next 
most common polymorphism that maintains the total length of the AT-tract was A9T11 
with a frequency of 0.190 (Terry et al., 2000) to 0.211 (Fishman et al., 1998). A8T12 
was in strong allelic association with -174C and A9T11 with -174G (Twine et al., 
2003). Other polymorphisms identified were A10T9, A10T10, A10T11, A9T10, A9T12 
and Al 1T9. To investigate the possible influence of AT-tract polymorphisms on levels 
of IL-6 transcription, the 61 lbp AG construct with AT-tract A8T12 (AG8/12) was 
compared to a AG construct with AT-tract A9T11 (AG9/11), but otherwise identical. 
These constructs were transfected into HeLa cells and compared for unstimulated and 
IL-ip-stimulated expression at 6 hours (the time of maximum stimulation). AG8/12 
resulted in 1.2-fold higher levels of IL-6 transcription than AG9/11, both for 
unstimulated (p=0.029) and IL-ip-stimulated expression (p=0.007), (figure 4.5). These 
results indicate that the AT-tract has functional significance in IL-6 transcription and 
that AT-tract polymorphisms influence levels of expression in HeLa cells. It is possible 
that the reduced level of transcription seen with deletion mutants AGD and ACD was at 
least in part due to removal of the AT-tract.
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Figure 4.5. Com parison of A G 8/12 and AG 9/11 constructs transfected into HeLa 
cells.
HeLa cells in 24-well plates were co-transfected with the IL-6-luciferase constructs AG8/12 or 
AG9/11 and control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS and 1ml o f 2%FCS 
medium ± 100U of IL-13 was added to each well. After 6 hours, the cells were harvested and 
luciferase and 3-galactosidase assays carried out (see section 2.10.1). Luciferase light-emission units 
were standardised for P-gal levels. Results show fold change in levels o f expression compared to 
baseline (Ohrs), representing three repeat experiments with 4 replica wells, y-error bars= standard 
deviation. The table shows comparison o f values by paired T-test, *denotes a significant difference 
within 95% confidence limits.
AG8/12 produced significantly higher levels o f  reporter gene expression than AG9/11 in 
unstimulated and IL-lp stimulated conditions.
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4.1.6. The -572 but not the -597 polymorphism has an independent functional effect 
on IL-6 transcription
Constructs of the most common naturally occurring haplotypes of the -174, -572 and -  
597 polymorphisms of IL-6  were used to investigate the influence of the up-stream 
polymorphisms on the -174 allelic effect. It was of particular interest to determine 
whether the -597 polymorphism had any independent or modifying functional effect 
with respect to the -174 polymorphism as strong allelic association had been shown 
between -174G and -597G, -174C and -597A (see section 3.6.1). 1.17kb constructs 
GGG (-597G-572G-174G), AGG (-597A-572G-174G), AGC (-597A-572G-174C) 
and GCG (-597G-572C-174G) were transfected into HeLa cells by calcium 
phosphate precipitation, for 18-hours as for the shorter constructs (see 2.10.1). All 
constructs had a constant A9T11 AT-tract. Although the AGG construct was not one of 
the common haplotypes, it was used to provide information regarding the functional 
significance of the -174 and -597 polymorphisms, in comparison to the AGC and 
GGG constructs.
A time course for IL-lp stimulation (lOOU/ml) confirmed maximal stimulation to be at 
6 hours for the 1.17kb constructs as for the 61 lbp constructs, shown in figure 4.6 for 
GGG and AG (6-fold, p<0.0001). Although a change of media alone (unstimulated 
conditions, 2% FCS) resulted in a small increase in transcription with the short 
construct (2-fold, p=0.004), this change did not induce a significant increase in 
transcription with the long construct (p=0.069) suggesting that the longer construct 
was less sensitive to cellular changes induced by exposure to serum factors. The 
1.17kb haplotype constructs were compared at the 6-hour time point.
Comparing levels of transcription between the four haplotype constructs, there was no 
significant difference with unstimulated IL-6 transcription (p>0.06), (figure 4.7). 
However, with IL-ip-stimulated transcription, the GGG haplotype construct (most 
common naturally occurring haplotype) was associated with a significantly higher 
level of expression than the AGC haplotype construct (the other common naturally 
occurring haplotype), (p=0.016, figure 4.7). This was consistent with the -174 allelic 
effect seen with the short constructs AG and AC (section 4.1.3).
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GGG-unstim 6hrs GGG-IL1 6hrs 3.334 0.0001*
G-unstim 6hrs G-IL1 6hrs 4.519 0.0004*
Figure 4.6. Time course for GGG and AG constructs transfected into HeLa cells, 
unstimulated and IL-lp stimulated.
HeLa cells in 24-well plates were co-transfected with the IL-6-luciferase constructs GGG or AG and 
control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS and l ml of 2%FCS medium ± 
100U IL-lp was added to each well. At the allocated time point, cells were harvested and luciferase 
and P-galactosidase assays carried out (see section 2.10.1). Luciferase light-emission units were 
standardised for P-gal levels. Results show fold change in levels o f expression compared to baseline 
(Ohrs). Results represent duplicate experiments with 4 replica wells, y-error bars= standard deviation. 
The table shows comparison of values by paired T-test, *denotes a significant difference within 95% 
confidence limits.
Maximal stimulation with IL-1 P occurred at 6 hours for GGG and AG in HeLa cells. AG but 
not GGG transcription was induced by 2 % FCS medium change alone (unstimulated 
conditions).
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GGG AGG 0.426 0.070 1.658 0.240
GGG AGC 0.038 0.434 4.711 0.016*
GGG GCG 0.690 0.063 6.637 0.019*
AGG AGC 0.728 0.101 3.053 0.054
Figure 4.7. Comparison of haplotype constructs GCG, GGG, AGG and AGC 
transfected into HeLa cells.
HeLa cells in 24-well plates were co-transfected with the IL-6-luciferase constructs GCG, GGG, AGG 
or AGC and control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS and 1ml o f 2%FCS 
medium ± 100U o f IL-1 P was added to each well. After 6 hours, the cells were harvested and 
luciferase and P-galactosidase assays carried out (see section 2.10.1). Luciferase light-emission units 
were standardised for p-gal levels. Results show fold change in levels o f expression compared to 
baseline (Ohrs), representing five repeat experiments with 4 replica wells, y-error bars= standard 
deviation. The table shows comparison o f values by paired T-test, * denotes a significant difference 
within 95% confidence limits.
With IL-ip stimulation, GGG was associated with higher levels o f  expression than AGC, 
with no significant difference between GGG and AGG. GCG was associated with 
significantly lower levels o f expression than GGG. There was no significant difference 
between haplotypes in unstimulated conditions.
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The -597 polymorphism did not appear to have an independent functional effect on IL- 
6  expression as there was no significant difference between the GGG and AGG 
construct with IL-lp stimulation (p=0.240, figure 4.7). The -572 polymorphism in 
contrast appeared to have an independent functional effect on IL-lp-induced IL-6 
transcription, with the GGG construct associated with significantly higher levels of 
expression than the GCG construct (p=0.019, figure 4.7).
4.1.7. IL-6 polymorphic effects are cell specific
To investigate whether the haplotype effect seen in HeLa cells may be cell-specific, 
comparative transfection studies were carried out in Huh7 cells. The haplotype 
constructs GGG, AGG, AGC and GCG were transfected by calcium phosphate 
precipitation into Huh7 cells for 18 hours as for HeLa cell transfections. A time course 
for EL-ip stimulation (lOOU/ml) for the 1.17kb and 61 lbp constructs established that 
the time of maximal stimulation of transcription for these constructs in Huh7 cells was 
at 9 hours rather than 6  hours as in HeLa cells (shown for GGG and AG, figure 4.8). 
The fold induction was generally lower in Huh7 cells (3.5-fold, p<0.003) than for 
HeLa cells. Doses of IL-lp greater than lOOU/ml did not result in any higher levels of 
stimulation. In Huh7 cells, change of medium alone (containing 2% FCS) resulted in a 
small but significant increase in the levels of transcription for both the long (1.3-fold, 
p=0.033) and short construct (1.4-fold, p<0.001), (figure 4.8). These differences 
compared to transfections in HeLa cells probably reflect different kinetics and 
transcription factor responses between the two cells to serum factors and IL-lp. The 
constructs were therefore compared at the 9-hour time point in Huh7 cells.
Levels of transcription in Huh7 cells were not significantly different between 
haplotype constructs whether unstimulated or IL-ip-stimulated (p>0.05, figure 4.9), 
though there was a trend towards the opposite effect to that seen in HeLa cells with 
GGG producing lower levels of transcription with IL-1 stimulation than AGC 
(p=0.06). This suggests that the 5’-flanking region polymorphisms of IL-6 have a cell- 
specific effect on IL-6 transcription, with differences in expression seen in HeLa cells 
but not Huh7 cells reflecting possible differences in transcription factor(s) expressed 
between these cell types.
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GGG-unstim Ohrs GGG-unstim 9hrs 1.288 0.033*
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GGG-unstim 9hrs GGG-1L1 9hrs 2.667 0.001*
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Figure 4.8. Time course for GGG and AG constructs transfected into Huh7 cells, 
unstimulated and IL-lp stimulated.
Huh7 cells in 24-well plates were co-transfected with the IL-6-luciferase constructs GGG or AG and 
control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS and 1ml o f 2%FCS medium ± 
100U IL-1 [3 was added to each well. At the allocated time point, cells were harvested and luciferase 
and P-galactosidase assays carried out (see section 2.10.1). Luciferase light-emission units were 
standardised for P-gal levels. Results show fold change in levels o f expression compared to baseline 
(Ohrs). Results represent duplicate experiments with 4 replica wells, y-error bars= standard deviation. 
The table shows comparison of values by paired T-test, * denotes a significant difference within 95% 
confidence limits.
Maximal stimulation with IL-1 P occurred at 9 hours for GGG and AG in Huh7 cells. Both AG and 
GGG transcription was induced by 2 % FCS medium change alone (unstimulated conditions).
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GGG AGG 0.040 0.367 0.542 0.109
GGG AGC 0.047 0.384 1.012 0.060
GGG GCG 0.238 0.232 0.943 0.180
AGG AGC 0.007 0.479 0.470 0.223
Figure 4.9. Comparison of haplotype constructs GCG, GGG, AGG and AGC 
transfected into Huh7 cells.
Huh7 cells in 24-well plates were co-transfected with the IL-6-luciferase constructs GCG, GGG, AGG 
or AGC and control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS and 1ml of 2%FCS 
medium ± 100U of IL-1 P was added to each well. After 9 hours, the cells were harvested and 
luciferase and P-galactosidase assays carried out (see section 2.10.1). Luciferase light-emission units 
were standardised for P-gal levels. Results show fold change in levels o f expression compared to 
baseline (Ohrs), representing duplicate experiments with triplicate wells, y-error bars= standard 
deviation. The table shows comparison of values by paired T-test, ^denotes a significant difference 
within 95% confidence limits.
There was no significant difference between haplotypes in unstimulated or IL-lp stimulated 
conditions in Huh7 cells.
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4.1.8 The -174 allelic effects are altered by glucocorticoid inhibition
Acute flare-ups of systemic arthritis respond quickly to treatment with 
glucocorticosteroids, which is the mainstay of initial therapy. Glucocorticoids, 
including dexamethasone, are known to inhibit IL-6 transcription (see section 1.3.2.5). 
A known glucocorticoid-receptor element (GRE) is located at -210 to -214 of the IL-6 
5’-flanking region, close to the -174 polymorphism. Two putative GRE sites are 
located just downstream of the -572 and -597 polymorphisms (-461 to —466 & -552 to 
-557). The possible influence of the 5’-flanking region polymorphisms on 
dexamethasone inhibition of IL-6 transcription was investigated.
1.17kb and 61 lbp constructs were transfected into HeLa for 18 hours as before 
(section 2.10.1) and stimulated with IL-ip (lOOU/ml) with or without the presence of 
dexamethasone (dissolved in ethanol). An equivalent amount of ethanol (4pi, 217nm) 
was added as a control to non-dexamethasone containing media. Ethanol can have 
inhibitory effects on transcription, however, the concentrations required to produce 
such an effect on other genes that have been studied was in the pM range (Mandrekar 
et al., 1999). A dose response curve was plotted for the 6-hour time point, shown for 
AG and AC (figure 4.10). The optimal dose of dexamethasone, for inhibition of 
reporter transcription was 10‘7M. Of note, the -174 G/C allelic effect with IL-lp 
stimulation is lost in the presence of maximal inhibitory concentrations of 
dexamethasone.
A time course for dexamethasone inhibition (10'7M) confirmed maximal inhibition of 
IL-lp-induced transcription of the constructs to occur at 6-hours (shown for GGG and 
AG, figure 4.1 la). A similar time course in Huh7 cells showed no significant inhibition 
of IL-ip-induced transcription of the constructs (figure 4.11b). Further investigations 
on the effect of dexamethasone inhibition were therefore confined to HeLa cells and 
compared at the 6-hour time point.
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G-10 7M dex C-10'7M dex 2.722 0.067
G-OM dex G-10‘7M dex 4.070 0.044*
C-OM dex C-10‘7M dex 2.219 0.079
Figure 4.10. Dose response curve for dexamethasone inhibition of IL-lp-induced 
expression of AG and AC constructs transfected into HeLa cells.
HeLa cells in 24-well plates were co-transfected with the IL-6-luciferase constructs AG or AC and 
control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS and 1ml of 2%FCS medium + 
100U IL-1 P and 0, 1 O'8, 10'7, 10"6, 10‘5 or 10"4 Molar Dexamethasone (with 4pl ethanol) was added to 
each well. After 6 hours, the cells were harvested and luciferase and P-galactosidase assays carried out 
(see section 2.10.1). Luciferase light-emission units were standardised for P-gal levels. Results show 
fold change in levels o f expression compared to baseline (Ohrs), representing duplicate experiments 
with duplicate wells, y-error bars= standard deviation. The table shows comparison of values by 
paired T-test, *denotes a significant difference within 95% confidence limits.
Optimal inhibition o f IL-lp-induced transcription o f AG and AC occurred with 10'7M 
dexamethasone. In the presence o f dexamethasone the -174G/C allelic difference is lost.
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G 3hrs 1.580 0.010* 0.134 0.261
GGG 3 hrs 3.262 0.018* 0.256 0.174
G 6hrs 2.529 0.001* 0.573 0.067
GGG 6hrs 3.493 0.006* 0.542 0.239
G 8/9hrs 1.843 0.023* 0.285 0.134
GGG 8/9hrs 0.766 0.098 0.230 0.288
Figure 4.11. Time course for dexamethasone inhibition of IL-lp-induced 
expression of GGG and AG constructs transfected into (a) HeLa cells and (b) 
Huh7 cells.
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Figure 4.11(cont.)
(a) HeLa cells or (b) Huh7 cells, in 24-well plates were co-transfected with the IL-6-luciferase 
constructs GGG or AG and control plasmid RSV-(3-gal. After 18hrs, cells were washed with PBS and 
lml of 2%FCS medium + 100U IL-ip ± 10'7M dexamethasone was added to each well. At the allocated 
time point, cells were harvested and luciferase and P-galactosidase assays carried out (see section
2.10.1). Luciferase light-emission units were standardised for p-gal levels. Results show fold change in 
levels of expression compared to baseline (Ohrs). Results represent duplicate experiments with 4 replica 
wells, y-error bars= standard deviation. The table shows comparison of values by paired T-test, ‘denotes 
a significant difference within 95% confidence limits.
Maximal inhibition of IL-lp-induced transcription by dexamethasone occurred at 6 hours in 
HeLa cells for GGG and AG. No inhibition of IL-lp-induced transcription was seen by 
dexamethasone in Huh7 cells.
The 611bp AG and AC constructs were compared in HeLa cells with dexamethasone 
inhibition (10" M), for unstimulated and IL-lp-stimulated (lOOU/ml) expression. 
Dexamethasone resulted in significant inhibition of unstimulated expression (p<0.01) 
and of IL-ip-stimulated expression (p<0.05), (figure 4.12). The reduction in IL-lp- 
stimulated expression was significantly greater (p=0.042) for AG (2.0-fold, p<0.001) 
compared to AC (1.7-fold, p=0.023) resulting in loss of the -174G/C allelic difference. 
Although the IL-lp-induced -174 allelic effect was lost with dexamethasone 
inhibition, dexamethasone produced a difference in the levels of unstimulated 
transcription between the two alleles. The AG construct was associated with a higher 
level of expression than AC under these conditions (p=0.016), with less constitutive 
inhibition of the -174 G than C allele (p<0.05), (figure 4.12).
Glucocorticoids can influence transcriptional activity via direct mechanisms involving 
glucocorticoid receptor binding to glucocorticoid-response elements in the gene, or via 
indirect mechanisms by inhibition of other transcription factors or co-factors (either 
through gene inhibition or protein-protein interactions), (discussed in section 1.3.2.5). 
Many mechanisms may be relevant in the context of the IL-6 gene and glucocorticoids 
are clearly involved in modulation of the -174 allelic effect. The different influences 
of dexamethasone on the -174 alleles for unstimulated and IL-1-stimulated 
transcription may reflect the different transactivation mechanisms operative in basal 
and induced expression.
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Comparison o f  conditions and constructs
Condition 1 Condition 2 mean difference p-value
G-unstim G-dex 0.447 0.007*
C-unstim C-dex 0.382 <0.001*
G-IL1 G-ILl/dex 4.147 <0.001*
C-IL1 C-ILl/dex 2.756 0.023*
G-unstim C-unstim 0.252 0.092
G-dex C-dex 0.192 0.016*
G-IL1 C-1L1 2.332 0.044*
G-ILl/dex C-ILl/dex 0.941 0.189
G-Ohr (baseline) G-unstim (6hr) 1.481 <0.001*
C-Ohr (baseline) C-unstim (6hr) 1.325 <0.001*
Figure 4.12. Comparison of dexamethasone inhibition of AG and AC constructs 
transfected into HeLa cells.
HeLa cells in 24-well plates were co-transfected with the IL-6-luciferase constructs AG or AC and 
control plasmid RSV-P-gal. After 18hrs, cells were washed with PBS and 1ml of2%FCS medium ± 
100U o f IL-lp ± 10‘7M dexamethasone was added to each well. After 6 hours, the cells were 
harvested and luciferase and P-galactosidase assays carried out (see section 2.10.1). Luciferase light- 
emission units were standardised for P-gal levels. Results show fold change in levels o f expression 
compared to baseline (Ohrs), representing six repeat experiments with duplicate wells, y-error bars= 
standard deviation. The table shows comparison o f values by paired T-test, *denotes a significant 
difference within 95% confidence limits.
Dexamethasone significantly inhibited levels o f  AG and AC transcription whether 
unstimulated or IL-l|3-stimulated. With IL-1(3 stimulation, AG was inhibited significantly 
more by dexamethasone than AC (p=0.042) resulting in loss o f  the -174  allelic effect. In 
unstimulated conditions, AC was inhibited significantly more by dexamethasone than AG 
resulting in a -174  allelic effect.
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The effect of Dexamethasone inhibition (10'7M) on the 1.17kb haplotype constructs 
was compared in HeLa cells under the same conditions. Dexamethasone inhibition of 
IL-lp-induced expression of the haplotype constructs in HeLa cells revealed 
significant inhibition of GGG (1.6-fold reduction, p=0.002) and AGG (1.3-fold 
reduction, p=0.011), but not of AGC (1.1-fold reduction, p=0.324), (figure 4.13a). This 
mirrors the effects seen for the short constructs. In both cases the glucocorticoid 
inhibition occurred more strongly for IL-lp-induced expression with the -174 G rather 
than C allele, and resulted in loss of the -174 associated allelic differences between 
haplotypes.
4.1.9. The -572 polymorphism alters inhibition by glucocorticoids 
Dexamethasone did not significantly inhibit IL-ip-induced expression of GCG in 
HeLa cells (1.2-fold reduction, p=0.066), although GGG was significantly inhibited 
(1.6-fold reduction, p=0.002), (figure 4.13a). This may reflect alteration of 
glucocorticoid binding to a site(s) adjacent to the -572 polymorphism that the -572G 
allele may facilitate but the -572C allele inhibit. According to consensus sequence 
comparisons, there are two putative glucocorticoid receptor binding sites down-stream 
o f-572 (-461 to —466 & -552 to -557) that the -572 polymorphism may influence.
4.1.10. Stripped FCS alters levels of transcription
FCS is necessary for cell viability and for IL-lp induction of IL-6  transcription. A 
series of transfection experiments were carried out in serum deplete medium (D-MEM 
without supplemented FCS or A-MEM, Gibco). Although the effect o f medium 
change, containing 2% FCS (unstimulated conditions, see 4.1.3), on levels of IL-6 
construct expression were abolished by using FCS deplete medium, no induction of IL- 
6 transcription with addition of IL-ip was seen without the presence of FCS. FCS can 
contain varying amounts of hormone and steroid compounds such as oestrogens, 
growth factors and cortisol (Nakama et al., 1995), which despite heat inactivation 
could be influencing levels of transcription in the transfection system. A treatment 
shown to bind and remove (strip) hormone and steroid compounds from FCS was 
described by Fenske (1991). This method, using activated charcoal and dextran, was 
adapted to produce stripped FCS for transfection studies (see 2.10.2).
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Comparison of conditions for each construct
_______________   FCS ( u n s t r i p p e d ) ______ Stripped FCS
Condition 1 Condition 2 mean
difference
p-value mean
difference
p-value
GGG-unstim AGG-unstim 0.427 0.070 0.239 0.156
GGG-unstim AGC-unstim 0.037 0.433 0.280 0.101
GGG-unstim GCG-unstim 0.691 0.062 0.142 0.385
GGG-IL1 AGG-IL1 1.186 0.307 1.714 0.073
GGG-IL1 AGC-IL1 3.930 0.037* 3.297 0.003*
GGG-IL1 GCG-IL1 6.635 0.019* 0.535 0.326
GGG-ILl/dex AGG-ILl/dex 1.457 0.238 0.575 0.318
GGG-ILl/dex AGC-ILl/dex 0.649 0.366 0.046 0.482
GGG-ILl/dex GCG-ILl/dex 2.815 0.102 0.695 0.338
GGG-IL1 GGG-ILl/dex 5.630 0.002* 1.299 0.102
AGG-IL1 AGG-ILl/dex 2.987 0.011* 0.990 0.231
AGC-IL1 AGC-ILl/dex 1.051 0.324 1.952 0.096
GCG-EL1 GCG-ILl/dex 1.810 0.066 0.069 0.487
Figure 4.13. Comparison of dexamethasone inhibition of haplotype constructs 
GCG, GGG, AGG and AGC transfected into HeLa cells with medium 
containing (a) FCS (unstripped) and (b) stripped FCS.
HeLa cells in 24-well plates were co-transfected with the IL-6-luciferase constructs GCG, GGG, AGG 
or AGC and control plasmid RSV-(3-gal. After 18hrs, cells were washed with PBS and 1ml of (a) 
2%FCS (unstripped) or (b) 2% stripped FCS (str-FCS, activated charcoal and dextran treated, see
2.10.2) media ± 100U of IL-ip ± 10'7M dexamethasone was added to each well. After 6 hours, the 
cells were harvested and luciferase and P-galactosidase assays carried out (see section 2.10.1). 
Luciferase light-emission units were standardised for P-gal levels. Results show fold change in levels 
of expression compared to baseline (Ohrs), representing six repeat experiments with triplicate wells, y- 
error bars= standard deviation. The table shows comparison of values by paired T-test, *denotes a 
significant difference within 95% confidence limits.
Dexamethasone inhibited IL-1 p-induced transcription of GGG significantly more than AGC, 
resulting in loss of the -174 allelic associated difference between haplotypes. GCG was not 
inhibited by Dexamethasone. Str-FCS reduced the level of IL-lp stimulation of GGG, AGG 
and AGC but not of GCG. Str-FCS also abolished the effect of dexamethasone inhibition.
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The presence of 2% stripped FCS (str-FCS) in the media instead of 2% unstripped 
FCS, from the same serum batch, was compared in unstimulated, IL-1 P-stimulated 
and dexamethasone inhibited transfections of the IL-6 haplotype constructs. 
Unstimulated levels of transcription for the four haplotype-constructs were not altered 
by the presence of str-FCS in the media (p>0.07, figure 4.13b). However, the levels of 
Il-lp-stimulated transcription were significantly reduced by str-FCS for the GGG, 
AGG and AGC constructs (p<0.001) but not the GCG construct (p=0.328). GGG was 
still associated with significantly higher levels of expression than AGC (p=0.003), 
with no significant difference between GGG and AGG (p=0.073). GCG on the other 
hand, showed no significant difference in levels of transcription from GGG (p=0.326). 
This would be consistent with the -572 allelic differences acting via glucocorticoid 
effects that are lost with stripping of the FCS. Str-FCS completely removed the 
inhibitory effect of dexamethasone on IL-1-induced transcription of the constructs 
(p>0.09). Several explanations for the effect of stripped FCS are possible. Stripping of 
the FCS may remove a co-stimulatory factor required for maximal IL-ip stimulation 
or introduce an inhibitory factor to IL-1 stimulation. It would appear to remove a factor 
necessary for dexamethasone inhibition or add a factor that inhibits dexamethasone 
activity. Dextran is a highly soluble compound that may not be completely removed in 
association with activated charcoal on filtration of the FCS after stripping. This could 
account for inhibitory effects seen. It is also possible that the str-FCS alters the 
expression of IL-1 receptors (IL-1R) on the cell surface either directly or by removal 
of factors that up-regulate IL-1R expression.
Interestingly, a similar comparison of the effect of str-FCS (same str-FCS as used for 
HeLa cell studies) on IL-ip induction of IL-6  haplotype constructs in Huh7 cells 
produced no significant differences in the levels of transcription compared to 
unstripped FCS. This could reflect different cell-specific mechanisms involved in IL-6 
transcription.
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4.2. Stable transfections
With stable transfectants, the plasmid construct is integrated into the genomic DNA of 
the host cell, histone bound and condensed into the chromatin structure. Cells derived 
from an individual clone will be identical for the number of copies of construct 
integrated and the position at which the plasmid is located within the genome. 
However, this will differ between cell colonies as integration of the plasmid into the 
genome occurs randomly. Stable transfectants represent the in vivo packaging and 
presentation of DNA more closely than transient transfections (Smith and Hager, 
1997). With random integration, or even with targeted integration, strong host genomic 
sequences near the integrated construct may influence the level of reporter expression. 
The majority of randomly integrated constructs are likely to insert into the extensive 
non-coding regions of the genome and are therefore less likely to be influenced by 
surrounding host sequences. However, it is important to remember that enhancers and 
repressors can act over many kilobases. Another genomic influence on the levels of 
construct expression may be the tightness of chromatin condensation at the site of 
integration and therefore the accessibility of the DNA sequence to transcription 
initiation factors. Despite these caveats, stable transfectants were generated in HeLa 
cells to enable the specific effect of various inducers and repressors of IL-6 
transcription to be investigated with reduced experiment-experiment variability. 
Comparison of several stable clones and pooled stable clones would help confirm that 
an observed effect between construct clones was a feature of the construct variant.
Stable transfectants were generated in HeLa cells using the 61 lbp AG & AC reporter 
constructs and the 1.17kb GGG, AGG and AGC haplotype reporter constructs (see 
section 2.10.8). Plasmids coding for G418 antibiotic resistance were co-transfected to 
enable selection for successful integration. Individual colonies were harvested and 
grown up for screening. Genomic DNA was isolated from those clones that expressed 
luciferase (approximately 50% of the G418 resistant clones). The genomic DNA was 
digested with the endonuclease Sphl that has only one restriction site in the IL-6- 
PGL3-basic construct (see figure 4.1). Southern Blot analysis was performed using a 
750bp probe, generated by Hindlll and Sphl restriction digestion of the PGL3-basic 
plasmid, isolated, purified and radiolabelled (see section 2.4.4). This allowed 
determination of the number of copies of construct inserted into each stable clone 
(figure 4.14).
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Figure 4.14. Southern blot analysis of IL-6-lucifearse constructs as stable transfectants in HeLa cells
(a) schematic representation (b) autoradiograph of probed blot.
20|ig of purified genomic DNA was digested overnight with 20U of Sphl, the products were separated on a 0.8% agarose slab gel with a DNA size ladder and transferred by 
electrophoresis onto nylon Hybond-N+ nucleic acid transfer membrane. The probe was prepared from PGL3-basic vector digested with Hindlll and Sphl, the fragment 
isolated, purified and end labelled with a32-P (see section 2.4 for method), (a) The dark bands represent putative locations of inserted constructs detected on probing (i) for a 
single inserted copy with band location dependent on where the construct has integrated into the genome, (ii) for multiple copies integrated at different sites, (iii) for multiple 
^  copies integrated at the same site. The length of the PGL3-basic vector plus construct is ~5.4kb for the 61 lbp constructs and ~6.0kb for the 1.17kb constructs, band thickness
^  will relate to the number of copies inserted at the site, (b) Lane 1=AG clone, 2=AC clone, 3=untransfected HeLa, 4=GGG clone, 5=AGG clone. Black arrows indicate bands
^  detected on probing, the blue and grey arrows indicate the expected position of bands due to multiple copies integrated at one site.
Only one copy o f the IL-6-luciferase construct had randomly inserted into each clone.
4.2.1. The -174 polymorphism has similar effects in stable transfections as transient 
transfections
Pooled stable transfectants for each construct were used to minimize the influences of 
host genomic factors on results. The stable transfectants were seeded into 24-well 
plates at the same concentration as HeLa cells for transient transfection (5x1 O'6 viable 
cells/ml) and grown to approximately 80% confluency before change o f media (2% 
FCS) and IL-lp stimulation. The cells were harvested after stimulation as for transient 
transfections and assayed for luciferase expression (see 2.10.4). Luciferase light 
emission units were normalised for any variations in cell numbers between wells by 
total protein content (see 2.12.2). A time course for IL-lp-stimulation (lOOU/ml) 
showed the time of maximal stimulation for IL-lp to be 8 hours with stable 
transfectants rather than 6 hours as for the transient transfectants (shown for AG & AC, 
figure 4.15). With the stable transfectants, media change with 2% FCS had no 
significant effect on levels of construct transcription over 12 hours (p>0.06) though 
these constructs in transient transfections had been sensitive (section 4.1.3). These 
differences may reflect the more compacted and packaged nature of the integrated 
construct within the host DNA. With stable transfectants, AG produce significantly 
higher levels of transcription than AC with IL-ip-stimulated (p<0.001) but not 
unstimulated (p>0.9) conditions, as had been found for transient transfections (figures 
4.15 & 16). The effect of dexamethasone inhibition was also similar with 
dexamethasone producing more inhibition of IL-ip-induced transcription for AG than 
AC (2.3-fold reduction compared to 1.8-fold, p=0.01), (figure 4.16). However unlike 
with transient transfections, the -174 allelic difference was maintained despite the 
differences in dexamethasone inhibition (p=0.002). The effect of dexamethasone 
inhibition on unstimulated transcription was out-with statistical significance though it 
showed a trend towards more inhibition for AC than AG (1.3-fold reduction compared 
to 1.1-fold, p=0.07), (figure 4.16). Dexamethasone in unstimulated conditions did not 
induce a -174 G/C allelic difference of statistical significance (p=0.066). However, as 
with transient transfections, the conclusion remains that glucocorticoids have a 
modulatory effect on the -174 allelic differences.
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__________________________  UNSTIMULATED IL-lft-STIMULATED
Time post media change (hrs) mean
difference
p-value mean
difference
p-value
3 0.082 0.116 2.130 <0.001*
6 0.086 0.174 2.897 0.002*
8 0.201 0.162 5.749 <0.001*
12 0.022 0.341 3.299 <0.001*
24 0.083 0.240 0.699 0.011*
Figure 4.15. Time course for AG and AC pooled HeLa cell stable transfectants, 
unstimulated and IL-1 P stimulated.
Pooled HeLa stable transfectants for IL-6-luciferase constructs AG or AC in 24-well plates were 
grown to -80% confluence, washed with PBS and 1ml o f 2%FCS medium ± 100U IL-1 (3 added to 
each well. At the allocated time point, cells were harvested and luciferase and total protein content 
assays carried out (see section 2.10.8). Luciferase light-emission units were normalised for total 
protein content. Results show fold change in levels o f expression compared to baseline (Ohrs). Results 
represent duplicate experiments with 4 replica wells, y-error bars= standard deviation. The table 
shows comparison o f values by paired T-test, *denotes a significant difference within 95% confidence 
limits.
Maximal stimulation with IL-1 (3 occurred at 8 hours for stable transfectants. With IL-1 P stimulation, 
AG clones produced significantly higher levels o f expression than AC.
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■  unstim U dex BIL1 OIL1/dex
G C
Comparison o f conditions for each construct
Condition 1 Condition 2 mean difference p-value
G-unstim G-dex 0.200 0.219
C-unstim C-dex 0.325 0.074
G-IL1 G-ILl/dex 4.650 0.005*
C-IL1 C-ILl/dex 0.531 <0.001*
Comparison o f constructs
Construct 1 Construct 2 mean difference p-value
G-unstim C-unstim 0.395 0.096
G-dex C-dex 0.536 0.066
G-IL1 C-IL1 4.685 0.003*
G-ILl/dex C-ILl/dex 1.751 0.002*
Figure 4.16. Comparison of dexamethasone inhibition of AG and AC pooled 
HeLa cell stable transfectants.
Pooled HeLa stable transfectants for IL-6-luciferase constructs AG or AC in 24-well plates were 
grown to -80% confluence, washed with PBS and 1ml o f 2%FCS medium ± 100U IL-1 (3 ± 10'7M 
dexamethasone added to each well. After 8 hours, cells were harvested and luciferase and total protein 
content assays carried out (see section 2.10.8). Luciferase light-emission units were normalised for 
total protein content. Results show fold change in levels o f expression compared to baseline (Ohrs). 
Results represent duplicate experiments with 4 replica wells, y-error bars= standard deviation. The 
table shows comparison of values by paired T-test, *denotes a significant difference within 95% 
confidence limits.
Dexamethasone significantly inhibited levels o f  IL-lp-induced AG and AC transcription. 
With IL-lp stimulation, AG was significantly more inhibited by dexamethasone than AC 
(p=0.01) though the -174  allelic difference was not lost. In unstimulated conditions, there 
was a trend towards AC being more inhibited by dexamethasone than AG (p=0.07).
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4.2.2. The -174 allelic effect is similar with TNFa and IL-1B induced transcription
The potential effect of the -174 polymorphism on IL-6 transcription with pro- 
inflammatory stimuli other than IL-1 was investigated using the pooled stable 
transfectants. Like IL-1, tumour necrosis factor (TNF) is another major mediator of 
inflammation and can induce IL-6 expression in vivo and in vitro. Signal transduction 
via the TNF-specific receptor, TNFR1, can activate several protein kinases in common 
to IL-1 transduction via IL-1R though the predominance of different pathways will 
vary between cell-types. This includes mitogen-activated protein kinase, MAPK 
(particularly dominant in fibroblasts), the NF-kB inhibitor, IkB kinase and the TNF- 
/IL-1 -activated P-casein kinase. In addition, TNF can activate apoptotic cell signaling. 
It has been shown that cultured cells can display a broader spectrum of IL-1-induced 
kinase activation than tissues in vivo, probably related to cells undergoing proliferation 
connecting receptors with more signaling pathways than resting or differentiated cells 
(Saklatvala et al., 1999). It was therefore important to confirm the results with a 
different inducer of IL-6. Pooled HeLa cell stable transfectants were seeded out and 
grown up as before. A dose response curve for TNFa stimulation showed lOOOU/ml to 
be within the range producing maximal stimulation of IL-6 construct expression 
(shown for AG stable transfectants in figure 4.17). A time course for stimulation with 
TNFa (lOOOU/ml) showed maximal stimulated expression of the constructs to be at 6- 
8 hours. Even with maximal stimulation, TNFa was approximately two-fold weaker at 
inducing construct transcription than IL-lp (3.7-fold compared to 8.0, p<0.001, figure
4.17). This may reflect a feature of the cells (for example fewer surface TNFR than EL- 
1R) or may reflect a feature of the TNF-signaling pathway and its effects on the IL-6 
gene.
The levels of construct transcription with TNFa were compared between pooled HeLa 
cell stable transfectants for the 1.17kb constructs GGG, AGG & AGC and the 611 bp 
constructs AG & AC. The results mirrored those for IL-1 (figure 4.18). GGG showed 
significantly higher levels of transcription than AGC with IL-1 (p=0.04) or TNFa 
(p=0.019) stimulation. This was due to the -174 allelic effect as there was no 
significant difference between GGG and AGG (p>0.1) and AG produced significantly 
higher levels of transcription than AC.
Chapter 4. Results 211 R Jeffery
IL-1 TNF
12
10
szo
t30)cnc
CD
sr.o2o
L l_
0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3 3.1 3.2 3.3
Log of dose
TNFa compared to IL-1 ft
Dose IL-1 P 
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mean difference p-value
1 0.321 0.017*
10 0.586 0.079*
50 8.69 <0.001*
100 6.895 <0.001*
200 7.523 <0.001*
500 5.458 0.002*
1000 6.392 <0.001*
2000 6.475 <0.001*
Figure 4.17. Dose response curve for TNFa and IL-ip stimulation of pooled AG  
HeLa cell stable transfectants.
Pooled HeLa stable transfectants for IL-6-luciferase construct AG in 24-well plates were grown to 
-80% confluence, washed with PBS and 1ml o f 2%FCS medium + 1, 10, 50, 100, 200, 500, 1000 or 
2000U o f TNFa or IL-1 P (shown as log o f the dose) were added to each well. After 8 hours, cells 
were harvested and luciferase and total protein content assays carried out (see section 2.10.8). 
Luciferase light-emission units were normalised for total protein content. Results show fold change in 
levels o f expression compared to baseline (Ohrs). Results represent duplicate experiments with 
duplicate wells, y-error bars= standard deviation. The table shows comparison o f values by paired T- 
test, *denotes a significant difference within 95% confidence limits.
Maximal stimulation occurred with >500U/ml TNFa and >50U/ml IL-lp with TNFa 
showing a lower maximal induction o f expression than IL-1 p.
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GGG AGG AGC G C
Comparison of constructs
Construct 1 Construct 2 mean difference p-value
GGG-unstim AGG-unstim 0.092 0.069
GGG-unstim AGC-unstim 0.012 0.378
G-unstim C-unstim 0.081 0.081
GGG-IL1 AGG-IL1 0.680 0.112
GGG-IL1 AGC-IL1 1.096 0.040*
G-IL1 C-IL1 2.437 <0.001*
GGG-TNF AGG-TNF 0.240 0.183
GGG-TNF AGC-TNF 0.527 0.019*
G-TNF C-TNF 0.665 0.002*
AGG-IL-1/TNF AGC-IL-1/TNF 0.300 0.005*
Comparison of IL-1 [3 and TNFa stimulation
Construct mean difference p-value
GGG 1.574 0.002*
AGG 1.134 <0.001*
AGC 1.005 <0.001*
G 2.078 <0.001*
C 0.306 0.134
Figure 4.18. Comparison of TNFa and IL-lp stimulation of GGG, AGG, AGC, 
AG and AC pooled HeLa cell stable transfectants.
Pooled HeLa stable transfectants for IL-6-luciferase constructs GGG, AGG, AGC, AG or AC in 24- 
well plates were grown to -80% confluence, washed with PBS and 1ml of 2%FCS medium ± 1000U 
TNFa ± 100U IL-1 p were added to each well. After 8 hours, cells were harvested and luciferase and 
total protein content assays carried out (see section 2.10.8). Luciferase light-emission units were 
normalised for total protein content. Results show fold change in levels of expression compared to 
baseline (Ohrs). Results represent duplicate experiments with 4 replica wells, y-error bars= standard 
deviation. The table shows comparison of values by paired T-test, *denotes a significant difference 
within 95% confidence limits.
GGG and AGG were significantly higher expressers than AGC, and DG than DC, with IL- 
1P or TNFa stimulation. There were no differences in unstimulated conditions.
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Of interest, with AC there was no significant difference in the levels of expression of 
IL-lp- and TNFa-stimulated transcription (p=0.134) although IL-ip-stimulated 
transcription was significantly higher for AG, GGG, AGG and AGC (p<0.002). It is 
possible that this reflects the difference in mechanisms of activation between the -174 
G and C alleles. There were no significant differences in the levels of transcription 
between constructs in unstimulated conditions (p>0.07).
Lipopolysaccharide (LPS) has been shown to be an inducer of IL-6 transcription in 
some cell types and IL-6 can induce C/EBPp expression, which could act as an auto- 
regulatoiy feed-back-loop for IL-6 expression (see section 1.3.2.2). Time course and 
dose response experiments were carried out using the pooled HeLa cell stable 
transfectants for IL-6 (up to 2000 U/ml) and LPS (up to lOOpg/ml) but did not produce 
any significant stimulation of construct transcription (p>0.1). IL-6 and LPS were 
biologically active with IL-6 (lOOOunits/ml) strongly inducing serum amyloid A- 
reporter gene constructs in HeLa cells and LPS (lOpg/ml) inducing IL-10-reporter 
gene constructs in cultured monocytes (S Cole, R Fellowes, personal communication).
4 3. Summary of transfection results
The results from the transient and stable transfections show that the -174G allele of 
IL-6 is associated with higher levels of transcription than -174C in the context of 
naturally occurring haplotypes in HeLa cells but not Huh7 cells, when induced by IL- 
ip  or TNFa. An up-stream region between -220 and -310 has modulatory effects on 
the -174 polymorphism as does inhibition by glucocorticoids. In addition, the -572 
and AT-tract polymorphisms have independent functional effects on IL-6 transcription 
with -572G associated with significantly higher levels of transcription than -572C, 
and A8T12 with higher levels than A9T11.
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CHAPTER 5 
RESULTS:
The influence of 5’-flanking region 
polymorphisms of IL-6 on transcription factor
binding
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5.1. Electrophoretic mobility shift assays
Following identification of DNA polymorphisms that alter the transcription of a gene, 
definition of protein factors that bind to these sequences is necessary to understand the 
mechanisms causing the effect of the DNA polymorphism. The first step to defining 
these interactions can be carried out by DNA electrophoretic mobility shift assay 
(EMSA). This technique involves incubation of a radiolabelled DNA probe with cell 
nuclear extracts to form DNA-protein complexes that can be resolved by 
electrophoresis on a non-denaturing polyacrylamide gel (see section 2.11 for method). 
The probe with no protein bound to it will have a high electrophoretic mobility and 
will be located at the bottom of the gel, while the probe with a protein or complex of 
proteins bound to it will migrate more slowly through the gel. The decreased 
electrophoretic mobility of the DNA-protein complex is influenced by the size, shape 
and charge of the complex and results in a location nearer the top of the gel (figure
5.1). The position of the radiolabelled DNA on the polyacrylamide gel can be 
visualised on an autoradiograph. To confirm the specificity of the protein binding to 
the radiolabelled DNA sequence, a large excess of an unlabelled DNA competitor 
sequence can be added to the binding reaction. If the unlabelled competitor sequence 
also binds the same protein(s), then this will occur preferentially as the unlabelled 
competitor is in excess. This will result in the reduction or loss of the radiolabelled 
DNA band. Addition in excess of a random, unrelated or artificial DNA sequence can 
also be used to confirm the specificity of protein binding. This should not alter the 
intensity of the radiolabelled DNA band. By using competitor DNA sequences 
containing previously established DNA binding sites for specific transcription factors 
(available through programmes such as Sigscan, see below), it can be established 
whether protein(s) bound to the DNA sequence under investigation are likely to be the 
same or related factors. Similarly, by using competitor DNA sequences that differ by 
one base (such as different polymorphic alleles) or a few bases to alter the transcription 
factor binding site, the effect on transcription factor binding efficiency can be 
compared. Once the presence of transcription factor(s) has been identified by EMSA 
competition studies, an antibody supershift can be carried out to provide further 
evidence that the specific transcription factor is involved in binding to the 
radiolabelled DNA probe. An excess of specific antibody when added to the binding 
reaction can result in one of three possible changes to the radiolabelled DNA band if 
the factor is involved in the DNA-protein complex (figure 5.1).
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Figure 5.1. Schematic representation of DNA EMSA.
Nuclear protein extracts are mixed with radiolabelled DNA probe and resolved by electrophoresis on a 
non-denaturing polyacrylamide gel (see 2.11 for method). Only bands marked by * contain radiolabelled 
probe and will be detected on an autoradiograph. *Pr=radiolabelled probe, Ex=nuclear extract, 
Comp=unlabelled competitor, Antib=specific antibody.
Lane 1= probe only, no protein binding 
Lane 2 -  probe bound by one nuclear protein 
Lane 3= probe bound by nuclear protein complex
Lane 4= nuclear protein binding to probe competed out by specific unlabelled competitor sequence, 
resulting in loss of radiolabelled band (compare with lane 2)
Lane 5= nuclear protein binding to probe not competed by unlabelled non-specific DNA sequence, 
resulting in no influence on radiolabelled band
Lane 6= radiolabelled band classically supershifted by specific antibody to a nuclear protein binding to 
the probe (compare with lane 3)
Lane 7= radiolabelled band is absent after specific antibody competition binding to a nuclear protein 
necessary for a complex o f factors to bind (compare with lane 3)
Lane 8= radiolabelled band shifted downwards by specific antibody binding a nuclear protein and 
removing it from a complex of factors that bind (compare with lane 3)
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Firstly, if  the antibody binds to the transcription factor, which in turn binds to the DNA 
probe, this will cause a decreased electrophoretic mobility of the complex resulting in 
a band position nearer the top of the gel (classic supershift). Secondly, if  the antibody 
binds to the transcription factor in such a way that the interaction with the probe is 
abolished, the radiolabelled band may be reduced or absent (antibody competition). 
This could happen if the antibody binds to or masks the binding site of the protein for 
the DNA probe or the binding site for other proteins essential as a complex for binding 
of the factor to the DNA sequence. Thirdly, the band may be shifted down the gel 
resulting from increased electrophoretic mobility, if the antibody binds to the 
transcription factor and removes it from a complex of proteins bound to the DNA 
probe.
EMSA and supershift studies were used to identify proteins that could bind to the 
specific DNA sequences at and around the polymorphic sites in the 5’-flanking region 
of IL-6 and to compare protein binding between allelic variants. Three probes were 
used to investigate the effect of the -174 polymorphism, a 26bp probe from base -164 
to -189 (designated probe 1), a 51 bp probe from base -134 to -184 (designated probe 
2) and a 75bp probe from base -161 to -235 (designated probe 3), (figure 5.2). A 75bp 
probe from base -539 to -613 (designated probe 4) was used to investigate 
transcription factor binding around the -597 polymorphism (figure 5.2). Nuclear 
protein extracts were prepared from HeLa cells, the cell type that in transfection 
studies showed functional differences for the -174 polymorphism on the levels of IL-6 
transcription (see chapter 4).
A number of computer programs have been developed that search for the presence of 
potential transcription factor binding sites in DNA sequences. The HGMP GCG 
Sigscan program (Prestridge, 1991) was used to analyse regions of the IL-6 gene 
around each polymorphic site with the different allelic sequences. This provided a 
starting point for investigation of potential binding factors at these sites. However, it is 
not exhaustive. The programme is limited by the comprehensiveness of the associated 
database, which lists consensus sequences and specific published sequences for 
transcription factors, but does not allow for degeneracy.
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Figure 5.2. EMSA probes of the 5’-flanking region of IL-6 used for transcription 
factor binding studies.
The 26bp probes (1G&1C) were obtained as complementary single-strand sequences to order from 
Gensosys. TTiese were 5’-end radiolabelled and annealed (see 2.11.2.1). The longer probes (2G&2C, 3G&3C 
and 4G&4A) were obtained as a single-strand DNA sequence to order from Genosys and the second strand 
was synthesised with integrated radiolabelled dCTP using Klenow (see 2.11.2.1). The DNA sequences of the 
probes is shown in table 2.10.
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Even if transcription factor binding-site homology is identified, this does not determine 
whether the factor (or co-factor) is present in a specific cell type or whether the factor 
will actually bind to the gene in question. Binding to a consensus sequence is 
influenced by surrounding flanking sequences.
5.1.1. EMSA probes and nuclear extracts
Double-stranded DNA probes of various lengths of the IL-6 gene sequence 
surrounding the -174 polymorphism were generated with either a G or a C allele at 
position -174 (figure 5.2). Short probes (< 30bp) were obtained as custom-made
3*7complementary single-stranded sequences that were end-labelled with y- P-ATP using 
T4 polynucleotide kinase and then annealed. Longer probes were generated using
3 '7Klenow to synthesise a second-strand containing a- P-dCTP from single-stranded 
sequences and a short primer (see 2.11.2.2). This produced long probes of high specific 
activity as required in EMSA. Attempts using Taq or Pfu DNA polymerase in a PCR 
reaction to generate double-stranded, radiolabelled probes, either failed to synthesise a
'X'Jsecond-strand (probably due to the relatively low molar ratio of a - P-dCTP compared 
to other dNTPs) or generated probes of only low radioactive specificity. The relative 
specific activity of each of the labelled probes was measured by applying 0.5pl of 1:0, 
1:10 and 1:20 dilutions of the purified working stock to a disc of 3MM Whatman paper 
and determining the counts per second (cps) at a distance of 1cm using a calibrated 
Mini-Monitor Geiger counter (GM Series 900, Mini-Instruments Ltd). Probes of 
>200cps/pl, were considered hot enough to use for EMSA studies.
Nuclear extracts were prepared from HeLa cells (section 2.11.1) that were either 
unstimulated (exposed only to media with 2% or 10% FCS) or stimulated for varying 
lengths of time with IL-lp (lOOunits/ml in media containing 2% FCS). The extracts 
were prepared in a range of salt concentrations, high salt (300mM NaCl), medium salt 
(150mM NaCl) or low salt (lOmM NaCl). This covered the range of salt 
concentrations in which most nuclear proteins are stable.
5.1.2. Optimization of EMSA conditions
For each set o f EMSA probes used, EMSA conditions were initially optimized (see 
2.11.3). Varying concentrations of poly dI.dC were pre-incubated with the extracts to
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determine the optimum concentration (lOpg) to reduce non-specific protein binding. A 
range of salt concentrations in the binding reaction buffer (0-65mM NaCl, O-lOOmM 
KC1) were compared, with little effect on the EMSA bands produced for two 
consensus probes (NF1 control and NF-kB, see table 2.11). These factors were chosen 
because they have known or putative binding sites in the IL-6 5’-flanking region 
sequence around the -174 site (see figure 5.5 and section 1.3.2). Two binding reaction 
buffers were compared; a specific nuclear factor 1 (NF1) buffer (glycerol based with 
NaCl, from Chodosh et al., 1988) and a universal Parker Buffer (ficoll based with KC1, 
see section 2.11.3). There was no difference between NF1 control EMSAs with the 
two buffers, however the NF-kB consensus EMSA was clearer with universal Parker 
buffer. Parker buffer also produced clear EMSA bands for a C/EBPp consensus probe 
from the serum amyloid A gene, as seen by Xia and co-workers (1997). Parker buffer 
was therefore used as the binding reaction buffer of choice.
EMSAs were carried out with unstimulated and IL-ip stimulated HeLa nuclear 
extracts (300mM NaCl) with the NF-kB consensus probe to confirm that IL-1 p~ 
inducible transcription factors were indeed up regulated in the stimulated extracts. 
Figure 5.3 shows this EMSA, with only one weak but specific band (d, competed out 
by cold probe) binding with unstimulated extracts and three additional bands binding 
with IL-1-stimulated extracts (a, b, c), with an increased intensity of band d. This is 
consistent with different isoforms of NF-kB being activated by IL-1 and translocating 
to the nucleus to be available for DNA consensus site binding (see section 1.3.2.1).
The EMSA for the NF1 control probe with HeLa cell extracts in Parker buffer (figure 
5.4) showed one specific band (A) that competed out with cold probe at 10-fold excess 
and one non-specific lower band (B) that did not compete out with cold probe at 50- 
fold excess. This was consistent with previously published results using this NF1 
consensus sequence (Chodosh et al., 1988). Band A was stronger with unstimulated 
HeLa cell extracts than after IL-1 stimulation suggesting that IL-1 may down-regulate 
nuclear NF1.
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Figure 5.3. EMSA of NF-kB consensus probe incubated with unstimulated and 
IL-lp-stimulated HeLa cell nuclear extracts.
5pmol radio-labelled NF-kB consensus probe (see table 2.11 for sequence) was incubated with lOpg of 
300mM NaCl HeLa nuclear extracts in Parker buffer, run on a 4% non-denaturing polyacrylamide gel at 
4°C for 3.5 hours (see 2.11). Un=unstimulated extracts, IL-1= 2-hour IL-1 P-stimulated extracts, 
Pr=probe only.
One specific band d that competed out with cold probe was seen with unstimulated extracts. 
Three additional specific bands a-c were seen with IL-1-stimulated extracts. The lower band was 
considered non-specific as it did not compete out with excess unlabelled probe.
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Figure 5.4. EMSA of NF1 control probe incubated with unstimulated and IL-lp- 
stimulated HeLa cell nuclear extracts.
5pmol radio-labelled NF1 control probe (see table 2.11) was incubated with lOpg of 300mM NaCl 
HeLa nuclear extracts pre-incubated with lOpg poly dl.dC, run on a 4% non-denaturing polyacrylamide 
gel at 4°C for 4 hours (see 2.11). Un=unstimulated extracts, IL-1= 2-hour IL-lp-stimulated extracts, 
Pr=probe only.
Band A is stronger with unstimulated than IL-1 stimulated extracts. It was shown that Band A 
could be competed out by 10-fold excess cold probe, while band B did not compete out with 
50-fold excess cold probe.
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5.2. The effect of the -174 polymorphism on transcription factor binding
Comparison of the -174G and -174C allelic sequences of IL-6 using Sigscan 
identified only one difference between the two alleles in transcription factor binding 
site homologous sequences (figure 5.5). The -174C allele created a possible NF-1 
transcription factor binding site of sequence TGGCA (bases -173 to -177), which was 
not present with the -174G allele.
Two known and several possible transcription factor binding-sites were also identified 
around the -174 polymorphic site (figure 5.5). Although these factors do not directly 
bind to the bases at position -174, allelic changes may alter their steric binding to 
nearby sequences. Further NF1 protein family binding-sequence comparisons revealed 
an alternative degenerate site for NF1. The -174C allele of IL-6 differed from the 
canonical NF1 consensus sequence by two bases, whereas the -174G allele differed by 
three bases (figure 5.6). NF1 was considered a potential regulatory transcription factor 
that could differentially bind to the -174 alleles and alter levels of transcription.
5.2.1. The -174 polymorphism does not alter transcription factor binding to a 26bp 
probe of the 5’-flanking region of IL-6
A 26bp probe of the 5’-flanking region of IL-6 from -164 to -189 was generated 
containing either the G-allele or the C-allele at position -174 (see figure 5.5), these 
were designated probes 1G and 1C respectively. The sequences for probes 1 are shown 
in table 2.10. Sigscan identified the presence of two common consensus sequences 
with either allele at position -174, a glucocorticoid receptor (GR) consensus sequence 
GACACA (Chan et al., 1991) from -179 to -184 and a c-Myb consensus sequence 
CAACT (Sureau et al., 1992) from -183 to -187. c-Myb was unlikely to be a 
candidate transcription factor in HeLa cells as it is a proto-oncogene almost 
exclusively expressed in immature haematopoietic cells and involved in their 
differentiation. The C-allele probe (1C) contained the putative NF1 consensus binding- 
site TGGCA (Paonessa et al., 1988) from -173 to -177, with this site being degenerate 
by one base with the G-allele probe. Both the C and the G allele probes were 
degenerate by two and three bases respectively for the canonical NF1 consensus 
binding sequence (figure 5.6).
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Figure 5.5. Results of HGMP Sigscan search for transcription factor binding-site homology in the 5’-flanking region of IL-6 from -134 to 
-235, with either the G or the C allele at position -174.
Purple lettering= -174 polymorphism, red lettering= known transcription factor binding-site, blue lettering= possible transcription factor binding-site, green lettering= 
possible transcription factor binding-site with the -174C allele but not with -174G, grey lettering= possible binding-site for unknown transcription factor, (+)/(-)= direction of 
binding-site consensus sequence.
NNTGGNNNNNNGCCAAN (NF1 consensus) 
CTAGTTGTGTCTTGCCATGCTAAAGG (IL-6 C-174) 
CTAGTTGTGTCTTGCGATGCTAAAGG (IL-6 G-174)
Figure 5.6. Comparison of the canonical NF1 consensus binding-site to the IL-6 
gene sequence from -171 to -186.
The -174C allele differs from the consensus sequence by two bases, whereas the -174G allele 
differs by three bases.
Underlined letteririg=NF1 consensus binding-site sequence (Chodosh et al., 1988; Jones et al., 1987). 
Red lettering=mis-matched base in the IL-6 sequence
Figure 5.7 shows the EMSA with probes 1G and 1C with HeLa cell nuclear extracts. 
Although several bands are produced with either probe and a lower band Z appears 
with probe 1C but not probe 1G, these bands were not competed out by excess cold 
probe up to 50 times the concentration of radio-labelled probe and were therefore 
unlikely to be specific bands. Probes 1G and 1C may have been too short to allow 
protein binding. Protein binding to specific DNA sites is not only dependent on the 
DNA base sequence of the consensus site but also in the context of adjacent DNA 
sequences. These will influence the tertiary structure of DNA helical turns, the 
exposure of specific DNA bases, hydrophobic, steric and electrophysiological forces, 
and co-factor binding.
5.2.2. The -174 polymorphism alters transcription factor binding to a 51bp probe of 
the 5’-flanking region of IL-6
Longer probes of the IL-6 sequence surrounding the -174 polymorphism were 
generated to investigate whether the -174 alleles altered transcription factor binding to 
adjacent transcription factor sites. A 51 bp probe from -134 to -184 with either a G or a 
C allele at position -174 were designated 2G and 2C respectively (see figure 5.5 and 
table 2.10 for sequence). These included the known down-stream transcription factor 
binding-sites of IL-6, the cAMP response element TGACGT from -158 to -163, the 
C/EBPp site ACATTGCACAATCT from -146 to -158 and a GR binding site between 
-145 and -173. The probe also contained part of the negative regulatory region from 
-73 to -181 with an Spl transcription factor consensus site TGCAC between -150 and 
-154. In THP-1 cells, Spl has been shown to be part of a negative regulatory complex 
interacting with this region of the IL-6 gene.
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Figure 5.7. EMSA of IL-6 probes 1G and 1C incubated with unstimulated and IL- 
lp-stiniulated HeLa cell nuclear extracts.
5pmol radio-labelled probe was incubated with lOpg of 300mM NaCl extracts pre-incubated with lOpg 
poly dl.dC, run on a 4% non-denaturing polyacrylamide gel at 4°C for 4 hours (see 2.11). Un= 
unstimulated extracts, IL-1= 2-hour IL-1 (3-stimulated extracts, Pr= probe only.
Band Z was only seen with probe 1C, however, neither this band nor the upper two bands 
common to both probes competed out with 50-fold excess cold probe.
A time course for unstimulated and IL-1 p-stimulated HeLa extracts (300mM NaCl) 
binding to probes 2G and 2C, revealed maximal up-regulation of transcription factor 
binding to these probes with 30min IL-1 p-stimulated extracts (figure 5.8). HeLa 
nuclear cell extracts stimulated by IL-1 p for 30min were therefore used in subsequent 
experiments to compare the banding pattern and specificity of transcription factor 
binding to the G and C allele probes. This was carried out with HeLa cell nuclear 
extracts at three salt concentrations, lOmM, 150mM and 300mM NaCl (see methods
2.11.1). In all three salt concentrations, probe 2G had two distinct upper bands C and 
D, whereas probe 2C produced only one distinct upper band that was equivalent in 
position to band C with probe 2G (figure 5.9). There were also two lower bands G and 
H with both probes.
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Figure 5.8. EMSA of IL-6 probes 2G and 2C incubated with unstimulated and 
increasing times of IL-ip-stimulated HeLa cell nuclear extracts.
5pmol radio-labelled 2G or 2C probe was incubated with 12pg o f 300mM NaCl extracts pre-incubated 
with lOpg poly dl.dC and run on a 4% non-denaturing polyacrylamide gel at 4°C for 4 hours (see 2.11). 
Un= unstimulated extracts, IL-1 = IL-lp-stimulated extracts for given length o f time, Pr= probe only, 
unlabelled arrows indicate bands induced or up-regulated by IL-1 [3.
Transcription factor binding was maximally up regulated with IL-1 stimulation for 30mins.
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Figure 5.9. EMSA of IL-6 probes (a) 2G and (b) 2C incubated with 30min IL-ip- 
stimulated HeLa cell nuclear extracts (lOmM NaCl) with competition from 
unlabelled 2G or 2C probe.
Radiolabelled probe* (5pmol) was mixed with the indicated ratio o f unlabelled probe, incubated with 
10pg o f lOmM NaCl extracts pre-incubated with poly dl.dC (lOpg) and run on 4% non-denaturing 
polyacrylamide gels at 4°C for 4 hours (see 2.11 for method). Unbound probe was run to the bottom of 
the gel. Red lettering= radio-labelled probe, blue lettering= unlabelled competitor probe. The ratio of 
radiolabelled to unlabelled probe is shown at the bottom of each lane.
Band C was common to both probes. With probe 2G, a lower ratio of unlabelled probe 2C was 
required to compete out band C than unlabelled probe 2G. Band D occurred with probe 2G and 
only required low ratios of unlabelled probe 2G or 2C to compete it out. Bands G and H were 
common to both probes.
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Band D was competed out at very low ratios of cold competition by either cold probe 
2G or 2C, despite probe 2C not producing this band. This suggested that band D was a 
non-specific band forming when the G allele was present and this was confirmed by 
cold competition with random probe (a universal heteroduplex generator for an exonic 
sequence of EL-4 receptor, see table 2.11). Random probe competed out band D but not 
the specific band C (figure 5.10). With 150mM NaCl HeLa extracts there was an 
additional lower band (I) produced on EMSA (figure 5.10), both this and band G were 
non-specific bands as they were competed out with random probe.
Band C appeared to be stronger with probe 2C than 2G. With radiolabelled probe 2G, 
lower ratios of the C allele competitor probe (20-fold of 2C) than the G allele 
competitor probe (50-fold of 2G) were required to compete out band C (figure 5.9). 
Similarly, in figure 5.10, a 20-fold excess of the C allele competitor probe (2C) was 
able to compete out band C for the 2G probe, but a 20-fold excess of the G allele 
competitor probe (2G) failed to do so. In an attempt to reduce non-specific protein 
binding, the EMSA binding reaction was carried out at the higher temperature of 21°C 
instead of 16°C (figure 5.11). Band D was no longer seen to form with probe 2G. 
However, band C remained stronger with probe 2C and higher ratios of unlabelled 
probe 2G than 2C were required to compete out band C.
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Figure 5.10. EMSA of IL-6 probe 2G with 30min IL-1 p-stimulated HeLa cell nuclear 
extracts (150mM NaCl).
(a) specific competition with increasing amounts of unlabelled 2G and 2C probe, (b) random 
competition with 20-fold random probe on radiolabelled probe 2G and 2C.
Radiolabelled probe* (5pmol) with the indicated ratio o f unlabelled probe was incubated with lOpg of  
150mM NaCl HeLa extracts pre-incubated with poly dl.dC (lOpg) and run on a 4% non-denaturing 
polyacrylamide gel at 4°C for 4 hours (see 2.11 for method). U= unbound probe, R= random probe (a 
universal heteroduplex generator for an exonic sequence of IL-4 receptor, table 2.11), red lettering= 
radiolabelled probe, blue letterings unlabelled competitor probe. The ratio of radiolabelled to unlabelled 
probe is shown at the bottom of each lane.
Non-specific bands D, G and I are competed out by random probe. Specific band C is not 
competed out by random probe. Band C is stronger with probe 2C than 2G. 20-fold unlabelled 
probe 2C competes out band C completely from radiolabelled probe 2G, whereas band C is still 
seen with competition from 20-fold of unlabelled probe 2G.
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Figure 5.11. EMSA of IL-6 probes 2G and 2C incubated with 30min IL-1 [3- 
stimulated HeLa cell nuclear extracts at 21°C with specific competition,
(a) increasing amounts of unlabelled probe of the same allele as the radiolabelled probe, (b) 
increasing amounts of unlabelled probe of the other allele from radiolabelled probe, (c) probe only, 
with no nuclear extracts or competition.
Radio-labelled probe* (5pmol) was mixed with the indicated ratio of unlabelled probe, incubated with lOpg 
of 300mM NaCl extracts pre-incubated with poly dl.dC (lOpg) and run on 4% non-denaturing 
polyacrylamide gels at 4°C for 4 hours (see 2.11 for method). R= random probe (see table 2.11), U= 
unbound probe, red lettering= radiolabelled probe, blue lettering= unlabelled competitor probe. The ratio of 
radiolabelled to unlabelled probe is shown underneath each lane.
Band C is consistently stronger with probe 2C than 2G. Competition of radiolabelled probe 2C 
with 50-fold excess unlabelled probe 2C but not probe 2G competed out band C. Competition of 
radiolabelled probe 2G with 10-fold excess unlabelled probe 2C but not probe 2G competed out 
band C. Band G was non-specific.
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Cold competition with unlabelled probe 2C or 2G added after the initial 20min binding 
reaction with radiolabelled probe also resulted in competition of band C from both 
probe (figure 5.12). This supports band C being a probe specific band, and the results 
support probe 2C being a stronger competitor than probe 2G. There was complete loss 
of band C for radiolabelled probe 2G with addition of 20-fold of the C allele 
competitor probe (2C), however band C was still faintly visible with addition of 20- 
fold of the G allele competitor probe (2G), (figure 5.12). With the radiolabelled probe 
2C, band C was stronger after addition of 20-fold of the G allele competitor probe than 
after addition of 20-fold of the C allele competitor probe.
The results shown are representative of five separate preparations of labelled and 
unlabelled probes, and three separate preparations of nuclear extracts at three different 
salt concentrations. They show that a nuclear factor, or complex of factors, binds to the 
IL-6 sequence between -134 and -184 producing band C on EMSA under a range of 
conditions. The -174C allele appears to bind this factor(s) more strongly than the -  
174G allele. Since the C allele was found to be associated with lower levels of 
expression with IL-lp-stimulation than the G allele in HeLa cell transfection studies 
(see chapter 4), it was hypothesised that the factor(s) binding more strongly to the C 
allele sequence would have an inhibitory influence on transcription. Since band C was 
present in unstimulated as well as IL-1 p-stimulated extracts, the transcription factor 
must be constitutively expressed in HeLa cells. To account for the transfection study 
results, the factors) would have to be down regulated in the nucleus by IL-lp- 
stimulation, but removed less effectively from the C allele sequence than from the G 
allele sequence due to stronger binding to the C allele sequence.
There was one lower band H produced consistently on EMSA that was not competed 
out by random probe. It was however, also not competed out by unlabelled specific 
competitor probe up to 50-fold excess, suggesting that this band was probably non­
specific.
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Figure 5.12. EMSA of IL-6 probes 2G and 2C incubated with (a) 30min IL-lp- 
stimulated HeLa cell nuclear extracts or (b) unstimulated (UN) HeLa cell nuclear 
extracts.
Competition in (a) was with 20-fold unlabelled competitor probe either added with (w) or after 
(a) the radiolabelled probe binding reaction.
5pmol of radio-labelled probe* was used for each reaction. A 20min incubation with lOpg o f 150mM 
NaCl HeLa extracts, pre-incubated with poly dl.dC (1 Opg) was carried out at 21°C with either 20-fold 
unlabelled competitor for ‘with’ reactions, or no competitor for ‘after’ reactions. For ‘after’ reactions 
20-fold unlabelled competitor was added after the initial binding reaction and incubated for a further 
20min at 21°C before running on a 4% non-denaturing polyacrylamide gel at 4°C for 4hrs (see 2.11). 
Red letterings radiolabelled probe, blue letterings unlabelled competitor. The ratio of radiolabelled 
probe to unlabelled competitor is shown underneath each lane. U= unbound probe. R= random probe 
(see table 2.11).
Band C is stronger for probe 2C than 2G, with IL-1-stimulated and unstimulated HeLa 
extracts. Band C is not competed out by random probe but is competed out by unlabelled probe 
2G or 2C, added ‘with’ or ‘after’ radiolabelled probe. With 20-fold excess of the 2C 
competitor probe added ‘after’ radiolabelled probe 2G, band C is no longer seen. However, 
with 20-fold excess of the 2G competitor probe added ‘after’ radiolabelled probe 2G, band C is 
still faintly visible. With 20-fold competitor probe 2C added ‘after’ radiolabelled probe 2G 
band C is weaker than when 20-fold competitor probe 2G was added. Band G is a non-specific 
band.
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5.2.3. The possible role of NF1 in altered transcription factor binding between -174 
alleles in a 51 bp probe of IL-6
The possibility that the factor, or one of a complex of factors, producing band C on 
EMSA with probes 2G and 2C (see above) could be NF1 was investigated. Dependent 
on the gene they act on, members of the NF1 family of transcription factors have been 
shown to display both transcription repressor and activator function. In the human 
metallothionein HA gene, NF1 has been shown to act as a transcriptional repressor 
(Osada et al., 1997b), which was also the case with rat hepatic aldehyde 
dehydrogenase 3 (Lindahl et al., 1999). However, in the rat aib adrenergic receptor 
gene, NF1 has been shown to act as a transcriptional activator (Gao et al., 1996), as 
with adenoviral RNA polymerase II (Jones et al., 1987). The -174C allele contains an 
NF1 consensus binding-site. It was plausible that NF1 could bind preferentially to the 
C allele producing a stronger band on EMSA. As the C allele resulted in lower levels 
of IL-1-induced IL-6 transcription in HeLa cell transfection studies, the hypothesis was 
that if NF1 was involved it was likely to have inhibitory influences on transcription in 
the context of the human IL-6 gene. Western blot analysis of unstimulated and IL-1- 
stimulated HeLa nuclear cell extracts confirmed the presence of NF1 in these extracts 
(figure 5.13), although there were also some lower molecular-weight proteins detected. 
These were probably degraded NF1 protein fragments resulting from the method of 
preparation of nuclear extracts. The samples were dounce homogenised to rupture the 
cellular membrane and although this was carried out on ice, the friction generated may 
have resulted in heat production causing fragmentation of some nuclear proteins. 
Alternatively, proteolytic cleavage may have resulted in some fragmentation of the 
protein products, despite the presence of protease inhibitors in the buffers. Several 
species of C/EBP (3 have been found to arise from proteolytic degradation during 
extract preparation (Vales and Friedl, 2002). Protein fragments are less likely to bind 
specifically to DNA or form complexes with other bound proteins. As these fragments 
are smaller, they would be expected to have a higher electrophoretic mobility if they 
bound to DNA and to pass faster through the gel (it is possible that this accounts for 
some of the non-specific lower bands seen on EMSA). The salt concentration of the 
extracts may additionally influence protein stability.
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Equal quantities of total nuclear protein extracts were applied to the Western blot for 
unstimulated and IL-lp-stimulated extracts. NF1 formed a smaller proportion of the 
total protein in IL-lp-stimulated extracts compared to unstimulated extracts. This 
would suggest that NF1 levels are not significantly up regulated by IL-1-stimulation 
and may be inhibited.
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Figure 5.13. Western blot for NF1 in unstimulated and IL-lp-stimulated HeLa 
cell nuclear extracts.
5|ig o f nuclear extract was applied per lane. NF1 was detected using primary antibody Sc-870 rabbit 
polyclonal anti-NFl antibody (table 2.12), secondary antibody HRP-conjugated porcine anti-rabbit IgG 
polyclonal antibody (table 2.13) and detected by chemiluminescence (see 2.12.3 for method).
Lane 1 ^unstimulated extracts (150mM NaCl), lane 2 =30min IL-ip-stimulated extracts (150mM NaCl), 
lane 3 =30min IL-ip-stimulated extracts (300mM NaCl), L=ladder of protein molecular weight markers 
(Benchmark, Gibco). —► = protein band for NF1 according to molecular weight. Lower bands probably 
represent degradation products.
Two unlabelled competitor sequences of NF1 consensus binding sites were used to 
investigate the possible binding of NF1 to produce band C on EMSA with the 51 bp 
probes 2G and 2C (see 5.2.2). NF1 consensus 1 (NF1-1) competitor contained the 
canonical consensus sequence for NF1 (see table 2.11), present with two base 
differences in the C allele probe (2C) and three in the G allele probe (2G). NF1 
consensus 2 (NF1-2) competitor contained the short consensus sequence TGCCA (see 
table 2.11), present with the C allele but not with the G allele. Figure 5.14 shows that 
both NF1-1 and NF1-2 competitor probes could compete band C for radiolabelled 
probes 2G and 2C.
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Figure 5.14. Cold competition with NF1 consensus sequences for IL-6 probes 2G
and 2C incubated with 30min IL-lp-stimulated HeLa cell nuclear extracts.
Radiolabelled probe* (5pmol) was mixed with the indicated ratio of unlabelled NF1 consensus 1 (NF1- 
1) or NF1 consensus 2 (NF1-2) competitor (see table 2.11 for sequences), incubated with lOpg of 
150mM NaCl HeLa extracts pre-incubated with poly dl.dC (lOpg), and run on a 4% non-denaturing 
polyacrylamide gel at 4°C for 4 hours (see 2.11 for method). Red letterings radiolabelled probe, blue 
letterings unlabelled competitor, the ratio of radiolabelled to unlabelled is indicated underneath each 
lane.
Band C was competed out by both the NF1-1 and NF1-2 competitor sequences.
This suggested that NF1 may be involved in binding to the 2G and 2C probes to 
produce band C. However, supershift studies with a monoclonal antibody to the NF1 
family of proteins did not result in a shift (figure 5.15). Antibody incubations of 15- 
60min, at 4°C as well as at room temperature (21°C) were carried out with antibody 
concentrations of 100-300ng per pi of reaction, added before or after incubation of 
extracts with the radiolabelled probe. Under similar conditions as a positive control, it 
was shown that the same anti-NFl antibody resulted in a shift with radiolabelled NF1- 
1 consensus probe (figure 5.16). This confirmed that NF1 bound to the NF1-1 
consensus probe and that supershift conditions were suitable. The band ‘f  and ‘h’ did 
not compete out with cold probe suggesting that they were probably produced by non­
specific protein binding. The lower band ‘g’ did compete out with cold NF1-1 probe, 
but not with random probe, suggesting that this was a specific band. This band was not 
shifted however by anti-NFl antibody and may therefore have been due to an 
additional transcription factor binding to the sequence of the NF1-1 probe.
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Figure 5.15. Supershift EMSA of IL-6 probes 2G and 2C with monoclonal 
antibody to NF1.
Radiolabelled probe* (5pmol) was mixed with the indicated ratio of unlabelled competitor NF1-1 (table
2.11) and incubated with lOfig of HeLa nuclear extracts (150mM NaCl), pre-incubated with poly dl.dC 
(lOfig), (see 2.11 for method). For supershift reactions, 3pl o f anti-NFl antibody sc-870 (300ng/jil, table
2.12) was added either before or after radioiabelled probe and incubated at 21°C for 20min (see method 
2.11.4). Reactions were run on a 4% non-denaturing polyacrylamide gel at 4°C for 4hrs. Red letterings 
radiolabelled probe, blue letterings unlabelled competitor, green letterings specific antibody added. The 
ratio o f radiolabelled probe to unlabelled competitor is indicated underneath each lane, ‘b’ and ‘a’ refer 
to whether antibody was added before or after radiolabelled probe. UN= unstimulated HeLa nuclear 
extracts, IL-H 30min IL-ip-stimulated HeLa nuclear extracts.
Band C was competed by NF1-1 competitor probe, but no shift was seen with antibody to NF1 
whether added b e f o r e  or a f t e r  the binding reaction with radiolabelled probe.
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Figure 5.16. Supershift EMSA of NF1-1 consensus probe with monoclonal 
antibody to NF1.
Radiolabelled probe* (5pmol) was mixed with the indicated ratio of NF1-1 unlabelled competitor or 
random competitor R (see table 2.11 for sequences) and incubated with 10pg of HeLa nuclear extracts 
(150mM NaCl), pre-incubated with poly dl.dC (lOpg), (see 2.11 for method). For supershift reactions, 
3pl of anti-NFl antibody sc-870 (300ng/pl, table 2.12) was added before radiolabelled probe and 
incubated at 21°C for 20min (see 2.11.4). Reactions were run on a 4% non-denaturing polyacrylamide 
gel at 4°C for 4hrs. Blue lettering= unlabelled competitor, the ratio to radiolabelled probe is indicated 
underneath each lane, green lettering= specific antibody added. UN =unstimulated HeLa extracts, IL-1= 
30min IL-1 ^-stimulated HeLa extracts, PR= probe only.
The NF1 band was competed by NF1-1 competitor probe but not random competitor. It was 
shifted (lost) with antibody to NF1. Band g was competed out by NF1-1 competitor but not 
shifted by anti-NFl antibody. Bands f  and h were probably due to non-specific protein 
binding.
No alternative antibody to NF1 was available to investigate further the possibility of 
NF1 binding to probe 2G or 2C. It is possible that steric interactions between antibody 
and protein were hindered by the presence of other proteins in a complex. Despite 
competition from the NF1 consensus sequences, no definite conclusion can be drawn 
as to whether NF1 is involved in binding to probe 2G or 2C to produce band C (section
5.2.2).
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5.2.4. CREB interacts equally with probes 2G and 2C
Adjacent to the -174 polymorphism in the IL-6 gene, there is a cyclic AMP response 
element (CRE) from -158 to -163 (ACTGCA, figure 5.5). This site confers an 
enhancer effect on IL-6 transcription as demonstrated by site-directed mutagenesis 
studies (Dendorfer et al., 1994). A family of CRE binding proteins (CREB) can bind 
CRE sites and include CREB-1 and ATF-1 with transactivating function, and CREM 
and ICERs with inhibitory functions (see section 1.3.2.3). The possibility of CREB 
being present as part of a complex forming EMSA band C with probes 2G and 2C (see
5.2.2) was investigated using competition studies with a CREB consensus sequence 
competitor (table 2.11) and in supershift studies with two specific anti-CREB 
antibodies (table 2.12). CREB did not appear to be involved in band C as consensus 
probe did not compete the band, nor antibodies to CREB-1/ATF-1 family members 
produce a shift of the band. However, CREB binding to the IL-6 sequence in probes 
2G and 2C was confirmed. Anti-CREB antibodies resulted in an upward shift o f a 
lower band to form two supershifted bands (bands i and j, figure 5.17). This may 
represent binding of two distinct members or forms of CREB (such as phosphorylated 
and unphosphorylated forms). This could also represent alteration of another bound- 
factor, or complex of factors, following removal of CREB. The co-factor CREB 
binding protein (CBP) only binds to the phosphorylated form of CREB and would be 
expected to be lost from a protein complex on removal of phosphorylated CREB. 
CREB was presumed to be binding at the known CREB site between -158 and -163. 
The -174 G and C alleles did not appear to affect CREB binding. Western blot 
analysis confirmed the presence of CREB-l/ATF-1 (43kD) in the IL-ip-stimulated 
HeLa cell nuclear extracts, with lower levels present in unstimulated cells (figure
5.18).
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Figure 5.17. Supershift EMSA of IL-6 probes 2G and 2C with antibody to CREB.
Radiolabelled probe* (5pmol) was incubated with lOpg of 30min IL-l|3-stimulated HeLa cell nuclear 
extracts (150mM NaCl), pre-incubated with poly dl.dC (10pg). 3pl o f anti-CREB antibody sc-186 or 
sc271 (300ng/pl, table 2.12) was added before radiolabelled probe and incubated at 21°C for 20min (see 
methods 2.11.4). The indicated ratio of unlabelled random competitor (R, see underneath lane) was 
mixed with radiolabelled probe. Reactions were run on a 4% non-denaturing polyacrylamide gel at 4°C 
for 4.5hrs. Red lettering = radiolabelled probe, blue lettering = unlabelled random competitor, green 
lettering = specific antibody added.
Band C is not shifted by antibody to CREB, but a shift o f lower bands is seen to produce bands 
i and j.
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Figure 5.18. Western blot for CREB in unstimulated and IL-lp-stimulated HeLa 
cell nuclear extracts.
5pg o f HeLa cell nuclear extract was applied per lane. CREB was detected using primary antibody Sc- 
271 mouse anti-CREB monoclonal antibody (table 2.12), secondary antibody HRP-conjugated rabbit 
anti-mouse polyclonal antibody (see table 2.13), followed by chemiluminescent detection (see 2.12.3 for 
method).
Lane 1= unstimulated extracts (150mM NaCl), lane 2 =30min IL-ip-stimulated extracts (150mM NaCl), 
lane 3=30min IL-l(3-stimulated extracts (300mM NaCl), L=ladder of protein molecular weight markers 
(Benchmark, Gibco). —►= protein band for CREB according to molecular weight.
5.2.5. C/EBPB is involved in differential binding o f  a transcription factor com plex to
probes 2G and 2C
A known binding site for C/EBP(3 (TCTAACACGTTACA) occurs between bases -  
146 to -156 of the 2G and 2C probes (see figure 5.5). To investigate whether C/EBPp 
could be involved in a transcription factor complex producing EMSA band C with 
probes 2G and 2C (see 5.2.2) cold competition studies were carried out with C/EBP 
consensus sequence (table 2.11) and supershift studies with two anti-C/EBP 
antibodies, one specific for C/EBPp (table 2.12). Figure 5.19 shows that the C/EBP 
consensus probe competed band C, more apparent with probe 2G than 2C. Addition of 
anti-C/EBP and anti-C/EBPp antibodies before the binding reaction resulted in a 
reduction in band C with both probes (figure 5.19). This indicates the involvement of 
C/EBPp in EMSA band C. As band C was diminished but not lost by addition of 
antibody, some complex formation/binding was still able to occur. This could have 
been due to antibody concentration (though 300ng/pl is generally considered to be in 
excess of most nuclear protein concentrations) or due to antibody affinity for C/EBP. 
Alternatively, it could suggest that C/EBPp has a synergistic role in the complex
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formation or contributes to the stability of complex binding, when it is bound to its 
binding site, and may not be essential to complex formation. Antibody added after the 
binding reaction did not alter band C.
C/EBPp was present in the nuclear extracts and as expected was up regulated in IL-lp- 
stimulated extracts as demonstrated by Western blot analysis (figure 5.20).
2G 2C 2G 2C 2G 2C 2G 2C 2G 2C 
C/EBP C/EBP C/EBP C / E B P .................................................
sc-150 sc-150 sc-746 sc-746
1*:5 1*:5 1*:20 1*:20 1*:0 1*:0 1*:0 1*:0 1*:0 1*:0
Figure 5.19. Supershift EMSA of IL-6 probes 2G and 2C with antibody to C/EBP 
and C/EBPp.
Radiolabelled probe* (5pmol) was incubated with lOpg o f 30min IL-ip-stimulated HeLa cell nuclear 
extracts (150mM NaCl), pre-incubated with poly dl.dC (lOpg). 3pl o f anti-C/EBP(3 antibody sc-150 or 
anti-C/EBP antibody sc746 (300ng/fil, table 2.12) was added before radiolabelled probe and incubated 
at 21°C for 20min (see methods 2.11.4). For cold competition, unlabelled C/EBP consensus probe (table 
2.11) was mixed with radiolabelled probe in the ratio indicated underneath each lane. Reactions were 
run on a 4% non-denaturing polyacrylamide gel at 4°C for 4.5hrs. Red letterings radiolabelled probe, 
blue letterings unlabelled competitor, green letterings specific antibody added.
Band C was competed by unlabelled C/EBP consensus sequence, more noticeable for probe 
2G than 2C. Band C was reduced by the addition o f antibody to C/EBP and C/EBPp.
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Figure 5.20. Western blot for C/EBPp in unstimulated and IL-l(3-stimulated 
HeLa cell nuclear extracts.
5pg o f HeLa cell nuclear extract was applied per lane. C/EBPP was detected using primary antibody sc- 
150 rabbit polyclonal anti-C/EBPP antibody (table 2.12), secondary antibody HRP-conjugated porcine 
anti-rabbit IgG polyclonal antibody (table 2.13) and chemiluminescent detection (see method 2.12.3). 
Lane l=unstimulated extracts (150mM NaCl), lane 2=30min IL-ip-stimulated extracts (150mM NaCl), 
lane 3=30min IL-ip-stimulated extracts (300mM NaCl), L=ladder of protein molecular weight markers 
(Benchmark, Gibco). —►= protein band for C/EBPP according to molecular weight.
5.2.6. Other candidate factors for differential binding to probes 2G and 2C 
An alternative inhibitory factor with a known binding site within probes 2G and 2C 
was glucocorticoid receptor. The known binding site, demonstrated by in vitro foot- 
printing (Ray et al., 1990), occurs between bases -152 to -170. There is also a putative 
binding site from consensus sequence comparison between -179 and -184 (figure 5.5). 
However, transfection studies showed that glucocorticoids resulted in greater 
inhibition of transcription with the -1 74G rather than the C allele in HeLa cells, with 
resultant loss in the differential effects of the two alleles (see section 4.1.8). This 
would be against GR involvement in band C as the band was stronger for the C allele 
probe than the G allele probe. Functionally GR may have an important role in protein- 
protein interactions with NF-kB and C/EBP, or via competition for co-factors such as 
CBP, rather than direct DNA binding (see section 1.3.2.5). GR was therefore 
considered unlikely to be involved in production of band C with probes 2G and 2C.
The ubiquitously expressed transcription factor Spl has a putative binding site within 
the sequence of probes 2G and 2C between bases -150 and -154 (figure 5.5). In THP1 
cells (human monocyte cell line) Spl has been shown to be involved in a complex of
45kD
m
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factors binding to a region between -73 and -181 of the human IL-6 sequence 
(Sanceau et al., 1995, and see section 1.3.2.8). Spl is associated with constitutive 
activation of genes that bind this factor, although an additional regulatory role in 
induced levels of expression of such genes may occur via the binding of other Sp 
family members to an Spl site (Lania et al., 1997). Cold competition with an Spl 
consensus binding site sequence (see table 2.11) did not alter nuclear factors binding to 
the 2G or 2C probes.
Co-factors, such as CBP, may be involved via protein-protein interactions in the 
complex forming band C with probes 2G and 2C (see 5.2.2). These would be expected 
to bind in association with a DNA bound transcription factor with which they interact.
5.2.7. The -174 polymorphism does not alter transcription factor binding to the 
negative regulatory domain of IL-6
To investigate whether the -174 polymorphism altered any transcription factor binding 
to the up stream negative regulatory domain (NRD) of the IL-6 gene (from -164 to -  
225, see section 1.3.2.3), probes 3G and 3C were used (see figure 5.2). Probes 3G and 
3C consisted of a 75bp sequence of IL-6 from -161 to -235, with a G or C allele at 
position -174, respectively (see table 2.10 for sequences). This sequence included a 
region between -201 and -210 known to bind GR (Ray et al., 1990). Probes were 
labelled by Klenow synthesis of a second-strand containing a  P-dCTP, from a single- 
strand template and primer sequence (see section 2.11.2.2 for method). EMSA studies 
were carried out with unstimulated and IL-1 p-stimulated HeLa cell nuclear extracts of 
10 and 300mM NaCl salt concentration.
With lOmM NaCl extracts, an IL-1 inducible band was seen with 30min to 2hrs IL-ip- 
stimulated extracts, but diminished by 3hrs (band J, figure 5.21). With 300mM NaCl 
extracts, two additional IL-ip-induced bands were seen (bands K and L, figure 5.22). 
Band L runs slightly higher than an equivalent band produced by the unstimulated 
extracts and could represent an additional transcription factor binding after IL-lp- 
stimulation to a complex present in the unstimulated conditions.
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Figure 5.21. EMSA of IL-6 probes 3G and 3C incubated with unstimulated and 
increasing times of IL-lp-stimulated HeLa cell nuclear extracts (lOmM NaCl).
5pmol radiolabelled 3G or 3C probe was incubated with 12pg o f lOmM NaCl extracts pre-incubated 
with lOpg poly dl.dC and run on a 4% non-denaturing polyacrylamide gel at 4°C for 4.5hrs (see 2.11 for 
method).
Un= unstimulated extracts, IL-1= IL-l(3-stimulated extracts for given length of time, Pr= probe only. 
m= non-specific band (could be competed out by 20pg polydl.dC). Unlabelled (grey) arrows indicate 
specific bands present in unstimulated and IL-1-stimulated extracts (could not be competed out by 
increasing concentrations of polydl.dC but could be competed out by increasing concentrations of  
unlabelled probe 3G or 3C). U= unbound probe.
A specific band J was produced with IL-lp-stimulated extracts 30min-2hrs and diminished by 
3hrs, not present with unstimulated extracts. There was no difference between the G and C 
allele probes.
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Figure 5.22. EMSA of IL-6 probes 3G and 3C incubated with unstimulated and 
increasing times of IL-ip-stimulated HeLa cell nuclear extracts (300mM NaCl).
5pmol radiolabelled 3G or 3C probe was incubated with 12pg o f 300mM NaCl extracts pre-incubated 
with 10pg polydl.dC and run on a 4% non-denaturing polyacrylamide gel at 4°C for 4.5hrs (see 2.11 for 
method).
Un= unstimulated extracts, IL-1 = IL-ip-stimulated extracts for given length of time, Pr= probe only. m= 
non-specific band (could be competed out by random probe). Unlabelled (grey) arrows indicate specific 
bands present in unstimulated extracts (could not be competed out by random probe but could be 
competed out by increasing concentrations o f unlabelled probe). U= unbound probe.
Three specific bands J (same position as for lOmM extracts, figure 5.21), K and L (not seen 
with lOmM extracts) were produced with IL-lp-stimulated extracts (300mM NaCl). These 
bands were not seen in unstimulated extracts. Other specific bands present in the unstimulated 
extracts were not seen in the IL-1 p-stimulated extracts. There was no difference between the G 
and C allele probes.
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The upper most band ‘m’, seen with lOmM and 300mM NaCl extracts, was a non­
specific band competed out by random probe (table 2.11). Specificity of the other 
bands was confirmed by non-competition with random probe and competition with 
increasing concentrations of unlabelled 3G or 3C probe. EL-ip-inducible bands J, K 
and L were seen from 30min to 3hrs of stimulation. There was no difference between 
the -174G and C allele probes.
Consensus binding sites for three known transcription factors occur within the 
sequence of probes 3G and 3C (figure 5.5). A GR binding site from -201 to -210 
described by Ray et al., (1990), a GR consensus site GACACA from -179 to -184, an 
Spl consensus site CACGT from -198 to -202 and an NF1 consensus site TGGCA 
from -173 to -177 (with the -174C allele). Binding of these transcription factors was 
investigated by cold competition with specific transcription factor consensus sequences 
(table 2.11). There was no evidence that these factors bound to probe 3G or 3C as no 
competition was obtained with the consensus sequence probes for these factors (shown 
for the GR consensus probe, figure 5.23). Supershift studies with two anti-GR 
antibodies (table 2.12) did not produce any shift indicating that GR binding was 
unlikely to be present under these conditions with HeLa extracts. Glucocorticoid was 
present in the HeLa extracts and was reduced in IL-ip-stimulated extracts compared to 
unstimulated extracts as seen on Western blot analysis (figure 5.24).
The finding that IL-ip-inducible factors bind to a region of IL-6 that has previously 
been shown to be a negative regulatory domain, is of significant interest. As IL-lp 
induces IL-6 transcription, one might expect IL-lp stimulation to reduce rather than 
induce transcription factor binding in a negative regulatory region. The identity of 
these EMSA bands were not investigated further within the scope of this thesis as there 
was no observed differences between the -174G and C alleles to account for the 
functional allelic effects of this polymorphism seen in transfection studies (see chapter
4).
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Figure 5.23. Cold competition with GR consensus sequence for IL-6 probes 3G 
and 3C incubated with lhour IL-ip-stimulated HeLa cell nuclear extracts 
(300mM NaCl).
Radiolabelled probe* (5pmol) was mixed with the indicated ratio of unlabelled GR consensus sequence 
competitor (see table 2.11 for sequences), incubated with 10pg of 300mM NaCl HeLa extracts pre­
incubated with polydl.dC (lOpg), and run on a 4% non-denaturing polyacrylamide gel at 4°C for 4.5hrs 
(see 2.11 for method). Red lettering= radiolabelled probe, blue lettering= unlabelled competitor, the 
ratio of radiolabelled to unlabelled probe is indicated underneath each lane. GR=glucocorticoid receptor 
consensus sequence, R= random probe, U= unbound probe, Pr= probe only, m= non-specific upper 
band, unlabelled (grey) arrows indicate other specific lower bands present with unstimulated and IL-1- 
stimulated extracts.
None o f the bands were competed out by GR consensus sequence or random probe.
Chapter 5. Results 249 R Jeffery
L 1 2 3
kDa
120
40
I— 40kD
(processed form)
Figure 5.24. Western blot for GR in unstimulated and IL-lp-stimulated HeLa cell 
nuclear extracts.
5(ig o f HeLa cell nuclear extract was applied per lane. GR was detected using primary antibody Sc-1003 
rabbit anti-GR polyclonal antibody (table 2.12), secondary antibody HRP-conjugated porcine anti-rabbit 
IgG polyclonal antibody (table 2.13) and chemiluminescent detection (see 2.12.3 for method).
Lane 1 ^ unstimulated extracts (150mM NaCl), lane 2=30min IL-ip-stimulated extracts (150mM NaCl), 
lane 3=30min IL-1 (3-stimulated extracts (300mM NaCl), LHadder of protein molecular weight markers 
(Benchmark, Gibco).—► = protein band for GR (processed form) according to molecular weight. Upper 
bands probably represent unprocessed protein. Full size unprocessed GR=92kDa.
5.3. The effect of the -597 polymorphism on transcription factor binding
Although an independent functional effect was not attributed to the -597 
polymorphism from transfection studies in HeLa or Huh7 cells, it was of interest to 
confirm this by investigating whether there were any differences in transcription 
factors binding around this polymorphic site with either allele. Double stranded probes 
of 75bp in length, from -539 to -613 of the IL-6 5’-flanking region sequence with 
either the G or the A allele at position -597, were generated by Klenow synthesis of a 
second-strand containing 32P-dCTP from a single-strand template and primer sequence 
(see section 2.11.2.2). These were designated probes 4G and 4A respectively (see 
figure 5.25 for sequence). The allele at position -572 was kept constant at G for both 
probes. The probes were used in EMSA studies with unstimulated and IL-lp- 
stimulated HeLa nuclear extracts to compare transcription factor binding between the 
alleles. Conditions were as previously for probes 2 and 3 (see methods section 2.11).
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A
5 '  -GCACGAAATTTGAGGGTGGCCAGGCAGTTCTACAACAGCCGCTCACAGGGA...
3 '  -CGTGCTTTAAACTCCCACCGGTCCGTCAAGATGTTGTCGGCGAGTGTCCCT...
G
...GAGCCAGAACACAGAAGAAC-3' 
...CTCGGTCTTGTGTCTTCTTG-5'
Figure 5.25. Sequence and putative GR binding site for IL-6 probes 4G and 4A.
The site o f the -597 polymorphism is indicated in red. The site o f the -572 polymorphism is shown in 
blue, this was kept constant at -572G. The putative glucocorticoid receptor binding site is indicated in 
green.
5.3.1. GR binds to a site on probes 4G and 4A
With 10, 150 and 300mM NaCl HeLa nuclear extracts there were no differences in 
EMSA banding pattern between the -597G and A allele probes, for unstimulated and 
IL-ip-stimulated extracts (shown for 150mM NaCl extracts in figure 5.26). Several 
specific bands were seen to occur (bands N, O, P and Q). Probes 4G and 4A contain a 
putative GR-binding site from -552 to -557 (figure 5.25). Although none of the bands 
were seen to compete out with 20 times cold GR-consensus sequence (see table 2.11 
for sequence), a supershift was obtained with two anti-GR antibodies to form band S 
(figure 5.27). The supershift indicates that GR binds to this region of the IL-6 
sequence, probably at the putative GR site.
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4G 4A 4G 4A 4G 4A 4G 4A 4G 4A 4G 4A
IL-1
30min
Figure 5.26. EMSA of IL-6 probes 4G and 4A incubated with unstimulated and 
increasing times of IL-lp-stimulated HeLa cell nuclear extracts.
5pmol radiolabelled 4G or 4A probe was incubated with lOpg of 150mM NaCl extracts pre-incubated 
with lOpg polydl.dC and run on a 4% non-denaturing polyacrylamide gel at 4°C for 4hrs (see 2.11 for 
method).
Un= unstimulated extracts, IL-1= IL-1 (3-stimulated extracts for given length o f time, Pr= probe only. 
Black arrows (bands N, O, P, Q) = specific bands present in unstimulated and IL-ip-stimulated extracts 
(could not be competed out by random probe but could be competed by unlabelled probe 4G or 4A), the 
grey arrow indicates a non-specific upper band (could be competed out by random probe). U= unbound 
probe.
There was no difference in the EMSA banding pattern obtained for unstimulated or IL-lp- 
stimulated extracts with the -597G  or A allele.
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Figure 5.27. Supershift EMSA of IL-6 probes 4G and 4A with antibody to GR.
Radiolabelled probe* (5pmol) was incubated with lOpg of lhr IL-1 P-stimulated HeLa cell nuclear 
extracts (300mM NaCl), pre-incubated with polydl.dC (lOpg). 3pl o f anti-GR antibody sc-1002 or 
sc 1003 (300ng/|il, see table 2.12) was added before radiolabelled probe and incubated at 21°C for 20min 
(see methods 2.11). For cold competition, unlabelled competitor probe was mixed with radiolabelled 
probe in the ratio indicated underneath each lane. Reactions were run on a 4% non-denaturing 
polyacrylamide gel at 4°C for 4hrs.
Red letterings radiolabelled probe, blue letterings unlabelled competitor, green letterings specific 
antibody added. GR= glucocorticoid consensus probe, R= random probe (see table 2.11), U= unbound 
probe, Uns unstimulated extracts, IL-1 lhr= 1 hour IL-1-stimulated extracts. Black arrows (bands N, O, 
P Q) = specific bands, the green arrow (band S) = the supershifted band with anti-GR antibody, the grey 
arrow= a non-specific band.
A band shift occurs with anti-GR antibody although no competition is seen with 20-fold GR 
consensus sequence.
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The possible effect of the -572 polymorphism on transcription factor binding was not 
investigated within this thesis. Despite the functional effects of this polymorphism in 
HeLa cell transfection studies. The rarity of the -572C allele in the Caucasian healthy 
and systemic arthritis population means this polymorphism is less significant than the 
-174 polymorphism.
5.4. Summary of EMSA findings
The EMSA studies in this section show that a transcription factor or complex of factors 
bind more strongly to the -174C than -174G allele. This is probably a transcription 
factor complex containing an inhibitory factor reduced by IL-1 (3-stimulation. C/EBPp 
seems to be involved in this complex, but not GR or CREB. No conclusion could be 
drawn as to whether NF1 was involved in the complex. CREB binding to the probe 
was demonstrated but did not appear to be influenced by the -174 polymorphism. An 
IL-lp-induced factors) binds to the region of the IL-6 gene between -161 and -235, 
previously considered a negatively regulatory domain. GR, Spl and NF1 binding to 
this region could not be demonstrated. GR binding was however demonstrated to the 
IL-6 gene in the region of the -597 polymorphism, probably at the putative binding 
site -552 to -557.
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CHAPTER 6 
GENERAL DISCUSSION
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6.1. Genetic susceptibility to JIA
The calculated sibling relative risk of disease (A,s) for juvenile idiopathic arthritis (JIA) 
based on 300 JIA sib-pairs from North America was high at 15 (Glass and Giannini, 
1999 and see section 1.2.10). Although this indicates that there is likely to be a 
relatively strong genetic component to JIA, the value is affected by the frequency of 
the disease in the general population. In a relatively rare disease such as JIA, the 
prevalence in the general population will be low and so A,s will be higher. The reverse 
is seen for common conditions that tend to have a small Xs. Rheumatoid arthritis has 
been calculated to have a Xs of 4.9 in a population from the UK (John et al., 1997), 
which may reflect the higher prevalence of rheumatoid arthritis than JIA in the general 
population, rather than a weaker genetic component. A study of 71 sib-pairs with JIA 
from North America has also supported a genetic component to JIA (Moroldo et al., 
1997). A higher than expected degree of concordance was found between the onset 
sub-type of JIA in the sib-pairs, though age at onset differed by an average of 4.4 
years. The genetic component of JIA, in this complex trait with distinct sub-types and 
different clinical phenotypes, is likely to be polygenic (Glass and Giannini, 1999). No 
one major gene effect is likely to account for the calculated degree of genetic 
component. Rather, several genes of low penetrance with allelic heterogeneity are 
likely to be involved. The association of the systemic arthritis form of JIA (SA) with 
the -174 polymorphism of the IL-6 gene is unique in that it is the only reported genetic 
association specific to the SA sub-type of JIA.
6.2. IL-6 genotyping methods
The genotyping methods used for this thesis were compared and validated within this 
study (see 3.2.1) and are discussed in section 3.2. Compared to the gold standard of 
automated sequencing, heteroduplex was the most accurate of the three techniques 
used at 100%, followed by restriction fragment length polymorphism (RFLP) and 
sequence specific oligonucleotide probing (SSOP) at 96-98%. However, heteroduplex 
was less efficient at generating results for samples than the other two methods because 
of problems obtaining PCR product that would anneal to the universal heteroduplex 
generators. A combination of techniques was therefore used for most samples to ensure 
the reliability of the genotype results obtained for each population. The techniques 
were chosen to be cost effective and allow relatively high sample throughput. An
Chapter 6. Discussion 256 R Jeffery
alternative method of RFLP using restriction endonuclease SfaNl was initially 
considered for determining the -174 genotype. This was tried with longer PCR 
products to include a down-stream SfaNl site in the IL-6 5’-flanking region that would 
have acted as an internal control for efficiency of enzyme digestion. However, PCR 
products including this site were less reliably produced than shorter products, and the 
SfaNl enzyme was more sensitive to salt combinations carried over from the PCR mix. 
M ain was therefore used in preference. Resource limitations during this thesis 
prevented newer techniques such as automated sequencing and Taqman allelic 
discrimination assay from being used on a large scale. Technology has significantly 
advanced recently and these techniques are now more widely available. The cost of 
equipment and reagents has also come down in price.
6.3. Use of association studies for IL-6 polymorphisms in SA
IL-6 is a glycoprotein involved in adaptive immune responses to inflammatory stimuli. 
High serum and synovial fluid levels of IL-6 and its soluble receptor agonist IL-6R in 
children with SA, together with the fact that levels rise and fall in parallel with disease 
activity, implicates IL-6 in the pathogenesis of SA. In this thesis, the IL-6 gene was 
investigated as a candidate gene in SA using a case-control study design. One of three 
single nucleotide polymorphisms (SNPs), a G to C at position -174 in the 5’-flanking 
region of IL-6 was shown to be associated with SA but not with other sub-types of JIA 
(section 3.3.1). That is to say, the null hypothesis that there was no difference in the 
proportion of patients carrying the putative disease allele and controls carrying the 
allele was not met by the results obtained for the distribution of the -174 genotype, but 
was for the -572 and -597 polymorphisms. A case-control study such as this is useful 
in the identification of genes showing association with rare diseases when only a small 
number of patient samples are available for study. However, of key importance is that 
the disease and control sample populations have the same genetic background to avoid 
problems of stratification where population diversity rather than disease association 
may result in a detected difference in genotype or allelic distribution. To avoid the 
effects of population stratification, the patient and control groups were ethnically and 
geographically matched, as much as possible (discussed in section 3.1), though 
complete matching was not possible. Geographical matching was to the recruitment 
centre location, however, the main recruitment centres (London, Birmingham and 
Manchester) are tertiary referral centres and it is recognised that some patients were 
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referred from a wider geographical location. Where samples from blood donors were 
used as controls, only first time donors were used to avoid potential biases of recall of 
individuals with a specific blood group and to ensure no individuals were sampled 
twice.
An alternative method to detect disease association is the transmission disequilibrium 
test (TDT), a family-based study that over-comes the problem of potential population 
stratification inherent in case-control association studies. The TDT tests for association 
and linkage disequilibrium (Spielman and Ewens, 1996). This requires genotype 
information for the candidate gene in the affected individual and at least one parent. 
Differences between the observed number of allele transmissions from a heterozygous 
parent to an affected child is compared to the null hypothesis that there would be only 
a 50% chance of transmission of the allele to the child under Mendelian inheritance if 
there was no linkage or disease association. A larger sample size is required for TDT 
than for case-control association study to obtain the same degree of power (Lewis, 
2002). For this reason, a TDT study was not initially conducted as not enough SA 
samples could have been recruited from the UK. Recent on going collaborative work 
of the laboratory of P. Woo has confirmed the association of the -174G allele of IL-6 
with SA in a multi-centre, multinational TDT study of simplex and multiplex families 
(Ogilvie et al., in press). Using genotype data from UK, US and French family cohorts 
it was shown that there was a significant excess transmission of the -174G allele to 
children affected with SA (p=0.041), whereas there was no significant difference in the 
frequency of allele transmission for JIA as a whole. This is a feasible approach in a 
disease of early onset such as SA when most parents are still alive. The disadvantage 
of TDT is that information cannot be used when both parents are homozygous. This is 
minimised when the allele frequency approximates 50% as with the -174 
polymorphism. An alternative family-base study in diseases where parental 
information is unlikely to be available, for example one that presents later in life, is 
using affected sib-pairs. This method compares allelic sharing between the pair, which 
would be expected to be 50% if there was no gene linkage or disease association. 
However, with a relatively rare condition such as SA, the number of affected sib-pairs 
is too small to allow for such a study. Other factors (genetic or environmental) may 
also contribute to the low incidence of SA in sib-pairs. In the North American
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collection of sib-pairs, although there are 300 JIA sib-pairs, very few have the SA sub- 
type (Glass and Giannini, 1999).
A difference in allele transmission was not seen in the association study in this thesis 
but rather a difference in genotype distribution. In the TDT study the larger number of 
patients allowed detection of the over transmission of the G allele in affected children, 
whereas the case-control study detected under representation of non-G allele carriers 
(that is CC genotype individuals). This is explained by the C allele occurring in a 
lower frequency than the G allele, so smaller numbers are needed to detect a difference 
in the homozygote genotype frequency. Both studies confirm an association between 
carriage of the G allele and susceptibility to SA.
The significant difference between the -174 genotype distribution for SA cases and 
controls in the association study was interpreted as a lack of the CC genotype, 
assuming a dominant allelic effect. This was supported by the significant difference in 
G-allele versus non-G allele carriage between cases and controls (p<0.05) and by the 
later TDT study results. An alternative possible interpretation is that there is a 
heterozygote effect with a contribution from both alleles, given that the heterozygote 
frequency was increased, and both the CC and GG homozygote frequencies were 
reduced in the association study cases compared to controls (figure 3.4). These results 
could also have arisen out of methodological error although every precaution had been 
taken to try to minimise this. A genotyping error resulting in over-calling of the 
heterozygotes (for example, under-cutting by RFLP) could have occurred, although all 
cases were genotyped by at least two methods to ensure high levels of confidence in 
the genotyping results. A sampling problem resulting in population stratification of the 
cases recruited from across the UK could have occurred with ethnic and geographic 
diversity, though care was taken to minimise this in the matching of control groups. 
Misclassification of the cases or missed cases (mainly recruited from rheumatology 
centres where cases under general paediatricians may have been missed) could also 
have contributed to the differences seen.
It is surprising given the close allelic association of the -597 and -174 polymorphisms 
that no association was found between the -597 polymorphism and SA. In addition to 
the interpretation that the main disease allele was located at -174, it could have been 
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due to smaller numbers in the case group analysed for the -597 polymorphism. This 
could be explored further using family studies. The weaker allelic association of the -  
572 and -174 polymorphisms, despite the strong -174/-597 allelic association may 
indicate that -572 is an older polymorphism.
6.4. Other genetic associations with SA
A G to C polymorphism at position -173 in the 5’-flanking region of the macrophage 
migration inhibitory factor (MIF) was reported to be associated with the SA sub-type 
of JIA in a UK study of 117 patients with SA (Donn et al., 2001a). Subsequently, an 
extended study in 526 UK JIA patients found that the MIF polymorphism conferred 
increased susceptibility to JIA irrespective of the sub-type of disease (Donn et al., 
2002). The MIF polymorphism appears to have functional association (De Benedetti et 
al., 2003). In SA, the -173C allele of MIF was associated with higher serum and 
synovial fluid levels of MIF, poorer response to glucocorticosteroid treatment, higher 
levels of joint inflammation and poorer functional scores.
A group from Japan has reported the association of the -1031C-863A haplotype of the 
TNFa gene and the -857T allele (alleles associated with higher TNFa production) 
with an increased susceptibility to the SA sub-type of JIA in a study of 111 Japanese 
patients with JIA compared to ethnically matched controls (Date et al., 1999). This 
association was stronger in the presence of the DRB 1*0405 HLA gene, suggesting that 
the association may be due to linkage disequilibrium between the TNFa and HLA 
genes. Other SNPs of the TNFa and TNF receptor genes have not been found to be 
associated with JIA in Caucasian populations (Ozen et al., 2002, Zeggini et al., 2002a). 
However, TNFa haplotype studies of nine polymorphisms within the gene, has 
established linkage of the TNF locus to the oligoarticular form of JIA in Caucasians 
(Zeggini et al., 2002b). The same group has also reported on linkage of the HLA loci 
with oligoarticular JIA in Caucasians (Zeggini et al., 2002c). One explanation for the 
reported ethnic differences may be an association with HLA, and linkage 
disequilibrium between HLA and TNFa or other genes. An investigation of possible 
HLA associations with IL-6 was beyond the scope of this thesis because of the limited 
number of SA samples. However, this is currently being examined.
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The major histocompatibility complex (MHC) loci have been one of the main areas of 
study of genetic associations with JIA and other autoimmune diseases. This is because 
of the importance of the context in which antigen is presented on these molecules to T 
lymphocytes. It has been hypothesised that autoimmune reactions may develop due to 
altered identification of antigens (self or foreign) depending on the context of 
presentation. Altered levels of cytokine production may then influence cellular 
responses triggered by activation of specific T cells. TDT studies have shown HLA 
allelic associations with oligoarticular JIA (Moroldo et al., 1998, Zeggini et al., 
2002c), but few clear associations with SA have been identified (discussed in section 
3.3.4). Results from studies have been confusing because of the different 
classifications of juvenile arthritis used, the different ethnic backgrounds analysed and 
the relatively small size of many studies. One UK study that tried to address these 
issues compared the frequency of distribution of HLA class II alleles and haplotypes in 
over 500 Caucasian JIA patients compared to Caucasian controls. They found HLA- 
DRB1*08 and 11 to be associated with an increased risk of JIA (Thomson et al., 
2002). The increased association with DRB1*11 was seen in the SA, persistent and 
extended oligoarticular sub-types of JIA (see table 1.1 for classifications). Whereas, 
HLA-DRB1*08 was mainly associated with the persistent and extended oligoarticular, 
and rheumatoid factor negative polyarticular sub-types of JIA. HLA-DQA1*05 was 
associated with SA and persistent oligoarthritis, and haplotype association studies 
showed DRB1*11-DQA1*05-DQB1*03 to occur in higher frequency in SA, persistent 
and extended oligoarticular arthritis. HLA-DRB1*04 was associated with a reduced 
risk of JIA in all sub-types except SA, enthesitis-related arthritis and rheumatoid factor 
positive polyarthritis. This is of interest as the DRB1*04 allele is associated with 
susceptibility to adult rheumatoid arthritis (Balsa et al., 2001, Jawaheer et al., 2003). 
Possible associations are further complicated by reported findings that HLA allelic 
associations may have age-specific effects (Murray et al., 1999). For example, Murray 
and co-workers (1999) found associations of HLA A2, DR5, DR8 and DPB1*0201 
with susceptibility to the oligoarticular form of JIA occurring in the early years of life 
(under three years of age), whereas the association tailed off after this age, with no 
increased susceptibility seen after the age of 10 years. HLA B27 and DR4 were 
associated with protection early in life, but with an increased risk of oligoarticular and 
polyarticular disease later in childhood. The study reporting an HLA DR4 association 
with susceptibility to the SA form of JIA in North American patients, though not
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reproduced in studies of European patients (see section 3.3.4), found no association of 
DR4 with adult Still’s disease, a disease of adulthood with clinically similar 
manifestations to the SA form of JIA (Miller et al., 1985).
A 3’-SNP in the transcription factor interferon regulatory factor-1 (IRF-1) has been 
associated with susceptibility to JIA, though not specific to any one sub-type (Donn et 
al., 2001b). Interestingly, this study of 417 Caucasian JIA patients (63 with the SA 
sub-type) showed no association of the -174 polymorphism of IL-6 with JIA, nor with 
the SA form of the disease. This apparently contradictory result could be explained by 
the lower power of the study for detecting a significant difference. This thesis has more 
SA patients, and a larger control population resulting in higher power to detect a 
potential difference in genotype frequency between the groups. The fact that the 
association found in this thesis has subsequently been confirmed by the multi-centre 
TDT study supports the findings that this is a true genetic association with SA. A 
number of other cytokine associations have been reported with other sub-types of JIA. 
McDowell et al. (1995) reported the first cytokine gene association with JIA. They 
found the -889T allele of the IL-1 gene to be associated with early-onset oligoarticular 
JIA with ocular complications. However, this was not supported by the study of Donn 
et al. (2002b). Vencovsky et al. (2001), have subsequently reported the association of a 
variable number tandem repeat (VNTR) polymorphism of the IL-1 gene with JIA and a 
prognostic association with development of the extended oligoarticular form. Crawley 
et al. (1999), showed that the -1082A-819T-592A haplotype of IL-10, which was 
demonstrated to be associated with lower IL-10 production, was associated with the 
extended oligoarthritis sub-type of JIA. All these case-control studies need replication 
in different populations by TDT analysis. However, cytokine genes clearly play an 
important role in the genetic susceptibility to JIA and in some cases to the disease 
course. The finding that an IL-6 polymorphism is associated with SA is an important 
contribution to building our understanding of factors influencing the development of 
SA. It is likely that the IL-6 genetic effect is modulated by other, yet unidentified 
genetic and environmental factors. Interaction between genes can be looked for by 
logistic regression analysis, modelling possible types of interlocus effects. This 
approach has been used in diabetes mellitus (Cordell et al., 2001) and in Crohn’s 
disease (Mizra et al., 2003) to identify genetic interactions.
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6.5. Environmental susceptibility to SA
A seasonal onset of SA in children has been reported in the Prairie region of Canada 
with peak incidence in the autumn and early spring (Feldman et al., 1996). No 
correlation with viral incidence was found, and across Canada overall there was no 
seasonal variation in onset of SA. It is possible that ‘windows of susceptibility’ 
associated with different HLA alleles are due to differing patterns of exposure to 
environmental factors at different ages. This could also explain the age effect that was 
found for the SA association with the IL-6 polymorphism. In this study, the hypothesis 
would be that an environmental trigger in a genetically susceptible individual could 
result in the expression of disease (Brown and Wordsworth, 1998). For example an IL- 
6 -174G allele carrier with a certain susceptible HLA allele, exposed at a certain age to 
an environmental pathogen such as a virus, could predispose the child to development 
of SA. The reaction to some viruses is known to be different at an early age. Epstein- 
Barr virus in early childhood is usually asymptomatic, though in later life it is 
associated with infectious mononucleosis (Chan et al., 2001). Similarly, primary 
varicella zoster virus infection in childhood is generally less severe than in adulthood 
(Hardy and Gershon, 1990). Virus infection of specific cells can influence levels of IL- 
6 and IL-6R expression (Janaswami et al., 1992, Tomeczkowski et al., 1997). Genes 
that affect the metabolism or eradication of an exogenous agent may contribute to the 
triggering of disease expression (Dooley and Hogan, 2003). IL-6 may influence host 
response to a pathogen or efficacy of clearance via induction of B-cell maturation, 
stimulation of antibody production (see section 1.2.1), influences on T-cell 
differentiation (see 1.2.2), macrophage differentiation and altered antigen presentation 
by dendritic cells (see 1.2.3). IL-6 may result in altered levels of inflammatory 
response via induction of the acute phase response (see section 1.2.6) and may result in 
perpetuation of inflammation by acting as a ‘switch’ between acute and chronic 
inflammation (discussed in section 1.2.8&9). IL-6 is one part of a network of pro- and 
anti-inflammatory cytokines that act in concert when triggered by an inflammatory 
stimulus. Functional allelic differences within these cytokine genes may alter the 
balance of cytokines and influence the extent of acute or chronic inflammatory 
response generated to a specific environmental trigger (as for example seen with the 
-376 polymorphism of TNFa and severity of malaria infection, see 1.3.3.2). Different 
genetic factors may be important later in life and in different parts of the World, 
dependent upon exposure to environmental triggers. It is certainly the case that some 
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complications of SA are distinct between Europe and North America. Secondary 
amyloidosis, a complication of deposition of the inflammatory protein serum amyloid 
A (SAA) in multiple organs resulting in impaired organ function, is rarely seen in 
patients with SA in the US compared to a higher incidence within European patients 
(at least until recent treatment developments controlled disease activity). Work from 
the laboratory of P. Woo has shown that development of secondary amyloidosis in UK 
Caucasian patients with SA was associated with a polymorphism of the SAA gene, the 
SAA2 a2 allele (Faulkes and Woo, 1997).
6.6. Severity versus susceptibility
In multifactorial diseases such as JIA, genetic effects may influence disease severity 
rather than susceptibility. Weyand and co-workers (1992) suggested HLA DRB1 genes 
influence disease severity in rheumatoid arthritis when they reported the association of 
distinct clinical features of disease in DRB1 positive individuals. More recently, a 
family-based study of IL-10 polymorphisms in Finnish patients with the inflammatory 
arthritis ankylosing spondylitis, found association of the IL-10 G4 microsatellite 
marker within the IL-10 promoter with poorer functional scores (corrected for duration 
of disease) but not with disease occurrence (Goedecke et al., 2003). This suggests that 
IL-10 promoter polymorphisms may influence disease severity in ankylosing 
spondylitis rather than susceptibility. This may also be a feature of certain HLA 
genotypes in the inflammatory bowel disease ulcerative colitis (Yamamoto-Furusho et 
al., 2003). In a study of Mexican patients, HLA DR15 was associated with extensive 
colitis rather than limited distal colitis. HLA DRB 1*0103 was associated with 
requirement for surgical intervention to manage the colitis. In family-based studies of 
the psychiatric condition attention deficit hyperactive disorder in children, a dose 
dependent association has been described between the dopamine transporter gene 
DAT1 and severity of a subset of symptoms of the disorder, namely hyperactive- 
impulsive behaviour (Waldman et al., 1998).
We found that the association of the -174 polymorphism of the IL-6 gene with SA 
could be accounted for by patients with early onset disease (< 5 years of age), (section
3.3.2). In SA, early onset disease has been shown to be associated with poorer 
prognosis in terms of functional outcome and requirement for surgery (Modesto et al., 
2001). Although this could be explained by longer duration of disease and
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complications of inflammation during earlier stages of growth and development, it is 
also considered to represent disease that is more aggressive and harder to control with 
immunosuppressive therapy. This would suggest that IL-6 genetic effects might 
influence the severity of SA as well as the susceptibility. A gene dose effect was not 
seen with age of onset, only that lack of the -174G allele protected against 
development of SA in the early age group. It was beyond the scope of this thesis to 
investigate disease course, outcome and severity markers in association with the -174 
polymorphism because of the heterogeneous nature of SA, small numbers of patients 
and differing lengths of disease duration. However, such a prospective study would 
help establish any role of IL-6 in severity and not just on susceptibility within the 
younger age group (as discussed above). It is of interest that in the TDT study, an age 
association with the younger onset patients was not found and that the association was 
strongest for older onset patients, > 5 years of age (Ogilvie et al., in press). This may 
be due to a numbers effect between the two studies as the case-control study had 
significantly more patients in the early age at onset group, where as the TDT study had 
more in the older age at onset group. Overall, it would suggest that the IL-6 
polymorphism might not have true effect on age of onset of SA.
6.7. IL-6 haplotype associations
IL-6 haplotype frequencies were determined in this thesis for the UK Caucasian 
population, estimated from the determined genotype frequencies for each 
polymorphism using the EH linkage-utility programme (see section 3.6). These 
correlated closely with haplotype frequencies published since the undertaking of this 
work, by another group, based on a smaller Caucasian population study (Jordanides et 
al., 2000). Jordanides and co-workers confirmed linkage disequilibrium of-597G  with 
-174G, and -597A with -174C, in 73 healthy, unrelated individuals from the West of 
Scotland. Four haplotypes of the 5’-flanking region polymorphisms -597, -572, -174 
emerged in this population. GGG (frequency 0.514), AGC (frequency 0.432), GCG 
(frequency 0.041) and GGC (frequency 0.014), compared to frequency 0.524, 0.374, 
0.070 and 0.018, respectively, found in our study. It should be noted that the 
numbering of the polymorphisms by Jordanides et al., (2000) is slightly different from 
that used in this thesis. They used another sequence of IL-6 (Ray et al., 1988) that 
though it has the same initiation site, differs by several bases from the sequence of 
Yasukawa et al., (1987) used in this thesis (and more generally adopted), (see section 
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1.3). Consequently what they describe as the -172 polymorphism is the same as the 
-174 polymorphism described in this thesis, their -570 is the same as our -572 and 
their -594 the same as the -597 polymorphism described here. The paper by 
Jordanides and co-workers (2000) also reported linkage disequilibrium of these 5’- 
haplotypes with three 3’-VNTRs of the IL-6 gene. The -597A-174C haplotype was 
found to be in allelic association with the 3’VNTR.3 allele, and the -597G-174G 
haplotype with the 3’VNTR.4 & 7 alleles. Interestingly, in a study of 63 African- 
American healthy individuals, the distribution of haplotype frequencies was 
significantly different from the findings in Caucasian populations (Osiri et al., 1999). 
Five probable haplotypes of the 5’-flanking region polymorphisms -597, -572 and 
-174 were reported GGG (frequency 0.841), GCG (frequency 0.095), AGC & AGG 
(frequency 0.024) and GGC (frequency 0.016). The GGG haplotype was present at 
much higher frequency, with AGC occurring in only 2.5% compared to over 40% in 
the Caucasian population. It would appear that the ancestral genotype is homozygous 
GGG, as a genotyping study in several primate species has revealed them all as GGG 
(Kelberman et al., submitted, personal communications). Although these studies are in 
small numbers and larger studies are required to confirm the different frequency of 
distribution of these haplotypes compared to the Caucasian population, it would 
suggest that there has been some evolutionary advantage in the African population to 
retaining the GGG haplotype, or advantage in the Caucasian population to acquiring 
the AGC haplotype. This suggests a functional influence of these haplotypes on IL-6 
expression, which may alter for example the way certain infections are dealt with 
(discussed in 6.5). Indeed, the -174GG genotype has been associated with significantly 
improved survival in 50 German Caucasian intensive care patients who developed 
sepsis post-surgery (Schluter et al., 2002).
Despite the strong allelic association between the -174 and -597 polymorphisms in the 
normal population this association was significantly weaker in patients with SA 
(section 3.6.2). This suggests that the -174 polymorphism is the functionally 
significant polymorphism. The weak allelic association between -174 and -572 we 
found in this study has not been reported in the literature, probably because in smaller 
studies the power would be too low to detect the association. In our larger study, we 
also found that all haplotype combinations were seen in the Caucasian population
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though the haplotypes ACC, AGG, ACG and GCC were extremely rare, occurring in 
<1% of individuals (section 3.6.3).
6.8. The AT-tract polymorphism of IL-6
The frequency of distribution of AT-tract polymorphisms between -373 and -392 of 
IL-6 was not determined within the scope of this project. Initial attempts to sequence 
this region using an Applied Biosystems (ABI) PRISM® polyacrylamide gel 
separation sequencer and Amersham Life Science dye termination detection kit (see
2.4.8.2), resulted in base detection slippage and consequently the number of sequential 
A-nucleotides and T-nucleotides could not be accurately determined. Subsequent 
advances in the technology of the dye terminator kits available (ABI PRISM® 
BigDyeT Terminators version 3.0 sequencing kit) and the software available to detect 
base spacing on an ABI PRISM® 3100 capillary sequencing machine, has allowed the 
AT-tract polymorphism to be accurately determined (Twine et al., 2003). A TDT study 
in 100 simplex families with SA as part of the on going work from this project has 
identified six AnTn alleles A8T12 (frequency 0.368), A9T11 (frequency 0.268), AlOTll 
(frequency 0.210), A10T10 (frequency 0.150), A9T12 & AllT9 (frequency <0.010). 
Strong allelic association was found between the -174 and AnTn tract loci (p<10‘10), 
with the -174C allele almost completely carried with the A8T12 allele (haplotype 
frequency 0.368), whereas the -174G allele was distributed between the AnTn alleles 
A9T11 (haplotype frequency 0.231), AlOTll (haplotype frequency 0.225) and A10T10 
(haplotype frequency 0.119), (Twine et al., 2003). Other haplotype frequencies 
occurred at less than 3%. No association was found between either AnTn genotype or 
-174/AnTn haplotype and SA, indicating that the AT-tract does not play a significant 
role in SA disease association. We had previously reported the AnTn tract frequency in 
a combined sample of 57 controls and SA patients (Fishman et al., 1998). In that 
cohort, in all but one case the -174C allele was associated with the A8T12 tract, while 
the -174G allele was found in association with a variety of other AnTn alleles, the 
most common being A9T11, followed by A10T10 (see table 1.3). Two other studies, a 
study of 78 healthy Caucasian patients (Terry et al., 2000) and a study of 132 
Caucasian patients undergoing coronary artery bypass grafting (Kelberman et al., 
submitted, personal communication), have confirmed A8T12 as the most frequently 
occurring AT-tract allele with a strong allelic association with the -174C allele.
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6.9. Other disease associations with the -174 polymorphism of IL-6
The results of the genetic studies presented in this thesis indicate that the -174 
polymorphism of IL-6 is important in the pathogenesis of SA. We were the first to 
report a disease association with the -174 polymorphism (Fishman et al., 1998). 
Subsequently, there have been many reports of associations of this same 
polymorphism with other diseases in which IL-6 is implicated in the disease 
pathogenesis (summarised in tables 6.1&2). In primary Sjogren’s syndrome, an 
autoimmune condition primarily affecting exocrine glands and joints, differing -174 
genotypes of IL-6 were associated with specific manifestations of the disease and 
altered plasma levels of IL-6 in 61 Finnish patients, although no association with 
susceptibility was found (Hulkkonen et al., 2001). In a similar way, the -174 
polymorphism was found to be associated with specific disease manifestations in the 
multi-system autoimmune disease systemic lupus erythematosus in 211 German 
patients, the -174G allele being associated with discoid skin lesions and anti-histone 
antibodies (Schotte et al., 2001). In 163 Spanish patients with rheumatoid arthritis, the 
-174 genotype was associated with a significant difference in the mean age at disease 
onset, indicating a possible influence on severity, but was not associated with 
susceptibility (Pascual et al., 2000). In relation to the effects of IL-6 on bone 
metabolism, Lorentzon and co-workers (2000) showed that in 90 healthy Swedish 
Caucasian males in late puberty, individuals with the -174CC genotype had 
significantly higher bone mineral density (BMD) than -174GG individuals and the 
genotype predicted peak bone mass. In 434 healthy North American women, the 
-174CC genotype was associated with lower bone resorption and a lesser decrease in 
BMD in the older postmenopausal women (Ferrari et al., 2001). We also found the 
-174CC genotype to be associated with a higher BMD in healthy post-menopausal 
French women, however this difference was no longer significant after correction for 
body height (Gamero et al., 2002).
In 53 patients with type 1 diabetes mellitus the -174GG genotype was found to occur 
in significantly higher frequency than in normal controls (Jahromi et al., 2000). A 
study in patients with type 2 diabetes mellitus suggested that the -174CC genotype 
was associated with an increased insulin sensitivity (Fernandez-Real et al., 2000a).
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Condition Feature Reference
Systemic arthritis sub- 
type of JIA
Susceptibility Fishman et al., 1998, 
Ogilvie et al., in press
Sjogren’s syndrome Specific disease manifestations Hulkkonen et al., 2001
Systemic lupus 
eiythematosus
Specific disease manifestations Schotte et al., 2001
Septicaemia
(post-surgery)
Improved survival Schulter et al., 2001
Rheumatoid arthritis Severity Pascual et al., 2000
Type 1 diabetes 
mellitus
Susceptibility Jahromi et al., 2000
Healthy subjects Atherosclerosis-associated lipid profile Fernandez-Real et al, 
2000b
Healthy men Asymptomatic carotid artery 
atherosclerosis
Rauramaa et al., 2000
Healthy subjects Higher IL-6 serum levels Fishman et al., 1998
Peripheral artery 
occlusive disease
Susceptibility Flex et al., 2002
Coronaiy artery disease Longer hospital & ITU stay, higher 
serum IL-6 levels post bypass graft 
surgery
Burzotta et al., 2001
Bone marrow 
transplantation
Chronic graft versus host disease 
(recipient genotype)
Cavet et al., 2001
Table 6.1. IL-6 genotype studies that report association with -174G.
The pathogenesis of these conditions suggests that the -174G allele is associated with higher 
levels of IL-6 expression than -174C.
In healthy subjects, carriers of the -174G allele were found to have significantly higher 
levels of plasma triglycerides, veiy-low-density-lipoprotein and post-glucose load free 
fatty acids, a lipid profile associated with an increased risk of atherosclerosis 
(Fernandez-Real et al., 2000b). IL-6 mediated inflammation is implicated in the 
pathogenesis of atherosclerosis. The -174G allele of IL-6, in association with a 
functional stromelysin-1 promoter polymorphism, was found to be associated with 
asymptomatic carotid artery atherosclerosis, measured as intima-media thickening in 
109 middle-aged, Finnish men (Rauramaa et al., 2000). The -174GG genotype showed 
a strong association with peripheral artery occlusive vascular disease in an Italian 
study of 84 patients (Flex et al., 2002). Antibodies to the 60kDa heat shock protein, 
associated with coronary heart disease and carotid atherosclerosis, were significantly 
lower in -174C allele carriers than in -174G carriers, in a Hungarian study of 176 
healthy male blood donors (Veres et al., 2002). In 111 Italian patients undergoing 
elective coronary artery bypass graft surgery, the -174GG genotype was associated 
with significantly higher levels of IL-6, with longer hospitalisation and the need for 
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longer stays in the intensive care unit post-operatively than C-allele carriers (Burzotta 
et al., 2001). This contrasts with the findings of Brull and co-workers (2001) who 
reported increased IL-6 levels post coronary artery bypass graft surgery in association 
with the -174CC genotype compared to -174G allele carriers, in 127 UK Caucasian 
patients. It is difficult to explain these contradictory results, both groups showed no 
baseline differences pre-operatively and were not significantly different in terms of 
other factors potentially affecting IL-6 levels such as age, sex and smoking status 
(other possible associations are discussed more fully below). The same group reports 
higher plasma IL-6 concentrations in patients with small abdominal aortic aneurysms 
who were carriers of the -174C allele compared to -174 GG homozygotes, though this 
was not related to rate of aneurysm growth (Jones et al., 2001). They have also 
reported an association of the -174C allele with increased systolic blood pressure in 
healthy men and increased risk of coronary artery disease, not explained simply by 
blood pressure effects alone (Humphries et al., 2001). In an older patient age group 
with both men and women, they found no association of cardiovascular incident events 
(angina, myocardial infarction and cerebrovascular accident) with -174C, however this 
allele was associated with sub-clinical cardiovascular disease as detected on magnetic 
resonance imaging, with a higher acute phase response and plasma IL-6 levels (Jenny 
et al., 2002). Two further studies in cardiovascular disease have added to these 
conflicting results. A large study of 640 male patients from Northern Ireland and 
France showed a higher carriage frequency of the -174C allele with myocardial 
infarction compared to age-matched controls, indicating a susceptibility association 
(Georges et al., 2001). However, in the French population within this study, the -174C 
allele was associated with fewer stenosed coronary vessels, suggesting that the -174G 
allele may have an influence on extent of atherosclerosis. The authors suggest that 
these results are compatible with a lower IL-6 secretion in association with the -174C 
allele. A study of 498 patients from the West of Scotland found no association of 
cardiovascular risk with the -174 polymorphism in patients who were not on a lipid- 
lowering agent (Basso et al., 2002). However, patients treated with the lipid-lowering 
agent, pravastatin, had a significantly lower risk of coronary artery disease in 
association with the -174CC genotype compared to -174G allele carriers. They found 
no association between the -572 polymorphism and coronary heart disease. Higher 
baseline C-reactive protein levels, a heritable cardiovascular risk factor, were 
associated with the -174C allele in 588 members of 98 nuclear Caucasian UK families 
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(Vickers et al., 2002). The -174C allele of the donor IL-6 gene in 145 cadaveric renal 
allograft transplants was associated with an increased incidence and severity of acute 
rejection in the recipient (Marshall et al., 2001). In 80 sibling bone marrow transplants, 
chronic graft-versus-host disease was associated with recipient -174GG genotype 
(Cavet et al., 2001).
Condition Feature Reference
Healthy male Higher bone mineral density* Lorentzon et al., 2000
Postmenopausal women 
(osteoporosis)
Lower bone resorption, higher BMD* 
(protective factor)
Ferrari et al., 2001 
Gamero et al., 2002
Type 2 diabetes 
mellitus
Increased insulin sensitivity* 
(protective factor)
Fernandez-Real et al., 
2000a
Coronary artery disease Higher serum IL-6 levels post bypass 
graft surgery
Brull et al., 2001
Small abdominal aortic 
aneurysms
Higher serum IL-6 levels Jones et al., 2001
Healthy men Increased systolic blood pressure, 
increase risk of coronary artery disease
Humphries et al., 2001
Older asymptomatic 
subjects
Sub-clinical cardiovascular disease, 
higher serum IL-6 levels
Jenny et al., 2002
Myocardial infarction Susceptibility Georges et al., 2001
Myocardial infarction Fewer stenosed coronary arteries Georges et al., 2001
Cardiovascular disease Lower risk of coronary artery disease in 
those taking pravastatin
Basso et al., 2002
Renal transplantation Increased rejection of transplant 
(donor genotype)
Marshall et al., 2001
Table 6.2. IL-6 genotype studies that report association with -174C.
The pathogenesis of conditions marked with * suggest that the -174G allele is associated with 
higher levels of IL-6 expression than -1 74C. The other studies suggest that the -174C allele is 
associated with higher levels of IL-6 expression than -174G.
This plethora of IL-6 disease association studies, many of which are yet to be 
corroborated in an independent population or family study, nevertheless indicates a 
likely functional effect of the -174 polymorphism. The nature of this effect is difficult 
to hypothesise from the association studies alone, as some diseases associated with the 
-174G allele or GG genotype such as SA, would suggest that this allele would be 
associated with higher IL-6 expression, whereas other studies, particularly in 
cardiovascular disease, would suggest that the -174C allele could be associated with 
higher IL-6 expression. IL-6 of course, does not operate in isolation but functions as 
part of the cytokine network. Interactions of other cytokines and influences on the 
balance of cytokines operating in different disease states are likely to influence
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outcome. This needs to be taken into consideration, together with the effects of 
possible confounders such as disease treatments (for example, steroids) or 
environmental risk factors for disease. Such an effect is suggested by the results of the 
West of Scotland study where IL-6 genetic influences were only seen to be significant 
in patients receiving a lipid-lowering agent (Basso et al., 2002). In addition, the 
possible modulation of one genetic effect by other genetic influences, and linkage 
between genes must be considered. Some of these possible influences are discussed 
below.
6.10. Transfection techniques
Transfection studies were used as an in vitro system to investigate the functional 
significance of the IL-6 5’-flanking region polymorphisms, focusing particularly on the 
-174 alleles. Transient transfections were initially used, and have the advantage that 
the transfected plasmid remains circularised within the cell nucleus with minimal 
disruption to the regulatory sequence under investigation. Additionally, the plasmids 
are independent of potential influences of host genomic DNA regulatory regions. 
However, transfection efficiency will vary between experiments. This was controlled 
for by co-transfecting with P-galactosidase ((3-gal) as an internal control. An 
alternative option that became available during this thesis would have been to use sea 
pansy renilla as a control reporter. This would have allowed assay of the luciferase 
reporter from the constructs and the renilla control on the same sample aliquots. The 
choice of promoter driving renilla expression would be important. The 
cytomegalovirus promoter and simian virus 40 promoter (driving renilla expression in 
control plasmids available from Promega) are known to be induced by EL-ip and 
TNFa (Ritter et al., 2000, Plaetinck et al., 1989). The p-gal reporter was available on a 
respiratory syncitial virus promoter that was tested in our study and found not to be 
sensitive to IL-1, IL-6 or TNFa stimulation. Stable transfections were subsequently 
used to confirm transient transfection findings with the plasmid construct integrated 
into the genomic DNA of the host cell. While this is considered to more closely 
represent the in vivo DNA packaging, the plasmid is linearised and the regulatory 
region under investigation could be disrupted, or host regulatory regions influence 
reporter gene expression. Any influences of this nature were minimised by using 
pooled stable clones for each construct, representing many randomly inserted reporter
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constructs. Flanking sequences to target the reporter construct to a specific region of 
the genome can be used. However, although this will control for comparisons between 
constructs inserted in the same location, it will not prevent unpredictable host genomic 
influences on the regulatory region under investigation. The stable transfectants 
allowed a wider range of inducer and repressor effects on the IL-6 polymorphisms to 
be investigated. Only allelic and haplotype effects were investigated using the 
transfection studies, not genotypic effects.
6.11. Functional effects of IL-6 haplotypes
The influence of the -597, -572, -174 haplotype on levels of IL-6 transcription was 
compared using 1.17kb constructs transfected into the transformed epithelial cell line 
HeLa cells. The constructs had a constant A9T11 AT-tract allele that proved 
technically difficult to mutate to allow comparison of other AT-tract alleles (see 
discussion in section 4.1.1). The -597G-572G-174G haplotype construct produced 
significantly higher levels of IL-1-induced reporter expression than -597G-572C 
-174G or -597A-572G-174C, but not higher than -597A-572G-174G (section 4.1.6). 
This indicates that in the context of the most common naturally occurring haplotypes 
GGG and AGC, the -174G allele produced higher levels of IL-6 transcription than the 
-174C allele and that this was independent of the -597 or -572 allele. It also indicates 
that the -572G allele produced higher levels of transcription than the -572C allele as 
an independent effect. With TNFa induced expression, similar results were obtained 
with the -174G allele producing higher levels of IL-6 expression than -174C, in the 
context of the naturally occurring haplotypes (see section 4.2.2). These functional 
effects were however cell-specific. When compared in the transformed hepatoma cell 
line Huh7 cells, there was a trend towards a reverse in the order of transcriptional 
activity of the haplotype constructs in these cells compared to HeLa cells but it did not 
reach statistical significance (p=0.06, see section 4.1.7). See discussion in section 6.17.
6.12. Functional associations in vivo
The -174 allelic effect identified in the transfection studies in HeLa cells corresponds 
to in vivo genotype effects on plasma IL-6 levels measured in 102 healthy individuals 
(Fishman et al., 1998). IL-6 levels were measured first thing in the morning to avoid 
effects of diurnal variation (Seiler et al., 1995). Carriers of the -174G allele had 
approximately two fold higher levels of plasma IL-6 than non-carriers of the G allele 
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(Fishman et al., 1998). There was no allelic dose effect, that is, GG homozygotes had 
similar levels of plasma IL-6 to GC heterozygotes. These results would support a 
dominant role for the -174G allelic effect. What is different in the transfection studies 
however, is that the -174 allelic effect was only seen with acute phase stimulation (IL- 
lp  and TNFa), but not constitutively. This contrasts with the in vivo study results, 
where care was taken in collecting the patient samples to obtain constitutive levels of 
plasma IL-6, and a genetic difference in this basal level of IL-6 expression was seen. 
This would imply that different or additional mechanisms influence levels of IL-6 
expression constitutively in vivo than in the HeLa cell model. This may reflect a 
different cell type as the main producer of constitutive levels of IL-6 in vivo in health, 
which could include adipocytes, p-adrenergic stimulation of adipocytes is associated 
with increased plasma IL-6 concentrations (Mohamed-Ali et al., 2001). The in vivo 
samples were taken after an over-night fast and individuals may have had increased 
adrenergic stimulation secondary to sympathetic activation from fasting and then 
attending for a blood test, which may have meant that the IL-6 levels were induced, 
though not by the acute phase response. Preliminaiy results from transfecting the same 
IL-6 haplotype constructs as used in the HeLa cell studies into 3T3F442A cells, a 
human differentiated adipocyte cell line, has yielded results with IL-1 stimulation 
similar to those obtained in HeLa cells, that is, -174G was associated with higher 
levels of IL-6 expression than -174C (L Luong, personal communications).
Reports of the influence of the -174 genotype on serum IL-6 levels in disease states 
have differed. A study of IL-6 protein levels produced by ex vivo culture of peripheral 
blood mononuclear cells (PBMCs) from SA patients compared to controls, showed SA 
patients to have significantly higher unstimulated levels of IL-6 production (Pignatti et 
al., 2001). There was no difference in the levels of IL-10 produced. However there was 
significantly reduced inhibition of IL-6 production by IL-10. These effects were not 
associated with the -174 polymorphism of IL-6, though small numbers limited the 
power of the study to detect a possible association. The most confusing results have 
been from Burzotta and co-workers (2001) who found higher levels of IL-6 post 
coronary artery bypass grafting in -174GG individuals, and Brull and co-workers 
(2001) who found higher levels of IL-6 post coronary artery bypass grafting in 
-174CC individuals. The Brull et al. study found peak IL-6 levels at 6-hours post­
operative with maximum genotyping effect at 12 hours. The Burzotta et al. study did 
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not measure levels before 24 hours post-operative and reported the peak at 24 hours, 
with maximum difference in genotypic effect at 48 hours. Though the stimulant to 
raised IL-6 expression was considered as surgical trauma, other factors will have been 
involved and may have differed between the two surgical centres. For example, 
surgical effects such as hypoxia associated with length of operation may have differed, 
need for peri-operative blood transfusion and use of cooling techniques. The plastic 
tubing of the bypass circulation creates an inflammatory response. Different 
anaesthetics, or exposure to different bacterial organisms, may all have influenced the 
mechanism of IL-6 induction and the predominant cell type producing it. Burzotta and 
co-workers included only those individuals undergoing operation between 8 and 10am 
to avoid effects of circadian variations of IL-6 levels. Brull and co-workers reported 
higher peak IL-6 levels post-operatively in -572C allele carriers than in -572GG 
individuals. The -572 genotype distribution was similar to previously reported 
frequencies in Caucasian population, but no information was available for the -572 
genotype in the Burzotta et al. study as to whether this could have influenced IL-6 
levels post-operatively, and no information was available from either study on the AT- 
tract or -597 genotype (see discussion below). The fact that the time of maximum 
genotypic differential effect on IL-6 levels was after the time of maximum IL-6 
induction, could suggest that in vivo factors (possibly other cytokines) contributing to 
perpetuation of IL-6 induction are influenced by the allelic differences. It is clear that 
the in vivo situation is much more complicated than the in vitro transfection model. 
However, the HeLa cell results seem representative of the -174 polymorphic effect in 
health and in some pathophysiological conditions. To date the Brull et al. (2001) study 
is the only report of in vivo -572 genotypic associations with IL-6 levels.
6.13. Other in vitro evidence of functional effect
Transfection studies by another group published during the preparation of this thesis, 
compared IL-6 5’-flanking region haplotype effects on levels of transcription in HeLa 
cells and ECV304 cells, thought to be an endothelial cell line* (Terry et al., 2000). 
Although Terry et al. reported no significant differences in levels of transcription 
between haplotypes in HeLa cells, this apparent discrepancy with our results could be 
explained by methodological differences.
♦It should be noted that ECV304 cells have been recalled by the European cell line repository for further 
analysis as extended phenotype analyses have suggested that they may be an epithelial cell line rather 
than an endothelial cell line as originally thought.
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In our study, construct expression was compared at the time point of maximum IL-1- 
induced expression using luciferase-reporter constructs; this was 6 hours post­
stimulation (see section 4.1.3 and figure 4.6). At 24hrs post-stimulation, we found only 
a small difference in the level of transcription between haplotypes. The later time-point 
of 24hrs was used by Terry et al. in their study based on a time-course carried out with 
the chloramphenicol acetyl transferase (CAT) reporter that has a longer half-life 
(~50hrs) than luciferase (~3hrs). However, it was the luciferase reporter constructs that 
they used in the comparative studies at time point 24hrs, not the CAT reporter 
constructs, and so they may have over-looked an earlier haplotype effect.
In ECV304 cells, Terry and co-workers (2000) found that the up-stream context of the 
-174 allele was important in determining allelic effect of IL-6 expression. In the 
context of the -597G-572G[A9Tl 1] haplotype, the -174G allele was associated with 
significantly higher levels of reporter expression than the -174C allele when induced 
by IL-1. However, in the context of -597A-572G[A8Tl2] haplotype, the -174C allele 
was associated with higher levels of reporter expression than the -174G allele when 
unstimulated or induced by IL-1. The results of Terry et al. suggest a functional role 
for the -597 allele of IL-6 in combination with the —174 polymorphism, in ECV304 
cells. We did not see this in HeLa cells, nor did the genotype studies in SA suggest a 
functional role for the -597 polymorphism. In HeLa and ECV304 cells, Terry et al., 
found no significant difference between levels of reporter expression with the -572G 
and C alleles in the context of the -597G[Al0Tl0]-174G haplotype (assayed at the 
24hr time-point).
6.14. The functional influence of the AT-tract
Short constructs of the 5’-flanking region of IL-6 (611bp) containing only the -174 
polymorphism (either G or C allele) and the A8T12 polymorphism (the most common 
AT-tract allele) produced significantly higher levels of reporter expression with -174G 
than -174C when induced by IL-lp, but no difference in constitutive (non-induced) 
levels of expression (section 4.1.3). The AT-tract was kept constant between constructs 
to allow comparison of -174 allelic effect alone. However, while the -174C allele is in 
strong allelic association with A8T12, -174G rarely occur with this AT-tract allele (see 
discussion section 6.8). The -174G allele occurs most commonly with A9T11. A 61 lbp 
-174G-allele construct with the A9T11 AT-tract allele was compared to the 
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-174G/A8T12 construct (see section 4.1.5). The AT-tract polymorphism showed 
functional effects independent of the -174 polymorphism with -174G/A8T12 
producing higher levels of expression than -174G/A9T11, both constitutively and with 
IL-1 induction. Levels of reporter expression were still significantly higher for the 
-174G/A9T11 construct when compared to the -174C/A8T12 construct with IL-1 
induced, but not constitutive expression (data not shown).
Comparison of haplotype constructs differing by the AT-tract allele transfected into 
ECV304 cells showed that the more A-nucleotides in the AT-tract the lower the levels 
of associated IL-1-induced reporter expression (Terry et al., 2000). AT-tract allele 
A9T11 was associated with significantly higher levels of IL-1-induced expression than 
either AlOTiO or AlOTll alleles in the context of the -597G-572G-174G haplotype. 
This is in agreement with the findings in our study of the AT-tract allelic effects on IL- 
6 transcription in HeLa cells, though we found these effects in unstimulated as well as 
IL-1-induced expression. Alterations in the tertiary DNA structure by the AT-tract may 
alter ease of strand opening and access for transcription (see section 1.3.3.3). 
Alternatively, variations in the helical structure resulting in bending of the DNA may 
produce steric hindrance or facilitation of transcription factor binding to adjacent 
regions of the DNA. Electrophoretic mobility shift assays would yield information as 
to whether any transcription factors bind at the AT-tract itself. The functional effects 
of the AT-tract alleles in transfection studies suggest significance, though in the 
context of SA, the genotype studies did not identify an association between AnTn or 
the -174/AnTn haplotype and disease. In vivo effects of the AT-tract polymorphisms 
on levels of IL-6 transcription have been investigated following coronary artery by­
pass graft as a stimulus to IL-6 production (Kelberman et al., submitted, personal 
communications). They found significantly higher post-operative IL-6 levels in A9Tl 1 
homozygotes compared to AlOTll homozygotes, in the context of the -597GG- 
572GG-174GG genotype. This supports the in vitro reporter assay results for 
functional effects of the AT-tract polymorphism.
6.15. Information from deletion mutant studies
The use of deletion mutants of the 61 lbp 5’-flanking region constructs of IL-6, showed 
a functional effect on transcriptional activation for a region within -310 to -550 
(section 4.1.4). This region included the AT-tract. The finding that even in the absence 
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of the AT-tract, the -174G allele produced higher levels of IL-1 induced reporter 
expression than the -174C allele confirmed an independent effect of the -174 
polymorphism. The lower levels of expression with deletion of the region -310 to 
-550 may have been due to removal of the AT-tract with reduced strand accessibility 
to transcription. The only other known site within the deleted region is a putative GRE 
at -461 to -466 that if functional would be expected to repress IL-6 transcriptional 
activation rather than activate it. With deletion of the region -220 to -310 a further 
functional element of IL-6 transcription was removed (section 4.1.4). A region within 
this appeared to interact with the -174 polymorphism resulting in a differential 
reduction in the levels of reporter expression with the -174G allele compared to the C 
allele. Two binding sites have been identified within the deleted region both enhancing 
IL-6 transcription, an API site at -277 to -283 mediating cAMP responsiveness 
(Dendorfer et al., 1994) and an IRF-1 site at position -254 to -267 shown in HeLa 
cells to up-regulated IL-6 expression in the co-presence of down-stream NF-kB 
(Faggioli et al., 1997). Either of these sites could be involved. A 3’UTR polymorphism 
in IRF-1 has been associated with susceptibility to JIA (Donn et al., 2001b). Although 
to date, no functional effect has been ascribed to this polymorphism, functional effects 
on levels of expression in transfection studies have been found with promoter region 
polymorphisms of the IRF-1 gene that may be in allelic association with the 3’UTR 
polymorphism (Saito et al., 2001). This could link a susceptibility factor for JIA with 
risk of developing the SA form of disease in IL-6 -174G carrying individuals, via the 
IRF-1 binding site in the IL-6 5’-flanking region. Alternatively, the co-activator CBP 
required for transcriptional activation by Fos-Jun complexes via the API site may be 
available when the API site is absent to bind co-operatively with GRE and allow 
increased repression of IL-6 transcription (see sections 1.3.2.4 & 5). Site-directed 
mutagenesis studies would allow these possibilities to be investigated further.
6.16. The influence of glucocorticoids on polymorphic effects
Dexamethasone has a differential inhibitory effect on the -174G and C alleles (see 
section 4.1.8). With the 611bp constructs, dexamethasone resulted in more inhibition 
of IL-1-induced transcription with the -174G allele than the -174C allele, though 
levels of transcription were not returned to unstimulated levels. With the 1.17kb 
haplotype constructs, a similar effect was seen. The -174G allele showed significant 
inhibition of IL-1-induced reporter expression in the presence of dexamethasone, in the 
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context of its common natural haplotype -597G-572G-174G, and in the context of 
-597A-572G-174G. In contrast, the -174C allele showed no significant inhibition of 
IL-1-induced transcription with dexamethasone in the context of its naturally occurring 
haplotype -597A-572G-174C. In fact, the differential allelic effect of the -174 G/C 
polymorphism with IL-1 stimulation was lost in the presence of dexamethasone 
inhibition. The mechanism underlying this effect could be due to influences on GRE 
binding to DNA, GRE co-factor competition, prevention of activating transcription 
factor binding or altered levels of NF-kB availability for binding. For example, the 
-174G allele may facilitate GRE binding compared to -174C. GRE may compete the 
transcriptional co-factor CBP that could be involved in differential up-regulation of the 
-174G allele with IL-1 stimulation compared to the -174C allele, via API, CREB or 
other enhancer sites. GRE may directly block transcription factor binding to DNA (for 
example, by steric hindrance of CREB binding at the overlapping GRE and CREB 
sites, -145 to -173) or indirectly by protein-to-protein interactions (for example, with 
Fos and Jun, or NF-kB), involved in up-regulation of the -174G allele compared to 
-174C. Alternatively, GRE could result in reduced availability of a transcriptional 
enhancer such as NF-kB, via indirect influences on release of the active form of 
protein (see section 1.3.2.1&5). Electrophoretic mobility shift assays and site-directed 
mutagenesis would help to differentiate these possibilities. It should be noted that 
ethanol was present in the medium for the dexamethasone studies, as it was required to 
dissolve the crystalline form of dexamethasone (Sigma). This form of the drug was 
used in preference to water-soluble dexamethasone (Sigma) that contained a high 
molar ratio of cyclodextrins to dexamethasone (>20-fold), with unpredictable cellular 
effects. Although ethanol has been reported to inhibit NF-kB activation, the 
concentrations reported to produce such inhibitory effects were of the order of 100- 
fold higher than the concentrations present in our studies (Mandrekar et al., 1999). The 
ethanol concentration was standardised in the medium of all comparative wells within 
the dexamethasone study and no inhibitory effect of ethanol alone at these levels was 
detected.
Interestingly, the effects of dexamethasone inhibition differed with the -174 allele in 
unstimulated compared to IL-1-stimulated transcription (see section 4.1.8). With 
unstimulated transcription, dexamethasone resulted in more inhibition of the -174C
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allele compared to the -174G allele, and resulted in significantly higher levels of 
reporter expression with -174G than -174C. This can only be explained by a different 
inhibitory mechanism of dexamethasone acting under unstimulated compared to EL-1 
stimulated conditions. It may be that effects are modulated via a different GRE site. 
Any of the mechanisms discussed above could be effective, however in the 
unstimulated situation, the -174C allele would favour GRE binding/inhibition. This 
suggests that a constitutively bound factor, binding more strongly to the -174C than G 
allele is likely to be involved, to convert the inhibitory mechanisms for GRE in favour 
of the -174C allele instead of G allele. Alternatively, an IL-1-induced factor could 
bind more strongly to the -174G allele to favour GRE binding with IL-1 exposure, 
however EMSA study results do not support this hypothesis (see discussion 6.23).
Dexamethasone inhibition of IL-1-induced expression of the -597G-572G-174G 
haplotype construct compared to -597G-572C-174G showed that only the -572G 
allele was significantly inhibited (see section 4.1.9). This is most likely due to 
facilitated GRE binding by the -572G allele at one of the adjacent GRE sites (position 
-461 to —466 & -552 to -557). EMSA studies within this thesis have confirmed GRE 
binding to the region -539 to -613 with the -572G allele, though comparison with the 
-572C allele have not been made (see section 5.3.1). Site-directed mutagenesis would 
allow identification of the binding site for GRE in this region. No effect of the -597 
polymorphism was seen on dexamethasone inhibition nor on GRE binding in this 
region.
6.17. Cell-specific transcriptional effects
The results for the transient transfections in HeLa cells were confirmed in the stable 
transfections of these cells (see 4.2.1). In contrast, no significant differential effect of 
the -174 polymorphism was seen in Huh7 cells, for IL-1 stimulation or dexamethasone 
inhibition (section 4.1.7&8). IL-1-induced transcription of IL-6 was not inhibited by 
dexamethasone in Huh7 cells. This cell-specific difference is unlikely to be due to 
insensitivity of Huh7 cells to dexamethasone as mRNA levels of the acute phase 
protein serum amyloid A have been shown to be up regulated by dexamethasone in 
Huh7 cells (Steel et al., 1996). It may therefore reflect differences in the mechanism of 
IL-1-induction of IL-6 transcription between the cell types, or differences in the 
mechanisms of glucocorticoid inhibition in Huh7 cells. In ECV304 cells, Teny et al. 
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(2000) found no difference in the effect of dexamethasone inhibition on the -174 or 
-572 alleles with IL-l-induced expression of IL-6, though IL-1-induction alone 
resulted in allelic differences in expression. They reported a small difference with the 
AT-tract polymorphism, in the context of the -597G-572G-174G haplotype. 
Dexamethasone inhibition of IL-l-induced expression of IL-6 was less for A9T11 than 
AlOTll, though there was no difference between the two most common haplotypes 
-597A-572G[A8Tl2] -174C and -597G-572G[A9Tll]-174G. These results support 
the case that cell-specific differences occur in regulation of IL-6 transcription. Such 
differences may explain the array of gene association results in different disease states 
(see 6.9), where the effects of IL-6 polymorphisms may vary dependent on the 
predominant cell-type involved in IL-6 production.
Cell-type differences in the expression and regulation of certain transcription factors, 
and isoforms of a transcription factor, influence levels of EL-6 transcription (discussed 
in section 1.3.2) and may therefore alter the -174 allelic effect. One such candidate 
transcription factor is C/EBPp. NF-kB and CREB can up regulate the expression of 
C/EBPp in hepatoma cells (Niehof et al., 2001a). Inflammatory stimuli, including 
cytokines, alter the nuclear localisation of C/EBP isoforms within hepatocytes, up 
regulating nuclear concentrations of C/EBPp and 8 and down regulating C/EBPa (Yin 
et al., 1996). Dexamethasone can induce C/EBPp expression at the level of 
transcription in hepatocytes and increase C/EBPp DNA-binding activity (Matsuno et 
al., 1996). In addition, the ratio of the activating to the repressor isoforms of C/EBPp 
(LAP to LIP, see section 1.3.2.2) may vary with inflammatory stimuli and between cell 
types. In HepG2 (hepatoma) cells, the albumin promoter can be activated by C/EBPp. 
However, in HeLa or L (fibroblastic) cells, C/EBPp activation of the promoter was 
inhibited, dependent on the presence of the repressor region of C/EBPp (Williams et 
al., 1995). All of these mechanisms could influence cell-specific activation of IL-6 
transcription via C/EBPp. If C/EBPp acts differentially with the -174 G and C allele, 
as suggested by the involvement of C/EBPp in the differential binding of a protein 
complex to these alleles in EMSA studies (see section 5.2.5 & 6.27), then this could 
influence the level of induced transcription for each allele and determine cell-specific 
effects.
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6.18. The effect of stripped FCS
Stripped FCS was used in comparing the dexamethasone effect to try to reduce any
hormonal or glucocorticoid influences the cells were exposed to from the serum. Of
interest, the use of activated charcoal and dextran to strip the FCS resulted in loss of
the inhibiting effect of dexamethasone on IL-6 transcription, reduction of the IL-1
stimulatory effect, and loss of the -572 allelic effect on EL-1 induced reporter
expression (see section 4.1.10). The loss of inhibition with dexamethasone may have
been due to dextran remaining in the stripped medium, binding the dexamethasone and
preventing its interaction with the cells. Similarly, if the -572 allelic differences were
due to differential inhibition by glucocorticoids then this could have been lost if
glucocorticoids were removed from the serum by the stripping of FCS. EMSA studies
showed that GR does bind at a site adjacent to the -572 polymorphism (see sections
5.3.1 and 6.29), though possible influences of the -572 polymorphism on this binding
were not investigated. The reduction in IL-1 p-induced transcription of IL-6 with
stripped FCS medium may also have been due to effects of residual dextran in the
medium, possibly binding IL-1 and reducing bioavailability for cell stimulation. A
fluorescence-activated cell sorter (FACS) was used to determine the percentage of
cells carrying detectable levels of IL-1 RI (the signalling molecule of the tri-molecular
EL-1R complex) on HeLa cells and Huh7 cells after exposure to medium containing
2% FCS or stripped FCS (see section 2.10.7.2 for method). Both 2% FCS and stripped
FCS significantly increased the proportion of HeLa and Huh7 cells expressing
detectable levels of cell surface IL-1RI (data not shown). For HeLa cells this was
maximal from 1-6 hours (p<0.03) and for Huh7 cells at 4-6 hours (p<0.03) post change
of medium. This would explain the increased level of IL-6 expression following
medium change alone and the later time to peak IL-6 expression with Huh7 cells.
Overall levels of detectable IL-1RI expression on HeLa and Huh7 cells were low (6-
8%) compared to B-cells or monocytes (75-80%). Neither IL-1 nor dexamethasone had
any significant effect on the number of HeLa cells expressing IL-1R, however,
consistent with reported findings in murine hepatocytes (Ito et al., 1999), the number
of Huh7 cells expressing detectable levels of IL-1RI significantly increased with
dexamethasone exposure (p=0.046). This provides a possible explanation as to why
inhibition of IL-6 expression was not seen with dexamethasone in Huh7 cells.
Increased IL-1 induction of IL-6 may have counteracted any inhibitory actions of
dexamethasone on EL-6 expression. Overall the use of 2% FCS (unstripped) was 
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considered a better model for studying IL-6 transcription in HeLa and Huh7 cells. In 
vivo serum factors would be present.
6.19. What drives IL-6 expression in SA?
Since in several cell types no difference was seen between constitutive levels of IL-6 
production with the -174 allele, it raises the question as to what may be inducing IL-6 
in the pathogenesis of SA to result in the -174G allele association. We have already 
said that IL-lp and TNFa, the acute-phase inducers of IL-6 used in the transfection 
model, are not elevated pre-IL-6 levels rising in SA, in comparison to other 
inflammatory states (see section 1.2.10). Traditionally other cytokines have been 
considered. However, recent evidence suggests that regulators of cell cycle activity 
may be important. The cyclin-dependent kinase inhibitor p21 in synovial fibroblasts 
has been found to arrest cell growth in the G(0)/G(1) phase of the cell cycle (Perlman 
et al., 2003). Lack of p21 has been associated with significantly increased IL-6 
expression (up to 100-fold higher) and enhanced activation of the transcription factor 
API. Perlman and co-workers found significantly lower levels of expression of p21 in 
synovial fibroblasts from the inflammatory synovium of rheumatoid arthritis compared 
to the synovium of the degenerate arthropathy osteoarthritis. This has not been 
investigated in the context of SA, nor in other cell types, however, it suggests a 
possible mechanism for differential expression of IL-6 that could be modified by the 
-174 allelic effects. It is also possible that more than one inducing factor is important 
and may vary between cell-type and stage of cell differentiation. In mouse 
mononuclear phagocytes, the stage of cellular differentiation has been shown to be 
important in determining the response to monocyte-macrophage colony-stimulating 
factor and hence the cell sensitivity to a secondary stimulus such as lipopolysaccharide 
to induce IL-6 expression (Kamdar et al., 1996).
6.20. Other factors that modulate genotypic effects
The genotypic effects of IL-6 are also subject to modulation by other factors. At the 
extremes of age, the effects of the -174 polymorphism appear to differ, and may be 
associated with a different spectrum of benefits versus disadvantage. In healthy, full 
term neonates bom by normal vaginal delivery or elective caesarian section, the 
-174CC genotype was associated with higher IL-6 plasma levels taken at delivery and 
higher levels of in vitro production of IL-6 from cultured mononuclear cells (Kilpinen 
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et al., 2001). In a control group of healthy adults, no effect of the -174 polymorphism 
was found on in vitro or in vivo IL-6 levels. In contrast, another group found in a more 
elderly population that PBMCs from healthy adults of mean age 60 years produced 
lower levels of IL-6 in vitro with -174C-allele carriers compared to non-C-allele 
carriers (Olivieri et al., 2002). They found lower plasma IL-6 levels in association with 
-174C-allele carriage in males but not females, and found a significant under­
representation of the -174GG genotype in centenarian males, but not females (Bonafe 
et al., 2001). This lead to the proposition that in men the -174GG genotype results in a 
disadvantage for longevity. Differential influences on IL-6 levels of varying levels of 
oestrogens and androgens with age could contribute to these effects (see section 
1.3.2.6). Together, the results suggest that while the production of IL-6 is genetically 
controlled, the control may also be age and gender dependent. Although we found age- 
at-onset associated differences with IL-6 genotype in the SA patients, no associated 
differences were found with gender (section 3.3.3).
6.21. Electrophoretic mobility shift assay technique
EMSAs are a useful technique to compare transcription factor binding between 
sequences and investigate specific transcription factors that may bind to certain DNA 
sequences. However, there are limitations that must be taken into account. Only a 
limited length of DNA can be used as a probe. As a result, interactions may be missed 
of transcription factor sites over long distances of DNA, even 1000s of bases as for the 
immunoglobulin heavy chain gene (Lieberson et al., 1995). Once transcription factor 
binding has been established in vitro, this needs to be confirmed in vivo. For example 
the glucocorticoid receptor can bind in vitro without the presence of glucocorticoids, 
however in vivo it requires glucocorticoids to induce a conformational change and 
facilitate binding (Wilmann & Beato, 1986). The context and configuration of the 
DNA sequence, influenced by flanking DNA sequences, may be different in vivo. In a 
similar way, factors that could bind in vivo may not be found to bind in vitro. In vitro, 
the optimal conditions for each transcription factor to bind a DNA sequence may vary 
with different salt conditions and varying protein to DNA concentrations of the 
binding reaction. This will also influence the formation of non-specific bands. Similar 
factors apply when it comes to cold competition studies and antibody binding for 
supershift studies. Antibody binding is also dependent on the epitope to which they are 
raised and on whether this is exposed on the DNA-bound protein. The use o f Trizma®
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(Sigma) in the polyacrylamide gel and running buffers, as in this study, instead of Tris- 
base that has a lower salt concentration, may affect the running and clarity of the bands 
on electrophoresis and the degree of dissociation of protein from DNA. Some 
degradation of nuclear protein was seen on Western blot analysis. This probably 
reflects over-heating or mechanical sheer during the dounce homogenisation process 
(see method section 2.11.1), although this was carried out on ice. Up to 100 strokes 
were required to lyse the HeLa cell membranes, even with the additional use of Triton. 
This was more than normally utilised for other cell-types such as HepG2 cells. Use of 
chemical lysis with a short freeze-thaw step would be an alternative method of cell 
extract preparation that may have reduced this (Schreiber et al., 1989). Co-factors 
required for transcription factor binding and/or function may also be altered or lost by 
the preparation process or binding conditions. The identity of a bound factor can only 
be determined by cold competition and supershift assay if the nuclear factor can be 
hypothesised or is known to bind, and if antibodies are available to it. A factor may not 
be hypothesised to bind if  it is part of a protein complex involved in protein-to-protein 
interactions rather than direct DNA binding. Once a transcription factor has been 
identified as binding to a sequence of DNA on EMSA, site-directed mutagenesis 
and/or foot-printing studies are required to determine the exact site of binding. 
Isolation and purification of the protein factor may be necessary to identify an 
unknown factor. Functional studies are then required with transfected protein and site- 
directed mutated constructs to confirm functional effects of the factor on the gene 
(discussed further in section 6.30).
EMSAs were used in this study to identify any differences in the pattern of 
transcription factor binding between the IL-6 single nucleotide variance -174G or C, 
and when a difference was detected to begin to identify factors involved, within the 
limitations of the technique.
6.22. Choice of EMSA probes
Probes were chosen to encompass the -174 allele with surrounding down-stream or 
up-stream, known and putative transcription factor binding sites. Probes of less than 
lOObp were chosen to avoid too many binding sites that would have given complex, 
multiple bands on EMSA and made interpretation more difficult. The shortest probe 
was 26bp (probes 1G and 1C, figure 5.2). This included the putative NF1 binding
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sequence around the -174 allele and 10 bases on either side to allow one helical turn of 
the DNA to try to ensure correct orientation of the site. This principle was followed for 
the other probes; there were no less than 10 bases at the end of each probe from the 
sites of interest Probes 2G & 2C were designed to include the CRE and C/EBPp site 
downstream of -174 and probes 3G & 3C were designed to include the up-stream 
negative regulatory domain (figure 5.2). Probes 4G & 4A were used to investigate 
transcription factor binding around the -597 polymorphism and included 1 of the 
putative GRE sites.
The specific-activity of the labelled probes was compared by serial dilutions counted 
with a Geiger counter at a fixed distance, and run on an agarose gel. As far as could be 
determined, the probes used were of equal activity though this was a rather crude 
method of comparison. Had the facility been available, comparing the level of activity 
between the two allelic probes using a scintillation counter would have been more 
accurate.
6.23. Implications of EMSA findings
Probes 2G & 2C were identical apart from the allele at position -174. A nuclear 
protein (or protein complex) was found to bind more strongly to the -174C than G 
allele (see section 5.2.2). Not only was the band stronger with the C-allele, but also the 
C-allele could compete out the band at lower concentrations than the G-allele, whether 
added before or after the binding reaction. To account for the transfection results 
obtained in HeLa cells, this factor was hypothesised to have an inhibitory influence on 
IL-6 transcription, with a stronger residual influence on the -174C allele than G after 
partial removal of the effect following IL-1 stimulation.
It is also possible that despite HPLC purification and OD260 quantification of the 
oligonucleotide probes obtained from the manufacturer (see table 2.10) that the C- 
allele probe was at slightly higher concentration than the G-allele probe. The 
lyophilised oligonucleotides were dissolved in water and the concentration re-checked 
by OD260 and by serial dilutions on an agarose gel. This would not however have been 
sensitive enough to detect a difference in concentration of as little as 1-2% which may 
have been enough to account for a stronger band with the C-allele probe when radio­
labelled and stronger cold competition. One way to check this would have been to 
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obtain re-synthesized probes and repeat the experiment. Alternatively, cold 
competition of the probes 2G and 2C with probes 1, 3 or longer probes covering the 
—174 region, could have been used to compare the effect on the bound complex.
6.24. NF1 consensus binding site
Members of the transcription factor family nuclear factor 1 (NF1) are expressed in 
HeLa cells, in fact NF1-C was initially purified from HeLa nuclear extracts (Santoro et 
al., 1988). Four NF1 proteins have been identified, NF1-A, -B, -C and -X. All four 
have been shown to bind to a common DNA sequence GCCAAT (Osada et al., 1999), 
however only NF1-A from rat origin has been shown to bind to the sequence TGGCA 
(Paonessa et al., 1988). The TGGCA sequence is present with the -174C allele of IL-6, 
though it is not established whether NF1-A from human cells or other members of the 
NF1 family will bind to this sequence. Members of the NF1 family have also been 
shown to bind a canonical DNA sequence NNTGGNNNNNNGCCAAN (Chodosh et 
al., 1988, Jones et al., 1987). This canonical binding sequence differs from the 
sequence of EL-6 between -171 and -186 by three bases for the -174G allele and by 
only two bases for the -174C allele (figure 5.6). It was hypothesised that NF1 may 
bind both alleles of IL-6 (by either of the NF1 consensus sequences) but with differing 
affinity, resulting in altered levels of transcription between the alleles. NF1 has been 
shown to act as a transcriptional repressor of some genes, human metallothionein IIA 
(Osada et al., 1997b) and rat hepatic aldehyde dehydrogenase 3 (Lindahl et al., 1999). 
However, it can act as a transcriptional activator of other genes, adenoviral RNA 
polymerase II (Jones et al., 1987) and rat aib adrenergic receptor (Gao et al., 1996). If 
NF1 bound preferentially to the -174C allele form of IL-6, in HeLa cells this could 
result in repression of IL-6 transcription and hence explain the lower levels of C allele 
expression in transfected HeLa cells. From the cold competition studies with either 
NF1 consensus sequence, the protein band was competed out from probes 2G & 2C, 
suggesting that NF1 may be involved in this complex (section 5.2.3). However, this 
was not confirmed by supershift studies with an antibody to NF1 and no definite 
conclusion could be drawn as to whether NF1 was involved. Availability of purified 
NF1 protein could have helped clarify whether this factor bound to probes 2G and 2C.
An alternative strategy was tried whereby two mutated sequences were generated of 
the NF1 consensus binding-site (NFlmutl and NFlmut2, see table 2.11) so that NF1
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would no longer bind (confirmed by EMSA, see figure 2.12). The probes were 
otherwise similar to the NF1 consensus 1 sequence probe. The mutated probes were 
used in cold competition studies with probes 2G & 2C. The theory was that if the 
factor competing for probe 2G & 2C binding was NF1, mutating this site should 
reduce competition. This was the case for NFlmut2, but not for NFlm utl (data not 
shown). It was therefore not possible to clarify whether NF1 was involved in the 
complex binding to probes 2G and 2C. The mutation sequence of NFlm utl may have 
introduced an artefact. To investigate the components of the protein binding complex 
on probes 2G and 2C, further studies with foot-printing and protein isolation would be 
necessaiy (see section 6.30).
6.25. Possible transcriptional co-factors in an IL-6 bound complex 
The possible role of co-factors needs to be considered. Many transcription factors can 
associate with co-regulatory molecules that will influence their regulatory actions on 
transcription (Lemon and Tjian, 2000). Five classes of co-factors have been described 
in eukaryotes, with functions as diverse as the general co-regulatoiy factors involved in 
the RNA polymerase II transcriptional activity, factors that associate with sequence- 
specific transcription factors to alter DNA specificity or interaction with other 
transcription factors, and factors that alter chromatin structure. A transcriptional co­
factor, common to transcription factors bound to the NF1 consensus, NFlm utl and IL- 
6 2G & 2C probes would be an alternative explanation for the competition results 
obtained. There were no known transcription factor sites other than NF1 that were 
common to these probes (Sigscan analysis), so the transcription factors binding a co­
factor may have differed. CBP is an example of a possible co-factor. This 
transcriptional co-factor is involved in protein-protein interactions with multiple 
transcription factors including CREB, c-Jun, Fos, GR, oestrogen receptor, TATA 
binding protein, transcription factor IIB and YY1 (Chan and La Thangue, 2001). CBP 
can act as a co-activator with these transcription factors by acting as a bridge between 
DNA-bound transcription factors and the basal transcription machinery, providing a 
‘scaffold’ for complex formation or by modifying transcription factors and chromatin 
through acetylation. It is possible that CBP is involved in the transcription factor 
complex differentially bound to the EL-6 -174G & C probe, and that it is CBP that is 
competed out by its involvement in a transcription factor complex bound to the NF1 
consensus and NFlmutl probes. (The NF1 consensus and NFlmutl probes have a 
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common YY1 site on Sigscan analysis, which the NFlmut2 probe does not). The 
possibility of CBP involvement in the IL-6 probe-protein complex was not explored in 
the context of this thesis, but remains to be investigated.
6.26. CREB binding to IL-6
CREB binding to the IL-6 gene between -134 to -184 was confirmed with supershift 
studies (section 5.2.4), although this binding was not altered by the identity of the -174 
allele. Two supershift bands were produced which probably represents two forms of 
CREB bound to this region of the gene. Only the phosphoiylated form of CREB will 
bind CBP, though dephosphorylated CREB will bind to the CRE. The two bands may 
represent the presence of phosphorylated and dephosphorylated CREB on the IL-6 
sequence with the phosphoiylated form associated with CBP, running more slowly 
through the gel. Alternatively, CREB may be associated with another factor such as c- 
Jun in one of the bands. The transcription factor c-Jun can form heterodimers with a 
variety of other transcription factors including ATF/CREB family members (Hai and 
Curran, 1991). The binding of c-Jun to CREB, results in altered DNA binding 
specificity. Western blot analysis did not test for the phosphorylation state of CREB, 
and the protein was denatured so associations would have been lost.
6.27. C/EBP binding to the -174G and C allele
Competition and supershift studies confirmed that C/EBPp bound to the IL-6 gene 
between -134 and -184 and was involved in the differential binding of a protein 
complex to the -174G and C allele (section 5.2.5). Even with antibody concentrations 
that were expected to be in excess of the C/EBP protein concentration (up to 
300ng/pl), the protein complex was not completely competed out. This, together with 
the transfection study results showing that the -174G was associated with higher levels 
of IL-6 expression than the -174C allele, though the EMSA band was bound more 
strongly with the -174C allele, makes it unlikely that C/EBPp alone accounted for the 
EMSA band. It is more likely that C/EBPp is involved either directly or in-directly in a 
complex of proteins binding to this region of the IL-6 gene. EMSA studies with site- 
directed mutagenesis of the C/EBP site in the IL-6 probes would help establish the role 
of C/EBP. DNA-bound C/EBPp may stabilise the formation of the differentially bound 
protein complex rather than forming a direct component of the complex. Different
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isoforms of C/EBP may bind the IL-6 probe in this region as heterodimers with 
C/EBPp (see section 1.3.2.2 & 6.17). Supershift studies with anti-bodies to other 
isoforms of C/EBP may provide evidence to support this possibility. Alternatively, 
disruption of synergistic co-operation between C/EBPp and NF-kB (see 1.3.2.2) by an 
inhibitory protein(s) bound differentially to the -174G and C alleles could explain the 
differential levels of expression seen in the HeLa cell transfection studies (section 
4.1.3).
6.28. Factor binding to the negative regulatory domain
EMSA studies showed transcription factor binding to the negative regulatory domain 
(NRD) of IL-6 though these were not influenced by the -174 alleles (section 5.2.7). 
This region contains a known GR binding site, however GR binding was not 
demonstrated by cold competition or supershift studies. This may have been due to the 
EMSA conditions. In vitro foot-printing had previously demonstrated GR binding 
from -201 to -210 (Ray et al., 1990).
The EMSA studies showed that an IL-1-inducible factor bound within the NRD. The 
NRD contains an Spl-consensus binding site between -198 and -202 (figure 5.5). The 
transcription factor Spl was initially identified in HeLa cells as an activator of in vitro 
transcription of the SV40 viral promoter binding to a repetitive GGGGCGGGGC 
sequence called the GC box (Dynan and Tjian, 1983). Two distinct regions of the Spl 
protein are responsible for DNA-binding specificity and affinity. It belongs to a 
subgroup of factors that are phosphorylated upon promoter sequence binding by a 
DNA-dependent protein kinase, Spl kinase (Jackson et al., 1990), therefore binding 
does not necessarily determine activity. In THP1 cells, Spl was found to be present in 
a protein-complex binding to a negative regulatory region between -73 to —181 of the 
IL-6 gene (see section 1.3.2.8). Cold competition studies were conducted for the Spl 
consensus sequence (see table 2.11) with the NRD IL-6 probes (3G and 3C) and HeLa 
cell nuclear extracts to investigate the possibility that Spl bound to this region of the 
IL-6 gene. No competition was observed (data not shown) and so it was considered 
unlikely that Spl was involved in the IL-1 inducible complexes bound to the NRD. It 
remains to be established what IL-1 inducible factor binds to this region.
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6.29. The -597 G/A polymorphism
Consistent with the transfection studies in HeLa cells that showed no independent 
effect of the -597 allele on levels of IL-6 transcription, no differences were seen 
between transcription factor binding around this site with either allele (section 5.3).
GR binding to the IL-6 gene at a site between -539 and -613 was identified by 
supershift studies (section 5.3.1). This binding was not influenced by the allele at -597. 
GR binding was identified in the context of the -572G allele, the effect of the -572C 
allele was not investigated but it would be interesting to compare as this polymorphism 
showed independent functional effects on IL-6 transcription in transfection studies (see 
section 4.1.6). The -572C allele was associated with lower levels of IL-6 expression 
than the G allele. For differences in GR binding to explain the -572 allelic effect, the 
-572C allele would have to bind GR more strongly, or facilitate GR binding to a 
second site. The site of GR binding was not established in this study but could be 
determined by site-directed mutagenesis or foot-printing studies. It was presumed that 
this was most likely to be at one of the two putative GR binding sites (see figure 5.2). 
No other transcription factor sites are known for this region of the IL-6 gene, nor were 
consensus sequences identified using the Sigscan programme.
6.30. Alternatives to EMSA
Although EMSA studies can be useful in identifying transcription factor(s) that bind to 
DNA sequence motifs, the technique is limited when the possible identity of the 
factors) is wide, or novel. In vitro foot-printing studies could narrow-down the 
identity of the specific sequence and site where the factor(s) are bound. Purified 
protein of hypothesised factors could be used instead of cellular nuclear extracts. 
However, this has the disadvantage that co-operative binding, factor complexes and 
non-direct DNA binding will be missed. In vitro foot-printing is currently underway as 
on-going work in the laboratory of P. Woo. It should yield more information on the 
site of factors bound to the -174G and C sequences, which may provide information 
on the identity of the factor(s) and allow a shorter probe sequence to be used for 
isolation and purification of the factor(s). With a shorter DNA probe, this could be 
biotinylated and incubated with HeLa cell nuclear extracts under the same conditions 
as for the EMSA studies. Protein bound probe passed over strepdavidin-coated 
magnetic micro-beads would adhere. The probe bound transcription factors could be 
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cautiously eluted and if  pure protein bands were identified in elution fractions (for 
example on a silver-stained gel), identification could be attempted by matrix-assisted 
laser desorption ionisation time-of-flight (MALDI TOF) mass spectrometry, which 
identifies proteins by peptide mass fingerprinting. This would be an adaptation of a 
method successfully used to isolate and identify BiP, an auto-antigen identified from 
rheumatoid arthritis patients (Corrigall et. al., 2001).
The results of in vitro studies must be interpreted in the context of functional studies. 
Transfection studies using constructs that have been manipulated by site-directed 
mutagenesis to abolish a transcription factor binding site thought to be important, 
would help support an ‘in vivo ’ role for that factor in a specific cell type. Alternatively, 
transfection into a cell line deficient in a certain transcription factor may yield 
information. However, alternative transcription mechanisms may over-come a 
deficiency if the factor is not essential, with many biological systems displaying 
redundancy. Re-introduction of the deficient factor by transfection of an expression 
plasmid may enable the role of the transcription factor to be identified. True in vivo 
studies using knockout animals deficient for a transcription factor are often difficult 
because many such mutations will be lethal due to the multiple functions of 
transcription factors on multiple genes, some of which may be essential. Developments 
in mouse ‘knock-out’ technology has meant that methods are available to flank a gene 
with a ‘knock-out’ sequence that can be induced to ‘switch o ff the gene expression 
after the birth or development of the animal, for example on exposure to an antibiotic. 
This could provide specific information in vivo.
6.31. Implications of the findings from this study
A number of novel findings arose from this thesis: The association of the -174
polymorphism but not the -572 or -597 polymorphism with SA; the independent
functional effects of the -174 polymorphism in HeLa cells with IL-1 [3 & TNFa
induction and glucocorticoid inhibition; the functional effects of the -572 and AT-tract
polymorphisms in HeLa cells; the differential binding of a transcription factor(s) to the
-174 C & G alleles in HeLa cells; the binding of an IL-lp-induced transcription
factor(s) to the NRD of the IL-6 gene; the binding of GR to a region adjacent to the
-597 & -572 polymorphisms. These results indicate the importance of genetic
influences on the regulation of IL-6 gene expression and that cell-specific differences 
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may result in different genetic effects in different cell types, possibly accounting for 
the different associations reported in vivo. In SA, carriage of the -174G allele may 
identify a poorer prognosis group who would warrant early aggressive 
immunosuppressive therapy. It is possible that this group would respond better to 
treatments aimed to reduce or inhibit IL-6 production or IL-6 effects. Glucocorticoid 
therapy may be more effective as the -174G allele was associated with increased 
sensitivity to glucocorticoid repression than the -174C allele. In addition, the -174G 
allele carriers, with associated higher levels of IL-6 production, may respond better to 
anti-IL-6 therapy with antibodies blocking IL-6 receptor binding and signalling. In 
-174CC genotype individuals, factors other than the regulation of IL-6 levels may play 
a more significant role. It is certainly evident that IL-6 is one of several multi-factorial 
genetic and environmental influences determining the susceptibility and out-comes of 
SA.
6.32. Future work
Now that it has been established that there is disease association with the -174 
polymorphism of EL-6 and SA, and that this polymorphism has functionality, the 
down-stream effects need to be investigated. Paired plasma samples and peripheral 
blood mononuclear cells from patients before and after first-time treatment with 
glucocorticosteroids, or on stable immunosuppressive therapy during quiescent disease 
and at the time of disease activity flare, can be used to investigate in vivo genotypic 
effects on IL-6 mRNA and protein levels in association with disease. Similar paired 
samples from children during and after an acute phase response, secondary to for 
example an infection, or before and after glucocorticosteroid therapy for another 
indication (for example an acute asthma exacerbation) would allow comparison of 
genotype effects in a different population. A prospective study of clinical disease 
course, disease activity and responsiveness to therapy in association with genotype 
analysis could also yield information on the role of IL-6 in SA, although diverse ethnic 
and geographical back-grounds would be difficult to control for. In addition, prior 
standardised protocols for the classification of disease activity, ratings of improvement 
and remission, and therapeutic strategies used, would have to be established and 
verified.
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In parallel, further investigations of in vitro functional effects of the IL-6 
polymorphisms will yield more information on the mechanisms involved. Transfection 
studies in a wider range of cell types and in primary cell lines rather than transformed 
cell lines are planned. Synovial biopsies from children with SA would allow fibroblast­
like synoviocytes to be isolated and used for transfection studies. Bone biopsies at the 
time of joint replacements would allow primary osteoblasts and osteoclasts to be 
isolated for use in transfection studies and may provide more insight into the role of 
IL-6 in osteoporosis. In vitro foot-printing studies, mutation studies and transcription 
factor isolation are underway to identify differentially bound transcription factor(s) 
around the -174G/C polymorphism (as discussed in section 6.30).
The ultimate test of whether IL-6 is involved in the pathogenesis of SA will be the use 
o f anti-IL-6 treatments to control disease. In adults with rheumatoid arthritis where IL- 
6 is implicated down-stream of other inflammatory mediators in the production of 
synovial inflammation, recombinant human anti-IL-6 receptor monoclonal antibody 
(MRA), that inhibits the biological activity of IL-6, has produced significant 
improvement in disease activity scores and acute phase response (Choy et al., 2002, 
Nishimoto et al., 2002). In the first trial, 45 patients were randomised to a single dose 
o f MRA or placebo and 5mg/kg of MRA produced significant improvement by 2- 
weeks post-treatment compared with placebo or lower treatment doses. In the second 
trial, 164 rheumatoid arthritis patients were randomised to placebo or MRA therapy 
every 4 weeks for 3 months. A dose of 8mg/kg of MRA produced a significant 
reduction in disease activity at 12-weeks compared to a dose of 4mg/kg or placebo. 
The drug was well tolerated. MRA has had encouraging results in two children with 
SA treated for 1 year in Japan (Yokota et al., 2002). Both boys, aged 6-7 years who 
had failed to respond to, and had complications from, other forms of treatment, 
improved with fortnightly MRA infusions (half-life of the antibody ~10days). Within 1 
week of the initiation of treatment, the acute phase response and disease activity fell 
and remained suppressed for the 18 months of follow-up. In addition, over the year 
their functional ability improved, they grew 10cm in height, gained in bone mineral 
density and were able to reduce glucocorticosteroid therapy. Neither experienced any 
adverse reactions to treatment. A 23-year old patient with adult onset Still’s disease (a 
condition very similar to the SA form of JIA and also thought to involve IL-6 in the 
pathogenesis) improved significantly in systemic and articular symptoms with MRA 
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treatment (Iwamoto et al., 2002). Controlled phase II trials are underway for MRA in 
Europe for children with SA.
6.33 Conclusion
IL-6 is involved in the pathogenesis of the systemic arthritis form of juvenile 
idiopathic arthritis. The 5’-flanking region polymorphism -174G of IL-6 is associated 
with disease. This polymorphism alters levels of IL-6 expression in a cell-specific 
manner and forms functional allelic associations with other IL-6 5’-flanking region 
polymorphisms. Transcription factor binding is altered by the -174 polymorphism and 
involves C/EBPp. These advances in our understanding of the role of IL-6 in SA and 
the mechanisms of control of IL-6 transcription could lead to development of more 
effective and specific treatment for SA.
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